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Abstract   
Cancer is a result of multiple genetic and epigenetic alterations that are acquired during 
tumour formation and progression. The development of cost-effective high-throughput 
technologies has positively contributed to the field of cancer research to identify cancer-
associated genes, in addition to diagnostic and prognostic markers. 
Using the most recent Illumina Infinium HumanMethyaltion450K BeadChip, this work 
has identified 23 genes that were significantly and differentially hypermethylated in 
short-term survivor (STS) glioblastoma patients and showed an association with poor 
prognosis. Interestingly, NR2F2 showed hypermethylation across multiple CpG loci and 
was significantly correlated with poor survival. In addition, the work has identified a 
subset of long-term survivors (LTS) that showed high DNA hypermethylation across 
many CpG loci indicating the presence of CIMP+.  
The other methylation study has identified 7 genes (EOMES, WDR69, MIR125B1, 
DZIP1, SOX1, PHOX2B and PRDM13) that were differentially hypermethylated in breast 
cancer brain metastasis (BCBM) tumours compared to non-metastatic breast tumours. 
These genes also showed hypermethylation in the paired breast tumours and BCBM 
samples, signifying the importance of the 7 genes in the development of brain metastasis 
in the early stages. Loss of expression of DZIP1, PRDM13 and PHOX2B was 
significantly associated with poor patient survival, indicating their potential as prognostic 
markers for BCBM patients. 
Whole exome sequencing (WES) analysis of sporadic non-NF2 vestibular schwannoma 
was disappointing and was not able to identify somatic mutations in the novel genes 
involved in schwannoma formation. However, the identification of novel deleterious 
mutations in the NF2 gene confirmed the validation of WES to identify cancer-associated 
variants. 
This study has used the most recent and developed high-throughput technologies to 
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Chapter One:  Introduction 
 
1.1 Cancer 
Cancer is defined as the abnormal growth of cells caused by alterations in gene 
expression leading to an imbalance of cell proliferations and cell apoptosis programmes, 
which results in the growth of tumour cells that can invade local tissues or spread to 
distant organs of the body (Ruddon 2007).  
There are >100 types of cancer which are named by their site of origin. Most cancer types 
can be categorised into: (i) carcinoma, which is the most common form of all cancers that 
originates from the skin or tissues surrounding the internal organs. Examples of this type 
of cancer include adenocarcinoma and squamous cell carcinomas, (ii) sarcomas, which 
arise from bone, cartilage, blood vessels and connective tissues such as osteosarcomas 
and ewing’s sarcoma, (iii) leukaemia, which is cancer of the blood forming tissues such 
as bone marrow that causes the production of abnormal cells in the blood, (iv) lymphoma, 
cancers of the immune system’s cells, and (v) central nervous system cancer, which 
arises from the brain and spinal cord such as glioblastoma and meningioma. However, 
not all tumour cells are cancerous; they can be either benign tumours or malignant 
tumours. Benign tumours can be surgically removed with no relapse or spreading to 
nearby organs, while malignant tumours are capable of invading local tissues and spread 




1.1.1 Cancer global incidence and mortality 
Cancers are among the leading causes of morbidity and mortality worldwide. In 2012, 
around 14.1 million new cancer cases were diagnosed in the world, there were 8.2 million 
cancer deaths and around 32 million individuals living with cancer (Ferlay et al. 2014) 
(Figure 1.1). The 5 most common forms of cancer diagnosed around the globe are lung 
cancer, prostate cancer, colorectal cancer, stomach cancer and liver cancer in males 
(Figure 1.2). Among females, breast cancer, colorectal cancer, cervix/uterus cancer, lung 
cancer and stomach cancer are the most common sites (Ferlay et al. 2014) (Figure 1.3). It 
is expected that the number of annual new cases will increase by 70% in the next two 
decades (World Cancer Report 2014). The World Health Organization (WHO) has 
recently listed the five leading behavioural risks for cancer: high BMI, unhealthy diet, 
absence of physical activity, smoking tobacco and alcohol consumption, which are 
responsible for 30% of cancer related deaths globally. Smoking tobacco is the biggest 
risk factor for lung cancer deaths (71%) worldwide and 20% of other global cancers. In 
developing countries, viral infections, e.g. HCV and HPV, are responsible for 20% of 
cancer related deaths (“WHO | Cancer”). Other factors may include air pollution, 
exposure to radiation, exposure to carcinogenic chemicals and risk of inherited cancer. 
In 2013, WHO and the International Agency for Research on Cancer (IARC) revealed the 
Global Action Plan for the Prevention and Control of Non-communicable Diseases 2013 
- 2030 which aims to relatively reduce the number of pre-mature mortality cases from 
cancer, diabetes, cardiovascular and respiratory diseases by 25% globally (“WHO | 
Global Action Plan for the Prevention and Control of NCDs 2013-2030”). Within the 
action plan, nine voluntary aims were set to be achieved by the end of 2025 and some 
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were relevant to cancer prevention such as the aim to reduce alcohol consumption by at 
least 10%, a 30% reduction in the current rate of worldwide tobacco consumption, 
increase physical activity among the global nations, and 80% availability of essential 
medicines and basic hospital facilities required for the treatment of non-communicable 
























This figure has been taken from Cancer Research UK’s website 
(www.cancerresearchuk.org) which shows global cancer statistics for cancer diagnosis 







































This figure shows the estimated incidence (blue) and mortality (red) rate of the most 
common types of cancers in males. ASR = age standard rate. The figure is taken from the 
World Health Organization, GLOBOCAN 2012 website (http://globocan.iarc.fr). 




Figure 1.3 Estimated global incidence and mortality rates in female cases 
This figure shows the estimated incidence (blue) and mortality (red) rate of the most 
common types of cancers in females. ASR = age standard rate. The figure is taken from 








1.2 Cancer genetics 
For many decades, researchers have tried to answer the question “what are the cellular 
alterations that may cause cancer”. To date, no definitive answer has been found and 
there is no single cause for these alterations.  
The probability for developing cancer increases with age which led to the hypothesis of 
multiple cellular hits. The theory that cancer is a result of the accumulation of multiple 
DNA mutations was initially proposed by Carl O. Nordling in 1953 (Nordling 1953). 
Nordling proposed that the incident of cancer increases by six to the power of age and 
requires 6 consecutive hits (Nordling 1953). Later in 1971, Knudson formulated the 
theory by performing multiple statistical analysis of 48 sporadic and familial 
retinoblastoma cases (Knudson 1971). Knudson observed that cancer could be caused by 
at least two DNA alterations which occur at certain rates. In familial retinoblastoma 
cases, one hit was inherited and the second hit was acquired later; while in sporadic 
retinoblastoma, both hits were somatic (“Milestone 9: Nature Milestones in Cancer”; 
Knudson 1971). In later years after the Knudson two-hits hypothesis, many related 
concepts have emerged till the current view of “the development of cancer”; that all 
cancers are developed due to multiple genetic and epigenetic alterations which are 
acquired during the progression of tumour development (“Milestone 9!: Nature 
Milestones in Cancer”). These alterations affect the process of carcinogenesis either by 




Proto-oncogenes are normal genes which when mutated become oncogenes that 
accelerate cell proliferation and division uncontrollably. The first discovered oncogene 
was Src, which was as an oncogene in a chicken retrovirus. Later, the American scientists 
J. Michael Bishop and Harold E. Varmus found that oncogenes were the activated form 
of proto-oncogenes and that they can be found in all organisms including humans 
(Bishop 1985). Bishop and Varmus were jointly awarded the Nobel Prize in physiology 
and medicine in 1989 for their discovery of the retroviral oncogenes.  
The main function of proto-oncogene proteins is the regulation of cell differentiation and 
proliferation. Any changes in a proto-oncogene’s sequence or an increase in its protein 
production leads to uncontrolled cell proliferation and later tumour formation. Proto-
oncogenes can be activated to oncogenes by different mechanisms; (i) point mutations, 
which can arise spontaneously or be acquired by exposure to carcinogenic agents or 
radiation. Mutations within a proto-oncogene sequence can change the protein structure 
and cause an increase in protein production. A famous example is RAS proto-oncogene, 
which is found to be mutated in >20% of human cancers including pancreas, colon, lung, 
breast, skin, kidney and leukaemia (Rajalingam et al. 2007). (ii) Chromosomal 
translocation which leads to high expression and uncontrolled production of the active 
protein. For instance, the Philadelphia chromosome translocation of chromosome 22 
(which contains BCR gene) and chromosome 9 (which contains ABL1 gene) in 
leukaemia. Translocation leads to uncontrolled expression of the BCR-ABL fused gene 
and causes cells to grow and proliferate uncontrollably (Talpaz et al. 2006), and (iii) gene 
amplification, resulting in an overproduction of the onco-protein such as amplification of 
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KRAS and BRAF in colorectal cancer (Little et al. 2011) and H-RAS in thyroid cancer 
(Várkondi et al. 2005). 
 
1.2.2 Tumour suppressor genes 
Tumour suppressor genes (TSG) mainly function as the regulator of cell cycle and 
promoting cell apoptosis by; (i) repression of genes inducing the cell cycle, (ii) increasing 
the expression of DNA repair genes, and (iii) initiating cell apoptosis for abnormal cells 
or cells with damaged DNA. The first discovery of a tumour suppressor gene was in 1987 
when Lee et al. cloned the retinoblastoma (RB1) tumour suppressor gene (W. H. Lee et 
al. 1987). Later in 1971, Knudson proposed the “two-hits hypothesis” based on the 
observation of genetic mutations in the RB1 gene (section 1.2) (Knudson 1971).  
In normal cells, tumour suppressor genes work in parallel with proto-oncogenes to 
control cell proliferation. Tumour suppressor proteins restrain cell growth, while proto-
oncogenes code for proteins that promote cell growth. DNA alterations of either type of 
gene lead to disruption of the cell cycle and uncontrolled cell growth. A number of well-
known tumour suppressor genes have been identified such as TP53 that encodes the p53 
protein. p53 plays many cellular roles by initiating apoptosis and inhibiting angiogenesis. 
More than 50% of all cancers contain mutations or deletions of the TP53 gene which led 
research studies to focus on developing gene therapy to restore p53 function in the cells 
(Ventura et al. 2007). Other examples include mutations in BRCA1 and BRCA2 genes 
which are associated with breast cancer and ovarian cancer (King, Marks, and Mandell 
2003), and mutations in the NF1 gene in neurofibroma (Sawada et al. 1996). Tumour 
suppressor genes should not be confused with metastasis suppressor genes (MSGs). 
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MSGs have the ability to inhibit the development of metastasis in distant organs without 
controlling tumour growth at the primary site (HORAK et al. 2008).  
With the development of cost-effective NGS technologies, many novel tumour 
suppressor genes have been identified and are frequently found to be mutated in many 
cancers such as in the genes of SWI/SNF signalling pathway complex, which were found 
to be mutated in many types of cancers (Shain and Pollack 2013; Smith et al. 2012; 
Rousseau et al. 2011).  
 
1.2.3 Pathways in cancer 
Cancer is a result of the accumulation of cellular alterations. These alterations may occur 
at the level of the chromosomes, such as gain/loss of regions or chromosomal 
rearrangement, or the level of the genes, such as mutations, deletion and amplification, or 
epigenetic alterations, such as histone modification and DNA hypermethylation. Despite 
the type of alteration, the end result affects either the structure or the function of the 
protein encoded by the gene. Therefore, many studies now focus on screening tumours to 
identify cancer-associated alterations. However, it has been proposed that proteins 
encoded by mutated genes are actually clustered in certain pathways, in certain tumour 
types, and are affecting the same functional processes (Baudot, de la Torre, and Valencia 
2010). Therefore, the pathway analysis approach is now widely applied due to the 
availability of the large-scale high-throughput technologies, including targeted NGS 
panels (such as TruSight sequencing panels from Illumina).  
Many of the identified signalling pathways are involved in cell adhesion, apoptosis, DNA 
repair, angiogenesis, cell cycle and other critical cellular functions. Alteration of these 
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signalling pathways results in the formation of cancer cells that have the ability to spread 
uncontrollably and invade other tissues. For instance, the epidermal growth factor 
receptor (EGFR) and HER2 signalling receptors play a role in cell proliferation and 
survival, which are frequently overexpressed in cancer cells (Bianco et al. 2006). Growth 
factor receptors of the insulin pathway are also commonly mutated in cancer, including 
K-RAS, B-RAF and insulin-like growth factor (I-GF). Pathways involved in angiogenesis 
have also been widely studied to understand the process of angiogenesis and to find 
therapeutic cancer treatments targeting this process.  
Some studies have found overlapping genes between different types of cancer by using 
bioinformatics analysis and mapping pathway genes. For example, studies have shown 
that mutations in K-RAS and EGFR are mutually exclusive in non-small-cell lung cancer 
and are associated with poor patient prognosis (Eberhard et al. 2005). 
The study of gene mutations involved in cancer pathways may reveal new cancer genes 
and investigation of the molecular mechanisms behind specific cancer types will help 
with the identification of diagnostic and prognostic biomarkers and developing targeted 
therapies.  
 
1.2.4 Genome-wide association studies (GWAS) 
Genome-wide association studies are used to identify single nucleotide polymorphisms 
(SNPs) or single nucleotide variants (SNVs) that may cause diseases such as cancer. This 
method has been widely used since the development of the HapMap (Haplotype Map) 
project in 2002. The principle of the HapMap project was to sequence the genomes of 
hundreds of individuals from different populations to produce a map of human genomes 
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showing human genetic variations. The project started with populations of European, 
African, Chinese and Japanese descent. Later, the project was expanded to include 11 
global populations to identify genome-wide SNPs and copy number polymorphisms 
(CNPs) (Nature 2010).  
In a typical GWAS design, a group of individuals that have the disease are matched with 
normal individuals (control) to reduce confounding variants between the groups. When a 
variant is found to be significantly more frequent in the population with the disease, this 
variant is called a disease-causing (or disease-associated) variant.  
With the numerous GWAS published studies, many databases have archived GWAS data 
of SNPs and CNVs from different diseases and different populations that can easily be 
accessed by researchers. The Single Nucleotide Polymorphism database (dbSNP) of 
NCBI, the 1000 Genomes Project database, and the Human Gene Mutation Database 
(HGMD) are well known SNP databases among different populations. Other databases 
are also available for certain diseases such as Exome Variant Server (EVS) for SNPs 
contributing to heart, lung and blood diseases, and the Catalogue Of Somatic Mutations 
In Cancer (COSMIC) database for variants associated with cancers.  
 
1.2.4.1 Next generation sequencing (NGS) technology 
The exponential development of cancer research requires advanced research tools that are 
cost effective and able to study dozens of tumours in depth and within a shorter period of 
time. In recent years, many high-throughput technologies have been developed to 
facilitate cancer research. For instance, next generation sequencing, through whole 
genome sequencing (WGS) and whole exome sequencing (WES), are promising 
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diagnostic techniques used in clinics for the identification of DNA alterations, genetic 
recombination and mutations, and are prognostic tools that guide clinicians to look for 
specific characteristics in patients. RNA sequencing (RNA-Seq) has recently 
revolutionized the study of gene expression by measuring the relative expression changes 
and identifying other transcripts and their isoforms, in addition to the identification of 
fusion genes (Wang, Gerstein, and Snyder 2009). Bisulfite sequencing and methylation 
microarrays are all examples of the high-throughput genomic technologies that  provide 
further insights into cancer biology.  
NGS technology finds genetic variations in human populations, in addition to identifying 
rare variants involved in diseases and copy number variants (CNVs). In cancer WGS, 
tumour samples are comprehensively sequenced to identify somatic variants in coding 
and non-coding regions. On the other hand, cancer WES finds cancer variants within the 
protein coding regions (exons). These technologies perform massive parallel sequencing 
of DNA fragments from one tumour sample in less than one day (Grada and Weinbrecht 
2013).  
Many platforms are available that provide low cost, high-throughput sequencing services. 
The most popular platforms are the Life Technologies Ion Torrent Personal Genome 
Machine (PGM) and the Illumina MiSeq (Figure 1.4). Both platforms use the same 
methodology for DNA template preparation; the DNA library is prepared by fragmenting 
the DNA and then adapters (synthetic primers of known sequences) are added to the end 
of each fragmented DNA. Then, DNA libraries are prepared for amplification and clone 
sequencing. In Ion Torrent PGM, emulsion PCR is used to amplify each library fragment 
onto microbeads. While Illumina MiSeq uses bridge amplification onto flow cells (Figure 
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1.4) (Berglund, Kiialainen and Syvänen 2011; Quail et al. 2012). Each amplified library 
fragment is sequenced through cycles to synthesize new DNA fragments by incorporating 
nucleotides in the growing DNA strand. Each PGM and MiSeq platform uses a different 
mechanism for detecting the synthesized sequences; the PGM platform detects pH 
changes caused by the production of hydrogen ion during the process of nucleotide 
incorporation into the growing DNA strand (Quail et al. 2012), whereas the Illumina 
MiSeq platform detects fluorescence light generated by fluorescence labeled nucleotide 
incorporation (Grada and Weinbrecht  2013; Quail et al. 2012) (Figure 1.4). Following 
the completion of sequencing, the generated raw data are processed through analysis 
pipelines to remove adapter sequencing and low quality reads, align sequencing data to a 









Figure 1.4 Comparison between Ion Torrent PGM and Illumina MiSeq next 
generation sequencing methodologies 









Researchers have to understand the purpose and the strategy of the experiment prior to 
selecting the WGS or WES method for sequencing. WES has been extensively used in 
cancer research to investigate somatic mutations in gene-coding regions. WES is faster 
and cheaper than WGS since the exome comprises 1% of the entire genome (Bick and 
Dimmock 2011). However, both technologies have a few limitations, some of which can 
be resolved or controlled. For instance, the generated data is massive which requires the 
time consuming analysis and application of additional bioinformatics tools to reduce the 
list of candidate variants such as tools of genomic prioritization, for example CANDID 
(dsgweb.wustl.edu/hutz/) and Endeavour (tomcat.esat.kuleuven.be/endeavour/), effect of 
the mutation on protein function using tools such as Polyphen and SIFT, and algorithmic 
applications for the identification of variants such as VarScan. In addition, different 
pipelines and multiple statistical analyses may be applied to reduce the probability for 
false calls and technical errors. In cancer studies, sequencing tumour samples and 
matching normal samples is required to overcome the heterogeneity of cancer cells. 
Furthermore, the identified candidate variants require validation in the lab. 
However, NGS is a powerful tool that is more efficient and easier to use for the 
identification of mutations compared to other methodologies. NGS has shown successful 
results such as the identification of NOTCH1 and MyD88 mutations in CLL patients, 
which leads to new subgroups for therapeutic targets being determined (Puente et al. 
2011), the discovery of IDH1 mutation in glioblastoma (Parsons et al. 2008a), and germ-
line mutation in PALB2 in hereditary pancreatic cancer (Jones et al. 2009). Therefore, 
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NGS has now emerged in clinical practice and is used as a diagnostic method for certain 
diseases. 
 
1.3 Cancer epigenetics 
Epigenetic alterations in cancer genome either affect DNA methylation or histone 
modification. This thesis studies DNA methylation changes in certain types of brain 
tumours. However, this introduction will provide a brief description of major epigenetic 
terminologies and mechanisms in cancer.  
 
1.3.1 Histone modification in cancer 
Histone modifications affect overall chromatin structure and control the binding of other 
molecules to the DNA, either positively or negatively. Chromatin structure is important 
in regulating gene expression by modifying the configuration of the chromatin. Histone 
modification, including methylation, acetylation, ubiquitination, phosphorylation, 
biotinylation and sumoylation can affect and change gene transcription (Figure 1.5) 
(Dalgliesh et al. 2010). Histone acetylation of lysine residue changes the configuration of 
histone by neutralizing the positive charge of lysine which may consequently reduce the 
attraction bond between the histone and the negatively charged DNA, leading to a more 
accessible chromatin for transcription. Acetylation and deacetylation are regulated by the 
activity of the enzymes histone lysine acetyltransferases (HAT family) and histone 
deacetylases (HDACs). Here HDAC removes the acetyl group from lysine residue and 
restores the positive charge and HAT adds the acetyl group. Both HAT and HDAC 
enzymes are required to function in equilibrium to regulate gene expression and 
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transcription. Dysregulation of the proteins was reported to cause gene silencing and 
cancer cell transformation. HAT was firstly identified as a histone modification enzyme 
in cancer and has the capability to transform the viral oncoprotein E1A (Bannister and 
Kouzarides 1996). Expression aberrations of HATs proteins were also reported in many 
types of cancer (Avvakumov and Côté 2007). 
The HDAC family contains 18 enzymes, which are divided into 4 classes depending on 
their sequence homology. Class I (HDAC1-3, and HDAC8), class II (HDAC4-7 and 
HDAC9-10) and class IV (HDAC11) require Zn+2 metal as a cofactor, while class III 
(sirtuin 1-7) is NAD+ dependant. In contrast to HATs proteins, HDACs proteins regulate 
histone and non-histone targets, such as in leukaemia where HDACs interact with BCL6 
to repress the protein activity by acetylation (Bereshchenko, Gu, and Dalla-Favera 2002).  
Phosphorylation usually occurs in serine, threonine and tyrosine residues of the histone. 
Phosphorylation causes an alteration of the protein’s charge, which affects the ionic 
properties and the overall configuration of the chromatin. Histone phosphorylation can 
affect either transcript regulation or chromatin condensation, however, H3S10 is 
associated with both functions (Baek 2011). 
Histone methylation in lysine residue has also been described widely in cancer.  Histone 
methylation affects gene expression by changing the structure of the chromatin rather 
than changing the charge of the residue. For instance, the methylation of H3K36 and 
H3K70 allows chromatin to open up which increases gene expression. On the other hand, 
methylation of H3K9 and H4K20 is associated with closed and repressive chromatin 
(Dawson and Kouzarides 2012). Several histone methyltransferases have been involved 
in cancer. The most important enzymes are EZH2 (H3K27 histone methyltransferase) and 
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its overexpression was associated with poor prognosis in breast and prostate cancer (Cao 
and Zhang 2004), and SMYD3 (H3K4 methyltransferase) in colon and liver cancer 
































Figure 1.5 Types of histone modifications, methylation, acetylation, ubiquitination, 
phosphorylation, and biotinylation that affect gene transcription. 
All these histone modifications can affect the chromatine structure and molecules binding 







1.3.2 DNA methylation in cancer 
Methylation of the cytosine residue at 5’ carbon (5mC) usually occurs within cytosine-
guanine (CpG) dinucleotides. Most studies that have observed epigenetic alterations in 
cancer have reported methylation changes within the CpG islands. CpG islands are 
regions with concentrated CpG sites and are distributed in >70% of gene promoters 
(Malzkorn et al. 2011). The methylation of CpG islands is associated with transcriptional 
alterations, which is commonly observed during tumour transformation (Baylin and Jones 
2011). Studies using advanced genome-wide technologies such as NGS have found that 
5-10% of unmethylated CpG islands become hypermethylated in various types of cancer 
genomes. In addition, DNA hypermethylation does not only affect the gene expression of 
coding genes but also affects the expression of non-coding RNAs, some of which have 
target genes that are also involved in tumorigenesis (Baylin and Jones 2011). More 
importantly, genome-wide methylation studies have identified DNA methylation 
alterations within CpG shores, which are located 2kb upstream from CpG islands, and 
CpG shelves, which are located upstream from CpG shores, that were strongly associated 
with aberrant gene expression (Irizarry et al. 2009).  
DNA methylation is regulated by 3 DNA methyltranferases (DNMTs) that modify 
cytosine methylation in CpG dinucleotides. DNMT1 is responsible for hemimethylated 
DNA maintenance and methylates newly synthesized CpG dinucleotides following DNA 
replication. On the other hand, DNMT3a and DNMT3b are also capable of maintaining 
hemimenthylated DNA but their primary role is de novo methyltransfereases targeting 
unmethylated CpG dinucleotides. The role of DNA methylation depends on the location 
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of the CpGs in the genome. For instance, DNA hypermethylation in the promoter regions 
represses transcription and causes gene silencing. While methylation of the repetitive 
regions increases genome instability (Malzkorn et al. 2011).  
Researchers have been focusing on TSGs in cancers. TSGs are frequently silenced in 
cancer by DNA hypermethylation. Global hypomethylation has also been observed in 
cancer and associated with repetitive DNA elements (Melanie Ehrlich 2009). The first 
reported epigenetic alteration in cancer was DNA hypomethylation in 1983 when Gama-
sosa and his group identified global DNA hypomethylation in benign/malignant tumours 
in comparison to normal tissues (Gama-Sosa et al. 1983). Promoter hypomethylation of 
proto-oncogenes may activate gene transcription such as promoter demethylation of the 
proto-oncogene, HOX11, in leukaemia (Watt, Kumar, and Kees 2000). Hypomethylation 
of highly repetitive DNA sequences are the main reason for global DNA 
hypomethylation in cancer which causes genomic instability (Figure 1.6). Cancer global 
hypomethylation was observed in satellite DNAs such as tandem centromeric and 
pericentromeric satellite repeats, and the interspersed Alu and LINE-1 elements in 
different types of cancer including ovarian cancer, prostate metastasis, leukaemia, liver 
and colon cancers (Bedford and van Helden 1987; Feinberg et al. 1988; Lin et al. 2001; 
M. Ehrlich et al. 2006; Hoffmann and Schulz 2005; Rodriguez et al. 2008).  
Cancer-associated DNA hypermethylation is usually found in CpG islands. A large 
methylation study of 98 primary cancers, including breast, colorectal, brain and 
leukaemia, using restriction landmark genomic scanning of CpG islands in the genome, 
showed that an average of 600 out of 45,000 CpG islands were highly methylated in 
tumour samples but not in normal control samples (Costello et al. 2000). 
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Hypermethylation of the promoter region CpG island(s) of TSGs reduces the expression 
of proteins that are involved in various regulatory processes such as cell apoptosis, DNA 
repair and anti-angiogenesis (Malzkorn et al. 2011) (Figure 1.6). However, recent studies 
indicate that regions outside CpG islands, such as the CpG shore (2kb from CpG island) 
and shelf (2kb from CpG shore), play an important regulatory role in cell proliferation 
and differentiation during tumorigenesis. The significance of the role of isolated CpGs 
within open sea regions remains unclear. 
DNA hypermethylation has been identified in several pathways; the frequently mutated 
gene in cancer, p53, has also been reported as inactivated by methylation-mediated 
repression of the TSG, p14ARF. p14ARF normally inhibits the MDM2 protein that 
promotes p53 degradation (Manel Esteller, Tortola, et al. 2000). The cell cycle inhibitor 
p16INK4a is commonly hypermethylated in various types of cancer (Gonzalez-Zulueta et 
al. 1995). Also, there is hypermethylation of DNA repair pathway genes such as the 
mismatch repair gene hMLH1 in gastric and colon cancer (Fleisher et al. 1999; Herman et 
al. 1998, 1), MGMT promoter in colorectal and brain cancer (M. Esteller et al. 1999; 
Mitsutoshi Nakamura et al. 2001), the mitotic checkpoint CHFR (Mizuno et al. 2002), 
and the DNA repair gene BRCA1 in breast and ovarian cancer (Manel Esteller, Silva, et 
al. 2000).  
Not all hypermethylation changes are an indication of disease, as methylation changes in 
some genes can be a prognostic factor or predictive of a treatment response factor. 
Hypermethylation of p16INK4a has been associated with poor prognosis for lung and 
colorectal cancer patients, while CpG island hypermethylation of hMLH1 is associated 
with good response to anti-cancer drugs. In addition, silencing of MGMT repair gene by 
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hypermethylation has been considered as an indication, in glioma and lymphoma cancer 
patients, of a patient’s sensitivity to chemotherapy (Manel Esteller et al. 2001; Plumb et 





























Figure 1.6 DNA methylation and cancer 
 
The above diagram represents a small region of genomic DNA in a normal cell and the 
contribution of DNA hyper/hypo methylation in cancer formation. DNA 
Hypomethylation at the pericentromeric regions causes genomic instability, while DNA 
hypermethylation of TSGs promoter region leads to loss of gene expression. This figure 








The 5mC can be further modified by adding hydroxyl group to generate 5-
hydroxymethylcytosine (5hmC), an oxidation process mediated by the TET (ten-eleven-
translocation) family (Pfeifer, Kadam and Jin 2013). 5hmC was found in 40% of brain 
tissues, indicating an important biological role (Kriaucionis and Heintz 2009). Yet, the 
main function of 5hmC is still poorly understood and still under research.  
Researchers have raised the question of how to differentiate 5hmC from 5mC. Laboratory 
methods based on the bisulfite treatment of DNA cannot distinguish between 5hmC from 
5mC since both cytosines are not converted by sodium bisulfite and are recognised as 
methylated cytosine. Methylation techniques based on restriction enzymes are usually 
inhibited by 5hmC and immunoprecipitation that uses antibodies against 5mC does not 
detect 5hmC (Jin, Kadam, and Pfeifer 2010). Specific antibodies against 5hmC have been 
commercially designed for 5hmC detection, in addition to other enzyme-based methods 
that modify the hydroxyl group of 5hmC by using T4 b-glycosyltransferase, which adds 
the glucose molecule to prevent DNA cleavage at the MspI restriction site (Malzkorn et 
al. 2011). 
 
1.3.2.2 CpG Island Methylator Phenotype in cancer 
CpG island hypermethylation is a main feature of cancer, especially when 
hypermethylation occurs within the promoter region of the tumour suppressor gene 
causing gene silencing. Many studies have reported aberrant DNA methylation that 
occurs in different types of cancer. However, a study in 1999 identified subgroups of 
colorectal cancer that demonstrated concordant tumour specific hypermethylation and 
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referred to such tumours as exhibiting a CpG island methylator phenotype (CIMP) (M. 
Toyota et al. 1999). Tumours exhibiting CIMP were characterised by a high methylation 
index and KRAS mutations in comparison to non-CIMP tumours (M. Toyota et al. 2000). 
Subsequently, additional studies have expanded these findings and were able to identify 
additional subgroups of colorectal cancers; non-CIMP tumours with TP53 mutations, 
CIMP tumours with mutations of BRAF gene, and CIMP tumours with KRAS mutations 
(Ogino et al. 2006; Shen et al. 2007). Additionally, in Noushmehr’s study, CIMP was 
identified in a subgroup of glioma tumours (G-CIMP) using 7 signature genes 
(ANKRD43, HFE, MAL, LGALS3, FAS, RHO and DOCK5) and the phenotype was 
tightly associated with IDH mutations (Noushmehr et al. 2010).  
CIMP has been observed in other cancer types such as breast cancer (Fang et al. 2011), 
lung cancer (Marsit et al. 2006), ovarian cancer (Strathdee et al. 2001) and leukaemia 
(Roman-Gomez et al. 2006). These findings indicate that CIMP is perhaps not restricted 
to certain types of cancer but involves different cancer-specific genes for each type.  
 
1.3.3 Genome methylation analysis 
Most of the methods used to detect DNA methylation changes are based on sodium 
bisulfite treatment of DNA, which converts the unmethylated cytosine base to an uracil 
base, while methylated cytosine remains protected. After DNA conversion, the modified 
DNA becomes a starting material in all subsequent techniques (Figure 1.7). Methylation 
specific PCR (MSP) is widely used for detecting methylation changes in DNA. MSP is a 
fast and very sensitive method, which has been selected as the standard method for 
MGMT DNA hypermethylation detection in diagnostic labs. Combined bisulfite 
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restriction analysis (CoBRA) is a semi-quantitative method that depends on a restriction 
enzyme site to differentiate between methylated and unmethylated DNA. MethyLight is a 
quantitative method based on fluorescent real-time PCR to quantify DNA methylation 
after bisulfite treatment. The golden standard technique for mapping the sequence of 
methylated DNA is bisulfite modified DNA sequencing, either by Sanger sequencing, 
which depends on the chain termination method, pyrosequencing, which is sequencing 
that uses the synthesis method, or NGS of whole genome bisulfite sequencing (WGBS).  
Technologies based on epigenome-wide analysis have been widely used for 
comprehensive DNA methylation analysis. For instance, HumanMethylation BeadChip 
arrays from Illumina have provided high-throughput and cost effective comprehensive 
methylome analysis and have been used in several methylation studies on diseases and 
disorders. Illumina has developed three high-throughput profiling assays; the first and the 
simplest array is the GoldenGate BeadChip array which covers over 1500 CpG sites per 
sample. While the HumanMethylation27 BeadChip array can analyse more than 27,000 
CpG sites per sample. The new generation HumanMethylation450 BeadChip array 
provides genome wide coverage and can assess the methylation status of more than 
480,000 CpG sites per sample (Figure 1.8). The principle behind the BeadChip 
technology is the same for all three assays and is based on genotyping bisulfite converted 
DNA. The BeadChip technology has been adapted to evaluate DNA methylation through 
SNPs assessment of C and T bases after DNA conversion. In the GoldenGate BeadChip 
array and HumanMethylation27 BeadChip array, each CpG locus is assessed by Infinium 
I assay that measures the intensity of methylation by one methylated and one 
unmethylated probe separately (Figure 1.9). On the other hand, HumanMethylation450 
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BeadChip array uses both Infinium I and Infinium II assays. Infinium II design uses one 
probe for each single CpG and determines the methylation status after hybridization and 


























Figure 1.7 Common methods used for DNA methylation analysis 
DNA modification by sodium bisulfite treatment is usually the first step in methylation 
analysis. Subsequent DNA methylation analysis methods such as MSP and CoBRA PCR, 
real-time Methylight, pyrosequencing, Sanger sequencing and genome-wide methylation 
arrays are based on distinguishing the converted C to T or unaltered C base, after DNA 





















Figure 1.8 Three high-throughput profiling assays from Illumima 












Figure 1.9 Schematic of Illumina Infinium I methylation assay 
GoldenGate BeadChip array and HumanMethylation27 BeadChip array use Infinium I 
assay to measure the methylation status. Infinium I assay uses two separate probes per 
CpG locus; one for methylated locus and one for unmethylated locus. This figure was 











Figure 1.10 HumanMethylation450 BeadChip array uses both Infinium I and 
Infinium II assays 
Infinium I assay uses two probes, methylated and unmethylated, for each CpG locus. 
Infinium II assay uses one probe per CpG locus where the methylation status is 






The most recent HumanMethylation450 BeadChip array is more comprehensive and is 
able to assess the methylation status of >450,000 CpG sites distributed around the 
genome that are within the CpG island, CpG shores, CpG shelves and also single isolated 
cytosine bases. In addition, the array covers regions within the transcription start sites, the 
gene’s 1st exon, gene body, 5’ and 3’ un-translated regions, and the coding gene’s and 
miRNA’s promoter regions.  
The GoldenGate BeadChip array and HumanMethylation27 BeadChip array have been 
used widely in cancer studies and were successfully able to identify the methylation 
changes involved in tumorigenesis, such as the successful identification of CIMP 
phenotypes in renal cell carcinoma and glioma (McRonald et al. 2009; Noushmehr et al. 
2010) and the identification of methylated genes in cancer pathways (E. M. Wolff et al. 
2010). The HumanMethylation450 BeadChip array has recently been introduced into the 
research field and most initial studies started to evaluate and validate the new assay. 
However, the number of published papers and research studies using 






1.4 Cancer genome online databases  
With the massive amount of data generated by the Human Genome Project since 2003, 
researchers are able to study the genetic factors and molecular mechanisms that are 
involved in human diseases including cancer.  
After sequencing the human genome by the National Cancer Institute (NCI) and the 
National Human Genome Research Institute (NHGRI), many international projects such 
as The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium 
(ICGC) were launched to catalogue and archive DNA changes involved in human cancer. 
These genome-based studies will facilitate biomedical researchers to identify prognostic 
and diagnostic markers, improve diagnostic tests and develop customised cancer 
therapies. In addition, they will provide a deeper understanding of the molecular 
mechanisms involved in carcinogenesis. 
 
1.4.1 The Cancer Genomic Atlas (TCGA) 
The Cancer Genome Atlas (TCGA) was initially launched in 2006 to catalogue most  
genomic abnormalities involved in human cancer (“The Cancer Genome Atlas” 2015). 
The TCGA project is managed by the National Cancer Institute (NCI) and the National 
Human Genome Research Institute (NHGRI) of the US National Institutes of Health 
(NIH). Glioblastoma multiforme (GBM) was the pilot project for TCGA which was 
published in Nature 2008 (McLendon et al. 2008). Based on gene expression profiling, 
copy number variations and sequencing analysis of 206 normal/tumour matched pair 
GBM cases, the study found that most of the cases carried frequent mutations in ERBB2, 
NF1 and TP53 in addition to other alterations in core brain cancer pathways (McLendon 
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et al. 2008). Since 2009, the TCGA project has been expanded to phase II and now to 
phase III with >11,000 samples and >20 tumour types. Most of the TCGA data are 
available and free to access, except for data that includes unprotected patient information. 
TCGA provides data from several platforms using high-throughput methods that analyse 
DNA mutations, chromosomal alterations and copy number variations; RNA alterations 
such as gene expression analysis and epigenetic aberrations including DNA methylation.  
All data in TCGA are generated and analysed by different centres and resources. The 
Biospecimen Core Resource (BCR) is responsible for the quality control assurance of 
tissues and samples as well as the quality control of DNA and RNA isolation from the 
samples (“The Cancer Genome Atlas” 2015). Each sample in TCGA must be examined 
and verified prior to being submitted to the TCGA data portal. General guidelines such as 
a minimum 200 mg of tissue weight, at least 80% tumour nuclei, and a matched normal 
(germ-line) pair sample (matched normal tissue, blood, or both) must be considered for 
sample approval (“The Cancer Genome Atlas” 2015). However, other quality control 
standards that vary between tissue types and cancer types are also considered, for 
instance, brain tumour samples must contain at least 80% tumour nuclei and less than 
50% necrosis in addition to a secondary pathology assessment to validate the original 
diagnosis of the samples (McLendon et al. 2008). TCGA is funding three genome 
sequencing centres: The Genome Center at Washington University, the Baylor College of 
Medicine and the Broad Institute, to perform all the next generation sequencing NGS 
technologies. Also, TCGA is co-funding the Data Coordinating Centre (DCC) which is 
responsible for deposing data into the TCGA database and maintaining its website. This 
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work is a collaboration between DCC and SRA International for bioinformatics (“The 
Cancer Genome Atlas” 2015).  
Many published research studies have analysed tumour samples from TCGA and were 
successful in identifying genetic or epigenetic abnormalities and potential causative or 
marker genes in different types of cancer. For instance, the hallmark TCGA report on the 
comprehensive characterisation of 276 colorectal tumour samples from TCGA using 
exome sequencing, gene expression and DNA methylation analysis (Network 2012). 
Also, the DNA methylation analysis of glioma samples by Noushmehr et al. which 
identified a distinct subset of glioma with high and concordant DNA hypermethylation 
across many CpG loci, indicating the existence of Glioma CpG Island Methylator 
Phynotype (G-CIMP) (Noushmehr et al. 2010). 
By making TCGA data accessible to the public and all analytical tools available to 
researchers, TCGA will provide the opportunity to expand knowledge and improve 
cancer research, diagnosis, treatment and also cancer prevention.  
 
1.4.2 Catalogue Of Somatic Mutations In Cancer (COSMIC) 
The Catalogue of Somatic Mutations in Cancer (COSMIC) is a freely available online 
database for somatic mutations in human cancer which combines data from scientific 
literature, the Cancer Genome project (CGP) at the Wellcome Trust Sanger Institute, The 
Cancer Genomic Atlas (TCGA) and the International Cancer Genome Consortium 
(ICGC) projects (S.A. Forbes et al. 2008; Simon A. Forbes et al. 2015). COSMIC was 
first launched in 2004 when somatic mutation data from 4 cancer genes, HRAS, KRAS2, 
NRAS, and BRAF was published (Bamford et al. 2004). Now the COSMIC database has 
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been expanded to include data from 28,735 genes/transcripts, >1 million tumour samples 
and >2 million mutations including coding mutations, non-coding mutations, gene 
rearrangements, abnormalities in copy number and more (Simon A. Forbes et al. 2015) 
(Table 1.1). Approximately half of the data in COSMIC are collected from published 
literature and the other half are from different cancer genomic projects. Data are analysed 
by a software pipeline and run through a specific quality control to be published later on 
the website with the reference. Evaluating each gene/mutation/tumour data prior to it 
being published is important to exclude false imperfect results.   
The COSMIC website (cancer.sanger.ac.uk/) is user friendly and free to access which 
makes it possible to browse the data either in a gene-centric or tissue-centric fashion. 
Typically, the search starts by selecting the gene name or cancer type, then different main 
webpages show different information that can be navigated separately and in depth such 
as gene overview, sample overview, mutation overview and tissue overview (Figure 
1.11). To navigate the data, diagrams of pie charts and histograms provide a breakdown 
of mutation types (non-sense, missense, frameshift, etc.),  mutation counts and sample 
type (primary samples, cell-line or unknown).  
With the increase in the development of cancer genome data, COSMIC allows the 
integration of all cancer genomic data directly into the Ensembl Genome Browser 
(www.ensembl.org). Data of gene mutations have been uploaded from COSMIC into the 
Ensembl database and incorporated in the Ensembl website as ‘Somatic_SNV’ 
annotations to differentiate these somatic variants from other common SNPs (Simon A. 
Forbes et al. 2015). The COSMIC mutations can be found in the Ensembl gene 
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transcripts and are provided with links to the COSMIC website for more detailed 
information about the variant. In addition, many other projects and databases are 
supporting and integrating COSMIC data, such as Intogen 
(http://www.intogen.org/home), UniPort (http://www.ebi.ac.uk/uniprot) and Pfam 
(http://pfam.sanger.ac.uk) projects. However, Ensembl was the first external project 
which added COSMIC data to their website and established “COSM” ID (Cosmic 
















Total contents in v70 of the COSMIC database (the August 2014 release) 
Genes (transcripts) 28,735 
Tumour samples 1,029,547 
Coding mutations 2,002,811 
Curated publications 19,703 
Fusion mutations 10,435 
Genomic rearrangements 61,299 
Whole genomes 12,542 
Copy number aberrations 695,504 
Gene expression variants 60,119,787 
 
Table 1.1 Total contents in v70 of the COSMIC database (the August 2014 release) 









Figure 1.11 Main webpages to navigate COSMIC database 





1.5 CNS tumours 
In 2012, it was estimated that 256,000 brain and other CNS tumour cases were diagnosed 
worldwide (Ferlay et al. 2015). CNS tumours are named after the cell of origin and they 
are classified into: (i) benign tumours; the most common types are meningioma, 
schwannoma and neuroma, (ii) malignant tumours; these include glioblastoma 
multiforme (GBM), astrocytoma, oligodendroglioma and ependymoma, (iii) metastatic 
brain tumours; where cancer starts in a different primary organ and later spreads to the 
brain. The most common primary sites for brain metastasis are breast, lung, melanoma, 
colon and kidney (Gavrilovic and Posner 2005). 
 
1.5.1 Classification of CNS tumours 
In 1979, the WHO announced a new classification and grading of tumours of the CNS to 
standardise the nomenclature of CNS tumours and communication around the world 
(Louis et al. 2007a). This classification was revised several times by different 
international groups and edited in 1993, then in 2000, and the final fourth edition was 
published in 2007 (Molnar 2011). The classification was based on the premise of tumour 
initiating cells (Figure 1.12), while the grading was according to their malignant potential 
(Figure 1.13). The CNS tumours grades ranged from grade I (benign) tumours to grade 











Figure 1.12 Central nervous system tumour initiating cells 
Common progenitors are expected to produce neuronal and glial progenitors that 
differentiate into mature cells. The origin cells of medullablastoma and some of diffuse 
glioma are still unknown. The candidate cells of origin are indicated by dotted lines. This 



















Grade I Low proliferative potential and possibility of 
surgical cure 
Well-differentiated 
Grade II Diffuse growth, tendency to recur, though 
only few mitoses 
Moderately-differentiated 
Grade III Histological evidence of malignancy, 
destructive growth, brisk mitotic activity, 
anisonucleosis 
Poorly-differentiated 




Table 1.2 WHO four-tier grading scheme for CNS tumours 






















The WHO’s grading is based on a combination of criteria used to predict patients’ 
therapy response and patients’ outcome in addition to other criteria including genetic 
alterations and clinical information about the patient such as age, site of tumour, etc. The 
WHO’s grading system is used as a parameter for patient prognosis, for instance, patients 
with WHO grade II tumours usually show a longer survival rate (>5 years), while the 
median survival rate for patients with WHO grade III tumours is 2-3 years. Tumours with 
WHO grade IV are typically fatal if untreated and patients can survive for up to 12 




Figure 1.13 WHO classification and grading of CNS tumours 




1.5.2 Vestibular Schwannoma  
Vestibular Schwannoma is a benign tumour which is characterised by uncontrolled 
proliferation of schwann cells in an encapsulation way around the nerves.  Schwannoma 
can develop anywhere from vestibular nerves to the nerves of sensory organs and can 
cause hearing loss, imbalance, tinnitus and death in the late stages (Kondziolka et al. 
2012).  
Vestibular schwannoma can be classified into 2 groups; sporadic unilateral or bilateral, 
which is associated with neurofibromatosis type 2 (NF2) and caused by mutations of NF2 
gene. However, patients with NF2 can develop other types of tumours such as 
meningioma and ependymomas (Torres-Martin et al. 2013). 
 
1.5.2.1 Molecular biology of schwannoma 
The genetic and epigenetic changes involved in schwannoma development have been 
studied in the past few years including NF2 gene mutation, chromosome 22 LOH and 
DNA methylation. 
 
1.5.2.2 NF2 gene 
NF2 gene has been shown to have tumour suppressing properties, and encodes for the 
cytoskeletal protein merlin (moesin-ezrin-radixin-like protein). This gene is located in 
chromosome 22 (17 exons) and is mutated in neurofibromatosis type 2 (NF2) and 
sporadic schwannoma patients (Torres-Martin et al. 2013). Merlin has the ability to 
control cell growth and proliferation by inhibiting ubiquitin cascade (Celis-Aguilar et al. 
2012).  Merlin protein is involved in several signalling pathways such as the Hippo 
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pathway and PI3K, deregulation of ErbB2/ErbB3 and EGFR (Torres-Martin et al. 2013). 
Mutations of the NF2 gene have been identified in NF2 as well as in sporadic vestibular 
schwannoma patients. According to Knudsen’s two-hit hypothesis, sporadic vestibular 
schwannoma is caused by somatic biallelic NF2 inactivation and later, NF2 acquires 
additional somatic mutations due to impaired DNA repair mechanisms (D. G. R. Evans, 
Maher, and Baser 2005; D. Gareth R. Evans 2009). However, a few sporadic vestibular 
schwannoma cases showed no alterations in the NF2 gene. Genetic alterations of other 
genes located on chromosome 22 have been identified in schwannoma cases such as 
SMARCB1 in 50% of familial schwannoma and 10% of sporadic schwannoma (Rousseau 
et al. 2011; Smith et al. 2012), and LZTR1 in schwnomatosis (Piotrowski et al. 2014). 
These findings indicated that chromosome 22 genes are essential and play an important 
role in schwannoma development.  
 
1.5.2.3 DNA methylation 
DNA methylation of vestibular schwannomas has not been fully studied. Some studies 
have analysed DNA hypermethylation in tumour associated genes that are frequently 
hypermethylated in other brain cancers such as VHL, MGMT, TP16, CASP8, TIMP3, 
DAPK and THBS1. Less than 10% of schwannoma cases displayed DNA 
hypermethylation (Lassaletta et al. 2006; Gonzalez-Gomez et al. 2003). In addition, NF2 
promoter hypermethylation is rare in vestibular schwannoma which suggests a different 
mechanism of NF2 inactivation (Kullar et al. 2010; J. D. Lee et al. 2012; Gonzalez-




1.5.2.4 Loss of heterozygosity  
Loss of heterzygocity on chromosome 22 was widely identified in schwannomas as the 
most common form of second hit with a frequency >50% (Celis-Aguilar et al. 2012). 
LOH on chromosome 22 is commonly found in the long arm of the chromosome and in 
conjunction with NF2 mutation and is correlated with the proliferation activity in 
schwannoma (Bian et al. 2005; Celis-Aguilar et al. 2012). Mainly, mitotic recombination 
is the cause of LOH which consists of deletion followed by the re-duplication of 
chromosome 22 that leads to the formation of 2 identical copies of the mutated gene and 
removal of the wild-type copy (R. K. Wolff et al. 1992; D. Gareth R. Evans 2009; 
Hadfield et al. 2010). 
 
1.5.3 Glioblastoma multiforme  
Glioblastoma is the most common and frequent type of primary brain tumour in adults. 
According to the World Health Organization’s (WHO) classification criteria, glioma can 
be histologically classified as astrocytoma, oligoastocytoma, oligoendroglioma and 
pilocytic astrocytoma (Louis et al. 2007b; Yan et al. 2009a; Riemenschneider et al. 
2010a). WHO grade I gliomas are benign and curable by surgery. On the other hand, 
grade II and III gliomas are malignant and more invasive forms. The majority of gliomas 
are glioblastoma multiform (GBM) (Astrocytoma grade IV) which is the most aggressive 
and lethal type of glioma (Wen and Kesari 2008; Chen, McKay and Parada 2012). 
Generally, GBM are classified into primary and secondary based on their clinical 
presentation. If the cancer has evolved from lower grade tumours, it is considered as 
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secondary GBM, while primary GBM is discovered at diagnosis (de novo) as advanced 
cancer (Parsons et al. 2008a). 
Currently, the standard treatment for GBM patients is surgical removal of the tumours in 
addition to radiotherapy and chemotherapy with alkylating agent temozolomide (Parsons 
et al. 2008). Yet, the median survival time of GBM patients is 12 months (Barbus et al. 
2011a). However, 3%-5% of glioma patients survive for more than 36 months (Krex et 
al. 2007; Liu et al. 2010) and these patients are called Long Term Survivors (LTS). These 
patients are mostly young (<50 years old) and have a good clinical performance. 
Generally, glioblastomas from LTS are characterised by promoter hypermethylation of 
the MGMT gene and mutations of the IDH gene (Barbus et al. 2011b). 
 
1.5.4 Genetic alterations in glioma 
Like other cancers, gliomas are developed due to genetic alterations. Recent publications 
have identified several genes that are involved in glioma development and progression. 
The presence or absence of these chromosomal and genetic changes depends on the 
progression of the tumour toward higher grades (Yan et al. 2009b). For instance, IDH1 
and IDH2 mutations are more common in secondary glioblastoma, WHO grade II and III 
diffuse astrocytoma, WHO grade II oligodendroglioma and WHO grade II oligoastrocytic 
glioma (Losman and Kaelin 2013; Riemenschneider et al. 2010b). Mutation of TP53 is 
mostly found in WHO grade II diffuse astrocytoma, while WHO grade II 
oligodendroglioma is usually characterised by 1p/19q deletion. Additional genetic 
changes can been found in these lower grade gliomas during the progression towards 
higher grades, such as mutations in RB1, methylation of CDKN2A/B and deletion of the 
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short arm of chromosome 9 during the progression from WHO grade II gliomas as well 
as loss of 10q and loss of expression of DCC through the progression from WHO grade 
III anaplastic astrocytoma to secondary glioblastoma (WHO grade IV). Primary 
glioblastomas (WHO grade IV), which are the most aggressive type, carry several 
genetic, epigenetic and loss/gain chromosomal alterations. These alterations include 
mutations in the genes involved in the receptor tyrosine kinase pathway (EGFR, ERBB2, 
PTEN, PIK3R1 and PI3KCA), the p53 pathway (TP53, MDM2 and MDM4) and the Rb1 
(CDKN2A/B, CDK4/6, and RB1) as well as 19q and 20q gain, monosomy 10p and 
trisomy 7p. The most frequent alterations in WHO grade I pilocytic astrocytoma are 
mutations and fusion/duplication of BRAF in addition to gain on chromosomes 7q and 





























































































1.5.4.1 IDH mutations 
IDHs are key enzymes in the Krebs cycle, which catalyse the oxidative carboxylation of 
isocitrate to α-ketoglutarate (α-KG) and reduce NAD+ (or NADP+) to NADH (or 
NADPH). α-KG is important for the demethylation of 5-methylcytosine (5mC) and 
histone that are essential for epigenetic regulations in the cells. There are 3 IDH genes 
that are expressed in various tissues including the brain. These are IDH1 which is found 
in cells’ cytoplasm, IDH2 sequence is 70% identical to IDH1 (Xu et al. 2004) and is 
localized in cells’ mitochondria and IDH3 is also found in the mitochondria and is 
structurally unrelated to IDH1 and IDH2 (Nichols et al. 1995).  
The discovery of IDH gene mutations in brain tumours is an example of NGS success in 
the identification of disease-associated SNVs. To date, the identified mutations in 
gliomas are found in IDH1 or IDH2 genes. No IDH3 mutations have been discovered in 
gliomas (Krell et al. 2011).  
When IDH is mutated, the conversion of isocitrate to α-KG drives the synthesis of 2-
hydroxyglutarate (2-HG), which acts as an inhibitor of the α-KG-dependant demethylase 
















Figure 1.15 The enzymatic activity of the wild-type IDH and mutated IDH genes 
When IDH is mutated, the conversion of isocitrate to α-KG drives the synthesis of 2-
hydroxyglutarate (2-HG), which acts as an inhibitor of the α-KG-dependant demethylase 








IDH1 and IDH2 mutations are somatic missense changes which affect the arginine 
residue at codon R132 in IDH1 and codon R172 in IDH2, within the substrate binding 
site of the enzyme. IDH1 mutations are widely found in glioma tumours and mostly 
change arginine to histidine (Mellai et al. 2013). The most commonly reported missense 
change in glioma tumours is p.R132H (92.4%) followed by the less common mutations; 
p.R132C (3.2%), p.R132G (2.1%), p.R132S (1.6%) and p.132L (0.6%) (Mellai et al. 
2013). One rare mutation (p.R132V) was originally identified as a somatic IDH1 
mutation (Balss et al. 2008) until it was reported as a SNP according to the dbSNP 
database of NCBI. On the other hand, mutations in IDH2 are less common (3-5%) in 
glioma tumours and are found in glioma cases without IDH1 mutation. The missense 
mutation p.R172K accounts for 60% of the cases, while p.R172M, p.R172W and 
p.R172S are less common (27%, 11% and 2% respectively). Single studies have reported 
other new IDH mutations such as the missense mutation (p.R100Q) of IDH1 gene in 
grade III oligodendrogliomas and grade II astrocytoma (Pusch et al. 2011), the missense 
mutations (p.R49C and pG.97D) of IDH1 in paediatric glioblastoma (Paugh et al. 2010) 
and a single nonsense mutation of IDH2 gene identified in a brain biopsy sample 





Figure 1.16 Electropherograms of the most common IDH1 and IDH2 mutations 
A) Electropherograms of representative mutations in the IDH1 gene. A – DH1 wild-type; 
B – c.G395A (p.R132H); C – c.C394G (p.R132G); D – c.G395T (p.R132L); E – 
c.C394T (p.R132C); F – c.C394A (p.R132S). B) Electropherograms of representative 
mutations in the IDH2 gene. A – IDH2 wild-type; B – c.G515T (p.R172M); C – c.G516T 









The majority of IDH1 or IDH2 mutations were identified in adult secondary glioblastoma 
(~80%), while mutations in primary glioblastoma are less frequent and account for 
approximately <10% (Losman and Kaelin 2013). Also, other types of adult brain tumours 
showed high frequency of IDH1/IDH2 mutations, such as grade II diffuse astrocytoma 
(75%), grade III Anaplastic astrocytoma (58%) and grade III anaplastic 
oligodendroglioma (62%) (Yan et al. 2009b). In paediatric glioblastoma cases, 
IDH1/IDH2 mutations were rare (<16%) but showed higher frequency in children >14 
years old (35%) (Pollack et al. 2011).  
Many studies have found an association between IDH mutations and glioma patient’s 
survival. Patients with IDH mutated glioblastoma and other WHO grade III gliomas have 
shown significant longer overall survival and better progression-free survival rates 
(Sanson et al. 2009; Weller et al. 2009). The correlation between IDH mutations and 
survival in WHO lower grade gliomas is not clear. Many studies have reported the 
prognostic role of IDH mutations in WHO grade II gliomas (Sanson et al. 2009; 
Hartmann et al. 2011; Mukasa et al. 2012), however, other studies using a larger set of 
WHO lower grade glioma samples have shown no prognostic correlation of IDH 
mutations (Ahmadi et al. 2012; Juratli et al. 2012; Kim et al. 2010). Also, patients with 
WHO low grade glioma that do not harbour IDH mutations have shown poor prognosis 
(Metellus et al. 2010). The findings of the favourable outcome in glioma patients with 
IDH mutations raised the consideration of using IDH mutation analysis as a diagnostic 




1.5.5 Epigenetic alterations in glioma 
1.5.5.1 DNA methylation  
Several studies have reported changes in DNA hypermethylation and hypomethylation in 
glioma. For instance, global hypomethylation has been identified in primary glioblastoma 
in Sat2 (satellite 2), D4Z4 and interspersed Alu elements. The hypomethylation event in 
these genes was associated with the copy number changes of the adjacent euchromatin, 
suggesting that hypomethylation is responsible for genomic instability (Cadieux et al. 
2006). Also, promoter demethylation of MAGEA1 has been found to increase the activity 
of the gene which is involved in transcriptional regulation of the histone deactelyase 
HDAC1 (Cadieux et al. 2006). Interestingly, a recent study has reported that 
overexpression of DNMT1 by histone modification and overexpression of DNMT3B by 
promoter hypomethylation in glioma resulted in the re-expression of a number of tumour 
suppressor genes by inhibiting these DNA methyltransferases (Rajendran et al. 2011).  
On the other hand, DNA hypermethylation events are common in glioma which usually 
affects tumour suppressor genes and genes involved in different cellular processes. For 
instance, promoter hypermethylation of cell cycle regulatory genes p14, p16 and RB1, the 
DNA repair gene MGMT, cell migration genes TIMP3 and EMB3 and the WNT 
signalling pathway inhibitor DKK1 are more frequent in secondary glioblastomas 
compared to primary glioblastomas (Götze et al. 2010; M. Nakamura, Watanabe, et al. 
2001; M. Nakamura, Yonekawa, et al. 2001; Mitsutoshi Nakamura et al. 2001; Kunitz et 
al. 2007; Mitsutoshi Nakamura et al. 2005). On the other hand, down regulation by 
promoter hypermethylation of SFRP1, SFRP2, the tumour suppressor gene NDRG2 and 
the negative regulator of WNT signalling pathway NKD2 are found in 40% of primary 
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glioblastomas (Götze et al. 2010; Tepel et al. 2008; Malzkorn et al. 2011). Other 
important regulatory genes such as the tumour suppressor genes PTEN, RASSF1, CTMP 
and ECRG4 (Baeza et al. 2003; Horiguchi et al. 2003; Knobbe et al. 2004; Götze et al. 
2009); cell apoptosis regulatory gene, PYCARD (Stone et al. 2004) and cell migration and 
invasion genes, CDH1 and SOCS3 (Lindemann et al. 2011; D’Urso et al. 2011) have also 
been reported to be hypermethylated in primary glioblastomas. Moreover, the phenomena 
of hypermethylation of several genes in certain types and grades of glioma are known as 
glioma CpG Island Methylator Phenotype (G-CIMP), which will be explained later in 
section 1.5.5.3. 
 
1.5.5.2 Hypermethylation of MGMT 
Hypermethylation of O6-methylguanine-DNA methyltransferase (MGMT) is seen in 50% 
of glioma patients and has become a significant marker for prognosis (Krex et al. 2007).  
The association between MGMT promoter hypermethylation and glioma patients’ 
response to chemotherapies, such as carmustine and temozolomide, radiotherapy or both 
has been reported in many studies (Mitsutoshi Nakamura et al. 2001; Hegi et al. 2005; 
Herrlinger et al. 2006). In Hegi et al.’s study on primary glioblastoma patients who were 
treated with radiotherapy combined with a temozolomide agent, the results showed that 
patients with MGMT promoter hypermethylation tumours have survived significantly 
longer than patients with unmethylated MGMT tumours. 
(Hegi et al. 2005).  
MGMT is a DNA repair enzyme which counteracts DNA damage caused by the 
temozolomide agent during chemotherapy by removing the alkyl group from the O6 of 
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guanine residue to induce apoptosis and, thereby, poor response to treatment 
(Riemenschneider et al. 2010b). MGMT promoter hypermethylation decreases expression 
of the protein, which leads to the inability to counteract the DNA damage and results in a 
better response to chemotherapy and better prognosis in glioma patients (Hegi et al. 2005; 
Malzkorn et al. 2011).  
Therefore, testing for MGMT promoter hypermethylation is increasingly performed in 
clinical trials for high grade glioma patients in addition to some routine diagnostic 
settings (Riemenschneider et al. 2010b). Nowadays, some trials are selective to perform 
studies with either MGMT hypermethylation or unmethylated tumours by analysing the 
methylation status of the MGMT promoter (Malzkorn et al. 2011). Furthermore, in 
anaplastic gliomas, MGMT promoter hypermethylation was associated with better 
prognosis, not only in temozolomide-treated patients but also in patients just receiving 
radiotherapy (Weller et al. 2010). MGMT methylation is less frequent in ependymal 
glioma, medullablastoma and anaplastic meningioma (Ebinger et al. 2004; Brokinkel et 
al. 2010; Buccoliero et al. 2008). 
 
1.5.5.3 G-CIMP 
Many genome-wide methylation studies have identified CpG island methylator 
phenotypes (CIMP) in cancers. Interestingly, CIMP was first identified in colorectal 
cancer in 1999 (M. Toyota et al. 1999) to define a distinct methylation profile subtype. 
CIMP is defined as an overall increase and concordant DNA hypermethylation in many 
CpG loci and has been identified in other types of cancer including AML (Figueroa et al. 
2010) and clear cell renal carcinoma (Arai et al. 2012). Remarkably, in glioma, G-CIMP 
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is strongly associated with IDH mutation and is more frequent in lower grade glioma 
(Noushmehr et al. 2010). Later, the study by Turcan et al. found that the IDH1 mutations 
are the lead cause for CIMP phenotype formation (Turcan et al. 2013). Patients with G-
CIMP+ are characterised by younger age and better survival in comparison to G-CIMP- 
patients (Christensen et al. 2011; Turcan et al. 2012; Noushmehr et al. 2010). In rare 
events, CIMP can occur in IDH wild-type gliomas and the reason behind the formation of 
the phenotype is still unknown (Brennan et al. 2013; Hill et al. 2014). 
Also, many studies have been conducted to discover the association between G-CIMP, 
IDH mutations and MGMT promoter hypermethylation. The G-CIMP glioma subgroup 
with IDH mutations is associated with longer survival and glioma patients with MGMT 
promoter hypermethylation are also characterised by better prognosis. However, no direct 
association has been reported between MGMT hypermethylation and G-CIMP status 
(Bady et al. 2012; van den Bent et al. 2011). 
 
1.5.5.4 Histone modifications  
Genome-wide studies have reported many alterations in genes involved in histone 
modification in gliomas. In a study by Parsons et al. that used large-scale sequencing 
analysis of glioblastoma, several genetic mutations have been detected in genes involved 
in histone demethylation (JMJD1A, JMJD1B) and histone methyltrasnferase (SET7, 
SETDB2, MLL3, and MLL4) in addition to MBD1 gene (Methyl-CpG Binding Domain 
Protein 1) (Parsons et al. 2008b). Also, mutations in MLL2 and MLL3 were identified in a 
few cases of medulloblastoma (16%) (Parsons et al. 2011). In neuroblastoma, CpG island 
methylation was observed in NSD1 (Nuclear Receptor Binding SET gene) that encodes 
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histone methyltransferase which leads to inactivation of the gene (Berdasco et al. 2009). 
Another study using immunohistochemistry expression analysis of histone H3 and H4 
modifications in a large set of glioma cases identified 10 distinct prognostic subgroups 
based on the expression of the histone modifications H3K9Ac, H3K4diMe, H3K18Ac 
and H4K20triMe (Liu et al. 2010). 
 
1.5.6 Brain metastasis from distant organ 
Metastasis to the brain is the most common form of CNS tumour which usually indicates 
a patient’s poor prognosis. The incidence of brain metastasis is increasing and 
outnumbers primary brain cancer by 10 times (Patchell 2003). Mostly, tumour cells reach 
the brain by blood circulation from different sites, most commonly from the breast, lung, 
melanoma and liver (Gavrilovic and Posner 2005) (Figure 1.17). Most breast cancer 
patients develop brain metastasis after metastasis formation in the lung, liver or bone 
(Issa et al. 2002).  
Metastasis in the brain usually forms in parenchyma tissue or leptomeninges. 
Leptomeningeal metastasis develops in the meninges (membranes surrounding the brain) 
which is the most common site for metastasis from a breast tumour (Palmieri et al. 2007). 
The brain is a special organ surrounded by the skull and protected by the blood-brain-
barrier (BBB). The BBB is a diffusion barrier that strictly selects and regulates the access 
of cells and other molecules to the brain. However, the BBB is responsible for poor drug 
delivery to the brain tumour site and limits drug efficacy, and as a consequence, drugs 
must be specifically designed to be able to cross the barrier (Palmieri et al. 2007). In 
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addition, even with the surgical removal of the tumour and radiotherapy, patients with 
brain metastasis only survive 6-9 months.  
In 1989, the hypothesis of “seed-and-soil” was proposed by Stephen Paget to suggest that 
metastasis to the brain does not randomly occur (Paget 1989) but tumour cells (the seeds) 
must be attracted to the new microenvironment of the metastatic organ (the soil). The 
hypothesis proposes that tumours are composed of heterogeneous sub-populations of 
cells that can disseminate, multiply, and selectively invade the brain which can be later 
colonized at the site depending on the interaction between tumour cells “seeds” and host 
microenvironment “soil” (Rahmathulla, Toms, and Weil 2012). Metastasis formation 
involves two stages: (i) cellular migrations, where cells start to invade the surrounding 
tissues, disseminate and adhere to new tissues and (ii) colonization of the tumour cells in 
the new site. The ability of tumour cells to go through all the previous processes depends 
on their ability to disturb the E-cadherin-Catenin molecular complex function and go 
through epithelial mesenchymal transition (Svokos, Salhia, and Toms 2014). Underlying 
these stages are various of genetic, epigenetic changes responsible for metastasis 
formation and development known as “metastasis cascade” (Rahmathulla, Toms, and 
Weil 2012). Therefore, further molecular biology and genetic studies have been 
conducted recently to increase knowledge and understanding of the underlying processes 











Figure 1.17 Illustration of the most common primary sites of brain metastasis 
Tumour cells from primary sites like the breast, lung and skin (melanoma) metastasise to 
the brain via blood circulation (red arrows) or to adjacent sites such as the liver and lung 












1.6 Aim of the research 
Now a day, with the availability of the high-throughput technologies, such as NGS and 
microarrays, cancer researches has improved our understanding of cancer biology and the 
molecular mechanisms behind cancer development and progression. The aim of this 
thesis is to identify genetic and epigenetic changes in CNS tumours. The main focus will 
be on GBM tumours, brain metastasis from breast cancer and sporadic vestibular 
schwannoma, using the following approaches. 
• Using&Illumina&Infinium&HumanMethylation450&BeadChip&array&to;&&
(i) Characterise& the& methylation& profile& of& STS& and& LTS& glioblastoma&
tumours&and& to& find& the&differences& in&methylation&between& the& two&
groups.& Also,& to& identify& epigenetic& markers& associated& with& poor&
prognosis.&
(ii) Identify& potential& epigenetic&markers& for& brain&metastasis& formation&
from& breast& cancer,& find& the& association& of& promoter&
hypermethylation&of&the&genes&with&patient&survival&and&compare&the&
methylation& event& of& these& genes& in& brain&metastasis& tumours& from&
different&primary&organs,&such&as&lung&cancer&and&melanoma.&&
• Using&WES& technology,& a&NGS& technology& that& covers& the& coding& regions& of&
the&genome,&and&different&bioinformatic&tools&and&international&SNP&and&SNV&





  Materials and Methods Chapter Two:
 
2.1 DNA and RNA Samples 
All samples used in the study were anonymised. The collection and use of the samples 
was ethically approved by the review boards of the institutions and local research 
committees. All studies were conducted according to the principles expressed in the 
Declaration of Helsinki. 
2.1.1 DNA from Patients’ Samples 
2.1.1.1 GBM DNA samples 
DNA from 35 glioblastoma patients (grade IV) and from 4 non-cancerous brain samples 
were kindly provided by our collaborator, Prof. Dietmar Krex (Klinik und Poliklinik fur 
Neurochirurgie, Universitatsklinikum Carl Gustav Carus, Technische Universitat 
Dresden, Germany).  
2.1.1.2 Brain metastasis DNA samples 
Brain metastasis DNA from breast tumours (n=15), melanoma (n=20) and lung cancer 
(n=20) were used in this thesis and provided by our collaborator, Prof. Dietmar Krex 
(Klinik und Poliklinik fur Neurochirurgie, Universitatsklinikum Carl Gustav Carus, 
Technische Universitat Dresden, Germany).  
2.1.1.3 Breast tumours and corresponding brain metastasis DNA samples 
DNA from 11 breast tumours and corresponding brain metastasis samples (matched 
pairs) were generously provided by Dr. Mark Morris (School of Biology, Chemistry and 
Forensic Science, University of Wolverhampton). RNA from brain metastasis samples 
was also provided by Dr. Mark Morris. 
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2.1.1.4 Schwannoma DNA samples  
DNA from 59 schwannoma tumour samples and their corresponding normal blood DNA 
samples, plus 2 peripheral nerve DNA samples (normal, non-cancerous), were provided 
by our collaborator, Dr. Juan A. Rey (Unidad de Investigacion, IdiPAZ Hospital, 
Universitario La Paz Paseo de la Castellana, Madrid, Spain).  
 
2.1.2 Cell lines 
2.1.2.1 Glioma cell lines 
Glioma cell lines (A172, U343, HS683, H4 and T17) were used in this study and were 
provided by Prof. Dietmar Krex (Klinik und Poliklinik fur Neurochirurgie, 
Universitatsklinikum Carl Gustav Carus, Technische Universitat Dresden, Germany).  
 
2.2 Nucleic acid extraction 
2.2.1 DNA extraction 
DNA was extracted from samples using the Qiagen DNeasy Blood and Tissue Kit (Cat. 
No.: 69506) and instructions were followed according to the “Total DNA extraction from 
animal blood or cells” protocol. Briefly, pellets were re-suspended in 200µl buffer AL, 
then 20µl proteinase K was added and mixed by vortexing. Samples were then incubated 
for 10 minutes at 56oC. After that, samples were washed using 200µl absolute ethanol 
and vortexed until the solution was homogenised. Using DNeasy Mini spin-column, 
samples were centrifuged at room temperature for 1 minute at 20,000 x g (14,000 rpm) 
and the flow-through solution was discarded. After that, 500µl buffer AW1 was added to 
the column and centrifuged for 1 minute at 20,000 x g (14,000 rpm) at room temperature 
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and the flow-through solution was discarded. The spin-column was washed again using 
200µl buffer AW2 and centrifuged for 3 minutes at 20,000 x g (14,000 rpm) at room 
temperature. This final flow-through was discarded along with the collection tube and 
was replaced by a new 1.5ml microcentrifuge tube. DNA was eluted from the spin-
column’s membrane by adding 200µl buffer AE to the membrane and incubated at room 
temperature for 1 minute followed by centrifugation for 1 minute at 20,000 x g (14,000 
rpm). Then, DNA was stored in the freezer at -20oC. 
 
2.2.2 RNA extraction 
RNA was extracted from cell lines using the EZ-RNA Total RNA Isolation kit 
(Biological Industries, Cat. No.: 20-400-100) according to the manufacturer’s 
instructions. Briefly, 0.5ml denaturing solution (guanidine thiocyanate) was added to 
each sample and mixed by repeated pipetting and then incubated for 5 minutes at room 
temperature. Then 0.5ml extraction solution (phenol and chloroform) was added and 
mixed vigorously followed by another incubation for 10 minutes at room temperature, 
then centrifugation at 12,000 x g at 4oC for 15 minutes. After that, the RNA precipitation 
step was carried out by transferring the upper phase to another tube. It was mixed with 
0.5ml isopropanol and stored for 10 minutes at room temperature then centrifuged for 8 
minutes at 12,000 x g (4oC). The supernatant was then discarded and RNA was washed 
using 75% (v/v) ethanol. RNA was then centrifuged at 7,500 x g for 5 minutes (4oC) and 
the supernatant was carefully removed. RNA was allowed to air-dry prior to the addition 
of 100µl 0.5% SDS solution and was incubated for 15 minutes at 55oC for RNA 
solubilisation. The samples were then stored at -80oC in the freezer until they were used. 
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2.2.3 Quantification of DNA and RNA concentration using Nanodrop 
Spectrophotometer 
DNA and RNA were quantified using the NanoDrop 1000 Spectrophotometer (NanoDrop 
Technology, USA). The blanking procedure was performed using 2µl of the same elution 
solution used to elute DNA/RNA during preparation (buffer AE or RNase free water). 
After that, 1-2µl of nucleic acid was added to the NanoDrop spectrophotometer and 
absorbance was read at 260nm and 280nm. The output readings of the NanoDrop 
consisted of nucleic acid concentration in ng/µl and nucleic acid purity. Purity was 
measured using the ratio of absorbance 260/280. DNA with a purity ratio of ≈1.8 was 
considered pure, while a ratio of ≈2.0 was generally accepted as pure for RNA.  
 
2.3 Bisulfite modification of DNA 
DNA conversion was performed according to the Qiagen EpiTect Bisulfite Kit (Qiagen, 
Cat.No: 59104) as follows; aliquots of Bisulfite Mix were dissolved by adding 800µl 
RNase-free water to each aliquot and vortexed until completely dissolved. Bisulfite 
reactions were prepared in 200µl PCR tubes by the addition of 500ng-1µg DNA and 
RNase-free water to make a total volume of 20µl. This was followed by the addition of 
85µl dissolved Bisulfite mix and 35µl DNA protect buffer. Then, the samples were 
mixed by pipetting until the solution turned into blue. After that, the bisulfite DNA 
conversion reaction was carried out using the thermal cycler according to the following 











Step Duration Temperature 
Denaturation 5 minutes 95oC 
Incubation 25 minutes 60oC 
Denaturation 5 minutes 95oC 
Incubation 1 hour 25 minutes 60oC 
Denaturation 5 minutes 95oC 
Incubation 2 hours 55 minutes 60oC 
Hold Indefinite 20oC 
 
Table 2.1 Thermal cycler conditions for DNA bisulfite conversion 







After completion of the bisulfite conversion reaction, samples were briefly centrifuged 
and transferred to new 1.5ml microfuge tubes. A freshly prepared Buffer BL containing 
10µg/ml carrier RNA was added to each sample and mixed by vortex. The samples were 
then transferred to an Epitect spin-column and spun down for 1 minute at 20,000 x g 
(14,000 rpm). The flow-through solution was discarded and the spin-column membrane 
was washed with 500µl buffer BW. Samples were centrifuged again at maximum speed 
for 1 minute and the flow-through was discarded. After that, the de-sulfonation step was 
carried out by adding 500µl buffer BD to each spin-column and the samples were 
incubated at room temperature for 15 minutes. The samples were then centrifuged for 1 
minute at maximum speed and flow-through was discarded again. The samples were 
washed twice with 500µl buffer BW and centrifuged at 20,000 x g (14,000 rpm) for 1 
minute. After the second wash, the spin-column of each sample was placed into a new 
1.5ml microfuge tube and 20µl of buffer EB was added to the centre of the membrane to 
elute the purified DNA. Samples were incubated for 2 minutes prior to the final 
centrifugation step to increase the yield of DNA in the eluate. Bisulfite modified DNA 
was stored at -20oC.  
 
2.4 Analysis of DNA methylation 
Several methods were used in this thesis to analyse DNA methylation status.  
 
2.4.1 Methylation/Unmethylated specific PCR 
Methylation specific PCR (MSP) and unmethylated specific PCR (USP) reactions were 
performed at the same time for the same gene. PCR reaction contained 1x of 10X 
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reaction buffer with 20mM MgCl2 (500mM Tris/HCL, 100mM KCl, 50mM ammonium 
sulphate, 20mM MgCl2, pH8.3/25oC), 1x 5X GC-RICH solution, 2.5mM PCR grade 
Nucleotide mix, 0.8µM of forward primer, 0.8µM of reverse primer and 1.0u FastStart 
Taq DNA polymerase (Roche, Cat. No. 12158264001). Deionized distilled water was 
used to make the reaction up to 50µl. In each PCR reaction, 3µl of bisulfite modified 
DNA was added as a template and then PCR was performed using the standard PCR 
programme listed in Table 2.2. Primer sequences and annealing temperatures are shown 























Temperature Duration Number of cycles 
95 oC 5 minutes 1 cycle 
95 oC 1 minute 
35 cycles Annealing 1 minute 
72 oC 2 minutes 
72 oC 10 minutes 1 cycle 
10 oC Indefinite 1 cycle 
 
Table 2.2 Standard MSP/USP PCR programme 













2.4.2 Agarose gel electrophoresis and UV light visualisation  
In this study, 2% (w/v) agarose gel (Bioline, Cat. No. E8751) was used to visualise PCR 
products. Agarose gel was made by mixing 4grams of agarose and 200ml of 1X Tris-
Borate-EDTA (TBE) that was diluted from 10X TBE (National Diagnostics, Cat. No. 
EC-860). The mix was heated in the microwave until it had completely dissolved. After 
cooling down, 2µl of 10mg/ml ethidium bromide (EtBr) was added to the gel and then 
poured in the tray to set at room temperature. Prior to loading, the samples were mixed 
with 5% (v/v) loading buffer (50% glycerol, 48.5% distilled water, 1% EDTA and 0.5% 
Orange G) and loaded into the gel electrophoresis to be migrated at ≈180 volts for 15 
minutes to be visualised later under UV light. 
 
2.4.3 Combined Bisulfite Restriction Analysis (CoBRA) 
2.4.3.1 Primer design  
All of the CoBRA primers were designed manually in this study unless they were pre-
designed and listed in other published studies. The UCSC genome browser was used to 
identify the region of interest and primers were designed around this area. For each gene 
or probe, primers were designed for semi-nested CoBRA PCR (set of 3 primers) unless 
the PCR product was poor or the covered region was >500bp, in this case fully-nested 
CoBRA PCR primers were designed. To design the CoBRA primers, several aspects 
were considered (whenever possible) to ensure the maximum effectiveness of the 
primers; (i) the 3" end of the primer was designed to end on the CAC or ACC of the 
genomic site to ensure high specificity to bisulfite modified DNA in addition to a string 
of Cs within the primer, (ii) to avoid biasing the PCR towards methylated or 
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unmethylated DNA, if CpG dinucleotides were within the primer sequence, a Y (C or T) 
was incorporated to replace a C in the forward primer and an R (G or A) to replace a G in 
the reverse primer, (iii) a restriction enzyme cutting site with the primer sequences was 
strongly avoided. Primers were designed to be around 30bp long (±5bp) and to produce 
300-450bp PCR products that contain at least one restriction site within the region. 
Annealing temperature was calculated using the following equation and CoBRA PCR 
was performed at 2oC below the calculated annealing temperature. All CoBRA primer 







GC = number of C and G nucleotides (Y and R are considered as 0.5) 
n = total number of nucleotides 
 
2.4.3.2 CoBRA PCR 
All PCR reactions were performed using either semi- or fully-nested primer sets. Two 
rounds of PCR were carried out for each CoBRA assay using FastStart Taq DNA 
polymerase kits (Roche, Cat.No.12158264001). Each PCR reaction was made up to the 
total volume of 25µl (for primary reaction) or 50µl (for secondary reaction) and 
contained 1x of 10X reaction buffer with 20mM MgCl2 (500mM Tris/HCL, 100mM KCl, 
50mM ammonium sulphate, 20mM MgCl2, pH8.3/25oC), 1x 5X GC-RICH solution, 
2.5mM PCR grade Nucleotide mix, 0.8µM of each of the forward and reverse primer, 
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0.5u (primary reaction) or 1.0u (secondary reaction) FastStart Taq DNA polymerase and 
distilled water. The bisulfite modified DNA template of 2µl (0.04µg) was added to the 
primary reaction as starting material and 5µl of the primary PCR product was used in the 
secondary reaction as starting material. CoBRA PCR’s reaction conditions were either a 








95 oC 5 minutes 1 cycle 1 cycle 
95 oC 1 minute 35 cycles 40 cycles 
Annealing 1 minute 
72 oC 2 minutes 
72 oC 10 minutes 1 cycle 1 cycle 
10 oC Indefinite 1 cycle 1 cycle 
B) 




95 oC 5 minutes 1 cycle 1 cycle 
95 oC 45 seconds 5 cycles, 
decreasing 2oC in 
each cycle 
5 cycles, 
decreasing 2oC in 
each cycle 
Annealing 45 seconds 
72 oC 45 seconds 
95 oC 45 seconds 35 cycles 40 cycles 
Annealing 45 seconds 
72 oC 45 seconds 
72 oC 10 minutes 1 cycle 1 cycle 
10 oC Indefinite 1 cycle 1 cycle 
 
Table 2.3 Standard and touchdown CoBRA PCR programmes 
 A) Standard CoBRA PCR programme for primary and secondary reactions. B) 
Touchdown CoBRA PCR programme for primary and secondary reactions. 
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2.4.3.3 Restriction of enzyme digest 
After visualisation of the PCR products using gel electrophoresis (section 2.4.2) and 
depending on the intensity of the bands, a suitable volume of the PCR product (5µl-20µl) 
was digested with one of the restriction enzymes listed in Table 2.4. 
The BstUI restriction enzyme (Fermentas, Cat. No. ER0921) is commonly used to 
analyse the methylation status of CpG islands due to the high frequency of its cutting site 
in the islands. The digestion reaction was carried out using 1u BstUI, 1x 10X buffer R, an 
appropriate amount of the PCR product and distilled water to make it up to the final 
volume of 25µl. Then, samples were incubated overnight at 37oC. 
Samples were digested with the HpyCH4IV restriction enzyme (New England Biolabs, 
Cat. No. R0619S) and TaqαI (New England Biolabs, Cat. No. R0149L) and were 
incubated at 37 oC and 65 oC respectively for two hours. The digestion reaction was 
carried out with 20u of the enzyme, 0.01µl BSA, 1x 10X NEBuffer 1 (for HpyCH4IV) or 
NEBuffer 4 (for TaqαI), a suitable amount of the PCR product and made up with distilled 
water to the volume of 25µl. 
Digested and undigested samples were loaded into gel electrophoresis (section 2.4.2) and 
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2.4.4 Bisulfite sequencing  
2.4.4.1 Gel extraction 
Prior to sequencing, the PCR products were initially purified from agarose gel using the 
Gel Extraction kit (Qiagen, Cat. No. 28704). Bands were excised carefully using a scalpel 
and transferred to a labelled 1.5ml microcentrifuge tube. According to the manufacturer’s 
protocol, gel slices were weighed and 3x volumes of Buffer QG were added to 1 volume 
of gel. Tubes were placed in a block heater and incubated for 10 minutes at 50oC with 
vortexing every 3-4 minutes. After that, 1x gel volume of 100% Isopropyl alcohol was 
added to the samples and mixed vigorously. The solution was then transferred to a 
QIAquick spin-column and centrifuged for 1 minute at high speed (20,000 x g) to allow 
DNA to bind to the membrane. The flow-through was discarded and another 0.5ml 
Buffer QG was added to the column, then a second centrifugation step was applied as 
earlier. Again, the flow-through was discarded and 0.75ml Buffer PE was added to wash 
the column. The samples were centrifuged again and the flow-through was discarded. A 
QIAquick spin-column of each sample was then placed in a new 1.5ml microcentrifuge 
tube and 30µl of deionised distilled water was added to the centre of the membrane to 
elute DNA. The samples were incubated for 1 minute at room temperature prior to 
centrifugation at high speed for 1 minute. The purified PCR products were stored at -




2.4.4.2 Plasmid vector ligation 
Purified PCR products were introduced into bacterial cells for cloning using the pGEM-T 
Easy vector system (Promega, Cat. No. A1360). The vector ligation reaction was 
prepared by gently mixing 0.5µl pGEM vector, 1µl T4 DNA ligase and 5µl 2X ligation 
buffer with 3.5µl purified PCR product. Samples were incubated overnight at 4oC to 
allow the ligation process to occur. 
 
2.4.4.3 LB media preparation  
Preparation of LB agar plates was carried out by mixing 35g/l LB powder agar (Sigma 
Aldrich, Cat. No. L2897) with distilled water before autoclaving. After cooling down the 
mixture, ampicillin drug (Sigma Aldrich, Cat. No. H0166) with a concentration of 
100µg/ml was added and the solution was poured into petri dishes to set before being 
stored at 4oC. 
 
2.4.4.4 Transformation of bacterial cells 
Initially, α-select silver efficiency chemically component cells (Bioline, Cat. No. BIO-
85026) were carefully defrosted on ice and 40µl aliquoted into microcentrifuge tubes. In 
each aliquot, 4µl of pGEM-PCR product ligation was added and gently mixed without 
damaging the cells. Each tube was incubated on ice for 20 minutes and then heat shocked 
at 42oC for 30 seconds. Then, 500µl SOC media (Invitrogen; Cat. No. 15544034) was 
added and cells were incubated for 1 hour at 37oC while being shaken. During the 
incubation period, 20µl X-gal (50mg/ml) (Bioline; Cat. No. BIO37035) was added to 
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each media plate and later, 200µl of each cultured cell was spread on the plate and 
incubated for 18 hours at 37oC. 
 
2.4.4.5 Single colony PCR 
After the incubation period, only white colonies that contained the insert were selected 
and transferred to 20µl deionised distilled water and heated to 95oC for 5 minutes to 
allow cell membrane rupture. Only the white colonies were selected due to the disruption 
of the β- galactosidase gene within the plasmid and therefore, white colonies were 
expected to have the insert. On the other hand, blue colonies were produced due to the 
undisrupted plasmids which allow the β- galactosidase enzyme to utilise the X-gal 
producing blue product. After the incubation period, 7-10µl of the solution was used as a 
template for a PCR reaction that was made up to the total volume of 30µl which 
contained 1x of 10X reaction buffer with 20mM MgCl2 (500mM Tris/HCL, 100mM KCl, 
50mM ammonium sulphate, 20mM MgCl2, pH8.3/25oC), 1x 5X GC-RICH solution, 
2.5mM PCR grade Nucleotide mix, 0.8µM of each of the forward and reverse primer, 
0.5u FastStart Taq DNA polymerase and distilled water. The forward and reverse primer 
sequences are: F primer: 5’-TAATACGACTCACTATAGGG-3; and R primer: 5’- 
ACACTATAGAATACTCAAGC-3’.  
 
2.4.4.6 ExoSAP for PCR product purification 
The PCR products were cleaned up prior to the sequencing reaction to ensure the removal 
of dNTPs and primers excess. A reaction was made up with 1ᴜ of FastAP, 0.01ᴜ of 1x 
10x FastAP buffer and ExoI each, and 10µl PCR product. The samples were then 
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incubated in a thermal cycler for 30 minutes at 37oC and then for 20 minutes at 80oC to 
inactivate the ExoI enzyme. 
 
2.4.4.7 Sequencing reaction 
The sequencing reaction was performed using the Big Dye Terminator V3.1 Cycle 
Sequencing Kit (Applied Biosystems; Cat. No. 4336917). For each sequencing reaction, 
5µl of the cleaned PCR product (see section 2.4.4.6) was mixed with 20pmol of forward 
(or reverse) primer, 0.5-0.75µl Big Dye, 2µl 5X sequencing buffer and nuclease free 
water. Then, the sequencing reaction was carried out using the programme in Table 2.5 





















Temperature Duration Number of cycles 
94 oC 4 minutes 1 cycle 
94 oC 25 seconds 
35 cycles 50 oC 25 seconds 
60 oC 4 minutes 
 












2.4.4.8 Alcohol precipitation  
Ethanol precipitation was carried out using 3.5µl precipitation buffer containing 1.5M 
NaOAc, 1.5M EDTA and 100µl of absolute ethanol, mixed with each sample prior to 
spinning down for 30 minutes at 2,000 x g (4oC). Then, the supernatant was removed 
carefully and the samples were spun upside down briefly prior to the washing step with 
200µl 70% (v/v) ethanol. Samples were centrifuged again at 2,000 x g (4oC) for 30 
minutes and the supernatant was removed as before and then allowed to air dry in the 
dark. After that, pellets were resuspended in 10µl HiDi Formamide solution (Applied 
Biosystems; Cat.No: 4311320) and DNA was allowed to denature at 95oC for 5 minutes 
prior to running on the Applied Biosystem DNA Analyzer. 
 
2.5 Gene expression analysis  
2.5.1 cDNA synthesis 
In all expression studies, cDNA synthesis was performed using 1µg total RNA. The 
reaction was set up using 1µl of 100µM random hexamers (Fermentas; Cat. No. S0142), 
1µl 10mM dNTP mixture, 1µg RNA and RNase free water to make up the reaction to 
14µl. Samples were incubated at 65oC for 5 minutes in the thermal cycler and then placed 
on ice for a minute to add the mixture of 4µl 5X First-Strand buffer (250mM Tris-HCL, 
375mM KCl, 15mM MgCl2), 1µl 0.1M DTT (Dithiothreitol), 1µl RNaseOUT (40ᴜ) and 
1µl (200ᴜ) Superscript III RT (Invitrogen; Cat.No: 18080-093). Then, the samples were 
again placed in the thermal cycler and incubated at 25oC for 5 minutes followed by 50oC 
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for 60 minutes. In the last step, the reaction was inactivated by incubation for 15 minutes 
at 70oC and the cDNA was stored in the freezer until needed.  
 
2.5.2 Primer design for Reverse transcription PCR (RT-PCR) 
Primers for expression analysis were designed using the Primer3 online tool 
(http://primer3.ut.ee/) according to the following criteria; (i) Primers were designed to 
cover a region of 250-400bp and did not match other regions in the human genome when 
using NCBI BLAST, (ii) Primer length does not exceed 25bp with Tm 50oC-65oC, (iii) 
GC content ranges between 50-60%, (iv) Primer does not have a long string of As and Ts 




RT-PCR reaction was prepared to a final volume of 25µl containing 2.5µl 10X buffer 
(500mM Tris-HCL, 100mM KCl, 50mM (NH4)2SO4, 2mM MgCl2, 1x 5X GC rich 
solution, 2.5mM dNTP mixture), 0.8µM each of the forward and reverse primers, 0.5ᴜ 
FastStart Taq DNA polymerase (Roche; Cat. No. 12158264001) and 1µl cDNA. The 
reaction was carried out using the touchdown programme in Table 2.6. RT-PCR for 











Temperature Duration Number of cycles 
95 oC 5 minutes 1 cycle 
95 oC 30 seconds 
3 cycles 60 oC 30 seconds 
72 oC 30 seconds 
95 oC 30 seconds 
3 cycles 58 oC 30 seconds 
72 oC 30 seconds 
95 oC 30 seconds 
34 cycles 56 oC 30 seconds 
72 oC 30 seconds 
72 oC 10 minutes 1 cycle 
 





2.5.4 Quantitative real time expression PCR qRT-PCR 
MIR125B1 expression was determined using the TaqMan Universal PCR Master Mix 
(Applied Biosystems, Cat. No. 4324018) and the TaqMan MicroRNA Reverse 
Transcription assay (Applied Biosystems, Cat. No. 4366596). Predesigned TaqMan 
probes, ordered from Applied Biosystems, for MIR125B1 and the endogenous control 
RNU24 were used to hybridise the previously synthesised cDNA. To determine cDNA 
concentration, the FAM dye protocol was selected to detect the amount of fluorescence. 
Standard DNA and sample cDNA were run in triplicates and the produced quantitative 
amplification was calculated from the standard curve. ΔCt was calculated after 
normalising to the endogenous control RNU24. 
 
2.5.5 Tissue culture and 5-aza treatments 
All tissue culture work was carried out by a laboratory technician, Dean Gentle, in a 
medical and molecular genetics laboratory (College of Medical and Dental Sciences, 
University of Birmingham, United Kingdom).  
 
2.5.5.1 Growth media preparation 
The glioma cell lines in this study were preserved in DMEM media (Sigma-Aldrich, Cat. 
No. D5671) containing 10% (v/v) foetal bovine serum (FBS) (PAA Laboratories; Cat. o: 
A15-151), 2mM L-glutamine (Sigma Aldrich, Cat. No. G7513), 100ᴜ/ml penicillin and 




2.5.5.2 Cell line resurrection 
Frozen cell lines were defrosted by placing the tubes in a 37oC water bath and then 
transferred to a 10ml pre-warmed culture media. After that, the cells were spun down at 
room temperature for 4 minutes at 280 x g and the supernatant was carefully discarded. 
Then, cells were resuspended in 1ml media and transferred to a tissue culture flask prior 
to the addition of 7ml growth media. Cells were then maintained in the 37oC incubator 
with 5% CO2. 
 
2.5.5.3 Cell line passaging  
Every two days, approximately half of the media were discarded from the flask and 
replaced with fresh pre-warmed media to feed the cells. When cells reached ∼80% 
confluency, they were passaged into 1:3, 1:5 or 1:10 depending on the growth rate. Then, 
the media were removed and the cells were washed with 4ml PBS (Phosphate Buffered 
Saline) and 3ml 1x 0.25% Trypsin-EDTA (Invitrogen, Cat. No. 25200056). After that, 
the cells were placed in 37oC incubator until the cells displaced from the flask wall and 
were resuspended in 7ml culture media to be split into the desired volume. Media was 
added to make up a final volume of 15 ml prior to the cells being placed in the 37oC 
incubator. 
2.5.5.4 Counting of cells 
Prior to cell counting, the cells were first trypsinised as described in section 2.5.5.3 and 
then resuspended in 7ml media. Before the haemocytometer chamber was used, the 
chamber and its cover slip were disinfected thoroughly. Then, 70µl of the media 
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containing the cells were placed on each haemocytometer slide and counted under the 
microscope to calculate the average. Preferably, each ml of media contained 1x104 cell 
counts. 
 
2.5.5.5 Cell line treatment with 5-aza-2’deoxycitidine  
Cell line treatment with the demethylation agent, 5-aza-2’deoxycitidine (5-azaDC), was 
carried out when cells reached 30%-50% confluency. This is due to the fact that  
demethylation by 5-azaDC only affects cells under DNA replication. Cells were 
maintained in media supplemented with 5µM 5-azaDC (Sigma-Adrich; Cat. No. A3656) 
and changed every day for five consecutive days. For each cell line, a non-treated control 
was grown simultaneously.  
 
2.5.5.6 Cell pellets preparation 
When cells reached 90% confluency or on the fifth day of 5-azaDC treatment, they were 
washed by PBS and then trypsinised to detach from the flask’s wall. Then, the cells were 
resuspended in media and centrifuged at 1000 x g for 4 minutes. The supernatant was 
discarded carefully and then 1ml PBS was added to each pellet followed by  
centrifugation for 4 minutes at 1000 x g. The supernatant was removed and the pellets 
were placed in liquid nitrogen and then stored at -80oC until needed. 
 
2.6 Infinium HumanMethylation450K BeadChip 
The Infinium HumanMethylation450K BeadChip from Illumina and DNA bisulfite 
modification was performed by Cambridge Genomics Services, Department of 
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Pathology, Cambridge University. Raw data from the array were initially run in the 
GenomeStudio software and then processed using Lumi package from GenomeStudio 
software (Du, Kibbe, and Lin 2008) for normalization and colour correction between the 
Infinium I and Infinium II channels. The β-value was then calculated to estimate the 
methylation level for each probe using ratio of intensities between methylated and 
unmethylated alleles: β = Methylated allele intensity (M) / (Unmethylated allele intensity 
(U) + Methylated allele intensity (M) + 100). The β-value ranged between 0-1; where 0 
represents no methylation (0%) and 1 represents full methylation (100%).   
In Chapters 3 and 4, the filtration steps were applied on the array data to remove 
technically failed and unwanted probes. Probes showing the detection p-value, which 
represents the hybridisation quality over the background, >0.01 in a sample were 
excluded. In addition to the removal of probes located on X or Y chromosomes, probes 
for imprinted genes and probes with SNPs were also excluded. 
 
2.7 Sanger sequencing 
Sanger sequencing was used in this study for mutation detection. 
2.7.1 Primer design 
Primers were designed around the mutation site using the Primer3 website 
(http://primer3.ut.ee/) with this criteria; (i) GC content ranges between 50%-60%, (ii) 
Design primers with 19-25bp long and 3’ end in G or C, (iii) Melting temperature of 
60oC (50oC -65oC), and (iv) product size does not exceed 300bp. Then, primers were 
checked to see whether they contain SNPs within their sequences to avoid PCR 
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To clean up PCR products, MicroCLEAN (Microzone; Cat. No. 2MCL-10) was used by 
adding 2.4µl of the solution to an equal amount of the PCR product. Samples were spun 
down at maximum speed for 40 minutes. 
Cycle sequencing reaction and ethanol precipitation were then carried out (as in sections 
2.4.4.7 and 2.4.4.8) prior to the samples being loaded on the Applied Biosystem 3730 
DNA Analyzer. 
 
2.8 Whole exome sequencing  
Whole exome sequencing (WES) for schwannoma samples was carried out by the NIHR 
GSTFT/KCL Comprehensive Biomedical Research Centre, King’s College of London. 
Briefly, WES capture was carried out using in-solution hybridisation, followed by 
massive parallel sequencing with the SureSelect All Exon v5 Target Enrichment System 
(Agilent) and sequencing on an Illumina HiSeq200 with 100bp paired-end reads. Later, 
the reference genome (hg19) was aligned to the sequence reads using Novoalign 
(Novocraft Technologies SdnBhd). Errors such as duplicate reads and reads mapping to 
several locations were eliminated from further analysis. Then, the depth and breadth of 
the sequence coverage were calculated by custom scripts and the BedTools package. 
Substitutions, insertions and deletion mutations were identified and filtered within the 
SamTools software package and in-house software tools. Variants were annotated with 
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respect to genes and transcripts with the Annovar tool. Novel variants were identified by 
comparing them to dbSNP137 and the 1000 Genomes Project SNP calls (December 
2010) and to variants identified in 900 control exomes (primarily of European origin).  
The average coverage is dependent on a number of variables; these include 
the amount of sequencing undertaken, the success of the hybridisation, and the clonality 
of the library. Acceptable coverage is considered to be when >80% of the exome is 
covered by >20x.  
Annotated, coding annotated and BAM files were downloaded from a webserver where 
annotated files contain all detected variants including those in non-coding regions and 
low quality calls. On the other hand, a coding annotated file only contains coding variants 




2.9.1 The Cancer Genome Atlas (TCGA) 
The TCGA data portal (http://cancergenome.nih.gov) provides information from different 
platforms, such as DNA methylation, somatic mutations, miRNASeq, gene expression 
and clinical information about the patient samples. These data are freely available for 
download and analysis. In Chapters 3 and 4, DNA methylation data 
(HumanMethylation450) were downloaded for selected samples of glioblastoma and 
breast tumours respectively. In Chapter 5, cBioPortal for the cancer genome 
(http://www.cbioportal.org/public-portal/) was used to investigate the overall percentage 




2.9.2 Gene structural and functional information  
2.9.2.1 UCSC Genome Bioinformatics 
Gene information, CpG island information, SNP detection in primer sequence and 
FASTA sequences of genomic DNA and coding DNA were obtained from the UCSC 
Genome Bioinformatics’ browser (http://genome-euro.ucsc.edu) using the latest human 
(Homo Sapiens) genome assembly (hg19). 
 
2.9.2.2 The National Center for Biotechnology Information (NCBI)  
The NCBI website was used to obtain information about an individual genome, such as 
gene function, publications and FASTA sequence and amino acid sequence for a specific 
transcript of a gene. 
 
2.9.2.3 Ensemble genome browser 
The Ensemble genome project (http://www.ensembl.org) is a freely available database 
that produces genomic data on humans and other species. The database was used in the 
study to analyse genes or SNPs (with rs ID), determine the number of exons of each gene, 
and to find the distribution of variants among populations.  
 
2.9.2.4 1000 genomes 
This website (http://www.1000genomes.org) contains a catalogue of human genetic 
variations from different populations. There are 14 populations which were divided into 5 
main populations: African, Mixed American, East Asian, European and South Asian. In 
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the study in Chapter 5, the Iberian population in Spain (IBS) were mostly considered in 
the study and compared to ALL populations (1,092 samples). According to the website, 
the IBS population contains 14 samples (7 males and 7 females) which are 
lymphoblastoid cell lines derived DNA. 
 
2.9.2.5 The Catalogue of Somatic Mutations In Cancer (COSMIC) 
The COSMIC website (http://cancer.sanger.ac.uk) contains information about mutations, 
publications and samples in relation to human cancer. The website’s database was used to 
investigate whether a specific mutation had been identified in any cancer tissue in 
addition to assessing the distribution of different mutations in a certain gene. 
 
2.9.2.6 Exome variant server (EVS) 
EVS is a SNP database (http://evs.gs.washington.edu) that contains variants generated by 
sequencing DNA from European American and African American populations. These 
populations share the same phenotype of having lung, heart and blood diseases.  
 
2.9.3 The Data for Annotation, Visualisation and Integrated Discovery (DAVID) 
The DAVID database (http://david.abcc.ncifcrf.gov) is a publically available database for 
analysing a large set of genes for pathways, functions and disease relations. It was used 




2.9.4 Prediction of functional effects of human SNPs  
2.9.4.1  Polymorphism Phenotyping v2 (PolyPhen-2) 
Polyphen-2 (http://genetics.bwh.harvard.edu/pph2) is a computational analysis tool for 
predicting the pathogenesis of missense variants on proteins. It uses a combination of two 
parameters; protein structure and protein function, to calculate the score of pathogenicity. 
Scores range from 0 (predicted to be benign) to 1 (predicted to be probably damaging).  
 
2.9.4.2 Splice site prediction by Neural Network 
This is an in silico method (http://www.fruitfly.org) to predict the effect of a splice-site 
mutation on gene splicing and proteins.  
 
2.9.5 Software and tools for analysis  
2.9.5.1 Ingenuity Pathway Analysis (IPA) 
This software (www.ingenuity.com) was used in Chapter 3 to analyse a list of 
hypermethylated genes for gene ontology and pathways. IPA software makes it possible 
to analyse and find the relevance between a list of genes for signalling pathways and cell 
networks in addition to gene functions. Part of the IPA analysis was carried out by my 





2.9.5.2 The Integrative Genomics Viewer (IGV) 
IGV (http://www.broadinstitute.org/igv/) is a visualising tool that allows the exploration 
and analysis of large exome sequencing data for SNP/SNV, number of reads, quality of 
calls, deletion or insertion of a region and many other aspects. It uses the most recent 
human genome (hg19) as a reference for genomic alignment. In Chapter 5, the IGV tool 
was used to validate SNV calls, reduce false positive calls and validate true findings. 
  
2.9.5.3 VarScan2 
VarScan2 tool is a somatic mutation and copy number alteration caller for exome 
sequencing and whole genome sequencing data. It analyses data from tumour/normal 
paired samples for the accurate detection of somatic mutations and alterations. VarScan2 
uses the SAMtools pipeline which reads BAM files generated from exome sequencing for 
normal and tumour pairs. It then analyses the paired samples simultaneously to identify 
LOH, germ-line and somatic calls. By applying pre-setup criteria for call quality and 
coverage, SNV was present in >15% in tumour samples and <5% in matching normal 
samples were considered as a somatic call, while variants found in both samples were 
classified as a germ-line call. VarScan2 analysis was carried out by the bioinformatician 





2.10  Statistical analysis 
2.10.1 Student t-test 
A student t-test was used in the study of LTS and STS methylation (Chapter 3). The test 
was performed using the function “TTEST” in Microsoft Excel software during the 
analysis. The formula selected for the calculation was two-tailed distribution and two-
sample unequal variance. Significance was taken when P-value <0.05. 
 
2.10.2 Fisher’s exact test 
This statistical test was performed to determine the significance of a methylated probe (p-
value) between different groups. P-value was calculated using GraphPad software 
(http://graphpad.com) and selecting two-tailed test. P-value <0.05 was considered to be 
significant in all studies.  
 
2.10.3 False discovery rate (FDR) 
When analysing a large dataset, the chance of identifying false positive results increases, 
therefore, FDR correction was applied after the calculation of P-value from the student t-
test. P-values showed significance (<0.05) from student t-test were ranked from smallest 
to largest and then each value was multiplied by its rank. Like other tests, P-value <0.05 
was considered significant. 
 
2.10.4 Kaplan-Meier survival analysis 
In Chapter 3, the univariate Kaplan-Meier survival test was carried out to estimate patient 
survival when a particular gene is methylated. Calculations of the test and survival graphs 
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were produced using SPSS statistics software from IBM. As with other tests, P-value was 
considered significant when <0.05. In Chapter 4, Kaplan-Meier survival curves were 
produced using the PrognoScan online tool (http://www.prognoscan.org/). The online 
tool finds the relationship between gene expression and patient clinical prognosis by 
calculating overall-survival (OS) and disease-free-survival using freely available cancer 








Chapter Three: DNA Methylation Profiling of Long-Term and Short-Term 
Glioblastoma Survivors  
 
3.1 Introduction  
According to the WHO classification, glioma is classified into 4 grades. Glioblastoma 
multiforme (GBM) is grade IV astrocytoma, which can be classified into primary GBM, 
when discovered de novo at diagnosis, or secondary GBM rises from a lower grade 
glioma. GBM is the most aggressive form of glioma in adults. Surgery and a combination 
of chemotherapy and radiotherapy are the standard treatment methods for GBM patients. 
However, the median survival rate for GBM patients is less than 1 year (Parsons et al. 
2008). Researchers have found that a small fraction (3-5%) of GBM patients showed a 
higher survival rate of up to 3 years and are so-called long-term survivor (LTS) GBM 
patients (Krex et al. 2007). These patients are younger in age, have a better clinical 
performance and have MGMT hypermethylated tumours (Krex et al. 2007; Hartmann et 
al. 2013).  
The development of Illumina methylation arrays from the GoldenGate DNA Methylation 
BeadArray to the Infinium HumanMethylation450 BeadChip allowed cancer researchers 
to expand and evolve to understand the epigenetic role in cancer development. The 
HumanMethylation450K array covers more than 485,000 CpG loci, of which 96% are 
located in CpG islands, CpG shores and CpG shelves Also, the array covers almost 99% 
of RefSeq genes and is able to annotate the position of the CpG probe according to the 
functional genomic distribution (5’UTR, 3’UTR, 1st exon and gene body) and to the CpG 
content and neighbourhood context (CpG island, shore, shelf or open-sea).  
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This study utilises the HumanMethylation450K array to study the methylation profile of 
the LTS gliomas and short-term survivors (STS) glioma and to identify potential 
epigenetic markers for poor prognosis in STS patients.  
 
3.2 Aim of the study 
• Methylation profiling of short-term survival (STS) and long-term survival (LTS) 
gliomas by using the genome-wide Infinium HumanMethylation450K BeadChip 
from Illumina.  
• To identify a list of hypermethylated genes and potential candidates in STS that 
may be markers for poor survival.  
 
3.3 Results 
This study used the most advanced methylation detection array available at the time of 
the study, the HumanMethylation450K BeadChip array, on a panel of 35 grade IV 
glioblastoma tumours consisting of 19 STS and 16 LTS glioblastoma DNA samples, in 
addition to 4 normal non-cancerous brain DNA samples. Appendix 7.2 contains clinical 
information about the tumour samples. 
The latest Infinium methylation array from Illumina, the HumanMethylation450K 
BeadChip, evaluates the methylation levels of more than 485,000 CpG sites across 
promoter regions (within 200bp of the transcription start site, 1500bp of the transcription 
start site, the first exon or 5’UTR regions), 3’UTRs and regions of the gene body. It 
covers CpG loci located in 96% of CpG islands, in addition to sites outside the island 
region such as CpG shore, shelf and isolated CpG (open sea). The 
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HumanMethylation450K array differs from other methylation arrays by using two probe 
types, Infinium I and Infinium II, to detect methylation level. Methylation level is 
represented by a β value ranging between 0 (= 0% methylation) and 1 (= 100% 
methylation). 
Here, before starting the analysis of GBM methylation data, raw data were first corrected 
and normalised using a correction pipeline, Lumi R package, to adjust the colour bias 
between the two different assays of Infinium I/II. Then, a series of data filtration 
processes were applied by removing the probes showing detection p-value >0.01 (which 
reflects poor hybridization), probes located on X or Y chromosomes, probes for 
imprinted genes and probes with SNPs. Hypermethylation in tumour samples was 
considered when CpG loci demonstrated high methylation (β value >0.5) in >30% of the 
samples and β value <0.25 in any of the four normal samples. Hypomethylation was 
determined when the probe β value was <0.25 in 30% of tumour samples and methylated 
in any of the four normal samples (β value >0.5). At the end of the filtration process, 
129,545 and 197,297 probes were tumour specific hypermethylated and hypomethylated, 






   
   
   
   














































































































































































































































































































3.3.1 Array validation 
At the time of this study, the HumanMethylation450K BeadChip array was a very new 
assay in the field. Validation of the individual β value of the array data using another 
method was required, thus, a number of selected genes known to be methylated in 
glioblastoma (HOXA3, FZD9, RASSF1A, and SLIT2) were used to evaluate the β values 
of the Infinium probes (Di Vinci et al. 2012, 3; Dallol et al. 2003; Hesson et al. 2004; 
Martinez et al. 2009). For each gene, selected CpG sites were examined in different 
samples with high and low β values using bisulfite sequencing. From this data, a probe 
methylation value was determined (which should be most comparable to the β-value 
generated from the array) and the Methylation Index (MI) of the whole selected region 
was calculated as a percentage (MI = percentage of methylated CpGs out of the total 
number of CpGs in the region). For HOXA3, 3 adjacent probes (cg15982700, 
cg16748008 and cg16406967) were examined in 3 different samples (2 with high β 
values and 1 with low β values) using bisulfite sequencing. Sequencing of the highly 
methylated samples showed that the probe methylation level (0.8/0.8/1 and 1/0.8/1, 
respectively) was high enough to be considered methylated, matching the methylation 
status of nearly all of the array β values (0.4/0.55/0.7 and 0.53/0.52/0.7, respectively) 
Reassuringly, high methylation index (MI) values for the two methylated samples (87.5% 
and 88.88%, respectively) were also detected and matched the probe methylation value 
well (Figure 3.2). Importantly, probes with lower β values (0.17/0.04/0.03) showed low 




confirming the criteria used to determine methylation events, these findings demonstrated 
that the level of methylation of a single CpG site is generally representative for the 
methylation of the surrounding CpG island region. The same observation was applicable 
for the other probes of the remaining genes (FZD9, RASSF1A and SLIT2). The probe 
values and β values were similar and MIs were representative of the overall methylation 
of the region (Figures 3.3, 3.4 and 3.5). 
Generally, validation of the array’s probe by bisulfite sequencing showed that probes 
with a β value ≥0.4 indicated a high level of methylation at the level of the CpG site and 
the level of the CpG island, while probes with much lower β values demonstrated very 
low to no methylation in the probe position and the surrounding CpG island. These 
results supported the stringent criteria selected in this study, where a β value of <0.25 



















Illustration of clone sequencing results for the region within the HOXA3 CpG island, 
where the probes (cg15982700, cg16748008 and cg16406967) are located. A schematic 
diagram of part of the gene (blue) and CpG island (green) is shown. Sequencing results 
are shown for 3 samples with the corresponding ! value, probe value and methylation 
index (MI). For each case, "9 clones (each representing a single allele) were selected for 
bisulfite sequencing and then analysed using CpG Viewer software. Black lollipops 
represent methylated CpGs (retained as cytosine following bisulfite modification), while 
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Illustration of clone sequencing results for the region within the RASSF1A CpG island 
that contains the cg04743654 probe. A schematic diagram of part of the gene (blue) and 
CpG island (green) is shown. Sequencing results are shown for 3 samples with the 
corresponding ! value, probe value and methylation index (MI). For each case, "9 clones 
(each representing a single allele) were selected for bisulfite sequencing and then 
analysed using CpG Viewer software. Black lollipops represent methylated CpGs 
(retained as cytosine following bisulfite modification), while white lollipops represent 







































Illustration of clone sequencing results for the region within the FZD9 CpG island, where 
the probes (cg12300292, cg00866572 and cg08649099) are located. A schematic diagram 
of part of the gene (blue) and CpG island (green) is shown. Sequencing results are shown 
for 3 samples with the corresponding ! value, probe value and methylation index (MI). 
For each case, "9 clones (each representing a single allele) were selected for bisulfite 
sequencing and then analysed using CpG Viewer software. Black lollipops represent 
methylated CpGs (retained as cytosine following bisulfite modification), while white 
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Illustration of clone sequencing results for the region within the SLIT2 CpG island, where 
the probes (cg18972811 and cg13281139) are located. A schematic diagram of  part of 
the gene (blue) and CpG island (green) is shown. Sequencing results are shown for 3 
samples with the corresponding ! value, probe value and methylation index (MI). For 
each case, "9 clones (each representing a single allele) were selected for bisulfite 
sequencing and then analysed using CpG Viewer software. Black lollipops represent 
methylated CpGs (retained as cytosine following bisulfite modification), while white 






















Figure 3.5 Validation of array’s ! value for SLIT2 
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3.3.2 CIMP in a subset of LTS grade IV glioblastoma 
3.3.2.1 Hierarchical cluster analysis 
To gain a general insight into the methylation pattern of the glioblastoma tumour samples 
used in this study, unsupervised hierarchical clustering of the 500 most variable loci was 
performed on the 19 STS and 16 LTS glioblastoma samples. The cluster analysis 
separated glioblastoma samples into 2 distinct groups; the smallest of the cluster groups 
consisted of 5 LTS tumour samples, which showed extensive hypermethylation across the 
probes (average β value = 0.66). Such a high level of generalised methylation is 
indicative of a CpG island hypermethylator phenotype (CIMP), which has been 
documented in many cancer types, including glioblastoma (Noushmehr et al. 2010). 
These samples have therefore been classified as CIMP+ (Figure 3.6). The largest cluster 
group consisted of all STS samples plus 11 samples of non-CIMP LTS cases. Probes in 
this group demonstrated low levels of methylation (average β value = 0.25). To gain 
insight into the methylation differences between STS and non-CIMP LTS glioblastoma, 
another unsupervised hierarchical clustering was conducted on the 500 most variable 
probes in all non-CIMP glioblastoma tumours (n=30). The clustering divided the samples 
into two main cluster groups (Figure 3.7). Cluster 1 was associated with low level 
methylation (average β value = 0.22) and it mainly consisted of STS samples (n=10, 
71.4%), while LTS samples comprised 28.6% of the group. Cluster 2 was associated with 
higher levels of methylation (average β value = 0.44) and contained equal numbers of 
STS (n=7, 50%) and LTS (n=7, 50%) samples. Two STS outlier samples were found on 
the left hand side of the clustering. This observation suggested there were slight 





















The clustering identified G-CIMP+ in 5 LTS tumours with a concentration of 
hypermethylated loci. The remaining G-CIMP- STS and LTS tumours were clustered 
together. CpG loci are colour coded from red (high methylation) to green (low 
methylation). CIMP status (red, CIMP+; green, CIMP-), IDH mutation status (red, 
mutated; green, unmutated), MGMT methylation status (red, methylated; green, 
unmethylated; white, undetermined), and type of glioma (blue, STS; yellow, LTS) is 
shown in the information bar below the figure. 


















The clustering splits the samples into two main cluster groups. The first group is 
associated with a low level of methylation and it mainly contains STS samples (n=10, 
71.4%), while LTS samples comprise 28.6% of the group. Also, the majority of the 
samples show no methylation of MGMT gene (76.9%), whereas the other group is 
associated with a high methylation level and contains equal numbers of STS (n=7, 50%) 
and LTS (n=7, 50%) samples. This group also shows 50% methylation of MGMT gene.  
Two outlier samples are found on the left hand side of the clustering. The black and white 
shading of the cluster represents high or low methylation respectively. The box above the 
clustering represents MGMT methylation (black, methylated; white, unmethylated) and 
type of glioma (white, STS; black, LTS). 
 
Figure 3.7 Unsupervised hierarchical clustering was conducted on the 500 most 




3.3.2.2 IDH1/IDH2 mutation and MGMT methylation  
MGMT promoter hypermethylation and IDH1/IDH2 mutation status have been described 
extensively in many glioblastoma studies and associated with better prognosis and 
treatment response. Therefore, methylation specific PCR (MSP) was performed to 
examine MGMT promoter methylation status in all glioblastoma samples. The results 
showed that methylation of the MGMT gene was similar between STS and LTS samples 
(38.9% and 46.7% respectively) regardless of the glioma CpG island methylator 
phenotype. 
DNA sequencing was performed to determine the mutation status of 2 previously 
described hotspot mutations in the IDH1 and IDH2 genes in glioblastoma samples. The 
location surrounding the hotspot mutation in exon 4 (R132) was amplified and sequenced 
in the DNA of all STS and LTS samples. Only 5 cases demonstrated IDH1 (R132) 
mutation and all 5 were LTS tumours with CIMP+ phenotype (Figure 3.8). Samples of 
wild-type for IDH1 at the position R132 were subsequently analysed for IDH2 mutation 
at R172 position, which is the equivalent to R132 in IDH1. No IDH1 or IDH2 mutations 
were found in the remaining STS and LTS glioblastoma samples. In this study, 60% of 

























Sanger sequencing confirms IDH1 mutation in G-CIMP+ LTS glioblastoma tumours 
(LTS 31, LTS 34, LTS 36, LTS 47 and LTS 49) but not in G-CIMP- LTS glioblastoma 
(LTS 41). The identified IDH1 mutation in all G-CIMP+ LTS glioblastoma tumours was 








3.3.2.3 Confirmation of G-CIMP+  
During the original study that identified CIMP within glioblastoma (Noushmehr et al. 
2010), seven signature genes were identified (ANKRD43, HFE, MAL, LGALS3, FAS, 
RHO, DOCK5), whereby a specific methylation status indicated a hypermethylator 
phenotype within glioblastoma, referred to as G-CIMP+. According to the criteria in the 
Noushmehr study, a combination of at least 5 of the 7 signature genes must show low 
methylation in DOCK5 and/or high methylation in the other genes. To determine whether 
the CIMP classification from earlier clustering analysis was in agreement with previous 
G-CIMP descriptions, the probes for these 7 signature genes were assessed among the 
STS and LTS samples. When applying these criteria, only the 5 IDH mutated LTS 
samples showed hypomethylation of DOCK5 and hypermethylation of at least 4 of the 
remaining genes, matching Noushmehr’s criteria for G-CIMP+ (Figure 3.9). None of the 
remaining IDH-wt glioblastoma samples fulfilled the criteria (max 4/7) and therefore 
exhibited G-CIMP- phenotype. This finding confirms the previous classification of CIMP 
status within STS and LTS samples and illustrates the close association between the 
CIMP phenotype and IDH mutation, which is in agreement with other studies (Turcan et 
al. 2013; Noushmehr et al. 2010).  





























































































































































































































3.3.2.4 Identification of G-CIMP genes in LTS with IDH-mut 
Use of the HumanMethylation450K BeadChip was able to identify a massive number of 
hypermethylated loci within the 5 IDH mut G-CIMP+ compared to STS and non-CIMP 
LTS glioblastoma with wildtype IDH (11,293, 2,638 and 3,101 CpG loci, respectively).  
In order to use this data to identify additional G-CIMP+ genes, the IDH mut/CIMP+ and 
IDH wt/non-CIMP groups were subjected to further analysis. By applying a student’s t-
test and then selecting genes with >3 probes within the promoter region that exhibited an 
FDR corrected P value of <0.05 between the two groups of IDH mutated and IDH 
wildtype samples, 535 genes (2377 CpG loci) were identified as CIMP+ genes (Appendix 
7.3). DAVID bioinformatics functional analysis of the gene list indicated these genes 
were involved in various cell regulation processes such as regulation of cell migration (40 
genes), cell-cell signalling (105 genes), cell-cell adhesion (47 genes), Wnt signalling 
pathway (22 genes), regulation of cell growth (55 genes) and apoptosis (89 genes). 
Analysis of the gene list using the Ingenuity Pathway Analysis (IPA) showed that 31% of 
the genes (166/535) were associated with different types of cancer and cancer 
developmental processes such as epithelial tumours (125 genes), solid tumours (122 
genes), colon cancer (46 genes), metastasis (35 genes), tumour development (21 genes), 
growth of tumours (22 genes) and tumour angiogenesis (9 genes) (Appendix 7.4). 
Molecular and cellular function analysis of the CIMP genes divided the gene list into 5 
different functional categories, where the majority of the genes were involved in cell 
proliferation and growth (166 genes, 31%). The other categories consisted of cellular 
movement (121 genes, 22.6%), cell morphology (126 genes, 23.6%), cellular 
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organization (105 genes, 19.7%) and cellular maintenance (143 genes, 26.7%), where 50 
genes were common among the 5 categories (Table 3.1). Also, a large number of the 
hypermethylated CIMP+ genes were found to be involved in glutamate receptor 
signalling (Figure 3.10) and cell morphology, death and survival (Figure 3.11). 
Interestingly, when looking at the G-CIMP+ genes identified by Noushmehr et al.’s 
group, 31% of the identified CIMP+ genes in the current study were common. Taking all 
this together, these 535 hypermethylated genes in IDH-mut LTS glioblastoma might be 
markers for the G-CIMP+ phenotype. 




















































































































































































































































































































































































































































































































































































   
   
   










































































































































































































































Glutamate Signalling Receptor (7/69 molecules p=0.001) 
 
 
Figure 3.10 Canonical pathway generated from ingenuity analysis of the 535 CIMP 
associated genes list 
Methylated genes in glutamate receptor signalling (PICK1, GLNS, GRIN, GRM8, GLS, 























Methylated genes are shaded grey, while the necessary connecting genes are unshaded.  
This figure was kindly prepared by Victoria Hill (School of Clinical and Experimental 
Medicine, University of Birmingham). 
 
 




3.3.3 Methylome of glioblastoma  
Identification of IDH mutation in a subset of LTS glioblastoma samples led to splitting 
the study cohorts into 3 groups: STS, LTS with IDH-mut and LTS with IDH-wt. After 
filtering the methylation data and applying the hypermethylation and hypomethylation 
criteria (as discussed earlier at the beginning of the chapter), the number of 
hypomethylated CpG loci showing β value <0.25 was low in each of the 3 groups of 
glioblastoma (946, 690 and 1,402 CpG loci for STS, LTS with IDH-wt, and LTS with 
IDH-mut respectively) in comparison to hypermethylated loci (2,638, 3,101 and 11,293 
CpG loci for STS, LTS with IDH-wt, and LTS with IDH-mut respectively). The large 
number of hypermethylated loci in LTS with IDH-mut was due to the presence of the 
CpG island methylator phenotype.  
Despite the difference in the number of hyper/hypo methylated CpG loci, the distribution 
of these loci in the genome was very similar among the 3 groups. In STS glioblastoma, 
the majority of hypermethylated CpG loci (1,064 loci, 40%) were located in the gene 
promoter region, 863 loci (33%) in the intergenic regions, 636 loci (24%) in the gene 
body and 75 loci (3%) in 3’UTR (Figure 3.12). By looking at the distribution of CpG loci 
in relation to CpG island, the majority of the hypermethylated loci resided within CpG 
islands (1,747 loci, 66%) and the remaining were distributed in CpG shores (638 loci, 
24%), CpG shelves (77 loci, 3%) and open sea (176 loci, 7%). On the other hand, the 
majority of hypomethylated loci in STS glioblastoma were located in the gene body and 
intergenic regions, 33% and 38% respectively, and 74% were found as isolated CpGs 
distributed in the genome (open sea), while 4% resided within the islands.  
 
 123 
In LTS glioblastoma cases, hypermethylated CpG loci in LTS with IDH1-mut were 
mainly located in the promoter regions (5,232 loci, 46%) and CpG islands (7,402 loci, 
66%) and shores (2,846, 25%), while hypomethylated CpGs were found in the open sea 
(1,026 loci, 73%), intergenic regions (523 loci, 37%) and very few (14 loci, 1%) in CpG 
islands. CpG loci in LTS with IDH1-wt showed a similar distribution as in STS cases, 
where 46% (1,414 loci) of the hypermethylated loci were located in the promoter regions 
and 72% in CpG islands (2,241 loci), while 73% and 4% of the hypomethylated loci  

















































































































































































































































































3.3.4 In-silico validation using TCGA data 
To verify the observed hypermethylation patterns in glioblastoma samples a comparison 
between the top hypermethylated loci in STS glioblastoma and glioblastoma samples 
from The Cancer Genome Atlas (TCGA) data portal was carried out. All glioblastoma 
samples from the TCGA website (n=18) that had both (a) data available from the 
HumanMethylation450K array and (b) a survival time of < 1 year from the initial date of 
diagnosis were used for this comparison (n=18). Of 2,638 hypermethylated CpG loci in 
STS glioblastoma, the top 80 hypermethylated loci that showed a β value of >0.5 in 
>30% of the total number of tumour samples were selected and analysed in glioblastoma 
samples downloaded from the TCGA website. As expected, all CpG loci were confirmed 
to be hypermethylated in TCGA glioblastoma samples (Figure 3.13). Analysis of LTS 
tumours in the TCGA dataset was not carried out because methylation data from the 










































































































3.3.5 Differentially methylated genes in STS glioblastoma 
3.3.5.1 Hypermethylated loci in STS vs. LTS glioblastomas 
Differential analysis between STS and LTS glioblastoma was carried out to identify 
epigenetic markers for poor prognosis. To identify the hypermethylated genes in STS vs. 
LTS, the criterion of a FDR corrected P value below 0.05 and at least a median β value 
difference of 0.2 between STS and LTS cases was applied. Furthermore, to ensure 
hypermethylation and loss of expression association, only CpG loci located within the 
promoter region (TSS200, TSS1500, 5’UTR and 1st exon) were selected. This analysis 
generated a list of 23 genes (32 CpG loci) that showed significant hypermethylation in 
STS glioblastoma compared to LTS glioma (Table 3.2). Among the list, there were 
several genes previously known to be involved in cancer (HOX genes) or known to be 
methylated in glioma (CBLN1, CBLN4 and ISM1). IPA analysis of the gene list revealed 
that 43.5% (10/23) of the genes were associated with cancer, 30.4% (7/23) were involved 
in cell morphology and 8.7% (2/23) were related to cell death and survival respectively 
(Table 3.3). Univariate Kaplan-Meier survival analysis was carried out for NR2F2 and 
INA. DNA methylation was found to be associated with poor patient prognosis for both 
NR2F2 and INA, P value = 0.034 and 0.036 respectively (Figure 3.14A). We also looked 
at gene expression and patient survival using the free online tool PrognoScan. 
PrognoScan uses publically available cancer microarray expression datasets to find the 
relationship between gene expression and patient prognosis and calculates the 
significance of the difference in outcome as corrected P values. The overall survival (OS) 
of the 3 genes, CBLN1, HOXD13 and DKK2, was analysed in PrognoScan by selecting 
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cohorts of glioblastoma. The loss of expression of HOXD13 and DKK2 in the GSE7696 
dataset was significantly associated with poor overall survival (corrected P value = 0.03, 
and 0.01, respectively). For CBLN1, overall survival was also analysed in a different 
glioblastoma cohort (MGH-glioma) and showed a significant association between loss of 
gene expression and poor outcome (corrected P value = 0.02) (Figure 3.14B). The 
association of DNA methylation/loss of expression of these genes with poor prognosis 
suggests that the identified genes may be potential markers for disease outcome and also 






Table 3.2 List of 23 genes of the significantly differentially hypermethylated genes in 
STS tumours 
Gene name, probe ID, location in relation to CpG island and chromosome number are 







RELATION TO CpG 
ISLAND CHR
DKK2 dickkopf 2 cg00594011 0.02 Island 4
INA
internexin neuronal intermediate 










GRM6 glutamate receptor, metabotropic 6 cg12483476 0.02 Island 5
FAM190A family with sequence similarity 190 A cg17397028 0.02 Island 4
cg26715952 0.02 Island
cg22014661 0.03 Island
HOXD8 homeobox D8 cg03858756 0.022 Island 2
CBLN4 cerebellin 4 precursor cg20779964 0.022 Island 20
RAB6C member RAS oncogene family cg09676860 0.028 Island 2
HOXD13  homeobox D13 cg10418524 0.023 Island 2
CBLN1 cerebellin 1 precursor cg16573782 0.023 Island 16
ISM1  isthmin 1 homolog cg20081364 0.03 Island 20
HOXC4  homeobox C4 cg01473837 0.03 S_Shore 12
MSC  musculin cg14546394 0.03 S_Shore 8
DPP10  dipeptidyl-peptidase 10 cg21678377 0.03 Island 2
TFAP2A transcription factor AP-2 alpha cg10129408 0.03 N_Shore 6
PDX1  pancreatic and duodenal homeobox 1 cg25685262 0.03 N_Shore 13
NEFM neurofilament, medium polypeptide cg04118306 0.035 Island 8
TBX18 T-box 18 cg04515996 0.04 Island 6
TPBG trophoblast glycoprotein cg08478195 0.04 Island 6
HIST3H2
A
histone cluster 3, H2a cg06034933 0.046 Island 1
PRR16  proline rich 16 cg27107171 0.046 Island 5
PRKCB protein kinase C, beta cg08406370 0.049 N_Shore 16
NR2F2






 KH domain containing, RNA binding, 
signal transduction associated 2 6
Hist3h2a 




































































































































































































































































































































































































































































































































A) Curves show a strong association between CpG loci hypermethylation of NR2F2 (i) 
and INA (ii) and poor patient survival. Both loci showed significance and P values are 
shown. B) Kaplan Meier survival plots show the association of gene expression and poor 
survival in CBLN1 (i), DKK2 (ii) and HOXD13 (iii). Corrected P values are also shown 







i) CBLN1 P=0.02 
ii) DKK2 P=0.01 
iii) HOXD13 P=0.03 




3.3.5.2 Expression analysis using 5-azaDC treated cell lines 
To confirm the possible biological relevance of DNA promoter hypermethylation, 
expression analysis was carried out in glioma cell lines pre- and post-treatment with the 
demethylating agent, 5-aza-2-deoxycytidine (5-azaDC) for 3 genes from Table 3.4. 
Hypermethylation of the top gene in the list, DKK2, was associated with loss of 
expression in glioma cell lines and showed re-expression in cell lines treated with 5-
azaDC, thus functional validation of DKK2 DNA methylation (Figure 3.15). The other 2 
genes analysed, TFAP2A and NR2F2, also showed up-regulation in cell lines post 5-
azaDC treatment.  
 
3.3.5.3 Further confirmation of the methylation array data for DKK2 
DKK2 CpG probe cg00594011 was located in the promoter region (1st exon) and CpG 
island of the gene. Bisulfite clone sequencing was carried out on two hypermethylated 
STS samples and two unmethylated LTS samples to confirm the array data for DKK2. 
Both hypermethylated STS samples, β value = 0.68 and 0.7, showed high probe values 
(0.88 and 1, respectively) and a high methylation index (MI = 56.5% and 60.3%, 
respectively). On the other hand, the two unmethylated LTS samples showed a low β 
value (0.07 and 0.1) and a low probe value (0.0 and 0.1, respectively) with a low 

























CoBRA results (Meth.) for DKK2 and NR2F2 are shown for selected glioma cell lines 
along with expression (Exp.) with (5-aza) and without (-ve) treatment. U, Undigested; D, 
Digested; M, methylated; UM, unmethylated.  






    
A schematic diagram of the gene (blue) showing the location of the CpG island (green) 
(i), Clone sequencing of the selected region, (ii) for each sample MI was calculated for 
the infinium CpG loci and for the whole analysed region. 
 
 
Figure 3.16 Confirmation of DKK2 methylation by clone sequencing 
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3.4 Discussion  
Glioma is the most common form of primary brain tumour. According to the World 
Health Organization (WHO), gliomas are classified into four grades. Grade IV tumours, 
glioblastomas, are the most aggressive form and have limited treatment options with a 
median survival time of 12 months after diagnosis (Barbus et al. 2011). However, a small 
subset (3%-5%) of glioblastoma patients show a longer survival time of >3 years. These 
patients are called long-term survivors (LTS) and they are characterised by a good 
Karnofsky performance (KPS), younger age, tumours with MGMT hypermethylation and 
almost no EGFR amplification (Krex et al. 2007; Hartmann et al. 2013). 
The regulation of gene expression by DNA methylation is often altered in cancer. 
Generally, DNA hypermethylation at the promoter region represses the transcription of 
tumour suppressor genes, resulting in decreased gene expression, while methylation of 
the gene body is associated with oncogenes. Aberrant DNA methylation has been 
reported to be involved in glioma development. Some examples include DNA 
hypermethylation of the genes involved in apoptosis (PYCARD), cell migration genes 
(TIMP3, CDH1 and PCDH) and DNA repair genes (MGMT) among others (Malzkorn et 
al. 2011).  
In the past few years, many high throughput technologies have become available for 
genome-wide epigenetic studies including methylation arrays and next generation 
sequencing technology. Illumina methylation platforms for genome-wide DNA 
methylation analysis have been evolving since the release of the first methylation array, 
the 1,536 CpG Illumina GoldenGate DNA Methylation BeadArray followed by the 
Infinium HumanMethylation27 BeadChip, which was widely used in many studies 
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including those on cancer, aging and non-cancerous diseases. The most recent and largest 
platform from Illumina is the Infinium HumanMethylation450 BeadChip, which is able 
to assess the methylation level of more than 485,000 CpG sites. The 
HumanMethylation450K array is unique as it uses both Infinium I and Infinium II 
technologies where the Infinium I assay uses two separate bead types for each CpG 
probe, one for methylated C detection and one for the unmethylated or (T) detection, 
using one colour channel. On the other hand, the Infinium II assay uses one bead type to 
detect the methylated and unmethylated loci at the same time using two colour readouts 
(green/red) (Malzkorn et al. 2011). Then, the intensity of the signals is measured and 
calculated to generate the β value, which is the percentage of methylation represented in a 
range from 0 to 1 (corresponding to 0% and 100% methylation respectively) 
(Dedeurwaerder et al. 2011).  
At the gene level, the HumanMethylation450K array covers ∼99% of RefSeq genes and 
CpG loci distributed across the promoter region (200bp and 1500bp from transcription 
start site, 5’UTR and 1st exon), 3’UTR and gene body. One of the advantages of the 
technology is that it covers >96% of the CpG islands and areas adjacent to the islands 
(CpG shore; 2Kb away from the island and CpG shelf; 2Kb away from CpG shore) as 
well as independent CpG sites outside the islands (open sea). In this study, the latest 
genome wide HumanMethylation450K microarray was utilised to evaluate the 
methylation profiles of 19 short-term survivor and 16 long-term survivor glioblastoma 
patients and to gain an insight into promoter DNA methylation changes that may 
contribute to, or be indicative of, poor prognosis in STS glioblastoma patients.  
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3.4.1 Pre-processing the HumanMethylation450K array data  
3.4.1.1 Divergence of Infinium I and Infinium II probes 
After obtaining the array’s raw data and in order to ensure an accurate analysis of DNA 
methylation array data in this study, stringent quality control analyses were applied at an 
early stage to exclude any possible faults or weaknesses that may result in invalid 
decisions, which may affect downstream analysis. Bibikova et al. noticed the technical 
differences between β values generated by Infinium I and Infinium II probes (Bibikova et 
al. 2011) where the distribution and value range in Infinium II were narrow, suggesting 
that Infinium II is less accurate due to using two different chemistry methods. Another 
evaluation study of the Infinium HumanMethylation450K array using HCT116 colon 
cancer cell line and its unmethylated derivative (DKO) cell line was carried out, where 
data from Infinium I and Infinium II were analysed separately to compare the 
performance of the two assays. β values from Infinium type II showed a smaller range 
compared to the type I probes which affected the values near to 0 and near to 1 β values 
(Dedeurwaerder et al. 2011). In this study it was suggested to treat the 450K array data as 
two different arrays and that the results from the two types of probe should be analysed 
separately. According to Illumina, the difference between the two chemistries should not 
affect the accuracy of the data, as the analysis should be performed on an individual site 
across all samples rather than comparing between different probes within a single sample. 
To overcome this limitation of the 450K array, many pipelines are available to re-scale 
and normalise β values generated from type II probes such as R packages: Illumina 
Methylation Analyzer (IMA) (Wang et al. 2012), Subset-quantile Within Array 
Normalization (SWAN) (Maksimovic, Gordon and Oshlack 2012) and LUMI (Du, Kibbe 
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and Lin 2008). To ensure an accurate analysis of the current study, data correction and 
normalization was used to correct the colour bias between Infinium I/II probes. To 
achieve this, a pipeline to process Illumina array, LUMI, from GenomeStudio software 
(Du, Kibbe, and Lin 2008) was applied. The IMA pipeline is able to correct the data 
including missing β values and then perform a quantile normalization to exclude the 
technical variations across the probes without major alterations in the data.  
 
3.4.1.2 Detection p-value 
Generally, the detection p-value is the intensity of a CpG probe compared to the intensity 
of an internal negative control. Several problems can be generated during the 
hybridization process, which may lead to faulty results. Problems such as incorrect signal 
reads, reads with low intensity, defects in the probe design, weak hybridization or 
mutations within the sample’s DNA, are all translated as high detection p-values 
(Dedeurwaerder et al. 2013). Removing probes with a high detection p-value can reduce 
false-positive results, therefore in this study, more than 9,400 probes, showing a detection 
p-value of >0.01, were excluded from the analysis.  
 
3.4.1.3 Imprinted genes, probes on X/Y chromosomes and probes over SNPs 
Many sex-associated studies have discussed the methylation difference in X and Y 
chromosomes. Methylation levels can be affected by chromosome X inactivation or by  
having one X chromosome copy in males (Chen et al. 2013). To overcome this issue of 
gender bias, all probes located on X or Y chromosomes, or probes of imprinted genes 
were excluded from further analysis.  
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Polymorphic CpGs were also addressed as a problem in many studies, since the 
methylation array can detect naturally existing C/T SNPs in any sample. By matching the 
position of (C) of the Infinium array in the genome to the SNPs database in the 1000 
Genomes Project database, Illumina has identified that 13.8% of total probes (9.4% of 
Infinium I probes and 15.5% of Infinium II probes) are polymorphic CpGs (Chen et al. 
2013; Dedeurwaerder et al. 2013). For that reason, CpG with SNP were removed from 
the current study.  
After applying this filtration process along with the individual validation of the β value, 
the analysis of the hypo/hyper methylation profile of STS and LTS tumours was 
conducted with confidence. 
 
3.4.2 CIMP in a subset of LTS glioma 
The term CpG island methylator phenotype, CIMP, has widely emerged as a distinct sub-
classification in many types of tumour such as breast cancer, colorectal cancer and 
glioblastoma (Fang et al. 2011; Toyota et al. 1999; Noushmehr et al. 2010). The 
methylator phenotype was first observed in 1999 by Toyota et al. as massive 
hypermethylation of a specific group of loci in a subset of colorectal tumours (Toyota et 
al. 1999). Later, CIMP was extensively studied in colorectal cancer and other cancers 
using new technologies such as MethyLight and pyrosequencing. In glioma, CIMP was 
identified in a distinct subgroup and was tightly associated with IDH mutation 
(Noushmehr et al. 2010). Generally, IDH is required in the oxidative decarboxylation 
process of α-ketoglutarate (section 1.5.4.1). The arginine 132 residue (R132) in IDH1, 
and its analogue arginine 172 (R172) in IDH2, is functionally important for isocitrate 
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binding and converting the enzyme to α-ketoglutarate. However, mutated IDH1 drives 
the synthesis of 2-hydroxyglutarate which inhibits α-ketoglutarate dependant histone 
demethylases and leads to promoter hypermethylation (Figueroa et al. 2010; Xu et al. 
2011). 
Glioma specific IDH1 mutations (R132) were found in >95% of IDH mutated glioma 
cases and they always occur as somatic, missenses mutations (Krell et al. 2011; Turcan et 
al. 2012). The mechanism of how the mutant IDH form leads to G-CIMP in glioblastoma 
is still unclear and raises questions. Turcan et al. demonstrated that IDH1 mutation is the 
main cause of CIMP+ in glioblastoma and thus DNA hypermethylation (Turcan et al. 
2013). However, a few cases reported that CIMP could occur in wild-type IDH 
glioblastoma (Brennan et al. 2013; Hill et al. 2014). Interestingly, glioblastoma patients 
with the mutant IDH gene and that are positive for CIMP have shown a better prognosis 
and survival (Christensen et al. 2011; Turcan et al. 2012).  
Promoter hypermethylation of MGMT is also widely reported in glioblastoma and has 
been associated with better response to treatment with alkyating agents. MGMT 
hypermethylation was first reported as a dominant observation in glioma cases (M. 
Esteller et al. 1999) and was later found to be associated with better treatment response 
(Manel Esteller et al. 2000). Many studies have found an association between CIMP 
status and IDH mutation and MGMT promoter hypermethylation. G-CIMP subgroups are 
always associated with better survival and are strictly linked with IDH mutation. MGMT 
hypermethylation was also associated with better prognosis, but was more of a general 
and prognostically favourable genome wide methylation profile with no close relation to 
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CIMP status (Bady et al. 2012; van den Bent et al. 2011). In the current study, cluster 
analysis showed massive hypermethylation in 5 LTS cases across a large number of CpG 
loci exhibiting the G-CIMP+ phenotype. Only these 5 cases were mutated for IDH1 (5/5, 
100%), of which 60% (3/5) also demonstrated MGMT hypermethylation, which agrees 
with many recent studies (Noushmehr et al. 2010; Turcan et al. 2012), and fulfilled the 
criteria of G-CIMP+ addressed in Noushmehr et al.’s paper. Our study identified 535 G-
CIMP genes that were involved in many essential cell regulation processes and that had 
been reported previously in many cancer studies, suggesting biomarkers for the CIMP+ 
phenotype in glioblastoma. Among the identified list of G-CIMP+ genes, the cytokine 
signalling 3 gene (SOCS3), which was identified by 4 probes located within the promoter 
CpG island (Appendix 7.3), was confirmed to be statistically significantly 
hypermethylated in a group of LTS glioblastoma tumours as shown in a very recent study 
by Feng et al. (Feng et al. 2014). They were able to confirm the hypermethylation in an 
independent cohort using pyrosequencing and also in a TCGA glioblastoma cohort, 
which showed a significant association between DNA hypermethylation and longer 
survival, suggesting a novel marker for G-CIMP+. This study agrees with our finding and 
is an indicator of the validity of the identified G-CIMP+ gene list in our study.  
 
3.4.3 Genes associated with poor prognosis in STS patients 
Many genetic and epigenetic alterations have been associated with non-CIMP (or CIMP-) 
glioblastoma formation and identified as predictors of poor prognosis. Patients with 
mutations in LIG4, PTEN and BTBD2, EGFR amplification and hypomethylation 
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changes in LINE-1 had shown poor survival with a high risk of death at an early age 
(Malzkorn et al. 2011; Liu et al. 2010, 4). In addition, many studies have shown the effect 
of CpG island promoter hypermethylation in glioma malignancy, including the well-
known MGMT role in glioma patients’ treatment.  
In this study, the investigation aimed to find differentially hypermethylated genes that 
may be responsible for poor prognosis in STS patients. The differential analysis was 
carried out between STS vs. LTS tumours. The above analysis led to the identification of 
32 loci (representing 23 genes). These loci were located in CpG islands, shores or shelves 
and were associated with cancer, according to the IPA ingenuity analysis. Most of the 
genes within the list were represented by a single probe with the exception of NR2F2 
(nuclear receptor gene), which was represented by 9 CpG loci located in the CpG island 
and showed a strong correlation between gene hypermethylation and poor survival. 
Similarly, the disruption of NR2F2 expression was previously reported in ovarian cancer 
and was associated with short survival (Hawkins et al. 2013). Another gene amongst our 
list of differentially methylated genes, the alpha internexin gene (INA) was recently 
investigated in pancreatic tumours, where reduced gene expression was related to 
metastasis and short overall survival in pancreatic cancer patients (B. Liu et al. 2014), 
and in lower grade glioma (Figarella-Branger et al. 2012). Also among the list of 
differentially hypermethylated genes were a number of the Homeobox gene family, 
HOXD8, HOXD13 and HOXC4, which have been described in many cancers. 
Hypermethylation of HOXD genes has been reported previously in glioma (Wu et al. 
2010), mantle cell lymphoma (Leshchenko et al. 2010) and HOXC aberrant expression in 
leukaemia and prostate cancer (Miller et al. 2003). The transcription factor (TFAP2A) 
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was found to be epigenetically silenced in prostate cancer and head and neck carcinoma 
(Bennett, Romigh, and Eng 2009). Also, the glutamate receptor gene GRM6 was 
identified in clear cell renal cell carcinoma as a CIMP marker in ccRCC (Arai et al. 
2012). CBLN proteins are expressed throughout the cerebellum and genes from the 
CBLN family were found to be involved in many regulatory signalling pathways and 
receptors (Wei et al. 2012). Hypermethylation of CBLN1 and CBLN4 had not been 
reported prior to this study in any type of cancer. All these genes were hypermethylated 
in the short-term survival patients, suggesting a prognostic significance. The Dickkopf-2 
gene (DKK2) is a negative regulator of the Wnt/β-catenin signalling pathway. Studies 
have reported that DKK2, a homolog of DKK1, accelerates tumour cell growth and 
positively induces angiogenesis (DKK1 negatively regulates angiogenesis) (Park et al. 
2014, 1). Also, DKK2 is a target gene for multiple micro-RNAs which activate the 
Wnt/β-catenin signalling pathway and promote tumourigenesis such as MicroRNA-222 
and MicroRNA-21 in oral cancer cell invasion (Li et al. 2013; Kawakita et al. 2013). 
Furthermore, DKK2 was reported as a pro-metastatic gene in Ewing sarcoma and 
overexpression was associated with high invasiveness and differentiation in Ewing 
sarcoma cells (Hauer et al. 2013). The current study confirmed that promoter 
hypermethylation of DKK2 was significantly associated with loss of expression which 
was also associated with poor prognosis and worse overall survival in STS tumours. Our 
study suggests that DKK2 methylation should be analysed further to assess its potential as 





The aims of this study were to investigate the methylation profile of STS and LTS 
glioblastoma tumours and to identify differentially methylated genes that may be 
associated with worse patient prognosis using the latest technology from Illumina, the 
Infinium HumanMethylation450 array. This 450K methylation array is a cost effective 
method for epigenome wide analysis that utilises a large number of patient samples. This 
platform has more advantages compared to the old methylation platforms (27K array and 
GoldenGate array). The significantly increased number of probes in the 
HumanMethylation450 array allows the analysis of >96% of CpG sites in more than 99% 
of RefSeq genes in addition to CpGs outside the island regions such as CpG shores and 
CpG shelves which have been shown to be associated with gene expression. 
The generated list of differentially methylated genes consisted of novel and known genes 
that were hypermethylated in STS tumours. Further work is required to confirm these 
findings in a separate, larger cohort, and to investigate the biological and functional 
relevance of these genes in glioma development. Some of the genes, such as DKK2, 
NR2F2 and the transcription factor TFAP2A, are good candidates for additional analysis 
in grade IV glioblastoma to investigate whether these genes would be candidates as 
markers for disease outcome. Also, it would be beneficial to study the hypermethylated 
genes identified in CIMP+ LTS glioblastoma tumours to gain an insight into the role of 
IDH mutation and CIMP in gliomagenesis, which would later be helpful in cancer 
therapies. 
In summary, since the molecular genetic and epigenetic factors behind long-term and 
short-term survival in glioblastoma are still unclear, this study has used the latest 
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available technology to provide needed insight into the methylation profiles of STS and 
LTS glioblastoma. 
This work was presented at The Epigenetics conference (part of genomic research 














 Epigenetic Targets in Breast Cancer Brain Metastasis Chapter Four:
 
4.1 Introduction 
Brain metastasis is the most common type of central nervous system cancer with an 
incidence of 10:1 of brain metastasis to primary brain tumours, while lung, liver, skin or 
breast are usually the primary site for brain metastasis. Following on from the hypothesis 
of “seed-and-soil”, 15% of breast cancer patients develop metastasis in the brain where 
breast tumour cells prefer to disseminate, invade and adapt in the brain 
microenvironment. Therefore, brain metastasis usually indicates a patient’s poor 
prognosis with a median survival time of <8 months. Consequently, it is essential to 
understand the molecular mechanisms behind brain metastasis development from breast 
cancer (BCBM) and to identify the markers responsible for predisposing brain metastasis 
formation.  
Unlike tumour suppressor genes, metastasis suppressor genes are not involved in cell 
growth and proliferation; however, they regulate the processes required for cells’ 
dissemination, invasion and adaptation at the distant sites. Studies have shown that these 
genes are rarely mutated and other mechanisms, for instance epigenetic changes, may be 
responsible for the dysregulation of metastasis suppressor genes.  
Loss of gene expression due to DNA hypermethylation is a frequent event in cancer. The 
HumanMethylation450K array is the most appropriate method for investigating the 
methylation events within regulatory regions, such as gene promoters, in cancer samples. 
Probes located within CpG island proximity, and within the gene’s transcription start 
sites, 5’UTR, and 1st exon can be selected to ensure relevance between DNA 
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hypermethylation and loss of expression. In this preliminary study, the 
HumanMethylation450K array was utilised to identify potential signature genes for early 
prediction of breast cancer brain metastasis (BCBM) development.  
 
Aims of the study 
• To investigate DNA methylation profiles in BCBM samples and to identify 
gene(s) that may play a role in brain metastasis formation from breast cancer. 
• To compare the methylation level of these genes in brain metastasis samples from 
other primary organs, i.e. lung tumours and melanoma. 




4.2.1 Methylome of breast tumour vs. brain metastasis 
4.2.1.1 Cluster analysis 
In this study, methylation profile analysis of breast cancer brain metastasis (BCBM) was 
conducted by utilising HumanMethylation450K BeadChips on 5 brain metastasis (BM) 
derived from breast tumours. The HumanMethylation450K array data of breast tumours 
without metastasis (n=28) were obtained from the TCGA online data portal (batch 96) 
which were selected based on the criteria of having matched normal sample and having 
never formed metastasis to distant organs (by October 2012). Appendix 7.5 contains 
patients’ clinical information.  
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To gain an insight into the overall methylation pattern in BCBM and non-metastatic 
breast tumours, unsupervised Euclidean hierarchical clustering was conducted on the 
most 1000 variable loci from the combined data of 5 BM from breast cancer and non-
metastatic breast tumours (n=28) from the TCGA data portal (Figure 4.1). The clustering 
separated breast tumours (without metastasis) from BCBM samples and divided them 
into two major groups. The first group contains 6 samples, which were split into 2 
subgroups; one group contains 4 of the BM samples (67%), while the other group 
contains 2 of the TCGA samples (33%). The second major group contains the remaining 
TCGA samples (n=26, 96%) and one of the BM samples. Samples within the first group, 
which mainly contains BM samples, demonstrate the intermediate methylation level 
(mean β-value range 0.32) of the most 1000 variable loci, while the second group showed 
a high overall methylation level (mean β-value range 0.64). This observation indicates 
that the methylation profiles of the breast tumours without metastasis differ from the 
methylation profiles of BCBM. 
    
4.2.1.2 CpG loci distribution in the genome 
Following data assembly from GenomeStudio Illumina software, the raw data were 
normalized. A filtration process was then applied as follows: (i) probes with an unreliable 
detection p-value (>0.01) were removed as this reflects poor hybridization according to 
Illumina quality control (Dedeurwaerder et al. 2013) and (ii) probes for imprinted genes 
or overlapping SNPs were excluded from further analysis (Dedeurwaerder et al. 2013). 
Following the filtration process, probes showing β-value >0.6 in >60% of the tumour 
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samples were considered hypermethylated, while hypomethylation was considered if 
>60% of tumour samples had β-value <0.2. 
In order to obtain an insight into the methylome of breast tumours (without metastasis) 
and brain metastasis derived from breast tumours, analysis of hypermethylated and 
hypomethylated CpG loci in the array with respect to gene function and features (Figure 
4.2A) and in relation to CpG island (Figure 4.2B) was carried out. The majority of the 
hypermethylated probes in TCGA breast tumours (without metastasis) and breast cancer 
brain metastasis (BCBM) samples were located in the body of the genes, 48% and 50% 
respectively, and 20% and 19%, respectively, were located in the promoter regions. 
Distribution of the hypermethylated CpG loci in relation to the genomic location was also 
similar between breast tumour and BCBM samples, where the majority reside in CpG 
islands (39% and 38 respectively). Furthermore, 21% and 20% of the loci resided in CpG 
shores (up to 2Kb away from CpG islands) and 14% in CpG shelves (2-4Kb away from 
CpG island) respectively. This is consistent with other findings that many alterations in 
DNA methylation occur within the adjacent regions of CpG islands (Reyngold et al. 
2014). Analysis of hypomethylated loci was also carried out and the majority of the 
probes in TCGA non-metastatic breast tumours were located in the promoter regions 
(70%) as well as in BCBM samples (66%) (Figure 4.2B). With respect to genomic 
location, CpG loci were roughly equally distributed between CpG islands (38% and 35% 
respectively), shores (22% and 32% respectively) and open sea (39% and 32% 
respectively) in non-metastatic breast tumours and BCBM samples. The above data 
indicates that breast tumours without metastasis and BCBM show a similar distribution of 




















CpG loci are colour coded according to the methylation status (hypermethylation, red; 
low methylation, green). The type of sample is shown above the clustering (blue, brain 
metastasis sample; yellow, TCGA breast cancer samples) along with the status of the 
Estrogen receptor (ER), Progesterone receptor (PR) and HER2 receptor (positive, red; 
equivocal, orange; negative, green; not available, black) in breast tumour samples. The 
two groups are separated by a black line and the mean !-value of each group is shown 
below each group.
High Methylation 













































































































































































































































































Table 4.1 Unsupervised clustering of the most 1000 variable CpG loci in 5 BCBM 





    
   
  A
) 
       
   
 B
) 
     








   


















   



































































































































































4.2.2 Identification of hypermethylated signature genes in BCBM 
In order to identify signature genes in BCBM, differential methylation analysis between 5 
BM and 28 non-metastatic breast tumours was conducted on CpG loci located within 
gene promoter regions (200bp and 1500bp from TSS, 5’ UTR, and within 1st exon) to 
enrich the biological relevance between DNA methylation and gene silencing. Using the 
criteria of β-value <0.2 methylation in >60% non-metastatic breast tumour samples and 
β-value  >0.6 methylation in >60% of BM samples in addition to P value below 0.05, 37 
CpG loci (representing 28 genes) were identified (Table 4.1).  
To assess the function and types of gene within this panel, the DAVID functional 
analysis tool (http://david.abcc.ncifcrf.gov/) was used to assess the properties of the 
genes. The functional annotation tool identified tumour suppressor genes (2 genes), genes 
involved in cell differentiation (5 genes), cell migration and motility (3 genes), regulation 
of cell death (3 genes), cell adhesion (1 gene), regulation of cell proliferation and division 
(3 genes), and regulation of transcription (9 genes) (Figure 4.3). Ingenuity Pathway 
Analysis (IPA) of the list showed that 24 genes (86%) were associated with cancer. 
Molecular and cellular functional analysis of the list divided the gene list into 9 
functional categories that were involved in cell death and survival (11 genes; 39%), cell-
to-cell signalling (7 genes; 25%), cell cycle (2 genes; 7%), cellular growth and 
proliferation (9 genes; 31%), cellular movement (10 genes; 36%) and cell mediated 
immune response (3 genes; 11%) (Table 4.2). Taken together, the gene list produced was 





















Twenty-eight hypermethylated genes in BM were identified using the Infinium 450K 
array. Illumina probe ID, percentage of methylation in BCBM and in non-metastatic 
breast tumours, P-value, chromosome, gene feature with promoter region and probe in 
relation to CpG island were indicated for each probe. 
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The identified hypermethylated genes in BCBM were analysed by the DAVID functional 
analysis tool and categorised based on relevant function to tumorigenesis. The number of 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































4.2.2.1 Analysis of genes with multiple probes 
Within the list of candidate genes, seven genes (EOMES, WDR69, MIR125B1, NTM, 
TRIM68, WDR63 and DLX6AS) were represented by more than one probe (Table 4.1). 
DLX6AS was excluded from further analysis because it is a non-translated gene. Analysis 
was carried out by confirming the methylation data of the remaining 6 genes with a 
further set of 15 BCBM tumours using CoBRA to amplify the region containing both of 
the methylated CpG sites. BCBM tumours demonstrated high methylation levels for 
EOMES (71%; 10/14), WDR69 (93%; 14/15), MIR125B1 (50%; 7/14), NTM (67%; 
10/15) and WDR63 (53%; 8/15) (Figure 4.4). (Appendix 7.6 shows raw CoBRA data for 
this analysis). Hence, we have confirmed the HumanMethylation450K array data using 
our in-house CoBRA assay. 
The methylation status of TRIM68 in brain metastasis could not be obtained by CoBRA 
analysis, as there were no restriction enzyme sites that include a CpG dinucleotide around 
or within the two CG probes contained on the array; hence this gene was excluded from 
further analysis. 
 
4.2.2.2 Analysis of genes with a single probe 
Four genes (DZIP1, SOX1, PRDM13 and PHOX2B) were selected from the remaining 21 
genes with a single probe in the list to be further tested on 15 BCBM. These 4 genes were 
selected because of: (i) their location within the CpG island, shore or shelf (regions with a 
strong relation to gene expression) (Irizarry et al. 2009), (ii) restriction enzyme cutting 
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site was within the CG array probe, and (iii) within the list identified by the DAVID 
functional analysis tool (section 4.3.2). 
As expected, these genes were also hypermethylated in the new set of BCBM samples 
analysed by CoBRA at frequencies of 9/15 (60%) for DZIP1, 9/12 (75%) for SOX1, 9/14 
(64%) for PRDM13 and 11/15 (73%) for PHOX2B (Figure 4.4).  
Furthermore, to validate that the selected 9 genes from the above analysis (5 with 
multiple probes (EOMES, WDR69, MIR125B1, NTM, WDR63) and 4 (DZIP1, SOX1, 
PRDM13 and PHOX2B) with single probes) are unmethylated in non-metastatic breast 
tumours, a further set of non-metastatic breast tumour samples from the TCGA data 
portal (n=18) was selected and their β-values were examined. These 9 genes remained 
unmethylated (β-value <0.2) in >60% of the new set of breast tumours without 
metastasis. Since we were able to confirm the data in a further subset of samples and with 
all previous studies validating the HumanMethylation450 array (Roessler et al. 2012; Hill 
et al. 2014), analysis was continued with confidence for the methylation analysis of 







































































































































































































































































































































































































































































4.2.3 Methylation analysis of selected genes in paired breast tumour/brain metastasis 
samples 
To assess the specificity of the DNA methylation of these 9 genes to metastatic breast 
tumours, DNA methylation analysis was carried out in a cohort of matched breast 
tumours and brain metastasis paired samples (up to 10 pairs). Using the CoBRA PCR 
assays described and validated in the previous section, 7 of the 9 genes (EOMES, 
WDR69, MIR125B1, DZIP1, SOX1, PRDM13 and PHOX2B) demonstrated a high 
methylation level in breast tumours with BM, and also in the matching BM, compared to 
non-metastatic breast tumours from TCGA (Figure 4.5).  
EOMES, WDR69 and MIR125B1 were hypermethylated in 70% (7 of 10), 100% (8 of 8), 
and 71% (5 of 7) of the breast tumours with brain metastasis, respectively (Figure 4.5A, 
B, C). Also, the single probed genes, DZIP1, SOX1, PRDM13 and PHOX2B, showed a 
high level of methylation in 50% (4 of 8), 75% (6 of 8), 100% (6 of 6) and 83% (5 of 6), 
respectively, in the breast tumours (Figure 4.5D, E, F, G). These results suggest that these 
genes may play an early role in BCBM formation. The CoBRA results for the other 2 
genes, NTM and WDR63, showed a random methylation pattern between primary breast 
tumours and matching brain metastasis samples with no specific direction or selection for 
an early or late metastasis event. The data for NTM and WDR63 suggests that these genes 







































































































































































































































































































































































































































































































































































































































































































































































































































































































































   








































































































































































































































































































































































































































































































































































































   
   
 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
































































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   



















































































































































































































































































































































































































































































































































































































































































   

































































































































































































































































































































































   
   
   
   
   
   
   













   
   
   
   
   
   
   





































































































































































































































































































































































































































































































































































































































































































































































































































































   
 
   
   
   
   
   
   












































































































































































































































































































































































































































































































































































































   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   








4.2.4 Expression analysis in BCBM 
In order to assess whether DNA methylation of these genes affects gene expression, RT-
PCR was performed to assess the mRNA expression of these genes in methylated and 
unmethylated BM samples. Correlation between DNA methylation and loss/low 
expression was observed in EOMES, WDR69, PRDM13 and PHOX2B in BM samples 
(Figure 4.6A). MicroRNA are small sized molecules and analysis of their expression 
requires a more sensitive method. Therefore, analysis of MIR125B1 (cDNA size = 88bp) 
expression was performed using quantitative real-time RT-PCR. The results also showed 
decreased expression in methylated BM compared to unmethylated BM tumours (Figure 
4.6B). Furthermore, expression of these genes in non-metastatic breast tumours from 
TCGA was also investigated by analysing the publically available gene expression data 
from the Agilent Gene Expression Microarray in the TCGA data portal. EOMES, 
PHOX2B and SOX1 demonstrated expression in the majority of the samples, 95.8% 
(23/24), 100% (24/24) and 91.6% (22/24) respectively in non-metastatic breast tumours 
from TCGA. Taken together, these results highlight the importance of epigenetic 
silencing of these genes in metastasis development. However, the remaining genes 
(WDR69, DZIP1 and PRDM13) showed low expression in unmethylated TCGA breast 
tumours, which may be caused by other genetic alterations such as mutations or 
deletions/allelic loss of the gene. Expression data for MIR125B1 was not available in the 






















Figure 4.6 Expression analysis results for selected genes 
A) Expression results are shown for EOMES and WDR69 in methylated (loss of 
expression) and unmethylated BM samples (expression). For each case, !-actin is used as 
a control. B) Quantitative real-time expression results for MIR125B are shown for 
umethylated (UM, n=3) and methylated (M, n=5) samples, where unmethylated samples 
show high expression compared to the hypermethylated samples. The endogenous 




4.2.5 Association of gene expression and patient prognosis 
To determine the potential clinical relevance of these genes, the relationship between 
gene expression and breast cancer prognosis was examined using the PrognoScan online 
database (Mizuno et al. 2009) (http://www.abren.net/PrognoScan/). This tool uses 
publically available cancer microarray datasets to determine the relationship between 
gene expression and patient prognosis (section 2.10.4). In PrognoScan, patient 
populations are divided into high and low expression groups by selecting an appropriate 
cut-off point that maximises the statistical significance of difference in outcome, and 
results are corrected for multiple testing using the method of Miller and Siegmund 
(Miller and Siegmund 1982). 
Overall survival (OS), relapse free survival (RFS) and distant metastasis free survival 
were assessed for the 7 genes identified in this study. Three datasets, GSE1456-GPL96, 
GSE1456-GPL96 and GSE299, from GEO (Gene Expression Omnibus) were used for 
PrognoScan expression analysis. Low expression of DZIP1, PRDM13 and PHOX2B were 
correlated inversely with relapse free survival (RFS) in DZIP1, p=0.02 and p=0.005 (in 
GSE1456-GPL96 and GSE2990 dataset respectively), PRDM13 in GSE2990 (p=0.01) 
and PHOX2B in GSE1456-GPL96 (p=0.007). Low expression of DZIP1 and PRDM13 
were also significantly associated with worse distant metastasis free survival in GSE2990 
(p=0.001 and p=0.009, respectively). In addition, worse overall survival (OS) in 
GSE7390 (p=0.048) was correlated with reduced expression of PHOX2B (Figure 4.7). 
This analysis suggests a significant association between the loss of expression of these 
genes and the reduced time of patient survival. No significant correlation between clinical 
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outcome and expression of WDR69, EOMES and SOX1 was identified and data was not 




A) Relapse Free Survival 













 PHOX2B p=0.048 (GSE7390) 
 
 
B) Distant Metastasis Free Survival 







Figure 4.7 Kaplan-Meier survival analysis for DZIP1, PRDM13 and PHOX2B 
Graphs are shown for the association between gene expression (high, red; low, blue) and 
A) relapse free survival (FRS) for DZIP1, PRDM13 and PHOX2B, B) Distant metastasis 
free survival for DZIP1 and PRDM13, and C) overall survival for PHOX2B (OS). The 
GEO dataset and p-value are shown for each case. Kaplan-Meier plots were generated by 
the PrognoScan online tool. 
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4.2.6 ETS1 proto-oncogene is regulated by MIR125B1 
The microRNAs are small noncoding RNAs that regulate many biological processes 
(Jansson and Lund 2012). Many MicroRNAs are associated with cancer and their 
dysregulation contributes to tumorigenesis (Wang et al. 2012). MIR125B1 is known to 
affect various types of cancer and can act as either a tumour suppressor gene or an 
oncogene depending on their mechanism or target genes (Sun, Lin, and Chen 2013). 
In a previous study that was carried out by Yan Zhan et al. (Zhang et al. 2011), 
MIR125B1 was reported to be hypermethylated and downregulated in invasive breast 
tumours which is associated with poor patient survival. Also, it has been found that ETS1 
is a proto-oncogene and a direct target of MIR125B1 and that it showed overexpression in 
invasive breast cancer, suggesting its role in breast tumour progression (Zhang et al. 
2011). Here in this study, MIR125B1 was also frequently methylated in the primary 
breast tumours with brain metastasis (71.4%), which matches the findings of Zhang’s 
group and it was also frequently methylated in BM samples (79%). Furthermore, the gene 
expression analysis of ETS1 was carried out on 13 brain metastasis samples. As expected, 
ETS1 was expressed in MIR125B1 methylated brain metastasis samples (12/12, 100%) 
and ETS1 expression was reduced in a tumour where the MIR125B1 gene promoter was 
not methylated (Figure 4.8). Taken together, down regulation of MIR125B1 and high 
expression of its target gene ETS1 in invasive breast tumours and brain metastasis 
















Figure 4.8 Expression analysis for ETS1 in brain metastasis samples 
Expression of ESTS1 and GAPDH is shown for selected BM samples. Methylation status 














4.2.7 DNA methylation in BM from other organs 
To determine whether these changes in DNA methylation of EOMES, WDR69, 
MIR125B1, DZIP1, SOX1, PRDM13 and PHOX2B are specific to BM from breast 
tumours, methylation status analysis was performed on 40 BM which arise from other 
organs such as lung tumours (n=20) and melanoma (n=20) via CoBRA PCR, as described 
in previous sections (Figure 4.7). The methylation levels of EOMES, WDR69 were low in 
BM from lung tumours (27% and 11%, respectively) and melanoma (10%, and 16%, 
respectively), suggesting that DNA hypermethylation of these genes was mostly 
restricted to BM from breast tumours. On the other hand, the digestion of CoBRA PCR 
products shows that MIR125B1, DZIP1, SOX1, PRDM13 and PHOX2B were highly 
methylated in BM from lung tumours and melanoma. The results showed that 80% 
(MIR125B1), 65% (DZIP1), 70% (SOX1), 90% (PRDM13) and 60% (PHOX2B) of the 
BM from lung tumours were hypermethylated and 75% (MIR125B1), 63% (DZIP1), 66% 
(SOX1), 100% (PRDM13) and 58% (PHOX2B) were highly methylated in BM from 
melanoma. The above findings suggest that the DNA methylation of MIR125B1, DZIP1, 
SOX1, PRDM13 and PHOX2B is not restricted to BCBM but may play a broader role in 
























Figure 4.7 Methylation results of BM from lung cancer and melanoma  
A) CoBRA results of the 7 genes when analysed in 20 BM from lung cancer and 20 BM 
from melanoma. Digestion results are indicated with a red circle (digestion, methylation) 
or a green circle (no digestion, absence of methylation). Black circles indicate no PCR 
product for that particular sample. The frequency (%) of methylation in brain metastasis 
from lung tumours and melanoma are also shown for each gene. B) Examples of CoBRA 
digestion in selected BM from lung and melanoma samples. Digested positive control is 



















Distant metastasis is the last stage of solid tumour malignancies. Multiple primary 
tumour sites metastasize to the brain; the most frequent tumour sites include lung, breast 
and melanoma (Gavrilovic and Posner 2005). The incidence of brain metastasis from 
breast cancer is increasing. Currently, 15%-20% of breast cancer patients develop brain 
metastasis with a median survival time of 7.8 months (Wikman et al. 2014) and most 
breast cancer associated deaths occur due to the failure of metastasis treatments (Salhia et 
al. 2014; Li et al. 2011). Studies have found that even with early diagnosis and the 
treatment of breast cancer patients, some cases form metastasis, suggesting that initiating 
events in breast cancer are responsible for predisposing metastasis formation (Webb 
2003). This highlights the importance of understanding the underlying molecular biology 
and identifying poor prognosis signatures in primary breast tumours from early stages of 
diagnosis. 
In breast cancer, tumour cells usually spread and invade certain distant sites, for example, 
breast cancer metastasis to the bones, lungs and brain is common but metastasis to the 
liver is less common (Minn, Kang, et al. 2005). This observation of “seed-and-soil”, 
where disseminated tumour cells (seed) progress and adapt in certain sites (soils), 
depends on the microenvironment of the metastatic organ and genetic constitution of the 
tumour cells (Valastyan and Weinberg 2011; Wan, Pantel, and Kang 2013). For example, 
overexpression of CXCR4, IL11 and OPN genes in breast cancer showed a high affinity 
to metastasize to the bone (Kang et al. 2003), while breast cancer cells that overexpress 
COX, EREG and ANGPTL4 favour metastasis to the lung (Minn, Gupta, et al. 2005). In 
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addition, COX2, HBEGF and ANGPTL4 genes were specifically overexpressed in BCBM 
(Bos et al. 2009).  
The brain is a unique organ and differs from any other organ due to its specialized 
microenvironment. Successful metastasis to the brain requires specialised interaction 
between the circulating tumour cells and brain defences and microenvironment, which 
are characterised by the presence of a blood-brain-barrier (BBB) and the absence of a 
lymphatic drainage (Martín et al. 2008). Therefore, investigating signature genes in 
human brain metastasis and their matching primary breast tumours is important in order 
to identify new prognostic and diagnostic markers, which may be helpful in developing 
new therapeutic approaches. 
Loss of expression of tumour suppressor genes (TSGs) is a fundamental step in tumour 
formation. However, metastasis suppressor genes are different from TSGs since they are 
not involved in tumour growth but they control cancer cell dissemination, survival during 
circulation and adaptation at the distant organ site (Wikman et al. 2014). Since metastasis 
suppressor genes are rarely mutated (HORAK et al. 2008), epigenetic alterations, such as 
DNA methylation, could be one of the mechanisms involved in the dysregulation of gene 
expression leading to metastasis.  
To expand current knowledge of the epigenetic changes arising in BCBM, this study used 
the Infinium HumanMethylation450 array to investigate DNA methylation events in BM 
from breast cancer. This data was combined with the methylation array data of non-
metastatic breast tumours from the TCGA data portal to identify potential genes that may 




In order to identify BCBM signature genes, differential analysis was applied, which led 
to the identification of 28 genes (37 probes) that were differentially methylated between 
non-metastatic breast tumours and BCBM. Seven genes from the list (EOMES, WDR69, 
MIR125B1, DZIP1, SOX1, PHOX2B and PRDM13) were chosen for further analysis 
based on their relative function and the position of the CpG probe within the promoter 
region and CpG island/shore/shelf regions. CoBRA analysis was performed on matching 
paired breast tumours and brain metastasis samples and the results have shown that 
hypermethylation was not only found in BCBM, but also in the corresponding primary 
aggressive breast tumours, suggesting their role in the early stages of metastasis 
formation. The functional relevance between DNA methylation and gene expression was 
investigated and the lower expression level of EOMES, WDR69, MIR125B1, PHOX2B 
and PRDM13 was observed in methylated BCBM. Any clinical relevance for these genes 
was determined by assessing the publically available gene expression datasets (GEO 
database) and was analysed using the PrognoScan tool. Analysis showed that down 
regulation of DZIP1, PRDM13 and PHOX2B genes was significantly associated with 
worse patient survival.  
 
4.3.1 Signature BCBM genes 
4.3.1.1 EOMES 
Eomesodermin (Eomes, aka TBR2) is a member of the T-box transcription factor. The 
overexpression of EOMES in colorectal cancer was associated with significantly reduced 
lymph node metastasis (Atreya et al. 2007). In this study, EOMES was hypermethylated 
in paired breast tumours and the corresponding BCBM samples, but was unmethylated in 
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the non-metastatic breast tumours and the hypermethylation of BM was associated with 
the loss of gene expression. Also, methylation of the gene was less frequent in BM from 
lung tumours (27%) or in melanoma (10%). When considering all the identified 
methylation and expression results of EOMES, these results suggest that methylation of 




Also known as DAW1, WDR69 is a dynein assembly factor with WD repeat domains. 
This gene is located on chromosome 2 and contains one CpG island at the 5’ UTR within 
the promoter region. The size of the island is relatively small (314bp) as it contains 33 
CpG sites. WD repeat domain proteins are involved in various cellular functions such as 
signal transduction, cell cycle control, transcription regulation and apoptosis (Li and 
Roberts 2001). Genetic alterations of these genes can cause a wide range of diseases; 
examples include mutations in the WD repeat domain of AHI1 in some autosomal 
recessive disorders, chromosomal translocation of WDR11 in glioblastoma, upregulation 
of WD repeat protein, endonulein, in adenocarcinoma and others (Smith 2008). 
Currently, not much is known about WDR69 biology, hence further studies are required 
in order to understand the role of this gene in the development of brain metastasis. 
 
4.3.1.3 SOX1 
SOX1 is a one-exon gene located on chromosome 13. It has a 3018bp CpG island 
containing 274 CpG sites covering the TSS, 3’UTR and a large part of the 1st exon. SOX1 
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is a member of the SOX family and is known as a tumour suppressor gene because it 
deactivates Wnt/b-catenin signalling pathways in liver cancer (Tsao et al. 2012). 
Promoter hypermethylation of SOX1 has been observed in many types of cancer and 
showed an association with gene down regulation (Lai et al. 2014; Shih et al. 2013). 
Also, studies showed that the over expression of SOX1 is associated with the suppression 
of cell proliferation, cell migration and cell invasion in hepatocellular carcinoma (Tsao et 
al. 2012), ovarian cancer (Su et al. 2009) and cervical cancer (Lin et al. 2013). The results 
in this chapter showed that SOX1 was hypermethylated in the majority of metastatic 
breast tumours (75%; 6/8). Although the samples assessed here did not show evidence of 
methylation correlating with reduced expression, the overwhelming evidence of SOX1 
methylation playing a role in other cancers suggests that further analysis of additional 
samples would be worthwhile. Hypermethylation was frequently found in BM from lung 
tumours (70%) and melanoma (66%) as in BM from breast tumours (75%). Our findings, 
presented here, indicate that DNA hypermethylation of SOX1 may contribute to 
metastasis to the brain from different primary sites.  
 
4.3.1.4 PHOX2B 
The homeobox gene, PHOX2B, consists of 3 exons and contains 2 CpG islands where 
one is located in the 3’UTR region (31 CpG sites) and the second island is situated in 
exon 2 of the gene. Previous studies have found a relationship between PHOX2B 
alterations and cancer; for instance, somatic and germ-line mutations and LOH at 
PHOX2B were previously reported in neuroblastoma (Perri et al. 2005). Other small 
studies have found hypermethylation of PHOX2B in colorectal cancer and neuroblastoma 
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(Yang 2012; de Pontual et al. 2007). In this study, PHOX2B was only methylated in 
metastatic breast tumours (83%) but not in the non-metastatic breast tumours from 
TCGA. The PHOX2B promoter was also highly methylated in brain metastasis from 
breast cancer, lung cancer and melanoma (73%, 60% and 58%, respectively). 
Hypermethylation was strongly associated with the loss of expression. The unmethylated 
breast tumours without metastasis showed high expression of the gene, while expression 
was lost in the methylated brain metastasis. Loss of expression of PHOX2B was 




PRDM13 (PR domain containing 13) is a four exon gene situated at 6q16.2. Very few 
studies have been done on PRDM13, but PR proteins containing the PR domain have 
been reported to be tumour suppressive by regulating chromatin mediated gene 
expression (Jiang and Huang 2000). Results from the current study have shown a high 
level of methylation in breast cancer and brain metastasis pairs as well as in brain 
metastasis from lung and melanoma (92% and 100%, respectively). This suggests 
PRDM13 methylation may be involved in the development of brain metastasis from 
primary breast, lung and melanoma tumours. Loss of expression of PRDM13 was 
strongly correlated with promoter hypermethylation and was associated with poor relapse 





DAZ interacting zinc finger protein 1 is located on chromosome 13. It is known as a 
tumour suppressor gene that regulates the hedgehog signalling pathway in many types of 
cancer. It has been reported that mutations of DZIP1 might cause the aberrant expression 
of downstream genes in the hedgehog pathway (Kikuyama et al. 2012). So it is possible 
that the aberrant methylation of DZIP1 can also affect this signalling pathway during 
cancer formation. The results of this thesis showed frequent hypermethylation of DZIP1 
in BCBM samples (60%) as well as methylation in BM from lung cancer (65%) and 
melanoma (63%). Prognoscan data showed that loss of expression was strongly 
associated with poor survival in breast cancer patients. Although the expression of DZIP1 
could not be determined in the small number of BM samples assessed during this study, 
the previous links of DZIP1 with tumour suppressor functions, the loss of expression 
associating with worse survival and the results from our methylation analysis suggests 
that further investigation of DZIP1 and its biological functional relevance in BCBM is 
warranted.  
 
4.3.1.7 MIR125B1 and its target gene ETS1 
MicroRNAs are single stranded non-coding RNAs that are known to control many 
biological processes, including cell proliferation, death, differentiation and mRNA 
translation (Iorio et al. 2005). MIR125B1 is located on chromosome 11 and is involved in 
the posttranscriptional regulation of the mRNA expression of target genes. Recent studies 
have reported the important role and effect of MIR125B1 in carcinogenesis. MIR125B1 
was observed to be aberrantly expressed in different cancer types and may act as an 
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oncogene such as in prostate cancer and glioma (Shi et al. 2007; Schaefer et al. 2010; Wu 
et al. 2013) or as a tumour suppressor gene in breast, liver and bladder cancers (Iorio et 
al. 2005; Tang et al. 2012; Jia et al. 2012; Huang et al. 2011). To date, several MIR125B1 
target genes have been identified and are known to be involved in cancer, for example, 
Bak1 in prostate cancer (Shi et al. 2007), Bmf in glioma (Xia et al. 2009), ERBB2/ERBB3 
and the most recent ETS1 in breast cancer (Scott et al. 2007; Zhang et al. 2011). 
A significantly high expression of MIR125B1 was observed in breast tumours but not in 
invasive breast cancer, suggesting that MIR125B1 may play a role as a pro-metastatic 
factor in metastatic breast tumours (Tang et al. 2012). MIR125B1 was found to be 
methylated and down regulated in aggressive breast tumours, which was associated with 
poor patient survival. According to a study by Zhang and his group (Zhang et al. 2011), 
the overexpression of MIR125B1 in breast cancer cells promotes the G1 cell cycle to 
arrest through the target gene ETS1. Generally, the transcription factor ETS1 regulates 
cellular processes such as cell proliferation and migration and it has been associated with 
poor prognosis of cancer patients when it is upregulated (Davidson et al. 2001). The loss 
of expression of MIR125B1 in invasive breast tumours induces the expression of the 
target gene ETS1 and consequently, the activation of cell proliferation and cell growth. In 
this study, MIR125B1 showed hypermethylation in metastatic breast cancer as well as in 
brain metastasis samples but showed low methylation in breast tumours without 
metastasis. Hypermethylation and low expression of MIR125B1 also correlated with the 
overexpression of ETS1 in BM. MIR125B1 hypermethylation was not restricted to brain 
metastasis from breast tumours. Hypermethylation was also observed in BM from lung 




4.3.2 Conclusion and further work  
Metastasis is the most fatal stage of cancer. Many studies using expression or methylation 
profiling provided a closer look at the molecular biology events in cells contributing to 
metastasis. Recent studies suggest that the genes responsible for metastasis formation are 
expressed by primary tumour cells themselves (Ramaswamy et al. 2003; Bernards and 
Weinberg 2002; Bos et al. 2009; Minn, Gupta, et al. 2005; Kang et al. 2003). Therefore, 
the aim of this study was to identify methylation events that are specific to the 
development of BCBM. Using the latest Illumina HumanMethylation450K BeadChip in 
this study, a list of novel candidate genes was identified, which is considered worthy of 
further investigation. One of the advantages of using the HumanMethylation450K array 
is that probes can be selected based on their gene feature. The chosen probes were located 
in the promoter region of the gene to ensure relevance between DNA methylation and 
gene silencing. However, not all the identified genes were analysed further and a number 
of selected genes were chosen for further confirmation. The CoBRA digestion of TRIM68 
was not done due to the lack of a restriction enzyme cutting site within the CpG probe. 
Therefore, analysis was performed for the remaining selected genes based on the 
availability of a cutting site within the CpG probe. This could be corrected by analysing 
the whole region using bisulfite clone sequencing. In the current study, the CoBRA assay 
was favoured because it is a fast, cost effective and widely accepted method for assessing 
DNA methylation (Xiong and Laird 1997). Therefore, the CoBRA assay provided an 
opportunity to rapidly and effectively screen additional cohorts to confirm our findings.  
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For this type of study, where paired breast tumour and matching brain metastasis samples 
are required for analysis and validation, samples should be used with care. It is difficult 
to obtain matching metastases paired samples, where patients may develop metastasis 
several years after primary tumour diagnosis. We were fortunate to have 10 paired 
primary breast tumours and matching BCBM samples to validate the methylation data, 
and to our knowledge, this is one of the few studies where such a cohort of matched 
samples was available for analysis.  
A particular weakness encountered in this study was the use of only 5 BM samples in the 
array. Although the methylation of the identified genes was confirmed in a different set 
of BM samples, it would have been beneficial to include more BM samples in the array 
to produce more significant genes in the list. Yet, we have identified a set of genes that 
may be important for the development of BCBM and could be useful prognostic markers 
for BCBM risk assessment.  
Overall, this study was able to identify a list of genes that were significantly methylated 
in breast tumours that form brain metastasis compared to non-metastatic breast tumours. 
Some of the genes presented potential candidates to be epigenetically downregulated in 
metastatic breast cancer with an association with poor survival. Among the list, DZIP1 
was a good candidate to be analysed further and therefore, expression analysis was 
carried out for DZIP1 in brain metastasis samples to assess its functional relevance. 
However, several attempts, using three different sets of primers each time, were carried 
out for DZIP1 expression analysis and none of the attempts were successful. Since this 
study was the last project undertaken in my final year, no adequate time was available to 
carry out further analysis. Therefore, it would be worth investigating and carrying out 
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further biological and functional studies to confirm if these genes from the list contribute 
to metastasis formation from breast cancer. For example, cell migration and invasion 
assays can be performed on breast cancer cell lines that show hypermethylation and 
expression loss to investigate if reduced gene expression is associated with increased cell 
motility and invasion. Alternatively, expression could be knocked-out in non-methylated, 
expressing breast cancer cell lines. 
Additionally, it would be beneficial to confirm this data in a larger, independent cohort of 
samples and also to analyse our list more comprehensively before considering these 
genes as true prognostic and diagnostic markers for BCBM metastasis formation.  
Finally, another consideration could be taken into account by analysing the genes 
involved in the late stage of tumour progression rather than in the early stage of 
metastasis formation. This data can be analysed by finding genes that are 
hypermethylated in BM samples but show low/no methylation in metastatic breast cancer 
tumours. Identifying such genes will increase our understanding of tumour progression 
and metastases since these genes may be involved in cell survival during circulation in 
addition to adaptation and colonization in the brain. 
In conclusion, we have identified a preliminary set of genes/probes that may be 
developed into useful molecular diagnostic markers (gene signatures) for the early 
prediction of BCBM formation. 
 
This work was presented at The National Cancer Research Institute conference (NCRI) in 




 Genetic Alterations in Vestibular Schwannoma Chapter Five:
 
5.1 Introduction 
The benign tumour, vestibular schwannoma, is characterised by the continuous 
proliferation of schwann cells around the nerves which may cause impaired hearing, 
imbalance and may lead to death at later stages. Vestibular schwannoma has been studied 
extensively in the past few years and has been associated with NF2 gene mutation and/or 
Ch22 LOH. However, a subset of schwannoma patients showed no alterations in NF2 
gene, suggesting other causative genes are responsible for schwannoma tumour 
development. Recent studies have identified other genes that are involved in vestibular 
schwannoma and located on chromosome 22 near to NF2 gene, such as SMARCB1 and 
LZTR1.  
With the expansion of cancer research studies, scientists are looking for cheap, fast and 
high-throughput technologies to better understand the molecular biology and genetics of 
cancer formation. The development of NGS has offered many advantages to cancer 
research through WGS and WES technologies. Nowadays, WES technology is widely 
used because it is faster, lower in price and targeted to the sequence of the protein-coding 
regions of the genome to identify disease-causing variants.  
The current study utilises WES in combination with bioinformatics tools and applications 
to identify disease causing gene variants in non-NF2 schwannoma tumours. Despite the 
success of WES technology, this technology is full of challenges that were resolved and 
limited in this study by applying different strategies to reduce false positive variants and 





5.2 Aim of the study and approaches  
• Identification of somatic mutations and driver genes that may lead to non-NF2 
vestibular schwannoma formation using whole exome sequencing technology. 
• Utilising various bioinformatic tools, in combination with algorithmic software to 
investigate variants that may be involved in schwannoma development. 
 
5.3 Results 
Whole exome sequencing technology utilises parallel sequencing of the protein coding 
regions of the genome (exomes). It is a powerful and cost effective technique for the 
identification of causative mutations in many human diseases including cancer.  
This study used whole exome sequencing techniques on a panel of 8 sporadic unilateral 
vestibular schwannoma tumours (S14T, S21T, S36T, S37T, S44T, Lp152T, Lp272T and 
Lp303T) from Spanish patients, in addition to matching normal blood DNA for 3 samples 
(S14S, Lp272S and Lp303S). These samples did not harbour NF2 mutations by combined 
dHPLC/PCR and MLPA (MRC-Holland) analysis and demonstrated no LOH at 22q 
microsatellite markers (Torres-Martin et al., 2013). Exon 1 analysis was not conducted in 
the above samples, since exon 1 mutations are rare in SNP databases. Information about 
the tumour samples can be found in Appendix 7.7. 
 
Before starting the analysis, the gender of the samples was estimated and compared with 
patients’ clinical information to rule out a sample mix up during the sample preparation 
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for exome sequencing. This was conducted by counting the number of heterozygous X 
chromosome variants in each sample. Typically in exome sequencing data, female 
samples show an excessive number of heterozygous SNPs on the X chromosome (>200) 
compared to male samples (<100) (Guo Y et al. 2014). After counting the number of 
variants, the results showed that exome sequencing was able to estimate the sample’s 









Number of heterozygous X 
chromosome variants 
S14 Female 239 variants 
S21 Male 31 variants 
S36 Male 28 variants 
S37 Male 50 variants 
S44 Female 219 variants 
Lp152 Male 39 variants 
Lp272 Female 264 variants 
Lp303 Female 295 variants 
 
Table 5.1: Estimation of Schwannoma samples’ gender  
Gender estimation was performed by counting the number of heterozygous X 
chromosome variants in each sample. A sample showing >200 hits is considered female, 








5.3.1 Newly identified mutated genes in meningioma  
A previous study by Clark et al. identified somatic mutations in 4 genes: TRAF7 (TNF 
receptor associated factor 7), AKT1 (v-akt murine thymoma viral oncogene homolog 1), 
SMO (Smoothened frizzeled family receptor), and KLF4 (Krupple like factor 4), in 
meningioma samples that were exclusive of NF2 mutation (Clark et al., 2013). According 
to the paper, mutations in TRAF7 occurred in 25% of non-NF2 meningioma samples. 
These mutations co-occurred with either a recurrent mutation in KLF4 or with AKT1. On 
the other hand, SMO mutations were identified in less than 5% of meningioma samples 
and were exclusive of mutations to the other 3 genes (Table 5.2). 
Mutations in these genes were screened for as both meningioma and schwannoma are 
intracranial nervous system tumours and associated with genetic alterations in NF2 genes. 
This part of the study was carried out before receiving the exome sequencing data and the 
investigation of mutations in these genes was carried out in 20 non-NF2 schwannoma 
samples. 
Firstly, analysis was started by sequencing the recurrent mutations in KLF4, AKT1 and 
SMO. The hotspot mutations of KLF4 and AKT1 were missense mutations, p.K409Q and 
E17K respectively, which always co-occurred with TRAF7 mutations. On the other hand, 
the recurrent mutation L412F of SMO was exclusive of mutations in the other 3 genes. 
Conventional Sanger sequencing was performed on schwannoma tumour samples using 
pre-designed primers from the study of the 3 hotspot mutations. From the results of the 
electropherograms, sequencing was unable to identify these mutations in any of the non-
NF2 samples (Figure 5.1).  
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Clark et al. identified 12 mutations in 8 out of 21 exons of TRAF7 in meningioma (Table 
5.2). Analysis of these mutations in schwannoma samples was carried out using Sanger 
sequencing. These mutations were not detected in any of the samples (Figure 5.1). These 
mutations of the 4 genes may be exclusive to meningioma tumours and at the time of 
writing this part of the thesis, no other studies have identified such mutations in 
schwannoma tumours. 
After receiving and investigating exome sequencing data, none of these mutations were 
found in the samples included in exome sequencing, hence confirming the Sanger 









Table 5.2: Hotspot mutations identified in meningioma 
Table showing the recurrent mutations previously identified in meningioma by Clark et 
al. and that have been analysed in schwannoma tumours. 
 
Gene 
Symbol Gene Name 
Position of 
Hotspot Mutation 













KLF4 Krupple like factor 4 p.K409Q 
AKT1 
v-akt murine thymoma viral oncogene 
homolog 1 
p.E17K 
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Figure 5.1: Analysis of meningioma genes (AKT1, KLF4, SMO and TRAF7) in non-
NF2 schwannoma 
A schematic diagram of KLF4, AKT1, SMO and TRAF7 genes (blue) that shows the 
location of the hotspot mutations. In each case, Sanger sequencing of each hotspot is 
shown in non-NF2 schwannoma tumours and indicated by a red arrow. For TRAF7, 4 out 
of the 12 mutations are shown. No mutations were detected in any of the schwannomas 
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5.3.2 Analysis of exome sequencing data using in-house pipeline 
5.3.2.1 Exome sequencing data filtration pipeline 
After confirming the samples’ gender, the received exome sequencing data of all the 
schwannoma tumour samples were combined in one datasheet for analysis. The total 
number of variants was 194,318 with an average of 24,290 variants per sample. To 
reduce the vast number of variants in exome sequencing data, a series of filters and 
approaches were applied to identify the genes and variants that could be involved in non-
NF2 schwannoma development (Figure 5.2). Analysis initially started by removing 
synonymous SNVs and variants present in intronic regions. After that, germ-line 
mutations found in any of the normal blood samples were also excluded. To eliminate 
common SNPs from the remaining 3,493 variants, variants that showed a minor allele 
frequency (MAF) greater than 0.001 (1%) in the 1000 genomes database and/or more 
than 10 times within the in-house data (data from genome sequencing centre’s database) 
were also removed. Furthermore, any splice-site candidate mutation that was >3bp away 

























Figure 5.2: Filtration process applied to exome sequencing data to reduce the 
massive number of detected variants  
Total number of variants = 194,318 
SNV 
Removal of 89,141 synonymous 
and intronic variants  
Removal of 108,670 germ-line 
variants 
1
Removal of 1,621 variants with 
>1% MAF and >10 times within 
in-house data 
Removal of 251 variants >3bp 
away from splice site  
Remaining variants = 
1,621 SNV  
105,177 SNV 





After applying these filters, the number of remaining candidate variants was 1,621. 
Among these variants, 631 variants were novel, 662 variants had rs ID in dbSNP (with 
MAF <1%) and 328 variants were not identified in any SNP databases but had been 
reported multiple times within the in-house data (Figure 5.3A). Moreover, based on the 
type of coding variants, 47 variants were frameshift mutations (26 frameshift deletion and 
21 frameshift insertion), 39 variants were non-sense mutations (corresponding to 36 
genes), 152 variants were splice-site mutations (145 genes) and the majority were 
missense mutations with 1,383 variants (1,227 genes) (Figure 5.3B).  
It was noticeable that the number of variants present in the samples that had exome 
sequencing data for the matching normal blood samples (S14, Lp303 and Lp272) was 
less than the other samples with no matching normal blood samples (Lp152, S36, S37 
and S44). Samples S14T, Lp303T and Lp272T contained 23, 34 and 25 variants 
respectively, while Lp152, S36T, S37T and S44 contained 311, 323, 319 and 251 variants 
respectively. This major difference in the number of variants is a result of the filtration 
steps when removing germ-line variants (Figure 5.3C). 
Afterwards, different approaches were applied to analyse the data. Initially, in-silico 
analysis was carried out to conduct an in depth investigation of the candidate variants and 
























Figure 5.3 Distribution of variants after the filtration process A) Distribution of 
SNVs according to variant novelty. B) Distribution of SNVs based on the type of coding 
variants. A description of the colour legends is shown adjacent to the charts. C) Number 
of variants in each sample. Samples were divided into two groups, with or without 






5.3.2.2 Exome sequencing in-silico analysis 
The analysis began by prioritising the list of variants using different online tools. Genes 
or variants found in more than one sample were labelled as a high priority candidate. At 
the beginning, all genes were investigated in an exome variant server website for high 
impact mutations (non-sense, frameshift and splice-site) and those with fewer SNPs are 
more likely to be significant. Also, genes were checked to see if they were mutated in 
other types of cancer using the TCGA and COSMIC databases. In the COSMIC database, 
genes with high non-sense and frameshift mutation distribution among different types of 
cancer were labelled as significant. Similarly, genes were considered important if they 
showed mutations in more than 5 types of cancer with a mutation frequency of >2.5% in 
each type in the TCGA database. Variants were also investigated using the 1000 genomes 
Project database by looking at the frequency of the mutation in the Spanish population 
(IBS=Iberian population in Spain) compared to the total population (n=26 populations 
around the globe). Furthermore, different web-based tools were applied to the candidate 
variants. For splice-site variants, a splice-site prediction tool was used to predict the 
effect of intron splicing on the protein. Additionally, Polyphen-2 was used to assess the 
function effect of missense variants on proteins (benign or damaging). Figure 5.4 
illustrates the various online tools applied in the in-silico analysis using NF2 gene 








Figure 5.4 Examples of different online tools used in the study  
All examples represent mutations in NF2 genes. A) Distribution of mutation types in COSMIC 
database for NF2 gene displayed as a pie chart and each colour represents a mutation type. The 
adjacent table shows the number of samples and the mutation percentage out of the total number 
of mutations in NF2.  B) A summary of alterations in NF2 across different types of cancer in the 
TCGA database. In this study, a gene is considered significant if it shows mutations (green bars) 
in more than 5 types of tumour with >2.5% mutations in each type. C) Allele frequency of a 
variant in different populations in the 1000 Genomes Project database. The Spanish population is 
the Iberian population in Spain (IBS) which is a subpopulation of Europeans (EUR) (marked by a 
red triangle). D) Polyphen-2 protein function prediction tool. The figure shows the score of 2 
different variants; the variant of the top bar was predicted to be possibly damaging (score of 0.77) 













5.3.2.3 IGV tools 
IGV was used in conjunction with the in-silico analysis to support the list of candidate 
genes. IGV is a visualization tool that allows real time exploration and the analysis of 
large-scale genomic data. It supports a wide range of data types including NGS to 
visualize SNPs by comparing them to a reference genomic sequence, plus the deletion 
and insertion of regions of the genome. When uploading a special format file of the 
sample (BAM file), sequencing data that is aligned to the most recent human genome 
sequence (hg19) is displayed. When displaying sample information, the level of detail 
varies according to the zoom level. As the view is zoomed out, IGV displays the general 
read coverage of the sample (Figure 5.5A). This is useful for evaluating the overall 
coverage quality and for detecting technical issues in the sequencing of the interesting 
area. When the view is zoomed in IGV displays the sequence of the sample aligned to the 
reference genome. Nucleotides are colour coded and SNPs are highlighted as a mismatch. 
Bases that match the reference genome are displayed in the same colour, while 
mismatched reads are displayed in different colours. For example, in Figure 5.5B, IGV 
window displays the sequence of NF2 after zooming in. The histogram on the top 
displays the coverage quality of this area and the highlighted area represents where the 
stop-gain mutation p.W60X was found in the schwannoma sample Lp152T. The 
mismatched bases are displayed in a different colour than the reference base and when 
the cursor is moved over the base pair, a pop-up window shows the number of reads and 
the percentage of each base. IGV is a powerful tool for eliminating false positives, which 
will aid in identifying true findings. 
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The analysis was conducted to find (i) SNV in the genes involved in cancer pathways, (ii) 
variants located in chromosome 22 near NF2, (iii) high impact variants and finally, (iv) 






































































Figure 5.5 IGV display window using NF2 as an example 
The IGV application shows information about the sample according to the zoom level. A) 
Zoomed out view of NF2 gene showing the good coverage quality of the gene. B) 
Zoomed in view where the stop-gain mutation p.W60X is highlighted. The mismatched 
base (A) is given a different colour (green) and the information window shows that the 
SNP base (A) appeared 32 times out of 115 reads (28%), while the reference base (G) 
appeared 83 times (72%). C) Another zoomed in view where the nonsynonymous 
mutation p.Q121H is highlighted. The mismatched base (C) is given a different colour 
(blue) and the information window shows that the SNP base (C) appeared 13 times out of 






5.3.3 Identification of novel NF2 mutations 
After receiving and analysing the data, NF2 mutations were found in 4 tumour samples. 
Sample S14T contained a novel stop-gain mutation in exon 11 (p.Q387X), while sample 
S21T had two novel mutations, stop-gain (p.K15X) and frameshift deletion (p.24_24del), 
both in exon 1. Sample Lp152T showed a novel stop-gain mutation (p.W60X) and a 
novel missense (p.Q121H) mutation in exon 2 and exon 3, respectively. The fourth 
sample, S44T, contained one stop-gain mutation in exon 5 (p.E141X). This later mutation 
was previously identified as a SNP in various SNP databases (RS74315495) (Table 5.3) 
(Figure 5.6).  
The Human Gene Mutation Database (HGMD) is a free online resource that contains all 
published gene mutations in addition to some unpublished mutations from around the 
world. According to the HGMD database, NF2 contains 386 mutations, the majority of 
which were frameshift mutations (35%), nonsense mutations (24%), and splice-site 
mutations (20.5%). On the other hand, NF2 gene in the COSMIC database contains 1,026 
coding mutations that were identified in 31 different tumour tissues (17,692 samples). 
Based on tissue distribution, the majority of the mutations were identified in 
schwann/nerve cells (41.55%), Mesothelium tissue (37.65%) and meninges tissue 
(33.33%). Regarding coding mutation types, the majority were frameshift mutations 
(37%), 20.76% were nonsense mutations and 11.21% were missense mutations. The 
majority were confirmed to be somatic mutations. 
The NF2 mutations identified in this study were checked through the HGMD database. 
The SNP mutation (p.E141X) and the novel stop-gain mutation (p.W60X) were 
previously reported in NF2 and schwannoma patients respectively in two different studies 
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(MacCollin et al., 1994) (Jacoby et al., 1994). While none of the remaining novel variants 
were found in the HGMD database or the COSMIC database. 
These mutations were subsequently checked using IGV tools. Interestingly, the stop-gain 
mutation (p.Q387X) in S14T appeared as a somatic mutation in 25% (2/8) of total reads 
that showed the mutated base, while the corresponding normal blood sample showed a 
100% reference base. The remaining samples had no exome data for the corresponding 
normal samples, therefore; only the tumour samples were checked in IGV tools. The 
stop-gain mutation (p.K15X) and frameshift deletion (p.24_24del) of sample S21T were 
adjacent to each other and the two mutations appeared in 22% (4/18) and 37% (18/49) of 
the reads, respectively. The stop-gain (p.W60X) and the missense (p.Q121H) mutations 
of Lp152T were 28% (32/115) and 30% (13/44) mutated in total reads, respectively. 
Finally, the SNP in sample S44T appeared in 60% (75/125) of the total reads. 
In order to confirm the presence of these variants in the samples, primers were designed 
around the mutation sites and the tumour samples and their corresponding normal 
samples were sequenced using Sanger sequencing. The results from the sequencing 
confirmed the presence of these variants in the tumour samples only but not in the 
corresponding blood samples (Figure 5.7).  
It was noticeable that the stop gain mutations p.Q387X, p.K15X and p.W60X for S14T, 
S21T and Lp152T, respectively, were very weak. Low detection frequency is common in 
somatic hits in cancer and has previously been reported in other papers (Thomas et al., 
2007 & Lim et al., 2014). This is possibly due to the heterogeneous mixture of normal 
and tumour tissues in one sample and also the low sensitivity of conventional sequencing, 
which makes it difficult to identify somatic mutation in tumours.  
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The sequencing results were able to confirm the mutations and therefore, these samples 
were excluded from further analysis. However, these findings confirm the validity of the 















Reads in IGV 
S14T Stop-gain c.C1159T p.Q387X Novel 25% 
S21T 
Stop-gain c.A43T p.K15X Novel 22% 
Frameshift c.71-72del p.24_24del Novel 37% 
Lp152T 
Stop-gain c.G180A p.W60X Novel 28% 
Nonsynonymous c.G363C p.Q121H Novel 30% 
S44T Stop-gain c.G421T p.E141X RS74315495 60% 
 
Table 5.3: NF2 mutations identified in exome sequencing data  
Mutation type, the position of mutations in cDNA and amino acid sequence, and novelty 
of the variants are shown in the table along with the percentage of mutation appearance in 

















































































































































































































































































































































c.C1159T: p.Q387X  
 




        c.A43T: p.K15X 
 




    c.71-72del: p.24_24del 
Figure 5.7 Identification of NF2 mutations in schwannoma 
Sanger sequencing confirms the presence of NF2 mutations in schwannoma tumours. The 
corresponding normal samples show a wild type sequence. The mutation point is 
indicated by a red arrow.  
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5.3.4 SNV in cancer pathways 
Genes involved in cancer pathways have been discovered and are often mutated in more 
than one type of cancer. Therefore, this part of the study focused on genes in major 
cancer pathways.  
In order to identify the mutations present in genes involved in cancer pathways, a list of 
genes from 10 major cancer pathways were collected from the KEGG cancer database 
(http://www.genome.jp/kegg/). Analysis of the exome datasheet identified 3 genes (2 
novel variants and 1 SNP) that were involved in the SWI/SNF pathway, 6 genes (4 novel 
variants and 2 SNPs) in the Hippo pathway and 2 genes (1 novel variant and 1 SNP) in 
the VEGF signalling pathway (Table 5.4). 
The 3 nonsynonymous SNVs in the SWI/SNF pathway were found in the same sample 
(S36T). The mutations of ARID1B (p.D172A) and SMARCE1 (p.R297H) were novel 
mutations, while the mutation p.V766G of SMARCA4 was a known SNP (RS201128299) 
with no MAF data in the 1000 Genomes Project website. Interestingly, the in silico 
PolyPhen-2 prediction tool predicted these mutations to be “possibly damaging” to the 
corresponding proteins. Furthermore, the p.R297H mutation in SMARCE1 was  
previously found in the COSMIC database in a colon tumour sample (n=1) which was 
confirmed to be a somatic mutation. To confirm the existence of these mutations in the 
samples, Sanger sequencing was performed in the tumour sample and in the 
corresponding normal sample using primers covering the mutation sites. The results of 
the electropherograms showed that the two mutations p.D172A and p.V766G in ARID1B 
and SMARCA4, respectively, were false positive. On the other hand, the p.R297H 
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mutation in SMARCE1 was identified as a germ-line mutation and existed in the tumour 
and the corresponding blood samples (Table 5.4A).  
The 6 identified mutations of the Hippo pathway genes were nonsynonymous SNVs and 
were also checked in the COSMIC database and PolyPhen-2. Two genes from the 
RASSF family members were identified in the list, RASSF4 and RASSF1A. The p.V224I 
mutation of RASSF4 was a novel mutation, while the p.R106Q mutation of RASSF1A was 
a known SNP with MAF=0.002. Neither mutations had been reported previously in any 
other type of cancer, according to the COSMIC database, and also based on the 
PolyPhen-2 prediction tool, these missense mutations were predicted to be “probably 
damaging” to the proteins. The remaining 4 identified genes of the Hippo signalling 
pathway were cadherin related genes, FAT1, FAT3, FAT4 and DCHS2. The 3 mutations, 
p.R4359W, p.N1035S and p.R3342Q, of FAT1, FAT3 and FAT4, respectively, were 
novel nonsynonymous SNVs, while the mutation in DCHS2 (p.R263W) was a 
nonsynonymous common SNP (RS199621086). Interestingly, according to the COSMIC 
database, the same mutations of DCHS2 and FAT4 had been identified previously in 
other cancers. The p.R263W mutation in DCHS2 was identified as a somatic mutation in 
the breast cancer sample and the p.R3342Q mutation in FAT4 was previously reported in 
endometrium carcinoma and colon cancer samples. In order to confirm these mutations in 
the tumour samples, primers were designed to cover the mutation sites and sequencing 
was performed in the tumour/normal pair samples. Sanger sequencing was able to 
confirm all these mutations in the tumour samples as well as in the corresponding blood 
samples (Table 5.4B), hence these were germ-line changes in our samples. 
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Analysis of VEGF signalling pathway genes was interesting at the beginning. The 
identified SNV of MAPK12 was a novel frameshift insertion mutation (p.V33fs), while 
the nonsynonymous p.S611P mutation of ARNT was found in two different tumour 
samples. Primers were specifically designed to cover the mutation sites and samples were 
sequenced to confirm the presence of these mutations. The frameshift mutation in 
MAPK12 was a germ-line mutation that was identified in the tumour and the 
corresponding normal blood samples. The missense mutation was a false positive and 
was not detected by the conventional Sanger sequencing in both samples (Table 5.4C). 
The presence of this mutation in more than one sample could possibly be due to an error 
of exome capture sequencing. The summary of the identified cancer pathway’s genes and 
























































































































































































   
   
   
   
   























































































































































































   
   
   
   
   
   
   



















































































































































































































































































































5.3.5 Variants located on chromosome 22 
Genetic alterations of schwannoma are mainly associated with the loss of heterozygosity 
of chromosome 22 and mutations of LZTR1, NF2 and SMARCB1 which are associated 
with familial or sporadic schwannoma (Piotrowski et al., 2013). Therefore, variants 
located on chromosome 22 were investigated to identify schwannoma predisposing 
genes. Fifteen variants (1 frameshift, 1 splice-site and 13 nonsynonymous) located on 
chromosome 22 were identified from the list and none of the variants had ever been 
identified previously in any SNP database except for the p.I739V mutation of CECR2 
(RS199565531), which had been identified in 0.2% (0.0002) of the European American 
population. By looking at the TCGA data and EVS, genes that showed excessive SNPs 
and a low number of mutations in the TCGA cancer data were excluded. This reduced the 
list to 8 variants. Also, the splice-site mutation (c.1603-3->TCCC) was checked using the 
splice-site prediction tool and the deletion of 4bp from the intron showed no effect on the 
splicing. Therefore, this splice-site was not inspected further. Afterwards, the remaining 
variants were checked using IGV tools to reduce the chance of finding false positive 
results. The identified variants were found in tumour samples that had no exome data for 
their matching normal blood sample. Therefore, variants in each sample were 
investigated by IGV tools individually. Variants that showed less than 15% of total reads 
and low coverage of the mutation site were excluded due to the high chance of false 
positive mutations being detected by conventional sequencing. The remaining candidates 
were one novel frameshift insertion mutation (p.V33fs) of MAPK12 (previously analysed 
in section 5.3.4) and 4 nonsynonymouse mutations, the p.V258I mutation of MCM5, the 
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p.L333P mutation of PRODH, the novel p.V265A mutation of ACO2 and the novel 
p.E283K mutation of XBP1. These mutations showed a high percentage of mutation reads 
and good coverage according to the IGV tools (33%, 56%, 60%, 60% and 45%, 
respectively). The Polyphen-2 prediction tool predicted these nonsynonymous mutations 
to be probably damaging to the protein. To analyse these mutations in the samples, 
primers were specifically designed to cover the mutation site and Sanger sequencing was 
performed in the tumour and matching normal samples. Sanger sequencing was able to 
identify these mutations in the tumour samples as well as in the matching normal blood 
samples (Table 5.5). Finding germ-line mutations in all samples was unfortunate; 
however, these results indicated the importance of using paired samples when performing 


















































































































































































































































































































































5.3.6 High impact variants 
Analysis of the remaining exome sequencing data was started by investigating the most 
deleterious variants. Analysis of high impact (non-sense, frameshift and splice site) 
variants was conducted by applying several criteria (Figure 5.8). To reduce the large 
number of variants in the list (n=238), genes were initially checked through the exome 
variant server. Generally, genes with an excessive number of high impact SNPs are more 
likely to have another germ-line mutation when new variants are identified within the 
gene. Therefore, variants corresponding to such genes were removed from the list. This 
step reduced the list to 97 variants. After that, the TCGA and COSMIC databases were 
used to check whether these genes contained several somatic mutations in different 
cancer types. Genes that showed none or a low number of mutations in the COSMIC 
database or with a mutation frequency of <2.5% in less than 5 types of cancer in the 
TCGA database were also removed. The remaining 62 variants consisted of 14 frameshift 
variants, 4 stop-gain variants and 44 splice-site variants. All splice-site variants within the 
list were checked using the splice-site prediction tool and those showing no effect on the 
splicing were excluded. Moreover, variants with MAF <0.001 and with rs ID were 
checked in the 1000 Genomes Project database to investigate the frequency of these 
mutations in the Spanish population. All these variants have never been reported 
previously in the Spanish cohort. Finally, to eliminate false positive results, the remaining 
22 variants were analysed using IGV tools to investigate the quality and the reading 
coverage of the sequencing. Variants with poor coverage in the tumour samples or that 
 
 225 
were present in >5% of the normal blood samples (for the samples that had matching 
normal blood samples) were removed from the list. 
After applying these stringent criteria, the overall variants within the list were 10 novel 







































Figure 5.8 Filtration process applied to reduce the number of high impact variants 
A combination of manual and web-based tools were applied in the filtration process.
High Impact + Novel SNV= 
869 SNV 
Filtration Through EVS 
Filtration Through 1000 Genomes Project 
Filtration Through IGV tools = 17SNV 
Total = 62 SNV 
14 Frameshift 
SNV 















Total = 97 SNV 
 
 227 
Interestingly, the novel splice-site variant (c.121-3->TTTTTTT) of CACNB2 was found 
in two schwannoma samples and was predicted to affect the splicing, according to the 
splice-site prediction tool, and the region was read 36 times when analysed by IGV tools  
(Figure 5.9A). CACNB2 (calcium channel, voltage-dependent, beta 2 subunit) was 
considered as a good candidate since it is involved in the MAPK signalling pathway and 
its protein functions as calcium ion transport and cell-cell signalling (Figure 5.9B).  To 
confirm the presence of the variant in the tumour samples, primers were designed around 
the mutation point and then tumours and their matching normal samples were sequenced 
by conventional Sanger sequencing. When analysing the electropherograms, this 
mutation was not found in either of the two samples (Figure 5.9C). This could be due to a 
technical error of exome sequencing in this region since the exon-intron boundary 
contains multiple A bases. 
The remaining candidate variants within the list were analysed by Sanger sequencing in 
the tumour and matching normal blood samples. MAPK12 is involved in the cancer 
pathway and was analysed previously in section 5.3.5. However, the results detected in 































































































































































































































































































































































































































































































































































































































































































































































































































































































5.3.7 Nonsynonymous mutations 
The remaining missense mutations (n=1383) were investigated at the end of the analysis. 
The same criteria as above (section 2.4.6) were applied to the list to reduce the vast 
number of nonsynonymous variants. In addition, the Polyphen-2 tool was used to assess 
the effect of the mutation on the function of the proteins. All selected variants ranged 
from possibly damaging to probably damaging (50% - 99%). Variants predicted to be 
benign were excluded. The analysis began by looking for recurrent mutations that were 
found in more than one sample. Two variants that met the criteria were p.S611P of ARNT 
in the S36T and S37T samples and p.Q62P of RNF10B in Lp272T and Lp303T. Primers 
were designed around the region of interest and the tumour and corresponding normal 
blood samples were sequenced. These mutations were false positives and the reason for 
identifying a recurrent mutation in more than one sample is due to the errors that 
occurred during the sequencing (Table 5.7). Next, genes that showed multiple mutations 
were investigated. A list of 7 genes was identified and they were analysed by Sanger 
sequencing. The results were either false positive or germ-line variants (Table 5.7).  
Afterwards, the remaining nonsynonymous mutations that fit the criteria were 
investigated. The list contained variants that have previously been analysed in sections 
5.3.4 to 5.3.5. Interestingly, among the list, the possibly damaging p.S169N mutation of 
FRG1 in the tumour sample Lp303 was previously reported by COSMIC in 3 cases of 
ovarian cancer and 6 cases of melanoma (COSM225855) and was confirmed to be 
somatic in all cases (Figure 5.10A). To confirm the presence of the variant in 
schwannoma, tumour and matching normal blood samples were sequenced through 
Sanger sequencing. The result of the tumour sample was false positive as conventional 
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sequencing was unable to identify it (Figure 5.10B). The other nonsynonymous variants 
within the list were also investigated in the tumour samples and their corresponding 
normal blood samples were sequenced by Sanger sequencing. The results showed that 
none of the variants were confirmed to be somatic in any of the samples (Table 5.7). It 
was noticeable that the majority of the identified nonsynonymous mutations were in the 
two samples that have no exome data for the matching normal sample (S36 and S37). 
Having data on the tumour and matching normal samples will reduce germ-line variants, 






















ARNT c.T1831C p.S611P 
S36T 
No (no rs ID) 
False Positive 
S37T False Positive 




Lp303T False Positive 
Genes with Multiple Mutations 
LPRB1 
c.A13676G p.N4559S S36T No (RS148848707) Germ-line 
c.C6568A p.L2190M S36T Yes Germ-line 
c.A8039G p.H2680R S36T Yes Germ-line 
ENOSF 
c.T38C p.M13T S36T No (no rs ID) False Positive 
c.T20C p.M7T S36T No (no rs ID) False Positive 
c.T83C p.M28T S36T No (RS201382707) False Positive 
SP7 
c.G839T p.R280L S36T No (RS200582631) Germ-line 
c.C799T p.R267C S36T No (RS201666834) False Positive 
RCSD1 
c.T620G p.L207W S37T No (RS191098895) Germ-line 
c.A1235G p.Q412R S36T No (RS140531524) False Positive 
C2CD4A 
c.C554G p.P185R Lp272T Yes Germ-line 
c.G310C p.G104R S37T No (RS199710631) Germ-line 
MESP2 
c.C556G p.Q186E S36T No (no rs ID) False Positive 
c.G554C p.G185A S36T No (no rs ID) False Positive 
LINGO1 
c.C1284A p.D428E S37T Yes False Positive 
c.C1184G p.T395R S37T Yes False Positive 
Nonsynonymous Variants 
NRXN2 :c.C31G p.P11A Lp272T Yes False Positive 
GALNT12 c.G182A p.R61H LP303T Yes Germ-line 
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MLL2 c.G11129C p.G3710A S36T Yes Germ-line 
RHOU c.G391A p.V131M S37T Yes Germ-line 
NQO2 c.T116C p.V39A S36T Yes Germ-line 
EPPK1 c.C3577T p.R1193C S37T No (no rs ID) Germ-line 
RETN c.A245G p.D82G S36T No (no rs ID) False Positive 
 
Table 5.7 Nonsynonymous variants analysed in non-NF2 schwannoma  
Different approaches were applied to analyse nonsynonymous variants; recurrent 
variants, genes with multiple variants and single variants. The position of mutation in the 
cDNA and amino acid sequence, sample ID, novelty status and Sanger sequencing result 
































Figure 5.10 Analysis of the non-synonymous mutation p.S169N of FRG1 
A) The c.G506A SNV was previously identified in the COSMIC database in skin and 
ovarian cancer (COSM225855). The position of the mutation in cDNA is marked in red. 








5.3.8 VarScan2 tool  
In-silico analysis of the exome sequencing data did not reveal any somatic mutation in 
schwannoma tumours. Using simple steps to subtract the variants present in tumour and 
matching normal samples, or applying certain filtration criteria is probably inadequate for 
exome sequencing analysis. Many algorithmic tools have been developed to evaluate the 
next generation sequencing data of normal/tumour paired samples in order to detect 
somatic mutations (Koboldt et al. 2012). 
VarScan2 is an exome data analysis tool for somatic mutations and the detection of copy 
number alterations (section 2.9.5.3). It reads normal/tumour pair samples simultaneously 
to identify somatic/germ-line mutations and loss of heterozygosity (LOH) events. The 
analysis of exome data by VarScan2 was conducted by bioinformatician Michael 
Simpson of Kings College London. In brief, when Illumina exome sequencing reads are 
generated and aligned against reference sequences, the output reads will be converted to 
SAM (Sequence Alignment/Map) and then to BAM (binary version of SAM) file formats 
by the SAM tools package. Afterwards, the VarScan2 algorithm analyses BAM files from 
tumour and matching normal samples simultaneously by comparing the base cells and the 
depth of the sequence at each base position. To determine the somatic status of a variant, 
certain criteria were applied for coverage and base quality. Variants present in >15% of 
total reads in the tumour sample and <5% in the matching normal sample were classified 
as somatic, common variants found  between tumour and matching normal samples were 
classified as germ-line, and variants found to be heterozygous in the normal sample but 
















Figure 5.11: VarScan2 variants detection algorithm  
A flow chart showing the steps for the identification of variants from whole exome 
sequencing using the VarScan2 tool. 
Whole Exome Sequencing Data 
SAM File 
Tumour BAM File Matching Normal BAM File 
SAM tools Pipeline 
Somatic Variants Germ-line Variants LOH Variants 
Variants >15% in 
Tumour 













In the paired Lp272 samples, VarScan2 identified 6 LOH and 19 somatic hits. The 
identified somatic calls were 1 in UTR3, 1 in UTR5, 2 intronic, 9 splicing and 7 exonic 
variants (4 synonymous, 2 nonsynonymous, and 1 nonframeshift deletion). On the other 
hand, the identified somatic variants in Lp303 paired samples were 1 intronic, 1 in UTR3, 
2 splicing and 3 exonic (3 nonsynonymous) in addition to 10 LOH. In both cases, none of 
the LOH events were found on chromosome 22 (Table 5.8). None of these variants were 
identified by in-silico analysis because they did not fit the in-house criteria; 
nonsynonymous variants and some splice-site mutations were found more than 10 times 
in in-house data, and in addition, some of the splice site variants were >3bp away from 
the exon intron boundary.  
HRNR was a common gene between the two-paired samples Lp272 and Lp303. One 
synonymous and one nonsynonymous mutation were found in Lp272, while one 
nonsynonymous variant was found in the Lp303 sample. All these variants were known 
SNPs; RS76438416, RS61814943 and RS61814939, respectively, and were identified 
>10 times in in-house data (Table 5.8). Despite the fact that the 2 nonsynonymous 
mutations did not match our criteria and both were predicted to be benign to the protein 
when analysed by PolyPhen-2, the mutation regions were sequenced through Sanger 







    
 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































     
 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































5.4 Discussion  
5.4.1 General discussion of main findings 
Sporadic vestibular schwannoma is a benign tumour that is mainly affected by mutations 
in the tumour suppressor gene NF2 or/and chromosome 22 LOH. However, a small 
percentage of sporadic vestibular schwannoma showed no alterations in NF2 gene. 
Mutations of other genes on chromosome 22 have been reported in schwannoma cases 
such as SMARCB1, which has been found in 50% of familial schwannoma and 10% of 
sporadic (Rousseau et al., 2011; Smith et al., 2012), and LZTR1, in familial 
schwnomatosis (Piotrowski et al., 2014). These different gene alterations indicate that 
genes on chromosome 22 play a critical role in vestibular schwannoma development. 
Researchers are always looking for faster and cost-effective technologies to understand 
human disorders including human cancer. The advances in NGS have allowed this 
technique to characterise the molecular background of different cancer types mainly 
through whole genome sequencing (WGS) and whole exome sequencing (WES) 
techniques. While WGS is expensive for most researchers, WES is able to produce vast 
protein coding alterations data at a relatively low price. The application of exome 
sequencing in cancer studies has identified novel cancer causative mutations and genetic 
alterations that contribute to cancer development such as significant mutations in breast 
cancer (Banerji et al., 2012), colon cancer (Melissa S Derycke, 2013), leukaemia (Chang 
et al., 2013; Yan et al., 2011), lung cancer (Zheng et al., 2013) and many other cancer 
studies that are under study through TCGA.  
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In this study, whole exome sequencing was used in combination with bioinformatics 
tools to identify causative mutation for schwannoma tumours that do not contain NF2 
mutations. Different approaches and strategies were applied in order to increase the 
probability of identifying the causing variant. NF2 mutations were identified in half of 
the samples and the remaining non-NF2 samples showed no somatic mutation in any of 
the genes. Most of the identified variants were either germ-line mutations or false-
positive variants. The identification of this amount of germ-line mutations was surprising, 
however, finding false positive variants is frequent in such a high-throughput sequencing 
technique (MacArthur and Tyler-Smith, 2010) and finding hundreds of deleterious 
variants in a healthy human genome is generally common (MacArthur et al., 2012). 
Despite the widespread success of whole exome sequencing technology, this technology 
is full of challenges and limitations which will be discussed in the next section. 
 
5.4.2 Possible reasons for failing to identify somatic mutation in non-NF2 
schwannoma 
There are three possible explanations for failing to identify somatic driver mutation in 
non-NF2 schwannomas. First, the causing variant is located in areas not covered by 
exome sequencing, such as the non-coding regions of DNA. Secondly, the coding 
mutation in non-NF2 schwannoma was missed by exome sequencing or during the in-
silico analysis and filtration process. Finally, the causing variant was not detected due to 
tumour heterogeneity.  
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5.4.2.1 The causative is non-coding mutation 
Cancer sequencing studies mostly focus on driver mutations located in protein coding 
regions. However, a number of recent studies have identified significant cancer mutations 
in non-coding regulatory regions. A study by Horn and colleagues identified recurrent 
somatic mutations within the TERT promoter region in 33% of melanoma cases in 
addition to germ-line promoter mutations in familial melanomas (Horn et al., 2013). 
Moreover, another research group, led by Huang and colleagues, also found 2 recurrent 
somatic mutations in the promoter region of TERT in 71% of melanoma tumours using 
the whole exome sequencing technique (Huang et al., 2013). Other individual cases with 
non-coding mutation were also identified such as somatic and germ-line mutations within 
cis-regulatory genes found in colorectal cancer (Ongen et al., 2014) and the splice-site 
mutation in the non-coding region of BRCA2 in familial breast cancer (Bakker et al., 
2014).  
These findings increase the evidence that mutations in non-coding regulatory regions in 
the human genome are significant, which may play a crucial role in tumour genesis and 
cancer progression. It is possible that non-NF2 schwannomas are derived by mutations in 
non-coding regulatory genes that affect gene expression, especially regulatory elements 
on chromosome 22. This can be achieved by using whole genome sequencing, however, 
the whole genome sequencing is expensive and analysing the vast genome data is more 
challenging than the already overwhelming amount of data generated by whole exome 
sequencing. 
An alternative explanation for the failure to identify somatic mutation in non-NF2 
schwannoma is that the causative variant is within a protein-coding gene, however, the 
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variant was accidently missed by exome sequencing due to technical errors or because of  
the filtration process during in-silico analysis.  
 
5.4.2.2 Limitations of exome sequencing  
Whole exome sequencing covers 95% of the exons throughout the human genome 
(Rabbani et al., 2014). The application of this sequencing technology in cancer studies 
has discovered somatic mutations in cancer genomes such as the identification of the 
recurrent somatic mutation in IDH1 in glioblastoma (Parsons et al., 2008), NOTCH1 in 
head and neck cancer (Agrawal et al., 2011) and others. However, it is still difficult to 
identify true somatic mutations using this technology due to many reasons, such as low 
coverage of some regions, tumour/normal contamination, mis-matching, sequencing 
errors and others. 
Sequencing coverage is not uniform in all exons across the genome and even with newly 
discovered technologies and tools, to date no capture method can provide 100% high 
sensitivity with full coverage of all exons (Zhi and Chen, 2012). To overcome such 
problems, targeted sequencing is more effective in such cases because it provides a 
combination of different hybridization methods to increase sequencing efficiency. 
Examples of targeted sequencing specialised for cancer studies are Targeted Cancer 
Sequencing from Illumina and Ion AmpliSeq Cancer Hotspot Panel from Life 
Technology (Ion Torrent). Both technologies are based on sequencing a customised panel 
of cancer relevant genes and guarantee uniform coverage throughout the targeted region. 
Although this technology is cost effective, it is however, not a suitable technique for the 
identification of mutations in genes outside the panel.  
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When the exome sequencing data of each sample is generated, the data are aligned to the 
reference genome to produce SAM files and then BAM files. Typically, exome data 
match >99% of the bases of the reference genome and the remaining unmatched bases are 
considered as variants (Patel et al., 2014). Any fault or error during sequencing can cause 
mis-matches with the reference sequence and produce false positive calls. In contrast, 
false negative calls are when a variant is not detected due to low sequencing coverage of 
the mutation region. For instance, repetitive regions are enriched with false positive and 
false negative variants. Repetitive regions are hard to align and usually bases in such 
regions can easily be missed due to poor area coverage, but also, these regions can be 
falsely aligned and the mis-matched bases will be falsely flagged as variants.  
False calls are major challenges when analysing exome sequencing data. False negative 
calls lead to the failure to identify true causative variants. Failure to identify a somatic 
mutation in schwannoma is possibly due to insufficient coverage. On the other hand, 
applying the stringent criteria of filtration is required to reduce the false positive variants.   
 
5.4.2.3 In-silico analysis  
Whole exome sequencing is able to identify mutations in most protein-coding genes in 
the genome. In order to reduce the massive number of variants and identify the causative 
somatic mutation, series of filtering strategy were applied to the exome data. The 
filtration process was based on stringent criteria to exclude germ-line variants and 
common SNPs (Figure 5.1). Firstly, many web-tools were used to exclude common 
variants such as dbSNP and the 1000 Genomes Project database. Other tools were applied 
to prioritise the variants; COSMIC and TCGA databases for cancer related genes, 
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Polyphen-2 and splice-site prediction tools for the estimation of variants’ pathogenicity. 
Secondly, the application of the IGV tool was very important to reduce false call variants. 
Therefore, only variants/genes that were rare (MAF<0.001) or novel, commonly mutated 
in cancer, predicted to damage the coding protein, and showing good area coverage were 
analysed. 
It is possible that the above criteria could falsely exclude the causing variant. For 
example, excluding splice-site variants that were >3bp from the exon/intron boundary 
might exclude some mutations that would have been relevant and possibly somatic. The 
splicing process is controlled by specific sequences that flank the exon/intron boundary, 
which are called splice donor and splice acceptor sequences. Mutations within these 
sequences are deleterious and may lead to the formation of non-functional proteins; 
therefore, this criterion was selected. However, other cancer studies have identified 
splice-site mutations that are pathogenic and located many base pairs away from the 
exons. For instance, a study on 52 cases of neurofibromatosis type 1 (NF1) has found that 
splice-site variants affecting the splicing process of NF1 are the most common mutations 
in NF1 patients at a time when all studies were focusing on protein truncating mutations. 
In this study, the splice-site mutations ranged from ±1bp to -16bp from the exon (Ars et 
al., 2000). It is possible that splice-site mutations with different splicing distances are also 
common in schwannoma patients (neurofibromatosis type 2) in any other gene than NF2 
and analysing this type of mutation further is required.  
In addition, the assumptions that only variants affecting the amino acid sequence are 
important and that synonymous variants have no pathogenic effect on diseases may not 
be accurate in light of recent data. Generally in cancer studies, synonymous variants are 
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considered as passenger mutations or have no cancer genesis effect and are rarely 
investigated. However, a study by Gartner and colleagues on melanoma found a recurrent 
somatic synonymous mutation in the BCL2L12 gene and was associated with the 
overexpression of mRNA. By comparing the protein from WT and mutant BCL2L12, the 
two proteins were functionally similar but cells with a mutated version of the gene 
showed high cell survival and were more resistant to apoptotic signalling (Gartner et al., 
2013). Moreover, a recent study by Supek and colleagues using the exome data of 11 
different cancer tissues from the TCGA data portal and COSMIC, suggested that 
synonymous mutations can be oncogenic by affecting mRNA splicing and thereby 
altering protein function (Supek et al., 2014). This observation was mainly associated 
with the overexpression of oncogenes with mutations distributed non-randomly 
throughout the gene rather than in tumour suppressor genes. These studies indicate the 
importance of synonymous variants in human cancer and should be investigated in the 
cancer genomics field. Such analysis was beyond the scope of the present study. 
Finally, sample size in this study must be re-considered since the analysis started by 
using 8 non-NF2 schwannoma and 3 corresponding normal samples; hence exome 
sequencing was carried out on a total of 11 samples (3 normal/tumour pairs and 5 
schwannoma tumour samples). After the identification of NF2 mutations in some 
samples, the remaining samples of 2 normal/tumour paired samples and 2 tumour 
samples were used for the whole analysis. It is possible to identify somatic mutations 
with this number of samples, for example the study by Wang and colleagues on 
cholangiocarcinoma tumour, a type of liver tumour. They identified somatic mutations in 
IDH1 and IDH2 by using whole exome sequencing on one paired sample (Wang et al., 
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2013). However, even in malignant tumours, such as lung and liver cancers, driver 
mutations are scarce and difficult to identify. These challenges are increased when 
screening benign tumours and searching for driver mutations (Zheng et al., 2014). It is 
more challenging to identify the causing variant in benign tumours with a small sample 
size. 
Finding a mutation causing benign tumours among billions of variants is also 
challenging. The filtration and prioritization strategies applied in this study were strict. 
Even with these strict criteria, most of the analysed variants were germ-line mutations.  
Despite the limitations of whole exome sequencing and the difficulty in identifying true 
somatic variants in the present report, this technology has shown fascinating results in the 
identification of variants in many cancer genomes in a short time frame and for a 
reasonable cost. The combination of sufficient sequencing coverage, appropriate sample 
size, stringent filtration criteria and external bioinformatics tools are essential factors to 
increase the success of the whole exome sequencing study. 
5.4.2.4 Tumour heterogeneity  
Another challenge that exome sequencing faces in detecting a single somatic mutation in 
the cancer genome is tumour heterogeneity and/or the contamination of tumour cells by 
adjacent normal cells. The cancer genome is complex and each clone varies in its genome 
and mutational stage. Studies carried out on different tumour samples from the same 
patient found diversity in the intratumour heterogeneity between different tumour sites, as 
well as between the primary tumour and the distant metastatic organs. This extensive 
heterogeneity within the single tumour explains the difficulty in understanding cancer 
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genetics and the discovery of tumour biomarkers (Gerlinger et al., 2012). Also, the 
genome of tumour cells is different from normal cells. Most studies that use high 
throughput sequencing technology include tumour and matching normal samples and 
increase the sample size to overcome such problems and exclude common variants. It 
was noticeable in the current study that the number of variants in samples without 
matching normal was high compared to samples with matching normal which lead to the 
identification of high germ-line mutations in these samples. Generally, mutations in 
cancer occur at a very low frequency and having a small number of samples reduces the 
chance of finding significant mutations.  
 
5.4.3 Identification of novel NF2 mutations 
The NF2 gene, which functions as a tumour suppressor, has been widely investigated and 
many genetic alterations were reported in different types of cancer other than 
schwannoma, such as pleural mesothelioma (Sekido, 2001), meningioma (Vogan, 2013) 
and renal cell carcinoma (Dalgliesh et al., 2010). Loss of heterozygosity and other genetic 
mutations in NF2 identified in different studies were uploaded to several online 
databases. To date, the number of identified mutations in NF2 is 386 in HGMD, 1,026 in 
COSMIC and 2,124 in dbSNP. In this study, four deleterious mutations were identified in 
schwannoma samples and, to our knowledge; these mutations have never been reported 
in any SNP/genetic variation databases. These include the novel stop-gain mutations 
(p.Q387X and p.K15X), novel frameshift mutation (p.24_24del) and the novel 
nonsynonymous mutation (p.Q121H). Despite the fact that the objective of this study was 
to identify somatic mutations in non-NF2 schwannoma tumours, finding new NF2 
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mutations using whole exome sequencing was validation of the ability of exome 




 Discussion Chapter Six:
 
Cancer is one of the leading causes of death worldwide. The latest global statistics, in 
2012, have revealed that around 32 million people are living with cancer, 8 million deaths 
were associated with cancer and 14 million individuals were newly diagnosed with 
cancer (Ferlay et al. 2015). According to the origin site of the cells, cancer is classified 
into more than 100 types which are categorised into 5 groups: carcinoma, sarcoma, 
leukaemia, lymphoma and CNS cancer. 
Tumours of the CNS are relatively uncommon; however, malignant high grade tumours 
are fatal which increases the challenge to determine the genetic factors behind the tumour 
formation and progression. The number of cases associated with CNS tumours is 
increasing worldwide, with an estimated 256,000 CNS tumour cases diagnosed in 2012 
(Ferlay et al. 2015). The development of techniques and research methods that help to 
understand the molecular mechanisms of tumour development and the identification of 
molecular markers are important to reduce mortality and improve patient therapy. 
  
6.1 Genome-wide analysis of sporadic CNS tumours 
Several genome-wide technologies have been utilised in cancer research to identify the 
genetic and epigenetic factors that are associated with cancer development and 
progression. Next generation sequencing (NGS) has been widely performed to identify 
single nucleotide variants associated with cancer initiation and progression. Recently, 
NGS and microarray technologies have been introduced to the field which complement 
each other. Epigenetic microarray based technology has provided a better understanding 
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of DNA methylation profiling on a genome-wide scale. Although NGS provides 
information about genome sequence variations, methylation microarrays identify 
epigenetic variants and cancer-associated markers. The work in this thesis aimed to 
characterise: (i) DNA methylation changes in brain cancer, presenting two studies that 
were performed to identify hypermethylated genes in (A) glioblastoma, and (B) brain 
metastasis from breast tumours, using Infinium Illumina HumanMethylation450K 
BeadChip; and (ii) genetic variants associated with sporadic vestibular non-NF2 
schwannoma by utilising whole exome sequencing (WES).  
 
6.1.1 Epigenome-wide analysis of brain cancer  
Numerous platforms are available to measure DNA methylation using either locus-
specific or genome-wide methylation analysis. Examples of locus-specific DNA 
methylation analysis include methylation-specific PCR (MSP), Combined Bisulfite 
Restriction Analysis (CoBRA) and methylight real-time PCR. On the other hand, 
genome-wide methylation analysis includes either microarray based methods, such as 
Infinium Illumina or Affymetrix methylation arrays, or non-microarray based 
methylation methods including Restriction Landmark Genomic Scanning (RLGS), 
methylated DNA immunoprecipitation (MeDIP), Methylated CpG Island Recovery 
Assay (MIRA) and bisulfite converted DNA sequencing.    
The most recent array, Infinium HumanMethylation450K BeadChip by Illumina, is a 
revolutionary assay that provides a comprehensive DNA methylation analysis of more 
than 485,000 CpG sites per sample across the entire genome. Chapters Three and Four 
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have utilised this most up to date technique to evaluate the methylation profile of brain 
tumours. 
Grade IV glioblastoma multiforme (GBM) is the most fatal form of glioma in adults with 
a median survival rate of <1 year. However, a small fraction of GBM patients showed a 
longer survival time of up to 3 years, who are so-called long-term survivors (LTS). In 
Chapter Three, an evaluation of the methylation profile of 19 short-term survivors (STS) 
and 16 LTS glioblastoma tumours was conducted to identify methylation changes that 
contribute to STS patients’ poor survival. During the analysis, a subset of LTS 
glioblastoma (n=5) showed massive hypermethylation across many CpG loci, indicating 
the existence of the CIMP+ phenotype. Interestingly, these five LTS tumours carried 
mutations in the IDH1 gene and fulfilled the criteria of G-CIMP, which agrees with the 
findings in Noushmehr et al.’s paper. In addition, further analysis between G-CIMP+ LTS 
glioblastoma and non-CIMP glioblastoma has identified 535 genes (2,377 CpG loci) that 
were statistically and significantly associated with CIMP+. Analysis of the gene list using 
a bioinformatics tool demonstrated that these genes are involved in various cellular 
regulatory processes such as cell migration, cell signalling, cell growth and apoptosis. 
Also, several genes within the list were associated with various types of cancer and 
tumorigenesis including colon cancer, epithelial cancer, metastasis, tumour angiogenesis 
and tumour growth.  
This finding leads to the cohorts of the study being divided into three groups: STS 
tumours, LTS with IDH-wt (non-CIMP) and LTS with IDH-mut (CIMP+). However, the 
methylome of the three groups of glioblastoma was similar, where the majority of the 
hypermethylated CpG loci were located within CpG islands and in the promoter regions. 
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On the other hand, hypomethylated loci resided in the gene body and intergenic regions 
of the genome.  
Furthermore, the study was also able to identify differentially hypermethylated genes (32 
CpG loci) between STS and LTS glioblastoma that may be associated with STS patients’ 
poor prognosis. Amongst the list, NR2F2 was represented by multiple probes located 
within the CpG island and indicated a significant correlation between gene 
hypermethylation and poor survival. The association between the loss of NR2F2 
expression and patients’ poor prognosis was also reported earlier in ovarian cancer 
(Hawkins et al. 2013). Hypermethylation of the INA gene was also associated with  
glioblastoma patients’ poor survival. Alterations in INA expression have been related to 
short survival in other grades of glioma and pancreatic tumours (Liu et al. 2014; 
Figarella-Branger et al. 2012). Also, hypermethylation of the remaining genes has been 
found in other cancers, such as the Homeobox gene family in glioma, lymphoma and 
prostate cancer (Wu et al. 2010; Leshchenko et al. 2010; Miller et al. 2003), the 
transcription factor TFAP2A in prostate and head and neck cancer (Bennett, Romigh and 
Eng 2009), the glutamate receptor gene GRM6 in ccRCC (Arai et al. 2012) and DKK2 in 
Ewing sarcoma (Hauer et al. 2013). Hypermethylation of the generated list of genes in 
STS glioblastoma cases suggests their potential as prognostic markers and further 
investigation is required to assess their role in gliomagenesis.  
Metastasis is an indication of a patient’s poor prognosis. Around 15% to 20% of breast 
cancer patients acquire brain metastasis with a survival rate of less than 8 months. In 
Chapter Four, the HumanMethylation450K array was utilised to identify the 
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hypermethylation changes that promote brain cell metastasis from breast cancer and that 
are involved in metastasis development to the brain.  
Differential analysis between breast cancer brain metastasis tumours and non-metastatic 
breast tumours from the TCGA data portal was carried out and identified 28 differentially 
hypermethylated genes (37 probes). Further bioinformatics analysis lead to the selection 
of 7 candidate genes (EOMES, WDR69, MIR125B1, DZIP1, SOX1, PHOX2B and 
PRDM13) from the list to be investigated further in the study. Methylation analysis by 
CoBRA of 10 breast tumours and their matching brain metastasis samples showed that 
the candidate genes were hypermethylated in the paired breast tumours and BCBM 
samples, indicating the significance of the 7 genes in the early stages of brain metastasis 
formation from breast tumours. Furthermore, lower expression of EOMES, WDR69, 
MIR125B1, PHOX2B and PRDM13 genes was associated with DNA hypermethylation 
and down regulation of DZIP1, PRDM13 and PHOX2B genes was associated with  
patients’ poor survival. This preliminary study has provided some insights into candidate 
molecular markers for the prediction of BCBM development in the early stages. 
However, further biological and functional investigation must be carried out to confirm 
the involvement of genes in metastasis formation and progression.  
 
6.1.1.1 Processing the HumanMethylation450K BeadChip data 
The studies carried out in Chapters Three and Four utilised the most recently developed 
Illumina Infinium HumanMethylation450K BeadChip. This technology provides a 
comprehensive quantitative methylation measurement (β value) of each CpG 
dinucleotide, however, the array contains two differently designed probes (Infinium I and 
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Infinium II) that each evaluate DNA methylation status differently. Infinium I assay uses 
two separate probes (methylated and unmethylated) to assess the methylation intensity, 
while Infinium II assay measures the methylation intensity using one single probe for 
each CpG site. The difference between the two assays was considered in our studies and 
several quality control pre-analysis processes were applied to the array data to ensure an 
accurate analysis. For instance, using LUMI package pipeline to normalize the β value 
difference between Infinium I/II probes and removing probes with high detection p-
values along with individual β value validation, all were applied to overcome any 
potential faults that may influence downstream analysis. Despite this minor limitation of 
the 450K array, this technology provides a cost-effective, high throughput epigenome-
wide analysis that can assess more than 96% of CpG sites in the genome. 
 
6.1.2 Genome-wide analysis of CNS cancer  
NGS has been widely used in cancer research to identify nucleotide variants in genes 
involved in cancer formation and cancer progression. NGS, through WGS and WES, is a 
powerful and highly efficient technology that enables researchers to study tumour 
samples in depth and to identify cancer-associated variants within a short timeframe, 
especially with the development of targeted cancer sequencing that is based on a 
customised panel of cancer-associated genes. WES, which applies parallel sequencing of 
the protein-coding regions, was utilised in Chapter Five on 8 sporadic vestibular 
schwannoma and 3 DNA samples of matching normal blood. Several bioinformatic tools 
and different strategies were used to facilitate the analysis and to reduce false 
positive/negative variants. The analysis was carried out by investigating the SNVs 
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involved in major cancer pathways, genes located on chromosome 22 (where the NF2 
gene resides), high impact deleterious variants and then the remaining nonsynonymous 
SNVs. The initial analysis of the tumour samples identified four deleterious mutations in 
the NF2 gene within half of the schwannoma samples, while the remaining half showed 
many germ-line or false positive variants. Identification of several germ-line mutations in 
our samples was displeasing, however, finding deleterious mutations in the genome of 
healthy humans has been frequently reported (MacArthur et al., 2012). The identification 
of multiple false positive variants in our study may be due to technical errors such as poor 
DNA hybridization, insufficient coverage or false alignment with the reference genome 
that occurs during the sequencing. Such errors are well known and considered as serious 
limitations to WGS. However, to overcome such problems in our study, combinations of 
bioinformatics tools (Polyphen-2 and 1000 Genomes Project database), external software 
(IGVtools) and stringent filtration criteria were applied to the exome sequencing data to 
raise the possibility of identifying disease-causing SNVs. Despite the fact that the aim of 
the study in this chapter was to identify somatic mutations in the novel genes involved in 
non-NF2 schwannoma formation, WES was able to identify 4 deleterious variants in the 
NF2 gene, and to our knowledge, these variants are novel to all SNP/SNV databases.  
 
6.2 Future work 
The most recent Illumina HumanMethylation450K BeadChip was utilised to: (i) 
investigate differentially methylated genes that may be associated with poor prognosis in 
STS glioblastoma patients. The study has generated a list of differentially 
hypermethylated genes in STS tumours and it would be beneficial to confirm these 
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findings in a separate and larger cohort. Additionally, further work would also be 
required to determine the functional relevance of the genes in gliomagenesis. Examples 
of genes from the list are DKK2, NR2F2 and the transcription factor TFAP2A which are 
potential candidates as biomarkers for disease outcome.  
Furthermore, the study has identified a list of CIMP+ genes in a subgroup of LTS 
glioblastoma tumours. A thorough investigation would be beneficial to determine the 
association between IDH mutation and G-CIMP+ as it would be helpful to understand the 
mechanism of G-CIMP formation. (ii) Identify a list of candidate genes that were 
hypermethylated and associated with poor survival in breast cancer brain metastasis 
patients. These genes may contribute to breast cancer brain metastasis formation and 
further analysis is required to assess the biological and functional relevance of the genes. 
Within the list, EOMES, PHOX2B and DZIP1 were potential markers for BCBM and 
further investigation, such as migration and invasion assays, needs to be performed on 
breast cancer cell lines that show a correlation between DNA hypermethylation and loss 
of expression to find out if the reduced gene expression is correlated with increased cell 
motility and cell invasion. Other investigations may involve knocking out gene 
expression in unmethylated, expressing breast cancer cell lines.  
 
6.3 Final conclusion  
High-throughput technologies, such as NGS and methylation microarrays, are powerful 
technologies for the identification of disease-associated genetic/epigenetic changes 
without the knowledge of the exact location and function of the causative gene. Through 
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the use of such technologies in different CNS tumours, the results presented in this thesis 
have shown the validity of using high-throughput technologies to identify 
genetic/epigenetic markers. The results from Illumina Infinium HumanMethylation450K 
BeadChip have identified hypermethylated genes that are; (i) candidates for glioblastoma 
patients’ poor survival, DKK2, NR2F2 and TFAP2A, that require further investigation, 
(ii) a preliminary list of potential epigenetic markers for the early prediction of brain 
metastasis formation from breast tumours. WES was not able to identify the causative 
variants for non-NF2 schwannoma, however, this technology was able to identify new 
SNVs in the NF2 gene that, as far as we are aware, have not been previously reported in 




 Appendices Chapter Seven:
 
7.1 Primer Sequences 







F 5’ AGTATTTYGGGTTAGGGTGGTTTTATGTA 3’ 
R 5’ ATATACTTTCAAAACRCCCCAACCCTTAC 3’ 




F 5’ GAGYGYGTTTAGTTTYGTTTTYGGGTTTTAT 3’ 
R 5’ ATCRCCACAAAAATCRCACCACRTATACRTA 3’ 




F 5’ GAGGTTGTAGTGAGTYGATATYGYGTTAT 3’ 
R 5’ CTAAACCAAAACCRACRCAACCTCC 3’ 




F 5’ GGGAGGTGGGATTGTTTAGATATTT 3’ 
R 5’ CAAAAACTCCTTAAACAACTTTAAATCCTAAAA 3’ 
RN 5’ ACTAAAACTTCCAACAACTACTAAAATACAAAAA 3’ 
54 OC 
DKK2 
F 5’ TGAGTTTATAGGGTTTTGGGTTTTYGAATT 3’ 
R 5’ ACCACRCTCCRAATATTACAAAATACAATA 3’ 
FN 5’ ATTAGGAAGGGTTGAGGGAATATAATTTGT 3’ 
57OC 
EOMES 
F 5’  GGTATTGGGGATAGGATAAGAGTGA  3’ 
R 5’  CRCACTCAACAATCCTTTAACCATC  3’ 
RN 5’  CCRACATCTCAACCRAAAAATACRC  3’ 
58 OC 
WDR69 
F 5’  GTATGTAGTTTAGGTTGTGGTTTAGGT  3’ 
R 5’  CCACRTAAAAATAACRAAACCRAACTAATAC  3’ 
RN 5’   CTCTTAAACTTCATTTTCTTACTCTCTTATC   3’ 
57 OC 
MIR125B 
F 5’  GGTTATAGAAGTGTAAAGAYGAATAGYGT  3’ 
R 5’  ACCTTAACTTCAACCAAACAACTAATACAAAC  3’ 
RN 5’    CTAATACAAACRAAACCTCCRTTTACAAAAC    3’ 
58 OC 
SOX1 
F 5’   GGATTTTGAGGGTTTAATGGGATTT   3’ 
R 5’   AACCTACTATAATCTTTTCTCCACTA   3’ 
FN 5’    GGTTTAATGGGATTTTGAGGGTTTT     3’ 
54 OC 
PRDM13 
F 5’   AGTTTAGGTTGTTGGTTTTAGGGAA   3’ 
R 5’    TTCAAAACCRCTTTAATTCTCACTTCTA    3’ 
FN 5’     TGGTTTTAGGGAAGTTAGTTTAAGGAT     3’ 
55 OC 
PHOX2B 
F 5’   AGGATTYGTAGGTAGAGGAATTGAG   3’ 
R 5’    AAACRCCAACAATAAAACCAACCRCTT    3’ 





7.1.2  MSP/USP primers 
 
7.1.3 Expression Primers 
 
DZIP1 
F 5’   GTATTTTYGTYGGGGGYGTTTYGGTT   3’ 
R 5’    AACTCCCCACRCCTACCTTAAAAAC    3’ 
RN 5’     TTGTATAGGAGGAGTYGGGYGGTTT     3’ 
59 OC 
ETS1 
F 5’  GGTTATAGAAGTGTAAAGAYGAATAGYGT  3’ 
R 5’   AACCTACTATAATCTTTTCTCCACTA   3’ 








F 5’   TTTCGACGTTCGTAGGTTTTCGC   3’ 




F 5’  TTTGTGTTTTGATGTTTGTAGGTTTTTGT  3’ 










F 5’ GACCCCTTCAGTACCTCAACTACA 3’ 
R 5’ CTAAGCACTTGGTGGTGCAGGA 3’ 56
 OC 
EOMES F 5’ CGGGCACCTATCAGTACAGC 3’ R 5’  CAGCACCACCTCTACGAACA  3’ 59 
 OC 
WDR69 F 5’ TGTTTAGCCGTTTCCAAGGC 3’ R 5’   TGCTCTGTTCGTGAAGCTGT   3’ 59 
 OC 
SOX1 F 5’  TGATGATGGAGACCGACCTG  3’ R 5’    CTCGGACATGACCTTCCACT    3’ 58
 OC 
PRDM13 F 5’  CTAGCGGTGCCAAAAGGC  3’ R 5’    CTTGCCCAGCTTGAAGGTAC    3’ 58 
 OC 
PHOX2B F 5’  TGATAGGGAGGTTGGACAGC  3’ R 5’    TATGGAGAAGGTGGCTGGAG    3’ 58 
 OC 













F 5’  GACGGCAGGTGTGGGTG  3’ 




F 5’  ATCAGGGGTCTTGTGTGTGG  3’ 




F 5’  CTGATGGCTGGCATGGAC  3’ 




F 5’  CTGCCCTGTTCCTACCTTCG  3’ 




F 5’   CGCCAGACCAGACCAAAGTC  3’ 
R 5’     CAGAGCCTGTCCACCTATGC    3’ 59
 OC 
AKT1 F 5’   CTGGCCCTAAGAAACAGCTC  3’ R 5’     CGCCACAGAGAAGTTGTTGA  3’ 59 
 OC 
SMO F 5’   GATGGGGACTCTGTGAGTGG   3’ R 5’     TCGTCTGCCTAGAGGGTCAC     3’ 59 
 OC 




F 5’     GGGCTAAAGGGCTCAGAGTG   3’ 




F 5’    TTACACGCCCTCTCTCTGTG  3’ 
R 5’      CCAACAATGAATGGGCCTCA  3’ 59 
 OC 
ARID1B F 5’   CAGCAACAGCAACATCCCAT   3’ R 5’     CAGCGCTGCCATAGTAATTA     3’ 59 
 OC 
SMARCE1 F 5’    AGCTGACCTGTTGGCTGAAA  3’ R 5’      GAACGATGCTGCTCTGACTG 3’ 59 
 OC 
SMARCA4 F 5’   TGTCACACGTGTCCATCGTT 3’ R 5’  GCGATGGTCTGGATGGTCTT  3’ 59 
 OC 
FAT1 F 5’   CCGTCTTGGCCCATATACTT   3’ R 5’ GGCTTTAAGGGTAGATAGTGCG  3’ 59 
 OC 
RASSF4 F 5’   AGGTTGGGAGAGGACAGGTT   3’ R 5’   CCCATCTGGAAGGGAGTACA     3’ 59 
 OC 




RASSF1A F 5’   GTTCTTGGTGGTGGATGACC   3’ R 5’     CCTTCAGGACAAAGCTCAGG     3’ 59 
 OC 
DCHS2 F 5’   CGTTCTTCCAGTTGCGCTAC   3’ R 5’     CGGTACTCGTCCTGCTCAAA     3’ 59 
 OC 
MAPK12 F 5’   AGTGGCTTTTACCGCCAGGA   3’ R 5’     GCTTCTTGATGGCCACCTTA     3’ 59 
 OC 
ARNT F 5’   GCAGGAAGTCAAGGGGATCT 3’ R 5’     ACACAGGGAACACACAGATG     3’ 59 
 OC 
MCM5 F 5’   GGGTGGAATCAGAGACTTGC  3’ R 5’  TCACCAGAGCCATCTGTGTC 3’ 59 
 OC 
XBP1 F 5’   TTCCTTACCAGCCTCCCTTT   3’ R 5’     GTGGCTGGATGAAAGCAGAT     3’ 59 
 OC 
ACO2 F 5’   GGTCCTCACCCAAAGATGTG 3’ R 5’  CAAGTCCCCAAATGGAACAG 3’ 59 
 OC 
PRODH F 5’   CCACAGGATGCCTATGACAA 3’ R 5’  GGACACATGTGGCTGACAAG 3’ 59 
 OC 
LNX1 F 5’   AGCAAAGGTGAGCCTTCTTG  3’ R 5’  GTGTGTCCACACGGAGTGTC 3’ 59 
 OC 
CYP3A4 F 5’   GGAGTGTCTCACTCACTTTGATGC 3’ R 5’  TCTGGTGTTCTCAGGCACAG 3’ 59 
 OC 
CFHR5 F 5’   CTCTGTATATGAAGCCCCTTGC 3’ R 5’ GGTGACCACCCAAATTGGTA 3’ 59 
 OC 
SAMD9 F 5’   AGCAGAACATGCCTCAAGTG 3’ R 5’     TGGATCCCCTGGAATATCAC 3’ 59 
 OC 
NRD1 F 5’   TGATGCAGCTGACCTACCTG 3’ R 5’  AATGGAAGCCCTAAGGCAGT  3’ 59 
 OC 
USP40 F 5’   CAACAGAATCGACTCCCAAG 3’ R 5’  GGTTCCACCCTGATTTCTGA 3’ 59 
 OC 
PLEC F 5’   GTACCCTGCCTGCTGCCTTT  3’ R 5’  GATGCCTTCATTGGTGAGGT 3’ 59 
 OC 
COPZ2 F 5’   GGGAGAACGAGCAAGAGGAC 3’ R 5’   CGAGTTCTGAGTTGGCTGCT 3’ 59 
 OC 
TNFAIP6 F 5’ AGTGACAGCTGGAGGTTTCC 3’ R 5’  TGCAGTGGGATTATGAGAGG 3’ 59 
 OC 
CYBA F 5’   CACTCGGCCTGTTAGCTTTC 3’ R 5’  CCCCCTTCTCTACCTACTGTGG 3’ 60 
 OC 
SYTL2 F 5’   GCTGTAGGGAAAACCACCAA 3’ R 5’ CTGGGAAGAAGCAAAGCAAC 3’ 59 
 OC 




FASN F 5’ AGGCTGCCATTACCACACTT  3’ R 5’  AGATGGTGACTGTGTCCTTGG 3’ 59 
 OC 
ABCE1 F 5’ TGTTCGCCTCCAACCTTAAG 3’ R 5’  TGCAGCCTTAGGAATCTGGT  3’ 59 
 OC 
SNX30 F 5’   CCGTTAGACATTTGCTCCGC 3’ R 5’ CTTAACCCGAGGCCTTGCA 3’ 59 
 OC 
RNF19B F 5’   CGCTCCACATCGCTACATG 3’ R 5’ CTCCTCATCGTCGAACCCAG 3’ 59 
 OC 
LRPB1 F 5’   TGTTTGTGCCAGGGACAATG   3’ R 5’  GTGCATCACTGTAAAAGATTCGG   3’ 59 
 OC 
ENOSF F 5’   GATCCCGACCAGTCCTGAC 3’ R 5’  CCAAGGCATGAAAAGCGAGT 3’ 59 
 OC 
SP7 F 5’   CTAGAAGGGAGTGGTGGAGC  3’ R 5’     GCTCATCCGAACGAGTGAAC 3’ 59 
 OC 
RCSD1 F 5’   AACTTGGAGATTTCAGGGCG 3’ R 5’  TGGCCTTTTCACCGTTCTTG 3’ 59 
 OC 
C2CD4A F 5’   AAGAAGCAGGGATGGACGAG  3’ R 5’  CTCCTTGTCCTCGTTCCCG 3’ 59 
 OC 
MESP2 F 5’   GAGGAGAGTCTGCAGTGCC 3’ R 5’ CGACTGTATCTTGGGGCAGT 3’ 59 
 OC 
LINGO1 F 5’   GACACTCATCCTGGACTCCA 3’ R 5’  TGAGACCAGGTGCTTTCGG 3’ 59 
 OC 
NRXN2 F 5’   CTGAGGGAAGCCGGCATCT 3’ R 5’  CGTCGTCCAGGTAGAGCAG 3’ 60 
 OC 
GALNT12 F 5’ ATCCGGGTCCTGGCCTCCA 3’ R 5’  CGGTCGCTGAGGTAGATGTTAAT  3’ 59 
 OC 
MLL2 F 5’   CTGGTGGCCCCTTCCTTAAT 3’ R 5’  GGATTGCCACCTGTCCTAGA 3’ 59 
 OC 
RHOU F 5’   ATCGTTTCAAGGATGCTGGC 3’ R 5’   GACAGTGGCATCGAATCTCC 3’ 58 
 OC 
NQO2 F 5’   CTATGCACACCAGGAACCCA   3’ R 5’   ACTTCTGGGATACTGCTGGTG     3’ 59 
 OC 
EPPK1 F 5’   AGACTTCTGGCCTTCACCTC   3’ R 5’     GGGTCTCCTGGGTGATGATG     3’ 59 
 OC 





7.2 Clinical information of the 35 glioblastoma cases used in chapter three 
This table shows clinical features of 35 glioblastoma cases (STS=19 and LTS=16) used 
in the methylation array. Parameters include; gender of cases (male or female), age at 
diagnosis (range and median age), survival in years and median survival, case status 
(dead or alive), percentage score of KPS, radiotherapy and chemotherapy (yes or no), and 
IDH1 mutation status (mutated or wild-type). Number between brackets represents the 
percentage of total number of samples. 
 STS Glioblastoma LTS Glioblastoma 
Gender Male 12 (63%) 9 (56%) 
Female 7 (37%) 7 (44%) 
Age at diagnosis Range 38-82 33-72 
Median Age 63 52.5 
Survival Range (years) 0.54-0.97 3.06-11.11 
Median Survival 7 months 5 years 
Status Dead 19 (100%) 8 (50%) 
Alive 0 (0%) 8 (50%) 
KPS % Range 70-100 80-100 
Radiotherapy Yes 16 (84%) 16 (100%) 
No 3 (16%) 0 (0%) 
Chemotherapy Yes 10 (53%) 16 (100%) 
No 9 (47%) 0 (0%) 
IDH1 mutation Mutated 0 (0%) 5 (31%) 




7.3 CIMP+ CpG loci  
List of CIMP+ CpG loci with adjusted P value <0.05. The list contains gene names, 
adjusted P value, chromosomal location, accession number and relation to CpG island. 
Gene$NAME! Adj.$Pval! CHR! ACCESSION$Number! RELATION$TO$CpG$
ISLAND!
COL11A2$ 2.96501E*25! 6! NM_001163771! N_Shore!
KIAA0495$ 1.35115E*23! 1! NM_207306! Island!
ADAMTSL4$ 1.13621E*22! 1! NM_019032! Island!
NPM2$ 1.27923E*20! 8! NM_182795! Island!
GNMT$ 2.99914E*20! 6! NM_018960! Island!
TCEA3$ 1.31214E*18! 1! NM_003196! Island!
KCNB1$ 1.35837E*18! 20! NM_004975! Island!
CBLN3$ 1.36898E*18! 14! NM_001039771! Island!
NGB$ 3.212E*18! 14! NM_021257! Island!
CFTR$ 8.70933E*18! 7! NM_000492! Open!sea!
MACROD1$ 1.01481E*17! 11! NM_014067! Island!
CBLN3$ 1.12008E*17! 14! NM_001039771! Island!
CLSTN1$ 1.27718E*17! 1! NM_014944! Island!
FRZB$ 1.31641E*17! 2! NM_001463! Island!
CMYA5$ 5.15879E*17! 5! NM_153610! Open!sea!
TCEA3$ 5.41486E*17! 1! NM_003196! Island!
CBLN3$ 5.88516E*17! 14! NM_001039771! S_Shore!
CMYA5$ 1.6431E*16! 5! NM_153610! Open!sea!
RHBDF2$ 1.65905E*16! 17! NM_024599! Island!
NTSR2$ 1.69212E*16! 2! NM_012344! Island!
TPPP3$ 1.69791E*16! 16! NM_015964! Island!
KIAA0495$ 2.10287E*16! 1! NM_207306! Island!
PRR15$ 3.3098E*16! 7! NM_175887! Island!
LRRC3B$ 8.27429E*16! 3! NM_052953! N_Shore!
GIPC2$ 8.86418E*16! 1! NM_017655! Island!
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DLGAP3$ 9.7562E*16! 1! NM_001080418! Island!
KIAA0495$ 1.24367E*15! 1! NM_207306! Island!
CNGA3$ 1.25263E*15! 2! NM_001298! S_Shore!
LIMS2$ 1.26021E*15! 2! NM_001136037! Island!
COL9A2$ 3.55036E*15! 1! NM_001852! Island!
HLF$ 3.87448E*15! 17! NM_002126! S_Shore!
FCHSD1$ 4.33341E*15! 5! NM_033449! Island!
TPPP3$ 4.66527E*15! 16! NM_015964! Island!
CBLN3$ 5.08916E*15! 14! NM_001039771! Island!
SLC22A15$ 5.14119E*15! 1! NM_018420! Island!
RFX8$ 6.11908E*15! 2! NM_001145664! Island!
MAGI2$ 6.20939E*15! 7! NM_012301! Island!
ACTA1$ 7.85378E*15! 1! NM_001100! Island!
COL11A2$ 7.91063E*15! 6! NM_001163771! N_Shore!
PNKD$ 8.01914E*15! 2! NM_015488! Island!
FCHSD1$ 1.19621E*14! 5! NM_033449! Island!
CLDN10$ 1.19698E*14! 13! NM_006984! Island!
ALS2CL$ 1.2111E*14! 3! NM_147129! Island!
SPTBN4$ 1.35016E*14! 19! NM_020971! Island!
TCIRG1$ 1.39217E*14! 11! NM_006019! Island!
AKR7A3$ 1.472E*14! 1! NM_012067! Island!
MCFD2$ 1.49614E*14! 2! NM_001171508! S_Shore!
MACROD1$ 2.03981E*14! 11! NM_014067! Island!
TTC12$ 2.0444E*14! 11! NM_017868! N_Shore!
CLSTN1$ 2.22592E*14! 1! NM_014944! Island!
SPEG$ 2.94825E*14! 2! NM_005876! Island!
NR2E1$ 3.64853E*14! 6! NM_003269! Island!
DNAJA4$ 4.33928E*14! 15! NM_018602! Island!
TUBA4B$ 4.99997E*14! 2! NR_003063! Island!
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FCHSD1$ 5.1707E*14! 5! NM_033449! Island!
RHBDF2$ 5.28622E*14! 17! NM_024599! S_Shore!
CBLN3$ 5.28941E*14! 14! NM_001039771! Island!
PTPRU$ 5.81698E*14! 1! NM_133178! Island!
RARRES2$ 6.62572E*14! 7! NM_002889! Island!
GJA4$ 6.70831E*14! 1! NM_002060! Island!
PLD5$ 7.51899E*14! 1! NM_152666! N_Shore!
FGFRL1$ 7.56347E*14! 4! NM_001004358! Island!
G0S2$ 7.9631E*14! 1! NM_015714! Island!
LGALS3$ 8.82577E*14! 14! NM_002306! Island!
RARRES1$ 1.00482E*13! 3! NM_206963! Island!
ARL4A$ 1.03154E*13! 7! NM_212460! Island!
B3GNT7$ 1.03285E*13! 2! NM_145236! Island!
LGALS3$ 1.05926E*13! 14! NM_002306! Island!
TTC12$ 1.05948E*13! 11! NM_017868! N_Shore!
KCNB1$ 1.34636E*13! 20! NM_004975! Island!
SLC6A11$ 1.62366E*13! 3! NM_014229! Island!
LIMS2$ 3.19952E*13! 2! NM_001136037! Island!
EBF4$ 3.34346E*13! 20! NM_001110514! Island!
LRAT$ 3.41055E*13! 4! NM_004744! Island!
VSX1$ 3.43971E*13! 20! NM_014588! Island!
KCNB1$ 3.80101E*13! 20! NM_004975! Island!
ARL4A$ 4.69923E*13! 7! NM_212460! Island!
FABP5$ 4.76397E*13! 8! NM_001444! Island!
FAM132A$ 5.18265E*13! 1! NM_001014980! Island!
ANGPT4$ 5.84399E*13! 20! NM_015985! N_Shore!
THRB$ 6.17996E*13! 3! NM_001128177! Island!
CCNI2$ 6.23242E*13! 5! NM_001039780! Island!
CLSTN1$ 6.48294E*13! 1! NM_014944! Island!
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ACTA1$ 6.80792E*13! 1! NM_001100! Island!
ZDHHC8P$ 7.91967E*13! 22! NR_003950! Open!sea!
TNFAIP8L3$ 8.12941E*13! 15! NM_207381! Island!
CBLN3$ 8.18742E*13! 14! NM_001039771! Island!
CLSTN1$ 9.97038E*13! 1! NM_014944! Island!
SRRM3$ 1.06839E*12! 7! NM_001110199! Island!
P2RY2$ 1.23083E*12! 11! NM_176071! Island!
MYRIP$ 1.23898E*12! 3! NM_015460! Island!
ANGPT4$ 1.25895E*12! 20! NM_015985! Island!
DNAJA4$ 1.32375E*12! 15! NM_018602! Island!
CMYA5$ 1.41724E*12! 5! NM_153610! Open!sea!
COL18A1$ 1.41728E*12! 21! NM_130445! Island!
HIST1H4F$ 1.43376E*12! 6! NM_003540! N_Shore!
HSPA2$ 1.4873E*12! 14! NM_021979! Island!
G0S2$ 1.48934E*12! 1! NM_015714! Island!
KCNQ4$ 1.99214E*12! 1! NM_004700! Island!
GAL3ST2$ 2.98165E*12! 2! NM_022134! Island!
TMEM200B$ 3.20163E*12! 1! NM_001003682! Island!
GAL3ST2$ 3.6068E*12! 2! NM_022134! Island!
SLC6A11$ 3.67432E*12! 3! NM_014229! Island!
AKR7A3$ 4.14841E*12! 1! NM_012067! Island!
WWTR1$ 5.11334E*12! 3! NM_001168278! Island!
B3GNT7$ 5.30268E*12! 2! NM_145236! Island!
GLUL$ 6.89814E*12! 1! NM_001033044! Island!
NTN1$ 7.08416E*12! 17! NM_004822! Island!
TCEA3$ 8.80596E*12! 1! NM_003196! Island!
LGALS3$ 8.80784E*12! 14! NM_002306! Island!
KIAA0495$ 9.2286E*12! 1! NM_207306! Island!
KCNB1$ 9.58902E*12! 20! NM_004975! Island!
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HHIPL1$ 9.68948E*12! 14! NM_001127258! Island!
HSD11B2$ 1.0161E*11! 16! NM_000196! Island!
ACTG1$ 1.09732E*11! 17! NM_001614! Island!
ACTA1$ 1.43315E*11! 1! NM_001100! Island!
CORO6$ 1.50925E*11! 17! NM_032854! Island!
FAM19A1$ 1.51584E*11! 3! NM_213609! S_Shore!
TMEM143$ 1.68337E*11! 19! NM_018273! Island!
ONECUT1$ 1.88424E*11! 15! NM_004498! N_Shore!
CNTN2$ 1.88947E*11! 1! NM_005076! Open!sea!
VWDE$ 1.9411E*11! 7! NM_001135924! Island!
EFEMP1$ 2.1718E*11! 2! NM_004105! Island!
PYCARD$ 2.39917E*11! 16! NM_145182! Island!
GRIN1$ 2.43317E*11! 9! NM_000832! Island!
BMP8A$ 2.49937E*11! 1! NM_181809! Island!
TTC12$ 2.50293E*11! 11! NM_017868! N_Shore!
FCHSD1$ 2.56814E*11! 5! NM_033449! Island!
SRRM3$ 2.81192E*11! 7! NM_001110199! Island!
BRUNOL5$ 3.05977E*11! 19! NM_021938! Island!
TTC12$ 3.09297E*11! 11! NM_017868! N_Shore!
SRRM3$ 3.87383E*11! 7! NM_001110199! Island!
HCRT$ 3.99713E*11! 17! NM_001524! Island!
SOST$ 4.09479E*11! 17! NM_025237! Island!
TPPP3$ 4.25209E*11! 16! NM_016140! Island!
RARRES2$ 4.37675E*11! 7! NM_002889! Island!
VILL$ 4.3873E*11! 3! NM_015873! S_Shore!
PNKD$ 4.87514E*11! 2! NM_015488! Island!
RBP7$ 5.0358E*11! 1! NM_052960! Island!
PTPRU$ 5.11486E*11! 1! NM_133178! Island!
HSD11B2$ 5.58111E*11! 16! NM_000196! Island!
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GNMT$ 7.07328E*11! 6! NM_018960! Island!
RBP1$ 8.20699E*11! 3! NM_001130992! S_Shore!
ZNF704$ 8.6219E*11! 8! NM_001033723! Open!sea!
KCNJ3$ 8.92629E*11! 2! NM_002239! Island!
ZNF704$ 8.98827E*11! 8! NM_001033723! Open!sea!
APBA2$ 9.18522E*11! 15! NM_001130414! Island!
CYP11A1$ 9.50842E*11! 15! NM_001099773! Island!
OPCML$ 9.62434E*11! 11! NM_001012393! Island!
CORO6$ 1.04147E*10! 17! NM_032854! Island!
AKR7A3$ 1.06038E*10! 1! NM_012067! Island!
ZAR1$ 1.25964E*10! 4! NM_175619! Island!
SYCP2L$ 1.35275E*10! 6! NM_001040274! N_Shore!
NTN1$ 1.38251E*10! 17! NM_004822! Island!
PNKD$ 1.43386E*10! 2! NM_015488! Island!
HSD11B2$ 1.48671E*10! 16! NM_000196! Island!
PARVB$ 1.52295E*10! 22! NM_001003828! Island!
XKR8$ 1.55847E*10! 1! NM_018053! Island!
ACTG1$ 1.5637E*10! 17! NM_001614! Island!
ONECUT2$ 1.58326E*10! 18! NM_004852! S_Shore!
AKR7A3$ 1.67551E*10! 1! NM_012067! Island!
TTC12$ 1.74635E*10! 11! NM_017868! Island!
NRXN1$ 1.75167E*10! 2! NM_004801! Island!
HIST1H4L$ 1.81862E*10! 6! NM_003546! S_Shore!
TTC12$ 1.82673E*10! 11! NM_017868! N_Shore!
VWDE$ 1.9201E*10! 7! NM_001135924! Island!
CPNE8$ 1.9218E*10! 12! NM_153634! N_Shore!
CRYAB$ 1.97386E*10! 11! NM_001885! Open!sea!
THRB$ 1.97585E*10! 3! NM_001128177! Island!
KY$ 2.05855E*10! 3! NM_178554! Island!
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RASGRP2$ 2.19512E*10! 11! NM_001098670! Island!
NEUROD1$ 2.25262E*10! 2! NM_002500! N_Shore!
KIAA0495$ 2.26462E*10! 1! NM_207306! Island!
DLGAP3$ 2.26749E*10! 1! NM_001080418! Island!
FABP5$ 2.3945E*10! 8! NM_001444! Island!
IQSEC1$ 2.81205E*10! 3! NM_001134382! Island!
VILL$ 2.99136E*10! 3! NM_015873! Island!
KIAA0495$ 3.18681E*10! 1! NM_207306! Island!
SOST$ 3.263E*10! 17! NM_025237! Island!
GRIN1$ 3.3099E*10! 9! NM_000832! Island!
COL24A1$ 3.53914E*10! 1! NM_152890! Island!
RAB38$ 3.67308E*10! 11! NM_022337! S_Shore!
PLLP$ 3.82989E*10! 16! NM_015993! Island!
TMEM200B$ 4.27041E*10! 1! NM_001003682! Island!
RGS22$ 4.49194E*10! 8! NM_015668! Island!
DLGAP3$ 4.56483E*10! 1! NM_001080418! Island!
GPR12$ 5.1627E*10! 13! NM_005288! Island!
ZAR1$ 5.65035E*10! 4! NM_175619! Island!
SPEG$ 6.00618E*10! 2! NM_005876! Island!
MAST1$ 6.28323E*10! 19! NM_014975! Island!
SIM2$ 6.83717E*10! 21! NM_005069! Island!
MBP$ 7.14126E*10! 18! NM_001025101! Island!
GNMT$ 7.48248E*10! 6! NM_018960! Island!
CPNE8$ 7.60311E*10! 12! NM_153634! Island!
ESRP2$ 7.73806E*10! 16! NM_024939! Island!
TNFAIP8L3$ 8.01785E*10! 15! NM_207381! Island!
TRH$ 9.12691E*10! 3! NM_007117! Island!
PYCARD$ 9.66985E*10! 16! NM_145182! Island!
TMED7S
TICAM2$
9.9535E*10! 5! NM_001164468! Island!
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ALS2CL$ 1.00115E*09! 3! NM_147129! Island!
PDE4A$ 1.08222E*09! 19! NM_001111307! N_Shore!
NIPAL4$ 1.09779E*09! 5! NM_001099287! Island!
BRUNOL4$ 1.11E*09! 18! NM_001025088! Island!
EBAG9$ 1.17677E*09! 8! NM_004215! S_Shore!
BRUNOL4$ 1.2267E*09! 18! NM_001025088! Island!
TRANK1$ 1.35257E*09! 3! NM_014831! Island!
G0S2$ 1.37846E*09! 1! NM_015714! Island!
SCN9A$ 1.38213E*09! 2! NM_002977! S_Shore!
GLB1L3$ 1.40565E*09! 11! NM_001080407! Island!
PPP1R14A$ 1.54065E*09! 19! NM_033256! Island!
COL24A1$ 1.62838E*09! 1! NM_152890! Island!
MAGI2$ 1.64031E*09! 7! NM_012301! Island!
RHOD$ 1.72418E*09! 11! NM_014578! Island!
FRZB$ 1.78851E*09! 2! NM_001463! N_Shore!
ME1$ 1.85672E*09! 6! NM_002395! Island!
CACNG8$ 2.0007E*09! 19! NM_031895! Island!
GRASP$ 2.02091E*09! 12! NM_181711! Island!
PRR15$ 2.04571E*09! 7! NM_175887! Island!
MBP$ 2.14649E*09! 18! NM_001025100! Island!
ACTA1$ 2.32912E*09! 1! NM_001100! Island!
FAM132A$ 2.37147E*09! 1! NM_001014980! Island!
PPP1R14A$ 2.45059E*09! 19! NM_033256! Island!
EMILIN2$ 2.46475E*09! 18! NM_032048! Island!
NEUROD1$ 2.46552E*09! 2! NM_002500! Open!sea!
GRIN1$ 2.60576E*09! 9! NM_000832! Island!
ERBB2$ 2.61842E*09! 17! NM_001005862! N_Shore!
SYCP2L$ 2.99823E*09! 6! NM_001040274! N_Shore!
MYO18A$ 3.00675E*09! 17! NM_078471! Island!
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ZNF704$ 3.26079E*09! 8! NM_001033723! Open!sea!
GNMT$ 3.47673E*09! 6! NM_018960! Island!
OPCML$ 3.5346E*09! 11! NM_001012393! Open!sea!
HLF$ 3.53973E*09! 17! NM_002126! S_Shore!
RBM24$ 3.54088E*09! 6! NM_153020! S_Shore!
AOX1$ 3.54543E*09! 2! NM_001159! Island!
THRB$ 3.74574E*09! 3! NM_001128177! Island!
COL9A3$ 3.76526E*09! 20! NM_001853! Island!
SIAH1$ 3.84749E*09! 16! NM_001006610! Island!
ARAP1$ 3.88609E*09! 11! NM_001040118! Island!
MAPT$ 3.95153E*09! 17! NM_001123067! Island!
LBXCOR1$ 3.95717E*09! 15! NM_001031807! Island!
FABP5$ 3.98792E*09! 8! NM_001444! Island!
LINGO3$ 4.05388E*09! 19! NM_001101391! S_Shore!
NEUROD1$ 4.27673E*09! 2! NM_002500! Open!sea!
TOX2$ 4.37434E*09! 20! NM_001098796! Island!
KCNJ3$ 4.38721E*09! 2! NM_002239! Island!
GJA4$ 4.65156E*09! 1! NM_002060! Island!
GNMT$ 5.10955E*09! 6! NM_018960! Island!
CPNE8$ 5.12631E*09! 12! NM_153634! N_Shore!
MAPT$ 5.13135E*09! 17! NM_001123067! Island!
CPNE8$ 5.17443E*09! 12! NM_153634! N_Shore!
NID2$ 5.39083E*09! 14! NM_007361! Island!
CPNE8$ 5.41593E*09! 12! NM_153634! Island!
SULT1A1$ 5.72378E*09! 16! NM_177536! Island!
FAM19A1$ 6.9806E*09! 3! NM_213609! S_Shore!
COL24A1$ 7.70654E*09! 1! NM_152890! Island!
FAM59B$ 7.80868E*09! 2! NM_001168241! Island!
ZDHHC8P$ 8.08272E*09! 22! NR_003950! Open!sea!
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HAPLN3$ 8.75004E*09! 15! NM_178232! Island!
SST$ 8.94683E*09! 3! NM_001048! Island!
PPP1R14A$ 1.10818E*08! 19! NM_033256! Island!
NR4A1$ 1.17571E*08! 12! NM_002135! Island!
ADAM12$ 1.17842E*08! 10! NM_021641! Island!
NSD1$ 1.18483E*08! 5! NM_172349! Island!
IGSF21$ 1.20974E*08! 1! NM_032880! Island!
KCNIP3$ 1.28865E*08! 2! NM_001034914! Island!
EBAG9$ 1.31686E*08! 8! NM_004215! Island!
KCNIP3$ 1.31806E*08! 2! NM_001034914! Island!
SIM2$ 1.33973E*08! 21! NM_005069! Island!
DPYSL5$ 1.34012E*08! 2! NM_020134! Island!
ERBB2$ 1.34109E*08! 17! NM_001005862! N_Shore!
LRRC3B$ 1.3423E*08! 3! NM_052953! Island!
CACNG8$ 1.41268E*08! 19! NM_031895! N_Shore!
THRB$ 1.43165E*08! 3! NM_001128177! Island!
CPNE8$ 1.43917E*08! 12! NM_153634! Island!
TTC12$ 1.46281E*08! 11! NM_017868! Island!
SPEG$ 1.70576E*08! 2! NM_005876! Island!
PSD3$ 1.73387E*08! 8! NM_015310! Island!
CYP26B1$ 1.73812E*08! 2! NM_019885! Island!
LECT1$ 1.74085E*08! 13! NM_001011705! Island!
GPR153$ 1.8311E*08! 1! NM_207370! Island!
THRB$ 1.92323E*08! 3! NM_001128177! Island!
HLASL$ 1.98493E*08! 6! NR_027822! Island!
HPDL$ 2.06905E*08! 1! NM_032756! Island!
MIR155HG$ 2.09788E*08! 21! NR_001458! Island!
GSX2$ 2.18268E*08! 4! NM_133267! N_Shore!
CLSTN1$ 2.18571E*08! 1! NM_014944! S_Shore!
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MIR375$ 2.22701E*08! 2! NR_029867! Island!
ANGPT4$ 2.38933E*08! 20! NM_015985! Island!
SPIB$ 2.71796E*08! 19! NM_003121! Island!
CALHM2$ 2.86764E*08! 10! NM_015916! Island!
ONECUT2$ 2.95832E*08! 18! NM_004852! S_Shore!
VSX1$ 2.96362E*08! 20! NM_014588! Island!
SPINT2$ 2.96843E*08! 19! NM_001166103! Island!
UBE2E2$ 3.03837E*08! 3! NM_152653! Island!
SPEG$ 3.25285E*08! 2! NM_005876! Island!
SPTBN4$ 3.25679E*08! 19! NM_020971! Island!
CBLN3$ 3.28201E*08! 14! NM_001039771! Island!
MT1M$ 3.4623E*08! 16! NM_176870! Island!
ERBB2$ 3.88374E*08! 17! NM_001005862! N_Shore!
NGB$ 4.08781E*08! 14! NM_021257! Island!
PRR15$ 4.10773E*08! 7! NM_175887! N_Shore!
GRASP$ 4.1098E*08! 12! NM_181711! Island!
PDE4A$ 4.11383E*08! 19! NM_006202! Open!sea!
SHANK1$ 4.29561E*08! 19! NM_016148! Island!
BNC1$ 4.45325E*08! 15! NM_001717! Island!
ZDHHC8P$ 4.62192E*08! 22! NR_003950! Open!sea!
MDK$ 4.6908E*08! 11! NM_001012334! N_Shore!
MBP$ 5.11113E*08! 18! NM_001025100! Island!
CPLX1$ 5.11856E*08! 4! NM_006651! Island!
HPDL$ 5.70235E*08! 1! NM_032756! Island!
BRUNOL4$ 7.06902E*08! 18! NM_001025088! Island!
KY$ 7.33247E*08! 3! NM_178554! Island!
RHOD$ 7.37455E*08! 11! NM_014578! Island!
ARAP1$ 7.70264E*08! 11! NM_001040118! Island!
MIR155HG$ 7.71285E*08! 21! NR_001458! N_Shore!
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SST$ 7.71638E*08! 3! NM_001048! S_Shore!
TOX2$ 7.76271E*08! 20! NM_001098796! Island!
EHBP1L1$ 7.85964E*08! 11! NM_001099409! Island!
ERBB2$ 7.8731E*08! 17! NM_001005862! N_Shore!
PDE4A$ 8.00506E*08! 19! NM_001111308! N_Shore!
NEUROD1$ 8.20579E*08! 2! NM_002500! Open!sea!
GNMT$ 8.27018E*08! 6! NM_018960! Island!
LTBP3$ 8.40539E*08! 11! NM_001164266! Island!
RNF135$ 8.41256E*08! 17! NM_197939! N_Shore!
RHOD$ 8.49824E*08! 11! NM_014578! Island!
CNGA3$ 8.73701E*08! 2! NM_001298! Island!
SPINT2$ 8.86707E*08! 19! NM_001166103! Island!
CLDN5$ 8.90237E*08! 22! NM_001130861! Island!
GPR153$ 8.90836E*08! 1! NM_207370! Island!
FABP5$ 8.91126E*08! 8! NM_001444! Island!
KY$ 9.83017E*08! 3! NM_178554! Island!
RAB32$ 1.0256E*07! 6! NM_006834! Island!
COL9A2$ 1.07076E*07! 1! NM_001852! S_Shore!
ZBED3$ 1.13567E*07! 5! NM_032367! Island!
TMEM143$ 1.22034E*07! 19! NM_018273! Island!
NR4A1$ 1.23052E*07! 12! NM_002135! Island!
SOST$ 1.23681E*07! 17! NM_025237! Island!
ISLR2$ 1.2865E*07! 15! NM_001130136! Island!
MAGI2$ 1.31984E*07! 7! NM_012301! Island!
STL$ 1.32586E*07! 6! NR_026876! S_Shore!
MAGI2$ 1.42393E*07! 7! NM_012301! Island!
PARVB$ 1.48476E*07! 22! NM_001003828! Island!
TMED7S
TICAM2$
1.51051E*07! 5! NM_001164468! S_Shore!
COL21A1$ 1.52715E*07! 6! NM_030820! Island!
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CLSTN1$ 1.52732E*07! 1! NM_014944! Island!
VSIG10L$ 1.54101E*07! 19! NM_001163922! Island!
GAL3ST2$ 1.56171E*07! 2! NM_022134! Island!
GNMT$ 1.61567E*07! 6! NM_018960! Island!
CACNG8$ 1.61833E*07! 19! NM_031895! Island!
ZFHX3$ 1.63142E*07! 16! NM_001164766! Island!
FAM132A$ 1.68628E*07! 1! NM_001014980! Island!
PHLDB1$ 1.74419E*07! 11! NM_001144758! Island!
STL$ 1.74601E*07! 6! NR_026876! S_Shore!
EBAG9$ 1.99554E*07! 8! NM_004215! S_Shore!
LPCAT2$ 2.17308E*07! 16! NM_017839! Island!
SST$ 2.20068E*07! 3! NM_001048! Island!
NCRNA00085$ 2.20704E*07! 19! NR_024330! Island!
ESRP2$ 2.52006E*07! 16! NM_024939! Island!
NUDT16$ 2.70902E*07! 3! NM_152395! Island!
ISLR2$ 2.72085E*07! 15! NM_001130136! Island!
GRIN2C$ 2.72178E*07! 17! NM_000835! Island!
PGCP$ 2.74344E*07! 8! NM_016134! Island!
RBM24$ 2.76276E*07! 6! NM_001143942! Island!
ZBED3$ 2.79978E*07! 5! NM_032367! Island!
DNAJA4$ 2.89757E*07! 15! NM_018602! Island!
ACTG1$ 2.95119E*07! 17! NM_001614! Island!
NPHS2$ 2.96568E*07! 1! NM_014625! Island!
UNC13A$ 2.96933E*07! 19! NM_001080421! Island!
MAGI2$ 2.97706E*07! 7! NM_012301! Island!
RUNX1$ 3.00344E*07! 21! NM_001754! Island!
BRUNOL4$ 3.10917E*07! 18! NM_001025088! Island!
PXDN$ 3.16151E*07! 2! NM_012293! N_Shore!
MEGF11$ 3.3591E*07! 15! NM_032445! Island!
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RPP25$ 3.40642E*07! 15! NM_017793! N_Shore!
NRXN1$ 3.42477E*07! 2! NM_004801! S_Shore!
DRD4$ 3.47937E*07! 11! NM_000797! Island!
ONECUT1$ 3.50417E*07! 15! NM_004498! N_Shore!
MAL$ 3.5258E*07! 2! NM_022440! Island!
PARVB$ 3.63603E*07! 22! NM_001003828! Island!
PLLP$ 3.76368E*07! 16! NM_015993! Island!
DERL3$ 3.76956E*07! 22! NM_001135751! Island!
CTHRC1$ 3.89523E*07! 8! NM_138455! Island!
RADIL$ 3.90003E*07! 7! NM_018059! N_Shore!
IQSEC1$ 4.03095E*07! 3! NM_001134382! Island!
PDLIM4$ 4.44369E*07! 5! NM_001131027! Island!
ATP5G2$ 4.48553E*07! 12! NM_005176! N_Shore!
TMEM200B$ 4.57192E*07! 1! NM_001003682! Island!
KCNIP3$ 4.57794E*07! 2! NM_001034914! Island!
CHPF$ 4.91546E*07! 2! NM_024536! Island!
ZAR1$ 5.52091E*07! 4! NM_175619! Island!
ANKS1B$ 5.86543E*07! 12! NM_020140! S_Shore!
EMILIN2$ 5.9624E*07! 18! NM_032048! Island!
RAPGEFL1$ 6.01712E*07! 17! NM_016339! Island!
GLB1L3$ 6.16649E*07! 11! NM_001080407! Island!
RFX8$ 6.28833E*07! 2! NM_001145664! Island!
CACNG8$ 6.45787E*07! 19! NM_031895! Island!
RAB32$ 6.50709E*07! 6! NM_006834! Island!
TMBIM1$ 6.92699E*07! 2! NM_022152! Island!
MEI1$ 6.94679E*07! 22! NM_152513! Island!
NSD1$ 7.06567E*07! 5! NM_172349! Island!
LPCAT2$ 7.20732E*07! 16! NM_017839! Island!
HTR6$ 7.24957E*07! 1! NM_000871! Island!
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PDLIM4$ 7.8451E*07! 5! NM_001131027! Island!
CPLX1$ 7.94866E*07! 4! NM_006651! Island!
KIAA1614$ 8.45867E*07! 1! NM_020950! Island!
MEGF11$ 8.63642E*07! 15! NM_032445! Island!
VAX2$ 8.6517E*07! 2! NM_012476! Island!
MEI1$ 9.33021E*07! 22! NM_152513! Island!
ADAM12$ 9.38538E*07! 10! NM_021641! Island!
GLUL$ 9.81009E*07! 1! NM_001033044! Island!
CPNE8$ 9.95754E*07! 12! NM_153634! Island!
PDE4A$ 1.09134E*06! 19! NM_001111307! N_Shore!
PNMT$ 1.09471E*06! 17! NM_002686! Island!
LTBP3$ 1.096E*06! 11! NM_001164266! Island!
RFX8$ 1.09681E*06! 2! NM_001145664! Island!
COL12A1$ 1.12587E*06! 6! NM_004370! Island!
SLC6A11$ 1.13379E*06! 3! NM_014229! Island!
B3GNT7$ 1.13871E*06! 2! NM_145236! Island!
RADIL$ 1.16017E*06! 7! NM_018059! N_Shore!
TMEM144$ 1.16888E*06! 4! NM_018342! Island!
RGNEF$ 1.20935E*06! 5! NM_001080479! Island!
GNMT$ 1.2825E*06! 6! NM_018960! Island!
LPCAT2$ 1.297E*06! 16! NM_017839! Island!
SGK1$ 1.30842E*06! 6! NM_001143676! S_Shore!
CENPV$ 1.32096E*06! 17! NM_181716! Island!
GNMT$ 1.34815E*06! 6! NM_018960! Island!
RAPGEFL1$ 1.35888E*06! 17! NM_016339! Island!
SNX31$ 1.44133E*06! 8! NM_152628! Island!
SIAH1$ 1.4494E*06! 16! NM_001006610! Island!
IER3$ 1.47747E*06! 6! NM_003897! Island!
CYP11A1$ 1.48575E*06! 15! NM_000781! Island!
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CPNE8$ 1.51529E*06! 12! NM_153634! N_Shore!
GDNF$ 1.54643E*06! 5! NM_000514! Island!
NRG2$ 1.60925E*06! 5! NM_013982! Island!
CHPF$ 1.64908E*06! 2! NM_024536! Island!
CXCR4$ 1.67849E*06! 2! NM_003467! N_Shore!
NRG2$ 1.69043E*06! 5! NM_013982! Island!
ZBED3$ 1.75529E*06! 5! NM_032367! Island!
EFCAB4B$ 1.77213E*06! 12! NM_001144959! Island!
ANXA2$ 1.77852E*06! 15! NM_001002857! Island!
SPINT2$ 1.78155E*06! 19! NM_001166103! Island!
EBF4$ 1.81619E*06! 20! NM_001110514! Island!
VRK2$ 1.93206E*06! 2! NM_006296! Island!
BRUNOL4$ 1.94464E*06! 18! NM_001025088! Island!
DKK3$ 1.96118E*06! 11! NM_001018057! S_Shore!
CLDN10$ 1.9618E*06! 13! NM_006984! Island!
MEGF11$ 2.0221E*06! 15! NM_032445! Island!
ACRBP$ 2.02385E*06! 12! NM_032489! Island!
SRRM3$ 2.03009E*06! 7! NM_001110199! Island!
KCNB1$ 2.03625E*06! 20! NM_004975! Island!
TCEA3$ 2.08287E*06! 1! NM_003196! Island!
COL11A2$ 2.09805E*06! 6! NM_001163771! Island!
GNMT$ 2.26979E*06! 6! NM_018960! Island!
HPCA$ 2.36519E*06! 1! NM_002143! N_Shore!
BRUNOL4$ 2.40983E*06! 18! NM_001025089! Island!
MEI1$ 2.41711E*06! 22! NM_152513! N_Shore!
CLDN5$ 2.47482E*06! 22! NM_001130861! Island!
KY$ 2.65846E*06! 3! NM_178554! Island!
SGK1$ 2.86917E*06! 6! NM_001143676! S_Shore!
RHOD$ 2.8882E*06! 11! NM_014578! Island!
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BMP8A$ 2.92664E*06! 1! NM_181809! Island!
CENPV$ 3.05283E*06! 17! NM_181716! Island!
PIM3$ 3.10189E*06! 22! NM_001001852! Island!
RAP1GAP$ 3.21204E*06! 1! NM_002885! Island!
UBE2E2$ 3.3199E*06! 3! NM_152653! Island!
HIST1H4F$ 3.35752E*06! 6! NM_003540! N_Shore!
ANXA2$ 3.44406E*06! 15! NM_001002857! Island!
MYO18A$ 3.55392E*06! 17! NM_078471! Island!
CDH3$ 3.59693E*06! 16! NM_001793! Island!
DRD4$ 3.63809E*06! 11! NM_000797! Island!
IER3$ 3.6949E*06! 6! NM_003897! Island!
NRG2$ 3.72201E*06! 5! NM_013982! Island!
TOX2$ 3.79777E*06! 20! NM_001098796! Island!
PDLIM4$ 3.90265E*06! 5! NM_001131027! Island!
RUNX1$ 4.004E*06! 21! NM_001754! Island!
ACTG1$ 4.0321E*06! 17! NM_001614! Island!
CACNG8$ 4.1338E*06! 19! NM_031895! Island!
DLG1$ 4.28734E*06! 3! NM_004087! Island!
RASGRP2$ 4.28924E*06! 11! NM_153819! Island!
COL11A2$ 4.49895E*06! 6! NM_001163771! N_Shore!
CHST6$ 4.53616E*06! 16! NM_021615! Island!
GNMT$ 4.62465E*06! 6! NM_018960! Island!
CYP26B1$ 4.62579E*06! 2! NM_019885! Island!
TTC12$ 4.84256E*06! 11! NM_017868! N_Shore!
ATP5G2$ 4.92458E*06! 12! NM_005176! Island!
ACRBP$ 5.25092E*06! 12! NM_032489! Island!
RFX4$ 5.32549E*06! 12! NM_213594! Island!
ISLR2$ 5.46393E*06! 15! NM_001130136! Island!
ZEB1$ 5.47581E*06! 10! NM_030751! Island!
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PLLP$ 5.54378E*06! 16! NM_015993! Island!
FLJ23834$ 5.60889E*06! 7! NM_152750! Island!
BRUNOL4$ 5.61052E*06! 18! NM_001025088! Island!
NFKBIZ$ 5.68624E*06! 3! NM_001005474! Island!
TMEM22$ 5.69242E*06! 3! NM_001097600! Island!
LPCAT2$ 5.7984E*06! 16! NM_017839! Island!
LYPD1$ 5.81642E*06! 2! NM_001077427! N_Shore!
GPR12$ 6.34359E*06! 13! NM_005288! Island!
GDNF$ 6.37686E*06! 5! NM_000514! Island!
EFCAB4B$ 6.40282E*06! 12! NM_001144959! Island!
RAB38$ 6.574E*06! 11! NM_022337! S_Shore!
RAB33B$ 6.68713E*06! 4! NM_031296! S_Shore!
CPLX1$ 6.70691E*06! 4! NM_006651! Island!
HLASJ$ 6.86711E*06! 6! NR_024240! Island!
NIPAL4$ 7.09052E*06! 5! NM_001099287! Island!
LYN$ 7.22233E*06! 8! NM_002350! N_Shore!
MYO15B$ 7.37482E*06! 17! NR_003587! Island!
MACROD1$ 7.39016E*06! 11! NM_014067! Island!
NSUN7$ 7.45218E*06! 4! NM_024677! Island!
LINGO3$ 7.45908E*06! 19! NM_001101391! Island!
FRZB$ 7.55665E*06! 2! NM_001463! N_Shore!
KIF5C$ 7.56302E*06! 2! NM_004522! S_Shore!
SHANK1$ 7.64342E*06! 19! NM_016148! S_Shore!
IQSEC1$ 8.19722E*06! 3! NM_001134382! Island!
CLDN5$ 8.63791E*06! 22! NM_001130861! Island!
RASGRP2$ 8.64037E*06! 11! NM_153819! Island!
CFTR$ 8.81848E*06! 7! NM_000492! Open!sea!
LYPD1$ 8.85836E*06! 2! NM_001077427! N_Shore!
GALNTL1$ 8.93099E*06! 14! NM_001168368! Island!
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FABP5$ 9.1553E*06! 8! NM_001444! S_Shore!
SLC16A11$ 9.34485E*06! 17! NM_153357! Island!
DLGAP3$ 9.46213E*06! 1! NM_001080418! Island!
FLJ22536$ 9.50188E*06! 6! NR_015410! S_Shore!
UBE2E2$ 9.53926E*06! 3! NM_152653! Island!
KY$ 9.68867E*06! 3! NM_178554! Island!
TPPP3$ 9.90913E*06! 16! NM_015964! Island!
KBTBD11$ 1.01811E*05! 8! NM_014867! Island!
CNTD2$ 1.03826E*05! 19! NM_024877! Island!
ISLR2$ 1.0464E*05! 15! NM_001130136! Island!
GSX2$ 1.05811E*05! 4! NM_133267! N_Shore!
KLHL1$ 1.0705E*05! 13! NM_020866! S_Shore!
PDLIM4$ 1.08035E*05! 5! NM_001131027! Island!
EHBP1L1$ 1.10831E*05! 11! NM_001099409! Island!
EBF4$ 1.12927E*05! 20! NM_001110514! Island!
KCNAB3$ 1.13071E*05! 17! NM_004732! Island!
FGFRL1$ 1.14028E*05! 4! NM_001004358! Island!
MYO15B$ 1.14123E*05! 17! NR_003587! Island!
PYCARD$ 1.20804E*05! 16! NM_013258! Island!
NCRNA00092$ 1.29383E*05! 9! NR_024129! Island!
IER3$ 1.29585E*05! 6! NM_003897! Island!
LRAT$ 1.32656E*05! 4! NM_004744! Island!
KIAA1614$ 1.36678E*05! 1! NM_020950! Island!
MACROD1$ 1.3695E*05! 11! NM_014067! Open!sea!
HPDL$ 1.44986E*05! 1! NM_032756! Island!
ALS2CL$ 1.46712E*05! 3! NM_147129! Island!
CRIP3$ 1.47846E*05! 6! NM_206922! Island!
ARHGAP24$ 1.57274E*05! 4! NM_001025616! Open!sea!
EYA4$ 1.58661E*05! 6! NM_172105! Island!
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GRAMD2$ 1.59222E*05! 15! NM_001012642! Island!
RAPGEFL1$ 1.61086E*05! 17! NM_016339! Island!
GAMT$ 1.6159E*05! 19! NM_138924! Island!
ZNF296$ 1.66771E*05! 19! NM_145288! Island!
PITX3$ 1.68066E*05! 10! NM_005029! Island!
RASGRP2$ 1.70518E*05! 11! NM_001098670! Island!
MYO15B$ 1.71538E*05! 17! NR_003587! Island!
SIAH1$ 1.72744E*05! 16! NM_001006610! Island!
WWTR1$ 1.72852E*05! 3! NM_001168278! Island!
HIST1H4L$ 1.7318E*05! 6! NM_003546! Island!
EPS8L2$ 1.77488E*05! 11! NM_022772! Island!
TMED7S
TICAM2$
1.80699E*05! 5! NM_001164468! Island!
OSBPL9$ 1.81543E*05! 1! NM_148905! Island!
IQSEC1$ 1.81716E*05! 3! NM_001134382! Island!
RASSF10$ 1.82075E*05! 11! NM_001080521! Island!
VILL$ 1.85366E*05! 3! NM_015873! Island!
CRADD$ 1.88018E*05! 12! NM_003805! Open!sea!
GNMT$ 1.89112E*05! 6! NM_018960! Island!
TUBA4B$ 1.96087E*05! 2! NR_003063! N_Shore!
HLASH$ 2.04392E*05! 6! NR_001434! Island!
DRD4$ 2.07047E*05! 11! NM_000797! Island!
NBL1$ 2.07453E*05! 1! NM_005380! Island!
CORO6$ 2.08242E*05! 17! NM_032854! Island!
HLASH$ 2.11307E*05! 6! NR_001434! Island!
CCNI2$ 2.13917E*05! 5! NM_001039780! N_Shore!
TTC12$ 2.14197E*05! 11! NM_017868! N_Shore!
HHIPL1$ 2.17074E*05! 14! NM_001127258! Island!
DERL3$ 2.20237E*05! 22! NM_001135751! Island!
COL18A1$ 2.2513E*05! 21! NM_130445! Island!
 
 287 
MYL12A$ 2.25229E*05! 18! NM_006471! N_Shore!
BCAT1$ 2.35399E*05! 12! NM_005504! N_Shore!
GRAMD2$ 2.4753E*05! 15! NM_001012642! Island!
RBP1$ 2.47974E*05! 3! NM_002899! Island!
UCP2$ 2.50183E*05! 11! NM_003355! Island!
NSUN7$ 2.54102E*05! 4! NM_024677! Island!
NTN1$ 2.54146E*05! 17! NM_004822! Island!
RNF135$ 2.55788E*05! 17! NM_197939! N_Shore!
PTPRN$ 2.67136E*05! 2! NM_002846! Island!
SRRM3$ 2.70039E*05! 7! NM_001110199! Island!
FAM123C$ 2.70277E*05! 2! NM_001105194! N_Shore!
ZC3HAV1L$ 2.71198E*05! 7! NM_080660! Island!
SNX31$ 2.74493E*05! 8! NM_152628! Island!
HPCAL1$ 2.75465E*05! 2! NM_002149! Island!
COL11A2$ 2.83082E*05! 6! NM_001163771! Island!
SCRN1$ 2.83615E*05! 7! NM_014766! Island!
PNMT$ 2.99557E*05! 17! NM_002686! Island!
HLASL$ 3.00901E*05! 6! NR_027822! Island!
ANKRD34A$ 3.00976E*05! 1! NM_001039888! Island!
SFRP4$ 3.01268E*05! 7! NM_003014! N_Shore!
ARL4A$ 3.0146E*05! 7! NM_212460! Island!
NCRNA00085$ 3.02042E*05! 19! NR_024330! S_Shore!
CMYA5$ 3.10036E*05! 5! NM_153610! Open!sea!
COL9A2$ 3.10378E*05! 1! NM_001852! Island!
RAB11FIP4$ 3.12377E*05! 17! NM_032932! Island!
CNTN2$ 3.1676E*05! 1! NM_005076! Open!sea!
LZTS2$ 3.25539E*05! 10! NM_032429! Island!
ISLR2$ 3.33012E*05! 15! NM_001130136! Island!
TMEM22$ 3.38128E*05! 3! NM_001097600! Island!
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GSX2$ 3.38135E*05! 4! NM_133267! N_Shore!
GJA1$ 3.42258E*05! 6! NM_000165! Open!sea!
ZEB1$ 3.44758E*05! 10! NM_030751! Island!
NFKBIZ$ 3.4673E*05! 3! NM_001005474! N_Shore!
MAL$ 3.51821E*05! 2! NM_022438! N_Shore!
RAB27B$ 3.54795E*05! 18! NM_004163! Island!
SERINC2$ 3.54857E*05! 1! NM_178865! Island!
SLC22A16$ 3.65879E*05! 6! NM_033125! Island!
NIPAL4$ 3.69639E*05! 5! NM_001099287! Island!
PSD$ 3.69837E*05! 10! NM_002779! Island!
RASL12$ 3.78715E*05! 15! NM_016563! Island!
NAAA$ 3.94808E*05! 4! NM_001042402! Island!
ZC3HAV1L$ 3.94952E*05! 7! NM_080660! Island!
HSPA2$ 3.98801E*05! 14! NM_021979! S_Shore!
KIAA1614$ 3.99499E*05! 1! NM_020950! Island!
RASSF10$ 4.03091E*05! 11! NM_001080521! Island!
LRRC3B$ 4.08563E*05! 3! NM_052953! N_Shore!
ADAM12$ 4.13245E*05! 10! NM_021641! Island!
CYP11A1$ 4.13375E*05! 15! NM_001099773! Island!
DKK1$ 4.15904E*05! 10! NM_012242! N_Shore!
GDNF$ 4.23896E*05! 5! NM_199231! Island!
ATP5G2$ 4.3123E*05! 12! NM_005176! Island!
GIPC2$ 4.40169E*05! 1! NM_017655! Island!
RBP1$ 4.44154E*05! 3! NM_002899! Island!
SPINT2$ 4.44701E*05! 19! NM_021102! Island!
CACNG8$ 4.4541E*05! 19! NM_031895! Island!
PAX6$ 4.47243E*05! 11! NM_001127612! Island!
NRG2$ 4.49446E*05! 5! NM_013982! Island!
ARFGAP3$ 4.59309E*05! 22! NM_014570! Island!
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GDNF$ 4.59681E*05! 5! NM_199231! Island!
TMEM178$ 4.598E*05! 2! NM_152390! N_Shore!
ADAM12$ 4.60443E*05! 10! NM_021641! Island!
ALOX5$ 4.83246E*05! 10! NM_000698! Island!
CDH3$ 4.83567E*05! 16! NM_001793! Island!
HSPB1$ 4.84963E*05! 7! NM_001540! Island!
UNC13A$ 4.88228E*05! 19! NM_001080421! Island!
RAPGEFL1$ 4.88728E*05! 17! NM_016339! Island!
CACNG8$ 4.91099E*05! 19! NM_031895! N_Shore!
ACVRL1$ 4.98738E*05! 12! NM_000020! Island!
LZTS2$ 5.17107E*05! 10! NM_032429! Island!
GALNT14$ 5.1901E*05! 2! NM_024572! Island!
MIR375$ 5.24404E*05! 2! NR_029867! Island!
BCL2$ 5.26713E*05! 18! NM_000633! Island!
COL9A2$ 5.38567E*05! 1! NM_001852! Island!
NCRNA00085$ 5.45087E*05! 19! NR_024330! Island!
GLUL$ 5.45287E*05! 1! NM_001033044! Island!
MYRIP$ 5.48504E*05! 3! NM_015460! Island!
SPTBN1$ 5.49219E*05! 2! NM_178313! Island!
RAP1GAP$ 5.51272E*05! 1! NM_002885! Island!
GRAMD2$ 5.78441E*05! 15! NM_001012642! Island!
PPP1CC$ 5.8921E*05! 12! NM_002710! S_Shore!
HIST1H4L$ 5.92954E*05! 6! NM_003546! S_Shore!
IGDCC3$ 5.95457E*05! 15! NM_004884! Island!
TBR1$ 5.96627E*05! 2! NM_006593! N_Shore!
MACROD1$ 6.03535E*05! 11! NM_014067! Island!
SGK1$ 6.03837E*05! 6! NM_001143676! S_Shore!
CFLAR$ 6.0443E*05! 2! NM_001127184! Island!
GALNT14$ 6.09087E*05! 2! NM_024572! Island!
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VWDE$ 6.2665E*05! 7! NM_001135924! Island!
MEGF10$ 6.36591E*05! 5! NM_032446! Island!
CCNI2$ 6.4448E*05! 5! NM_001039780! N_Shore!
NFATC1$ 6.48E*05! 18! NM_006162! Island!
RBP7$ 6.54137E*05! 1! NM_052960! Island!
KIF5C$ 6.62432E*05! 2! NM_004522! Island!
MEGF11$ 6.72694E*05! 15! NM_032445! Island!
PAX6$ 6.78534E*05! 11! NM_001127612! Island!
HMSD$ 6.79669E*05! 18! NM_001123366! Open!sea!
SFRP4$ 6.79699E*05! 7! NM_003014! Island!
KBTBD11$ 6.80068E*05! 8! NM_014867! Island!
VILL$ 6.90776E*05! 3! NM_015873! Island!
PPP1CC$ 6.96391E*05! 12! NM_002710! S_Shore!
FRZB$ 6.96725E*05! 2! NM_001463! N_Shore!
ZBED3$ 6.99392E*05! 5! NM_032367! Island!
BCAT1$ 7.0823E*05! 12! NM_005504! N_Shore!
MCF2L2$ 7.19385E*05! 3! NM_015078! S_Shore!
LRAT$ 7.35241E*05! 4! NM_004744! N_Shore!
NRXN1$ 7.35685E*05! 2! NM_004801! S_Shore!
TOX2$ 7.41495E*05! 20! NM_001098796! Island!
VAX2$ 7.4417E*05! 2! NM_012476! Island!
SCGB3A1$ 7.51561E*05! 5! NM_052863! Island!
NSD1$ 7.51575E*05! 5! NM_172349! Island!
TGFB2$ 7.56556E*05! 1! NM_003238! S_Shore!
MAL$ 7.63432E*05! 2! NM_022438! Island!
DDN$ 7.67655E*05! 12! NM_015086! Island!
NR2E1$ 7.88711E*05! 6! NM_003269! Island!
HPDL$ 7.89306E*05! 1! NM_032756! Island!
LZTS2$ 7.9281E*05! 10! NM_032429! Island!
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OGDHL$ 8.07689E*05! 10! NM_001143996! Island!
BCL2$ 8.148E*05! 18! NM_000657! Island!
COL12A1$ 8.17385E*05! 6! NM_004370! S_Shore!
FKBP5$ 8.19039E*05! 6! NM_001145777! Island!
RASGRP2$ 8.27191E*05! 11! NM_001098671! Island!
PRDX1$ 8.27343E*05! 1! NM_181696! Island!
EMILIN3$ 8.29917E*05! 20! NM_052846! Island!
PGCP$ 8.59387E*05! 8! NM_016134! Island!
TXNRD1$ 8.5993E*05! 12! NM_182729! Island!
NPM2$ 8.62275E*05! 8! NM_182795! N_Shore!
RASL10B$ 8.68887E*05! 17! NM_033315! Island!
SSH3$ 8.79235E*05! 11! NM_017857! N_Shore!
KBTBD11$ 8.7929E*05! 8! NM_014867! N_Shore!
BRUNOL5$ 8.81939E*05! 19! NM_021938! Island!
HPCAL1$ 8.95337E*05! 2! NM_002149! Island!
RAB27B$ 8.9905E*05! 18! NM_004163! Island!
CHD5$ 8.99151E*05! 1! NM_015557! Island!
TMBIM1$ 9.00343E*05! 2! NM_022152! Island!
MYO15B$ 9.02204E*05! 17! NR_003587! Island!
NR4A1$ 9.04625E*05! 12! NM_173157! Island!
GNAL$ 9.09348E*05! 18! NM_002071! Island!
ZIC2$ 9.14732E*05! 13! NM_007129! Island!
HLASL$ 9.1517E*05! 6! NR_027822! Island!
UNC13A$ 9.23218E*05! 19! NM_001080421! Island!
BCAT1$ 9.2372E*05! 12! NM_005504! N_Shore!
COL21A1$ 9.30333E*05! 6! NM_030820! S_Shore!
ZFHX3$ 9.7927E*05! 16! NM_001164766! Island!
LYPD1$ 9.91959E*05! 2! NM_001077427! N_Shore!
SYCE2$ 9.93054E*05! 19! NM_001105578! Island!
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TRH$ 0.000100843! 3! NM_007117! Island!
MOSC2$ 0.000101356! 1! NM_017898! Island!
CCDC122$ 0.000101736! 13! NM_144974! Island!
RAB27B$ 0.000101912! 18! NM_004163! Island!
ZC3HAV1L$ 0.000102915! 7! NM_080660! Island!
RAB11FIP4$ 0.00010421! 17! NM_032932! Island!
BIRC3$ 0.000104841! 11! NM_001165! Island!
HLASJ$ 0.000107115! 6! NR_024240! Island!
KLHL35$ 0.000111784! 11! NM_001039548! Island!
DLGAP3$ 0.000112311! 1! NM_001080418! N_Shore!
RAB27B$ 0.000114046! 18! NM_004163! Island!
LOXL3$ 0.000114582! 2! NM_032603! Island!
CPLX1$ 0.000114756! 4! NM_006651! Island!
SYT7$ 0.000115329! 11! NM_004200! Island!
CHST6$ 0.000115423! 16! NM_021615! Island!
GALNT14$ 0.000117564! 2! NM_024572! Island!
RPP25$ 0.000120953! 15! NM_017793! Island!
GALNT14$ 0.00012399! 2! NM_024572! Island!
CYP11A1$ 0.000126031! 15! NM_001099773! Island!
NCAM2$ 0.000126057! 21! NM_004540! Island!
CFTR$ 0.000126119! 7! NM_000492! Open!sea!
MOGAT3$ 0.00012801! 7! NM_178176! Island!
GDNF$ 0.000128351! 5! NM_199231! Island!
ADAM8$ 0.000128841! 10! NM_001164489! Island!
HLASJ$ 0.000129697! 6! NR_024240! Island!
FOXP1$ 0.000130286! 3! NM_032682! Island!
CLSTN1$ 0.000130611! 1! NM_014944! Island!
MCF2L2$ 0.000130667! 3! NM_015078! Island!
CBR1$ 0.000135243! 21! NM_001757! Island!
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FBRSL1$ 0.000135372! 12! NM_001142641! Island!
HLASL$ 0.000136094! 6! NR_027822! Island!
HSPB1$ 0.000136471! 7! NM_001540! Island!
BIRC3$ 0.000136545! 11! NM_182962! Island!
USP2$ 0.000137746! 11! NM_004205! Island!
RASSF10$ 0.000137761! 11! NM_001080521! S_Shore!
KY$ 0.000137814! 3! NM_178554! Island!
IER3$ 0.000138789! 6! NM_003897! Island!
BMPR2$ 0.000143074! 2! NM_001204! Island!
TMEM63A$ 0.00014463! 1! NM_014698! Island!
BCAT1$ 0.000144928! 12! NM_005504! N_Shore!
LMO2$ 0.000148203! 11! NM_001142315! Island!
CFLAR$ 0.000149419! 2! NM_001127184! Island!
CACNB4$ 0.000149527! 2! NM_000726! Island!
CBR1$ 0.000153952! 21! NM_001757! Island!
GPR12$ 0.000154089! 13! NM_005288! Island!
GRID2IP$ 0.000156405! 7! NM_001145118! Island!
FGFRL1$ 0.000156594! 4! NM_001004358! Island!
MACROD1$ 0.000157296! 11! NM_014067! Open!sea!
DNAJA4$ 0.000158121! 15! NM_018602! Island!
FAM160A1$ 0.00015836! 4! NM_001109977! Island!
DPYSL5$ 0.000158927! 2! NM_020134! Island!
CHST8$ 0.000160048! 19! NM_001127895! Island!
NSUN7$ 0.000160526! 4! NM_024677! Island!
ISLR2$ 0.000160955! 15! NM_001130136! Island!
GDNF$ 0.000160979! 5! NM_199231! Island!
SSH3$ 0.000161026! 11! NM_017857! Island!
EVC2$ 0.000161093! 4! NM_001166136! Island!
HLASJ$ 0.000162642! 6! NR_024240! Island!
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ISLR2$ 0.000164173! 15! NM_001130136! Island!
AEBP1$ 0.000164177! 7! NM_001129! Open!sea!
IGDCC3$ 0.00016628! 15! NM_004884! N_Shore!
FAM132A$ 0.00016675! 1! NM_001014980! Island!
GPR12$ 0.000167887! 13! NM_005288! Island!
P2RY2$ 0.000167935! 11! NM_176071! Island!
GRAMD2$ 0.000169018! 15! NM_001012642! Island!
KLF16$ 0.000169879! 19! NM_031918! Island!
NFKBIZ$ 0.000170814! 3! NM_001005474! Island!
IGDCC3$ 0.00017192! 15! NM_004884! Island!
ADAM8$ 0.000176853! 10! NM_001164490! Island!
ITGB5$ 0.000176944! 3! NM_002213! Island!
RASL10B$ 0.000177054! 17! NM_033315! Island!
PRDX1$ 0.000177322! 1! NM_002574! Island!
TXNRD1$ 0.000178139! 12! NM_182729! Island!
KLHL35$ 0.0001786! 11! NM_001039548! Island!
RHBDF2$ 0.000179009! 17! NM_024599! Island!
NSD1$ 0.000179325! 5! NM_022455! Island!
BMP8A$ 0.000179329! 1! NM_181809! Island!
NGB$ 0.000180278! 14! NM_021257! Island!
BCAT1$ 0.000181158! 12! NM_005504! N_Shore!
ZNF575$ 0.000181242! 19! NM_174945! Island!
CALHM2$ 0.000181486! 10! NM_015916! Island!
TTBK1$ 0.000182945! 6! NM_032538! Island!
UBE2E2$ 0.000183072! 3! NM_152653! Island!
GALNT14$ 0.000183948! 2! NM_024572! Island!
PRDX1$ 0.000184226! 1! NM_181696! S_Shore!
XKR8$ 0.000185159! 1! NM_018053! Island!
CALHM2$ 0.000185203! 10! NM_015916! Island!
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CRADD$ 0.000185913! 12! NM_003805! Open!sea!
SOST$ 0.00018812! 17! NM_025237! Island!
QRFPR$ 0.000188558! 4! NM_198179! Island!
HLCS$ 0.000190231! 21! NM_000411! Island!
PAMR1$ 0.000190534! 11! NM_001001991! S_Shore!
SLC38A1$ 0.000192726! 12! NM_001077484! Island!
GRIN2C$ 0.000193939! 17! NM_000835! Island!
RBP1$ 0.000195343! 3! NM_001130993! Island!
NBEA$ 0.000196366! 13! NM_015678! Island!
EPHA2$ 0.000197708! 1! NM_004431! Island!
DDN$ 0.000198957! 12! NM_015086! Island!
PRKCZ$ 0.000199841! 1! NM_001033582! Island!
SHH$ 0.000200187! 7! NM_000193! Island!
NR4A1$ 0.000200228! 12! NM_173157! Island!
KCNAB3$ 0.000200753! 17! NM_004732! Island!
FKBP5$ 0.000200807! 6! NM_001145777! S_Shore!
BMP8B$ 0.00020095! 1! NM_001720! Island!
KCNAB3$ 0.000201472! 17! NM_004732! Island!
CLDN5$ 0.000201587! 22! NM_001130861! Island!
LZTS2$ 0.000201782! 10! NM_032429! Island!
CTHRC1$ 0.000202429! 8! NM_138455! Island!
CFLAR$ 0.00020347! 2! NM_001127184! Island!
SGK1$ 0.000204878! 6! NM_001143676! S_Shelf!
CACNB4$ 0.000208813! 2! NM_000726! N_Shore!
NFKBIZ$ 0.000210636! 3! NM_001005474! Island!
ATP5G2$ 0.000211745! 12! NM_005176! Island!
RASGRP2$ 0.000212867! 11! NM_001098670! Island!
LZTS2$ 0.000213195! 10! NM_032429! Island!
GRIN2B$ 0.000213739! 12! NM_000834! N_Shore!
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KLF5$ 0.000214272! 13! NM_001730! Island!
SNX31$ 0.000215981! 8! NM_152628! Island!
GAMT$ 0.00021791! 19! NM_138924! Island!
CENPV$ 0.000218035! 17! NM_181716! Island!
TMEM143$ 0.000222313! 19! NM_018273! S_Shore!
COL12A1$ 0.000222314! 6! NM_004370! Island!
CYP27A1$ 0.000222846! 2! NM_000784! Island!
RNF39$ 0.000224261! 6! NM_025236! Island!
HIST1H4L$ 0.000231123! 6! NM_003546! S_Shore!
NR2E1$ 0.000232616! 6! NM_003269! Island!
LIMS2$ 0.000233226! 2! NM_001136037! Island!
SFRP2$ 0.000233279! 4! NM_003013! Island!
LYN$ 0.000240488! 8! NM_002350! Island!
RAB3D$ 0.000242775! 19! NM_004283! Island!
ISLR2$ 0.000242805! 15! NM_001130136! Island!
NPPB$ 0.000244791! 1! NM_002521! Island!
PLLP$ 0.000245261! 16! NM_015993! Island!
ME1$ 0.000247165! 6! NM_002395! Island!
PACS2$ 0.000249165! 14! NM_015197! Island!
LRAT$ 0.000250667! 4! NM_004744! Island!
PRR15$ 0.000250969! 7! NM_175887! N_Shore!
ADAM8$ 0.0002511! 10! NM_001164489! Island!
NBEA$ 0.000255155! 13! NM_015678! Island!
HLASJ$ 0.000257788! 6! NR_024240! Island!
FBRSL1$ 0.000257951! 12! NM_001142641! Island!
ACTG1$ 0.000258316! 17! NM_001614! Island!
SFRP4$ 0.000258593! 7! NM_003014! Island!
SIAH1$ 0.000261228! 16! NM_001006610! Island!
MYCBPAP$ 0.000263215! 17! NM_032133! Island!
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SYT6$ 0.000266541! 1! NM_205848! Island!
HTR6$ 0.000267709! 1! NM_000871! Island!
SLC22A15$ 0.000275621! 1! NM_018420! Island!
ARL9$ 0.000275725! 4! NM_206919! Island!
RAB27B$ 0.000276821! 18! NM_004163! Island!
NRXN1$ 0.000276912! 2! NM_004801! S_Shore!
NR4A1$ 0.00027785! 12! NM_002135! Island!
ARL9$ 0.000278605! 4! NM_206919! Island!
PSD$ 0.000279501! 10! NM_002779! Island!
TGFB2$ 0.00028092! 1! NM_003238! Island!
SIAH1$ 0.000282675! 16! NM_001006610! S_Shore!
NCRNA00092$ 0.000285602! 9! NR_024129! Island!
RAB11FIP4$ 0.000291691! 17! NM_032932! Island!
RNF135$ 0.000291856! 17! NM_197939! N_Shore!
KLF5$ 0.000291973! 13! NM_001730! Island!
LPCAT2$ 0.000291986! 16! NM_017839! Island!
SRRM3$ 0.000292585! 7! NM_001110199! Island!
CD109$ 0.000295426! 6! NM_001159588! Island!
PDE4A$ 0.000295591! 19! NM_001111308! S_Shore!
RPP25$ 0.000299182! 15! NM_017793! N_Shore!
KBTBD11$ 0.000299954! 8! NM_014867! Island!
SSH3$ 0.000301119! 11! NM_017857! Island!
FBRSL1$ 0.000305063! 12! NM_001142641! Island!
LLGL2$ 0.000307948! 17! NM_001031803! Island!
SOCS3$ 0.000309082! 17! NM_003955! Island!
TMEM22$ 0.000309548! 3! NM_001097600! Island!
CXCR4$ 0.000309674! 2! NM_003467! Island!
PGCP$ 0.000311418! 8! NM_016134! Island!
IER3$ 0.000311625! 6! NM_003897! Island!
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RFX4$ 0.000311864! 12! NM_213594! Island!
FAM123C$ 0.000313282! 2! NM_001105194! N_Shore!
TEKT3$ 0.000313681! 17! NM_031898! N_Shore!
KLF16$ 0.000315159! 19! NM_031918! Island!
TTC12$ 0.000316088! 11! NM_017868! N_Shore!
NPPB$ 0.000316247! 1! NM_002521! Island!
LOXL1$ 0.00031876! 15! NM_005576! Island!
LOXL1$ 0.000319256! 15! NM_005576! Island!
CTSZ$ 0.000322055! 20! NM_001336! Island!
ANKS1B$ 0.000324755! 12! NM_020140! Island!
RFX4$ 0.000325104! 12! NM_213594! Island!
NCAM2$ 0.00032515! 21! NM_004540! Island!
TMEM63A$ 0.000327762! 1! NM_014698! Island!
DKK1$ 0.000328324! 10! NM_012242! N_Shore!
MT1M$ 0.000338177! 16! NM_176870! Island!
RBP1$ 0.000343437! 3! NM_001130992! S_Shore!
GRAMD2$ 0.000345173! 15! NM_001012642! Island!
TET1$ 0.000345868! 10! NM_030625! S_Shore!
EFEMP2$ 0.000346636! 11! NM_016938! Island!
LPAR2$ 0.000349826! 19! NM_004720! Island!
CRADD$ 0.000358521! 12! NM_003805! Open!sea!
HIST1H4L$ 0.000358669! 6! NM_003546! Island!
ZNF296$ 0.000358765! 19! NM_145288! Island!
TMBIM1$ 0.000359944! 2! NM_022152! S_Shore!
FAM132A$ 0.00036331! 1! NM_001014980! S_Shore!
ITGB5$ 0.000364907! 3! NM_002213! Island!
KIAA0495$ 0.000367181! 1! NM_207306! Island!
ACAA1$ 0.000367538! 3! NR_024024! Island!
BCAT1$ 0.000368659! 12! NM_005504! N_Shore!
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RTBDN$ 0.000368752! 19! NM_031429! S_Shore!
RNF135$ 0.000369371! 17! NM_197939! N_Shore!
CBR1$ 0.000372177! 21! NM_001757! Island!
CFLAR$ 0.000372281! 2! NM_001127184! Island!
ADPRH$ 0.000372768! 3! NM_001125! Island!
GDNF$ 0.000373604! 5! NM_199234! Island!
VILL$ 0.000374342! 3! NM_015873! S_Shore!
KLHL35$ 0.000375239! 11! NM_001039548! Island!
NTN1$ 0.0003792! 17! NM_004822! Island!
MGST2$ 0.000389027! 4! NM_002413! Open!sea!
LTBP4$ 0.000393103! 19! NM_001042544! Island!
RNF135$ 0.00039773! 17! NM_032322! Island!
RASSF10$ 0.000398322! 11! NM_001080521! Island!
GRASP$ 0.00039901! 12! NM_181711! Island!
CRIP3$ 0.000402684! 6! NM_206922! Island!
GRAMD2$ 0.000403322! 15! NM_001012642! Island!
VAX2$ 0.000408806! 2! NM_012476! Island!
CACNB4$ 0.000410292! 2! NM_000726! N_Shore!
MDK$ 0.000423663! 11! NM_001012334! N_Shore!
NBEA$ 0.000424288! 13! NM_015678! Island!
MT1M$ 0.000424987! 16! NM_176870! Island!
GNMT$ 0.000426799! 6! NM_018960! Island!
MACROD1$ 0.000428521! 11! NM_014067! N_Shore!
CHST8$ 0.000435957! 19! NM_001127895! Island!
PRDX1$ 0.000436502! 1! NM_181696! Island!
ANKRD34A$ 0.0004415! 1! NM_001039888! Island!
PRDX1$ 0.000441863! 1! NM_181696! Island!
TMEM51$ 0.000442834! 1! NM_001136218! Island!
RBM24$ 0.000443265! 6! NM_153020! S_Shore!
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GRAMD2$ 0.000448741! 15! NM_001012642! Island!
KLHL35$ 0.000451141! 11! NM_001039548! Island!
CFLAR$ 0.000451305! 2! NM_001127184! Island!
COL9A3$ 0.000453017! 20! NM_001853! Island!
GRAMD2$ 0.000459478! 15! NM_001012642! Island!
ARAP1$ 0.000465461! 11! NM_001040118! Island!
FLOT1$ 0.000465682! 6! NM_005803! Island!
CRIP3$ 0.000469137! 6! NM_206922! Island!
LHX9$ 0.000469572! 1! NM_020204! N_Shore!
DPYSL5$ 0.000473049! 2! NM_020134! Island!
DLG1$ 0.00047539! 3! NM_004087! Island!
CACNG8$ 0.000490409! 19! NM_031895! Island!
ADPRH$ 0.000492172! 3! NM_001125! Island!
SERPINB6$ 0.000493704! 6! NM_004568! S_Shore!
FBRSL1$ 0.000502562! 12! NM_001142641! Island!
LAMP3$ 0.000510495! 3! NM_014398! Island!
FAM19A1$ 0.000512292! 3! NM_213609! Island!
FBRSL1$ 0.000517161! 12! NM_001142641! Island!
MACROD1$ 0.000518072! 11! NM_014067! Open!sea!
LENG9$ 0.000519267! 19! NM_198988! Island!
HAPLN3$ 0.000522666! 15! NM_178232! Island!
PAMR1$ 0.000522928! 11! NM_015430! Island!
TET1$ 0.000529019! 10! NM_030625! S_Shore!
ALDH5A1$ 0.00052931! 6! NM_001080! Island!
TOM1L1$ 0.000535353! 17! NM_005486! Island!
TRIM36$ 0.000539535! 5! NM_018700! Island!
FBXO6$ 0.000539665! 1! NM_018438! Island!
MYCBPAP$ 0.000557761! 17! NM_032133! Island!
OGDHL$ 0.000567291! 10! NM_001143996! Island!
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MDK$ 0.000572534! 11! NM_001012334! N_Shore!
PRDX1$ 0.00057254! 1! NM_181696! Island!
LIN28$ 0.000572653! 1! NM_024674! N_Shore!
ACVRL1$ 0.000576039! 12! NM_000020! Island!
ARL9$ 0.000576254! 4! NM_206919! Island!
MEOX2$ 0.000592! 7! NM_005924! Open!sea!
SLC6A11$ 0.00059313! 3! NM_014229! Island!
NPHS2$ 0.000593292! 1! NM_014625! Island!
CRADD$ 0.000595679! 12! NM_003805! Open!sea!
NFKBIZ$ 0.000596648! 3! NM_001005474! Island!
RBP1$ 0.000598092! 3! NM_001130992! Island!
CFLAR$ 0.00060256! 2! NM_001127184! Island!
SWAP70$ 0.000605984! 11! NM_015055! N_Shore!
HLASJ$ 0.00061398! 6! NR_024240! Island!
PANX2$ 0.000622033! 22! NM_001160300! Island!
HHIPL1$ 0.000625052! 14! NM_001127258! Island!
DERL3$ 0.00062629! 22! NM_001135751! Island!
ARL9$ 0.000626651! 4! NM_206919! S_Shore!
FBP1$ 0.000626978! 9! NM_001127628! Island!
KLF16$ 0.000644953! 19! NM_031918! Island!
NPM2$ 0.000645147! 8! NM_182795! N_Shore!
NIPAL4$ 0.000650733! 5! NM_001099287! Island!
DDN$ 0.000650933! 12! NM_015086! Island!
NXPH4$ 0.00065259! 12! NM_007224! Island!
TMEM144$ 0.00065777! 4! NM_018342! N_Shore!
SEC31B$ 0.000662913! 10! NM_015490! Island!
ZNF575$ 0.000667616! 19! NM_174945! Island!
GRIN1$ 0.000673344! 9! NM_000832! N_Shore!
CLDN5$ 0.000676274! 22! NM_001130861! Island!
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MYRIP$ 0.000678628! 3! NM_015460! S_Shore!
SLC22A3$ 0.000678695! 6! NM_021977! Island!
PLA2R1$ 0.000680986! 2! NM_001007267! S_Shore!
MGST2$ 0.0006918! 4! NM_002413! Open!sea!
ZNF575$ 0.000692797! 19! NM_174945! Island!
TEKT3$ 0.000699201! 17! NM_031898! S_Shore!
UCP2$ 0.000705363! 11! NM_003355! Island!
HLASJ$ 0.00070811! 6! NR_024240! Island!
ME1$ 0.000712432! 6! NM_002395! Island!
EFEMP1$ 0.000714572! 2! NM_004105! Island!
RHBDF2$ 0.00072036! 17! NM_024599! Island!
RAB27B$ 0.00072269! 18! NM_004163! Island!
PAK1$ 0.000725238! 11! NM_002576! Island!
KCNB1$ 0.00072562! 20! NM_004975! Island!
KCNAB3$ 0.000728718! 17! NM_004732! Island!
RBM24$ 0.000729163! 6! NM_001143941! Island!
LOXL1$ 0.000729845! 15! NM_005576! Island!
STAT4$ 0.000744629! 2! NM_003151! Open!sea!
GJA1$ 0.000744755! 6! NM_000165! Open!sea!
NID2$ 0.000749638! 14! NM_007361! Island!
PHF11$ 0.000755566! 13! NM_001040444! N_Shore!
ARL4A$ 0.000767595! 7! NM_212460! Island!
HLASL$ 0.000773254! 6! NR_027822! Island!
SOCS3$ 0.000778414! 17! NM_003955! Island!
CLDN5$ 0.000778526! 22! NM_001130861! Island!
PIM3$ 0.000781687! 22! NM_001001852! Island!
PRKCZ$ 0.000781939! 1! NM_001033582! Island!
BMPR2$ 0.000787025! 2! NM_001204! Island!
CFLAR$ 0.000787095! 2! NM_001127184! Island!
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MOSC2$ 0.000804158! 1! NM_017898! N_Shore!
CACNG8$ 0.000817051! 19! NM_031895! N_Shore!
NFKBIZ$ 0.00082583! 3! NM_001005474! Island!
ISLR2$ 0.000826167! 15! NM_001130136! Island!
CHST6$ 0.000849933! 16! NM_021615! Island!
BMP8B$ 0.000850564! 1! NM_001720! Island!
RGS22$ 0.000851375! 8! NM_015668! Island!
KIAA0040$ 0.000859517! 1! NM_001162893! Island!
SSH3$ 0.000861295! 11! NM_017857! Island!
HPCA$ 0.000866829! 1! NM_002143! Island!
CYP11A1$ 0.000870469! 15! NM_001099773! Island!
HAPLN3$ 0.000870714! 15! NM_178232! N_Shore!
EYA4$ 0.000870775! 6! NM_172105! N_Shore!
COL9A2$ 0.000880496! 1! NM_001852! Island!
CDK5R2$ 0.000883543! 2! NM_003936! N_Shore!
PPP1R14A$ 0.000883631! 19! NM_033256! Island!
FBXO6$ 0.000895913! 1! NM_018438! Island!
CCNA1$ 0.000898514! 13! NM_003914! S_Shore!
MIR155HG$ 0.000901555! 21! NR_001458! Island!
ZIC2$ 0.000917402! 13! NM_007129! Island!
NXPH4$ 0.000919929! 12! NM_007224! Island!
PHLDB1$ 0.000922539! 11! NM_001144758! Island!
NPM2$ 0.000922649! 8! NM_182795! Island!
ZAR1$ 0.000924757! 4! NM_175619! Island!
DEDD2$ 0.000924899! 19! NM_133328! Island!
ZNF204P$ 0.000925361! 6! NR_024553! Island!
SEC31B$ 0.000925598! 10! NM_015490! Island!
HHIPL1$ 0.000925854! 14! NM_032425! Island!
CENPV$ 0.000932512! 17! NM_181716! Island!
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CALHM2$ 0.00093809! 10! NM_015916! Island!
TMEM144$ 0.000938365! 4! NM_018342! Island!
CFLAR$ 0.000949! 2! NM_001127184! N_Shore!
MGST2$ 0.000949334! 4! NM_002413! Open!sea!
SLC13A5$ 0.000949502! 17! NM_177550! Island!
TBR1$ 0.000952431! 2! NM_006593! Island!
SIAH1$ 0.000954333! 16! NM_001006610! S_Shore!
RNLS$ 0.000954731! 10! NM_001031709! Island!
KIAA0495$ 0.000964229! 1! NM_207306! Island!
SOCS3$ 0.000965236! 17! NM_003955! Island!
SST$ 0.00097032! 3! NM_001048! Island!
TMBIM1$ 0.000970676! 2! NM_022152! Island!
THRB$ 0.000979577! 3! NM_001128177! Island!
IQSEC1$ 0.000980822! 3! NM_001134382! Island!
SLC38A1$ 0.000982642! 12! NM_001077484! Island!
TXNRD1$ 0.000986673! 12! NM_182729! Island!
FBXO6$ 0.001002185! 1! NM_018438! Island!
MGST2$ 0.001012574! 4! NM_002413! Open!sea!
KCNJ3$ 0.001013161! 2! NM_002239! Island!
RBP7$ 0.001013165! 1! NM_052960! Island!
DNAJA4$ 0.00101521! 15! NM_018602! Island!
GRID2IP$ 0.001019732! 7! NM_001145118! Island!
HLASJ$ 0.001027075! 6! NR_024240! Island!
GRM8$ 0.001037613! 7! NM_001127323! N_Shore!
MAL$ 0.001049848! 2! NM_022438! Island!
KLC2$ 0.00105142! 11! NM_001134776! N_Shore!
ADPRH$ 0.001053024! 3! NM_001125! Island!
MAST1$ 0.001055483! 19! NM_014975! Island!
RAP1GAP$ 0.001056076! 1! NM_002885! Island!
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WWTR1$ 0.001061327! 3! NM_001168278! S_Shore!
RUNX1$ 0.00106174! 21! NM_001754! Island!
HIST1H4L$ 0.001062652! 6! NM_003546! S_Shore!
ADPRH$ 0.001085218! 3! NM_001125! Island!
EPS8L2$ 0.0010854! 11! NM_022772! Island!
BRUNOL5$ 0.001086274! 19! NM_021938! N_Shore!
DKK1$ 0.001087141! 10! NM_012242! N_Shore!
RHBDF2$ 0.001090169! 17! NM_024599! Island!
TBR1$ 0.001095059! 2! NM_006593! Island!
RBP7$ 0.001097744! 1! NM_052960! Island!
EHBP1L1$ 0.001103609! 11! NM_001099409! Island!
GPR12$ 0.00110507! 13! NM_005288! Island!
PANX2$ 0.001113958! 22! NM_001160300! Island!
CYB5R1$ 0.00112142! 1! NM_016243! Island!
CYP27A1$ 0.00113471! 2! NM_000784! Island!
RILP$ 0.001142421! 17! NM_031430! Island!
PRKCZ$ 0.001145758! 1! NM_002744! N_Shore!
PPP1R14A$ 0.001150891! 19! NM_033256! Island!
PLLP$ 0.001161565! 16! NM_015993! Island!
GRASP$ 0.001169359! 12! NM_181711! Island!
CTSZ$ 0.001172774! 20! NM_001336! Island!
ADPRH$ 0.001173162! 3! NM_001125! Island!
SLC22A3$ 0.001173438! 6! NM_021977! Island!
LAMP3$ 0.001178345! 3! NM_014398! Island!
ESAM$ 0.001183081! 11! NM_138961! N_Shore!
PRKCZ$ 0.001184579! 1! NM_001033582! Island!
ADPRH$ 0.001194517! 3! NM_001125! Island!
TGFB2$ 0.0011947! 1! NM_001135599! N_Shore!
TGFB2$ 0.001213378! 1! NM_001135599! Island!
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HIST1H4L$ 0.001215286! 6! NM_003546! S_Shore!
COL12A1$ 0.001217205! 6! NM_004370! Island!
DLC1$ 0.001217558! 8! NM_182643! Island!
MEGF10$ 0.001222943! 5! NM_032446! Island!
HSPA2$ 0.001223619! 14! NM_021979! Island!
ZNF204P$ 0.00123662! 6! NR_024553! N_Shore!
NXPH4$ 0.001236833! 12! NM_007224! Island!
ALOX5$ 0.001238671! 10! NM_000698! Island!
SPAG1$ 0.00124268! 8! NM_003114! N_Shore!
HPCA$ 0.001243993! 1! NM_002143! Island!
SLC25A20$ 0.001248383! 3! NM_000387! N_Shore!
CRIP3$ 0.001258951! 6! NM_206922! S_Shore!
MGST2$ 0.001283859! 4! NM_002413! Open!sea!
KIF5C$ 0.001286796! 2! NM_004522! Island!
ACTA1$ 0.001301267! 1! NM_001100! Island!
TNXB$ 0.001309436! 6! NM_019105! S_Shore!
PIM3$ 0.001312774! 22! NM_001001852! Island!
ACAA1$ 0.001313501! 3! NR_024024! Island!
MYO18A$ 0.001315034! 17! NM_078471! Island!
ANKRD34A$ 0.001316708! 1! NM_001039888! Island!
RAB27B$ 0.001326379! 18! NM_004163! N_Shore!
ESAM$ 0.001337996! 11! NM_138961! Island!
MOSC2$ 0.001361007! 1! NM_017898! N_Shore!
RBM24$ 0.001366241! 6! NM_001143941! S_Shore!
EFEMP1$ 0.001366859! 2! NM_004105! Island!
ONECUT2$ 0.001372006! 18! NM_004852! Open!sea!
SLC38A1$ 0.001372325! 12! NM_001077484! Island!
ARHGAP24$ 0.001376991! 4! NM_001025616! Open!sea!
MAP7$ 0.001384252! 6! NM_003980! Island!
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GIPR$ 0.001398656! 19! NM_000164! Island!
RGNEF$ 0.001399873! 5! NM_001080479! Island!
MEOX2$ 0.001424693! 7! NM_005924! Open!sea!
ZFHX3$ 0.001429172! 16! NM_001164766! Island!
NUDT16$ 0.001434994! 3! NM_152395! Island!
CD8A$ 0.001446664! 2! NM_001145873! Island!
KLF11$ 0.00144784! 2! NM_003597! Island!
FBXO6$ 0.001482306! 1! NM_018438! Island!
FZD6$ 0.001494476! 8! NM_001164616! Island!
PAMR1$ 0.001496345! 11! NM_001001991! S_Shore!
GRIN2B$ 0.00150214! 12! NM_000834! N_Shore!
ERBB2$ 0.001502237! 17! NM_001005862! Island!
CDH3$ 0.001502821! 16! NM_001793! Island!
GDNF$ 0.001513562! 5! NM_000514! Island!
FBRSL1$ 0.001551126! 12! NM_001142641! N_Shore!
DDIT4L$ 0.001561465! 4! NM_145244! S_Shore!
NCRNA00092$ 0.001568671! 9! NR_024129! Island!
RBP1$ 0.001572528! 3! NM_001130993! Island!
EFNB2$ 0.001584001! 13! NM_004093! Island!
LECT1$ 0.001591838! 13! NM_001011705! Island!
MAL$ 0.001592404! 2! NM_022440! Island!
ACAA1$ 0.001608885! 3! NR_024024! Island!
LGALS3$ 0.001624665! 14! NM_002306! S_Shore!
MIR375$ 0.001637917! 2! NR_029867! Island!
MYRIP$ 0.001647145! 3! NM_015460! S_Shore!
HLF$ 0.001669242! 17! NM_002126! S_Shore!
TMEM26$ 0.001678889! 10! NM_178505! S_Shore!
TGFB2$ 0.001679117! 1! NM_003238! S_Shore!
GNAL$ 0.001679871! 18! NM_002071! Island!
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GPR19$ 0.001681485! 12! NM_006143! Island!
BIRC3$ 0.001708525! 11! NM_182962! N_Shore!
GPR19$ 0.001711497! 12! NM_006143! Island!
CTHRC1$ 0.00171258! 8! NM_138455! Island!
FBXO6$ 0.001724421! 1! NM_018438! Island!
NCRNA00085$ 0.001725088! 19! NR_024330! Island!
PTEN$ 0.001733654! 10! NM_000314! Island!
ZMYND10$ 0.0017499! 3! NM_015896! Island!
RNLS$ 0.001763236! 10! NM_001031709! Island!
ARL9$ 0.001793677! 4! NM_206919! Island!
EVC2$ 0.001812681! 4! NM_001166136! Island!
GSX2$ 0.00181827! 4! NM_133267! Island!
ALOX5$ 0.001830098! 10! NM_000698! Island!
BCAT1$ 0.001835018! 12! NM_005504! Island!
RASGRP2$ 0.00185628! 11! NM_001098671! Island!
RNF39$ 0.001867537! 6! NM_025236! Island!
FAM160A1$ 0.001883402! 4! NM_001109977! Island!
GNAL$ 0.001888588! 18! NM_002071! Island!
GSX2$ 0.001890511! 4! NM_133267! Island!
ARHGAP24$ 0.001891343! 4! NM_001025616! Open!sea!
SSH3$ 0.001894589! 11! NM_017857! Island!
IGDCC3$ 0.001901522! 15! NM_004884! Island!
MOSC2$ 0.001910491! 1! NM_017898! Island!
NTSR2$ 0.001910701! 2! NM_012344! Island!
CPLX1$ 0.001911221! 4! NM_006651! Island!
RHOD$ 0.001914777! 11! NM_014578! Island!
SHH$ 0.001922714! 7! NM_000193! Island!
USP4$ 0.001922992! 3! NM_199443! S_Shore!
CHST8$ 0.001927017! 19! NM_001127895! N_Shore!
 
 309 
BCL6$ 0.001938216! 3! NM_001706! Island!
CALHM2$ 0.001950818! 10! NM_015916! N_Shore!
OSBPL9$ 0.0019942! 1! NM_148904! N_Shore!
TMEM200B$ 0.001995014! 1! NM_001003682! Island!
EYA4$ 0.001996214! 6! NM_172105! N_Shore!
EFCAB4B$ 0.001996492! 12! NM_001144959! Island!
PRR15$ 0.002021163! 7! NM_175887! Island!
QRFPR$ 0.002028012! 4! NM_198179! Island!
ISLR2$ 0.002028415! 15! NM_001130136! Island!
LYPD1$ 0.002037283! 2! NM_001077427! Island!
GAMT$ 0.00204182! 19! NM_138924! Island!
FOXP1$ 0.002051394! 3! NM_032682! Island!
EFNB2$ 0.002067769! 13! NM_004093! Island!
TMEM26$ 0.002075307! 10! NM_178505! S_Shore!
ALDH3A1$ 0.002080392! 17! NM_001135167! Island!
HDAC4$ 0.002083153! 2! NM_006037! S_Shore!
RBP1$ 0.002087149! 3! NM_001130992! S_Shore!
NIPAL4$ 0.002114898! 5! NM_001099287! Island!
APBA2$ 0.002115113! 15! NM_001130414! Island!
RASSF10$ 0.002125105! 11! NM_001080521! Island!
DERL3$ 0.002132223! 22! NM_198440! Island!
KLF5$ 0.002132477! 13! NM_001730! S_Shore!
HPCA$ 0.002137349! 1! NM_002143! Island!
COL19A1$ 0.002141188! 6! NM_001858! N_Shore!
MOSC2$ 0.00214662! 1! NM_017898! Island!
BCL2$ 0.002153084! 18! NM_000657! Island!
GDNF$ 0.002156056! 5! NM_000514! Island!
USP4$ 0.002157948! 3! NM_003363! Island!
TOM1L1$ 0.002158372! 17! NM_005486! Island!
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MEGF10$ 0.002162942! 5! NM_032446! Island!
PRDX1$ 0.002163387! 1! NM_002574! Island!
TNXB$ 0.002168941! 6! NM_019105! Island!
FBXO6$ 0.002176619! 1! NM_018438! Island!
HMSD$ 0.002185351! 18! NM_001123366! Open!sea!
SSH3$ 0.002211447! 11! NM_017857! Island!
SERINC2$ 0.00222372! 1! NM_178865! Island!
PACS2$ 0.00223506! 14! NM_015197! S_Shore!
TCEA3$ 0.002248886! 1! NM_003196! Island!
ALOX5$ 0.002254226! 10! NM_000698! S_Shore!
FBRSL1$ 0.002254532! 12! NM_001142641! Island!
PHF11$ 0.002273777! 13! NM_001040444! Island!
SLC16A11$ 0.002286188! 17! NM_153357! Island!
PAX6$ 0.002298184! 11! NM_001127612! Island!
RADIL$ 0.002302914! 7! NM_018059! Open!sea!
RTBDN$ 0.002318174! 19! NM_031429! S_Shore!
HSD11B2$ 0.002318522! 16! NM_000196! Island!
MACROD1$ 0.002322742! 11! NM_014067! N_Shore!
COL19A1$ 0.002346021! 6! NM_001858! N_Shore!
MMP14$ 0.002352248! 14! NM_004995! Island!
LYN$ 0.002355554! 8! NM_002350! N_Shore!
CCNI2$ 0.002373385! 5! NM_001039780! Island!
ELL3$ 0.002397895! 15! NM_025165! Island!
PSD$ 0.002398658! 10! NM_002779! Island!
WWTR1$ 0.002402441! 3! NM_001168278! S_Shore!
FBRSL1$ 0.002405435! 12! NM_001142641! Island!
TET1$ 0.002410655! 10! NM_030625! S_Shore!
LGALS3$ 0.002420096! 14! NM_002306! Island!
CABYR$ 0.002426493! 18! NM_153768! Island!
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ENC1$ 0.002439162! 5! NM_003633! S_Shore!
USP4$ 0.002440027! 3! NM_003363! Island!
LTBP4$ 0.002445648! 19! NM_001042544! Island!
FLJ22536$ 0.002452639! 6! NR_015410! S_Shore!
RASL12$ 0.002453232! 15! NM_016563! Island!
SERHL2$ 0.002468876! 22! NM_014509! Island!
SLC16A11$ 0.002499049! 17! NM_153357! Island!
MFSD2B$ 0.00250459! 2! NM_001080473! Island!
APBA2$ 0.002510097! 15! NM_001130414! Island!
LTBP4$ 0.002511049! 19! NM_001042545! Island!
LYPD1$ 0.002518794! 2! NM_001077427! Island!
ALOX5$ 0.002524516! 10! NM_000698! Island!
PXDN$ 0.002533684! 2! NM_012293! Island!
NFATC4$ 0.002534768! 14! NM_001136022! Island!
SPIB$ 0.002535883! 19! NM_003121! Island!
RGNEF$ 0.00254265! 5! NM_001080479! Island!
TBR1$ 0.002548825! 2! NM_006593! N_Shore!
KCNIP3$ 0.002553237! 2! NM_001034914! Island!
MAPT$ 0.002555742! 17! NM_001123067! Island!
BRUNOL5$ 0.002556894! 19! NM_021938! S_Shore!
RASGRP2$ 0.002561108! 11! NM_001098671! Island!
FOXP1$ 0.002562383! 3! NM_032682! Island!
CYP26B1$ 0.002587926! 2! NM_019885! Island!
HIST1H4L$ 0.002590172! 6! NM_003546! S_Shore!
MACROD1$ 0.002612887! 11! NM_014067!
!
CTSZ$ 0.002635721! 20! NM_001336! Island!
CCDC122$ 0.002641161! 13! NM_144974! Island!
FGFRL1$ 0.002642105! 4! NM_001004356! Island!
HLASL$ 0.002645666! 6! NR_027822! Island!
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SLC13A5$ 0.002655897! 17! NM_001143838! Island!
CCDC122$ 0.002669253! 13! NM_144974! N_Shore!
RAB11FIP4$ 0.00267758! 17! NM_032932! N_Shore!
CBR1$ 0.002694326! 21! NM_001757! Island!
SHANK1$ 0.002708705! 19! NM_016148! Island!
SERPINB6$ 0.002709904! 6! NM_004568! Island!
MAST1$ 0.002725751! 19! NM_014975! Island!
SHANK1$ 0.002726397! 19! NM_016148! Island!
EPHA2$ 0.002742936! 1! NM_004431! Island!
PGCP$ 0.002748735! 8! NM_016134! Island!
ARHGAP24$ 0.00275653! 4! NM_001025616! Open!sea!
MACROD1$ 0.002769756! 11! NM_014067! Open!sea!
CHAD$ 0.00277002! 17! NM_001267! Island!
MGST2$ 0.002772892! 4! NM_002413! Open!sea!
SYT6$ 0.002773259! 1! NM_205848! Island!
ANKRD34A$ 0.002773859! 1! NM_001039888! Island!
HLASJ$ 0.002786534! 6! NR_024240! Island!
LLGL2$ 0.002797133! 17! NM_001015002! Island!
LIN28$ 0.002805311! 1! NM_024674! N_Shore!
IGSF21$ 0.002816568! 1! NM_032880! Island!
LY75$ 0.002816571! 2! NM_002349! Island!
ALDH3A1$ 0.002817648! 17! NM_001135167! Island!
SLC25A20$ 0.002821121! 3! NM_000387! Island!
PTEN$ 0.002828289! 10! NM_000314! Island!
PANX2$ 0.002832555! 22! NM_001160300! Island!
ALOX5$ 0.002838385! 10! NM_000698! Island!
VRK2$ 0.002869284! 2! NM_001130483! Island!
RBM24$ 0.002874362! 6! NM_153020! Island!
SLC38A1$ 0.002879349! 12! NM_001077484! Island!
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THBS4$ 0.002886494! 5! NM_003248! Island!
LAMA3$ 0.002886898! 18! NM_198129! Island!
HAPLN3$ 0.002906967! 15! NM_178232! Island!
PICK1$ 0.002914599! 22! NM_001039583! N_Shore!
HDAC4$ 0.002925786! 2! NM_006037! Island!
CALHM2$ 0.002944701! 10! NM_015916! Island!
HDAC4$ 0.002953807! 2! NM_006037! Island!
CHPF$ 0.002954416! 2! NM_024536! Island!
RASL12$ 0.00297363! 15! NM_016563! Island!
USP4$ 0.002989883! 3! NM_003363! Island!
CAMTA1$ 0.003002334! 1! NM_015215! Open!sea!
FLJ23834$ 0.003034206! 7! NM_152750! Island!
BRUNOL4$ 0.003059428! 18! NM_001025089! Island!
ACTA1$ 0.0030596! 1! NM_001100! Island!
XKR8$ 0.003061132! 1! NM_018053! Island!
EFEMP1$ 0.003063539! 2! NM_004105! Island!
NR1I2$ 0.003069309! 3! NM_033013! Island!
SHH$ 0.003069903! 7! NM_000193! Island!
BCL2$ 0.003070722! 18! NM_000633! Island!
CFLAR$ 0.003071274! 2! NM_001127184! Island!
FAM19A1$ 0.003071786! 3! NM_213609! S_Shore!
EMILIN3$ 0.003080442! 20! NM_052846! Island!
SPTBN1$ 0.003085514! 2! NM_178313! Island!
NFKBIZ$ 0.003088809! 3! NM_001005474! Island!
ACTA1$ 0.003090134! 1! NM_001100! Island!
TMEM26$ 0.003104673! 10! NM_178505! S_Shore!
COL21A1$ 0.003110007! 6! NM_030820! S_Shore!
PTEN$ 0.003111448! 10! NM_000314! Island!
SEC31B$ 0.003145388! 10! NM_015490! Island!
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FKBP5$ 0.003151793! 6! NM_001145777! Island!
HSPB1$ 0.003151805! 7! NM_001540! Island!
FGFRL1$ 0.003152768! 4! NM_001004356! Island!
SLC22A16$ 0.003157786! 6! NM_033125! Island!
PAMR1$ 0.003168586! 11! NM_015430! Island!
MCFD2$ 0.003176594! 2! NM_001171511! S_Shore!
RUSC1$ 0.003177141! 1! NM_001105205! Island!
ACADS$ 0.003177309! 12! NM_000017! Island!
VSIG10L$ 0.003180668! 19! NM_001163922! Island!
SPAG1$ 0.00318508! 8! NM_003114! N_Shore!
RAB32$ 0.003190224! 6! NM_006834! Island!
BMP8B$ 0.003232972! 1! NM_001720! Island!
CAMK2B$ 0.003236688! 7! NM_172081! Island!
KBTBD11$ 0.003242599! 8! NM_014867! S_Shore!
HLASJ$ 0.00324821! 6! NR_024240! Island!
KIAA0040$ 0.003252647! 1! NM_001162893! Island!
RASGRP2$ 0.003256739! 11! NM_153819! Island!
UCP2$ 0.003265327! 11! NM_003355! S_Shore!
RNF39$ 0.003265709! 6! NM_025236! S_Shore!
ARFGAP3$ 0.00326654! 22! NM_014570! Island!
LLGL2$ 0.003293407! 17! NM_001015002! Island!
GRASP$ 0.003293927! 12! NM_181711! Island!
DEDD2$ 0.003296941! 19! NM_133328! Island!
ACTA1$ 0.003308264! 1! NM_001100! Island!
GPR12$ 0.003323214! 13! NM_005288! Island!
RGNEF$ 0.003337815! 5! NM_001080479! Island!
NAV2$ 0.003341296! 11! NM_182964! S_Shore!
OPCML$ 0.003403093! 11! NM_001012393! Open!sea!
RGS22$ 0.003425685! 8! NM_015668! Island!
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USP4$ 0.00344677! 3! NM_003363! Island!
THBS4$ 0.003490245! 5! NM_003248! Island!
GPR150$ 0.003495326! 5! NM_199243! Island!
PRR15$ 0.003514088! 7! NM_175887! Island!
PDPN$ 0.003535427! 1! NM_001006624! Island!
DLG1$ 0.003539151! 3! NM_004087! Island!
RADIL$ 0.003554246! 7! NM_018059! Open!sea!
MIR548H4$ 0.003569329! 15! NR_031680! S_Shore!
FAM5B$ 0.003604725! 1! NM_021165! Island!
CD2AP$ 0.003617623! 6! NM_012120! N_Shore!
KCNB1$ 0.003622917! 20! NM_004975! Island!
TEKT3$ 0.003637355! 17! NM_031898! N_Shore!
ADAM8$ 0.003638814! 10! NM_001164490! Island!
GPR19$ 0.003679264! 12! NM_006143! Island!
GRID2IP$ 0.003688207! 7! NM_001145118! Island!
GJA1$ 0.003705472! 6! NM_000165! Open!sea!
SOCS3$ 0.003721762! 17! NM_003955! Island!
MCFD2$ 0.003749857! 2! NM_001171508! S_Shore!
TNFAIP8L3$ 0.003753! 15! NM_207381! Island!
PNMT$ 0.003764244! 17! NM_002686! Island!
PANX2$ 0.003774904! 22! NM_001160300! Island!
SLC16A11$ 0.003775124! 17! NM_153357! Island!
PDPN$ 0.003790456! 1! NM_001006624! Island!
GSX2$ 0.003798511! 4! NM_133267! N_Shore!
RUSC1$ 0.003843649! 1! NM_001105203! Island!
PTEN$ 0.003854538! 10! NM_000314! Island!
PSD3$ 0.003856029! 8! NM_015310! Island!
GPR19$ 0.003931881! 12! NM_006143! Island!
COL21A1$ 0.003939097! 6! NM_030820! Island!
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CLDN5$ 0.003951431! 22! NM_001130861! S_Shore!
RNLS$ 0.003956223! 10! NM_001031709! Island!
LOXL3$ 0.003961595! 2! NM_032603! Island!
TOM1L1$ 0.003974287! 17! NM_005486! Island!
LIN28$ 0.003994067! 1! NM_024674! N_Shore!
STAT4$ 0.004012254! 2! NM_003151! Open!sea!
VWA1$ 0.004030376! 1! NM_199121! N_Shore!
KIF19$ 0.004042354! 17! NM_153209! Island!
GALNT14$ 0.004104764! 2! NM_024572! Island!
EMILIN3$ 0.004117449! 20! NM_052846! Island!
MYCBPAP$ 0.004143458! 17! NM_032133! Island!
TLX1$ 0.004147705! 10! NM_005521! N_Shore!
FBRSL1$ 0.004151893! 12! NM_001142641! Island!
GRM8$ 0.004163725! 7! NM_001127323! N_Shore!
ACRBP$ 0.004203739! 12! NM_032489! Island!
SEC31B$ 0.004263225! 10! NM_015490! Island!
MFSD2B$ 0.004276866! 2! NM_001080473! Island!
VRK2$ 0.00428493! 2! NM_006296! Island!
SLC22A16$ 0.004297289! 6! NM_033125! Island!
BIRC3$ 0.004300432! 11! NM_182962! N_Shore!
CALHM2$ 0.004334772! 10! NM_015916! Island!
ZMYND10$ 0.004338362! 3! NM_015896! Island!
PRDX1$ 0.004352991! 1! NM_181696! Island!
ALOX5$ 0.00440621! 10! NM_000698! N_Shore!
TRANK1$ 0.004407048! 3! NM_014831! Island!
BCAT1$ 0.004412162! 12! NM_005504! Island!
CCDC122$ 0.004421851! 13! NM_144974! Island!
TUBA4B$ 0.004447664! 2! NR_003063! N_Shore!
AOX1$ 0.004449394! 2! NM_001159! Island!
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ANKRD34A$ 0.004457647! 1! NM_001039888! Island!
RADIL$ 0.004483495! 7! NM_018059! Open!sea!
CYP27A1$ 0.004508567! 2! NM_000784! Island!
LBXCOR1$ 0.004508635! 15! NM_001031807! Island!
CYP27A1$ 0.004509907! 2! NM_000784! N_Shore!
PRSS27$ 0.004512352! 16! NM_031948! N_Shore!
NBL1$ 0.004513287! 1! NM_005380! Island!
PRSS27$ 0.004567002! 16! NM_031948! Island!
KIAA0040$ 0.004567514! 1! NM_001162893! Island!
VSX1$ 0.004597061! 20! NM_199425! Island!
COL24A1$ 0.004598473! 1! NM_152890! Island!
RNF135$ 0.004609756! 17! NM_197939! N_Shore!
SYT6$ 0.004609815! 1! NM_205848! Island!
CHAD$ 0.004629591! 17! NM_001267! Island!
ADPRH$ 0.004666175! 3! NM_001125! Island!
PLA2R1$ 0.004732611! 2! NM_001007267! S_Shore!
FLJ23834$ 0.004733441! 7! NM_152750! S_Shore!
STARD9$ 0.004741068! 15! NM_020759! Island!
ZC3HAV1L$ 0.004747218! 7! NM_080660! Island!
LBXCOR1$ 0.004748853! 15! NM_001031807! Island!
RAPGEFL1$ 0.004762787! 17! NM_016339! Island!
RASSF10$ 0.004824149! 11! NM_001080521! Island!
PTEN$ 0.00486326! 10! NM_000314! N_Shore!
GRASP$ 0.004865585! 12! NM_181711! Island!
NCAM2$ 0.004865729! 21! NM_004540! Island!
HLASJ$ 0.004867014! 6! NR_024240! Island!
ENC1$ 0.004890461! 5! NM_003633! Island!
CACNB4$ 0.004934731! 2! NM_000726! Island!
PXDN$ 0.004940753! 2! NM_012293! Island!
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DOK7$ 0.004942283! 4! NM_173660! Island!
CCDC122$ 0.004948573! 13! NM_144974! Island!
WWTR1$ 0.00495493! 3! NM_001168278! Island!
VRK2$ 0.004956768! 2! NM_006296! Island!
RAP1GAP$ 0.004970622! 1! NM_002885! Island!
SEC31B$ 0.004986795! 10! NM_015490! Island!
PYCARD$ 0.005019774! 16! NM_013258! Island!
CNTD2$ 0.005035828! 19! NM_024877! Island!
CNGA3$ 0.005037631! 2! NM_001298! Island!
UPK3A$ 0.005039328! 22! NM_006953! Island!
GRIN2C$ 0.005040825! 17! NM_000835! Island!
RTBDN$ 0.005075345! 19! NM_031429! S_Shore!
RASL12$ 0.005080122! 15! NM_016563! Island!
NGB$ 0.005080711! 14! NM_021257! Island!
SHH$ 0.005082027! 7! NM_000193! Island!
CD2AP$ 0.005101133! 6! NM_012120! N_Shore!
PDPN$ 0.005103112! 1! NM_001006624! Island!
PDPN$ 0.005167789! 1! NM_001006624! Island!
DEDD2$ 0.005171406! 19! NM_133328! Island!
SWAP70$ 0.005199175! 11! NM_015055! S_Shore!
DLGAP3$ 0.00520215! 1! NM_001080418! Island!
PAK1$ 0.005214291! 11! NM_002576! Island!
SCGB3A1$ 0.005218745! 5! NM_052863! Island!
PRSS27$ 0.005231043! 16! NM_031948! Island!
ITGB5$ 0.005237953! 3! NM_002213! Island!
UPK3A$ 0.005238347! 22! NM_006953! Island!
GPR153$ 0.005254085! 1! NM_207370! S_Shore!
TLX1$ 0.005281648! 10! NM_005521! Island!
MT1E$ 0.005282497! 16! NM_175617! Island!
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ERBB2$ 0.005288029! 17! NM_001005862! S_Shore!
PPP1R14A$ 0.005288706! 19! NM_033256! Island!
RPP25$ 0.005296227! 15! NM_017793! N_Shore!
GJA4$ 0.005367512! 1! NM_002060! N_Shore!
RNLS$ 0.005376423! 10! NM_001031709! Island!
XKR8$ 0.005418923! 1! NM_018053! Island!
RAB3D$ 0.005440149! 19! NM_004283! Island!
COL19A1$ 0.005440711! 6! NM_001858! N_Shore!
NFATC1$ 0.005536708! 18! NM_006162! Island!
DRD4$ 0.005556921! 11! NM_000797! Island!
COL12A1$ 0.005562696! 6! NM_004370! Island!
PPM1L$ 0.005567282! 3! NM_139245! S_Shore!
CNTD2$ 0.005610581! 19! NM_024877! Island!
EPAS1$ 0.005618624! 2! NM_001430! Island!
MT1E$ 0.00562495! 16! NM_175617! S_Shore!
HNRNPF$ 0.005666443! 10! NM_001098207! Island!
PPM1L$ 0.005690258! 3! NM_139245! S_Shore!
ANKS1B$ 0.005725518! 12! NM_020140! Island!
SULT1A1$ 0.005725875! 16! NM_177536! S_Shore!
GPR150$ 0.005736724! 5! NM_199243! Island!
CCDC122$ 0.005799884! 13! NM_144974! Island!
KLC2$ 0.005813253! 11! NM_001134776! N_Shore!
B3GNT7$ 0.005886979! 2! NM_145236! Island!
PDPN$ 0.005889797! 1! NM_001006624! Island!
FBRSL1$ 0.005896362! 12! NM_001142641! Island!
SLC35D3$ 0.005896742! 6! NM_001008783! N_Shore!
NFATC4$ 0.005929024! 14! NM_001136022! N_Shore!
AOX1$ 0.005936555! 2! NM_001159! Island!
ENC1$ 0.005936672! 5! NM_003633! S_Shore!
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PHF11$ 0.005973904! 13! NM_001040443! Island!
AOX1$ 0.005986724! 2! NM_001159! Island!
HLASJ$ 0.006017269! 6! NR_024240! Island!
HSPA2$ 0.0061106! 14! NM_021979! Island!
LPAR2$ 0.006118951! 19! NM_004720! Island!
HSPB1$ 0.00616837! 7! NM_001540! Island!
CLDN10$ 0.006177309! 13! NM_006984! Island!
FBP1$ 0.006183594! 9! NM_000507! Island!
CD8A$ 0.006190793! 2! NM_001145873! Island!
USP4$ 0.00620579! 3! NM_199443! S_Shore!
PGCP$ 0.00620612! 8! NM_016134! Island!
PPM1L$ 0.006256048! 3! NM_139245! S_Shore!
ADCY1$ 0.006286994! 7! NM_021116! Island!
ALS2CL$ 0.006340027! 3! NM_147129! Island!
EPAS1$ 0.00634919! 2! NM_001430! Island!
KIAA0040$ 0.006398056! 1! NM_001162893! S_Shore!
TMEM144$ 0.006428801! 4! NM_018342! Island!
FAM5B$ 0.006471441! 1! NM_021165! Island!
MOSC2$ 0.006473556! 1! NM_017898! Island!
FLOT1$ 0.006490307! 6! NM_005803! Island!
MFSD2B$ 0.006523961! 2! NM_001080473! Island!
KLF5$ 0.006527989! 13! NM_001730! S_Shore!
CHRNB1$ 0.006530839! 17! NM_000747! Island!
EPAS1$ 0.006536629! 2! NM_001430! Island!
ENC1$ 0.006538363! 5! NM_003633! Island!
GABRA1$ 0.006584328! 5! NM_001127645! Open!sea!
EFNB2$ 0.00664018! 13! NM_004093! Island!
IMPACT$ 0.006651793! 18! NM_018439! Island!
SHANK1$ 0.00668739! 19! NM_016148! Island!
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HPCAL1$ 0.006772969! 2! NM_002149! Island!
RASL10B$ 0.006795269! 17! NM_033315! Island!
FLJ23834$ 0.006800997! 7! NM_152750! Island!
SEC31B$ 0.006805669! 10! NM_015490! Island!
RNLS$ 0.00683059! 10! NM_001031709! Island!
GDNF$ 0.006831621! 5! NM_000514! Island!
RNF135$ 0.006880849! 17! NM_032322! Island!
CHAD$ 0.006924727! 17! NM_001267! Island!
CHAD$ 0.006942221! 17! NM_001267! Island!
SYT6$ 0.006975512! 1! NM_205848! Island!
MT1A$ 0.006989134! 16! NM_005946! Island!
VILL$ 0.006996234! 3! NM_015873! N_Shore!
HOXC4$ 0.007025624! 12! NM_014620! N_Shore!
KCNQ4$ 0.007025724! 1! NM_004700! Island!
LIN28$ 0.00703373! 1! NM_024674! N_Shore!
COL9A3$ 0.007046562! 20! NM_001853! Island!
EFEMP2$ 0.007072463! 11! NM_016938! Island!
CXCR4$ 0.007102259! 2! NM_003467! N_Shore!
MLLT10$ 0.007113888! 10! NM_004641! S_Shore!
SIM2$ 0.007258543! 21! NM_005069! Island!
VRK2$ 0.007273479! 2! NM_001130483! Island!
FLOT1$ 0.007276459! 6! NM_005803! Island!
PTPRU$ 0.007330693! 1! NM_133178! Island!
RNF39$ 0.007392462! 6! NM_025236! Island!
HIST1H4L$ 0.007420721! 6! NM_003546! S_Shore!
CFTR$ 0.007422369! 7! NM_000492! Open!sea!
HTR6$ 0.007430951! 1! NM_000871! Island!
GRB7$ 0.007449648! 17! NM_005310! Open!sea!
SSH3$ 0.007558297! 11! NM_017857! Island!
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NFATC1$ 0.007581332! 18! NM_006162! Island!
FGR$ 0.007604531! 1! NM_005248! Island!
HSD11B2$ 0.007679246! 16! NM_000196! Island!
TET1$ 0.007689163! 10! NM_030625! S_Shore!
SPAG1$ 0.007720732! 8! NM_003114! N_Shore!
CXCR4$ 0.007724038! 2! NM_003467! N_Shore!
VSX1$ 0.007725756! 20! NM_014588! Island!
FLJ40330$ 0.007737828! 2! NR_015424! Island!
WWTR1$ 0.007751772! 3! NM_001168278! S_Shore!
SCGB3A1$ 0.007767691! 5! NM_052863! Island!
RNLS$ 0.007797474! 10! NM_001031709! Island!
XKR8$ 0.007808935! 1! NM_018053! Island!
RAB32$ 0.00780926! 6! NM_006834! Island!
NPY5R$ 0.007831341! 4! NM_006174! Island!
TBR1$ 0.007835749! 2! NM_006593! N_Shore!
FAM59B$ 0.007845899! 2! NM_001168241! Island!
MFSD2B$ 0.007869988! 2! NM_001080473! Island!
USP4$ 0.007891386! 3! NM_003363! Island!
SHH$ 0.007893356! 7! NM_000193! Island!
RGNEF$ 0.007905393! 5! NM_001080479! Island!
PAMR1$ 0.007937377! 11! NM_001001991! S_Shore!
KIAA0146$ 0.007974009! 8! NM_001080394! Open!sea!
FAM5B$ 0.008061346! 1! NM_021165! Island!
EYA4$ 0.008068786! 6! NM_172105! Island!
HFE$ 0.008068881! 6! NM_139010! Open!sea!
COL21A1$ 0.008073495! 6! NM_030820! Island!
SPTBN1$ 0.008104432! 2! NM_178313! Island!
CRYAB$ 0.00821677! 11! NM_001885! Open!sea!
FRZB$ 0.008228262! 2! NM_001463! N_Shore!
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THBS4$ 0.008317269! 5! NM_003248! Island!
PPP1R14A$ 0.008442834! 19! NM_033256! Island!
MOSC2$ 0.008473765! 1! NM_017898! Island!
CNTN2$ 0.008481817! 1! NM_005076! Open!sea!
EPS8L2$ 0.008484551! 11! NM_022772! Island!
HLASJ$ 0.00851929! 6! NR_024240! Island!
CTHRC1$ 0.008600562! 8! NM_138455! S_Shore!
TOM1L1$ 0.008656979! 17! NM_005486! Island!
GRID2IP$ 0.00867619! 7! NM_001145118! Island!
TMEM178$ 0.00869922! 2! NM_152390! N_Shore!
RAPGEFL1$ 0.008722953! 17! NM_016339! Island!
SERPINB6$ 0.008744454! 6! NM_004568! Island!
NR1I2$ 0.008760442! 3! NM_033013! Island!
MGST2$ 0.008792528! 4! NM_002413! Open!sea!
LGR5$ 0.008816959! 12! NM_003667! S_Shore!
HSPB1$ 0.008881158! 7! NM_001540! Island!
SSH3$ 0.008901183! 11! NM_017857! N_Shore!
TMEM26$ 0.008928069! 10! NM_178505! S_Shore!
LPAR2$ 0.008945844! 19! NM_004720! Island!
FGR$ 0.008951717! 1! NM_005248! Island!
MFSD2B$ 0.008969807! 2! NM_001080473! Island!
IER3$ 0.008997907! 6! NM_003897! Island!
VAX2$ 0.009013311! 2! NM_012476! Island!
CHST8$ 0.009036995! 19! NM_022467! Island!
NR5A2$ 0.009037388! 1! NM_205860! N_Shore!
SLC22A15$ 0.009037778! 1! NM_018420! Island!
COL21A1$ 0.009049268! 6! NM_030820! N_Shore!
OSBPL1A$ 0.00907019! 18! NM_080597! Island!
SPATS1$ 0.00908249! 6! NM_145026! Open!sea!
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DLGAP3$ 0.009131369! 1! NM_001080418! Island!
LOXL3$ 0.009161581! 2! NM_032603! N_Shore!
SERINC2$ 0.009211597! 1! NM_178865! Island!
TTBK1$ 0.009211892! 6! NM_032538! N_Shore!
PDE4A$ 0.009220866! 19! NM_001111308! Island!
NR3C2$ 0.009242603! 4! NM_000901! N_Shore!
TMEM51$ 0.009242936! 1! NM_001136218! Island!
GPR19$ 0.009254774! 12! NM_006143! Island!
ARFGAP3$ 0.009320882! 22! NM_014570! Island!
P2RY2$ 0.009330767! 11! NM_002564! Island!
FAM59B$ 0.009331966! 2! NM_001168241! Island!
FGFRL1$ 0.00933691! 4! NM_001004358! Island!
MFSD2B$ 0.009366822! 2! NM_001080473! Island!
RAB32$ 0.009367517! 6! NM_006834! Island!
EFEMP2$ 0.009416179! 11! NM_016938! Island!
THBS4$ 0.009426863! 5! NM_003248! Island!
RNF39$ 0.009437857! 6! NM_025236! Island!
ME1$ 0.00945316! 6! NM_002395! N_Shore!
PAMR1$ 0.009482203! 11! NM_015430! Island!
SPAG1$ 0.00951145! 8! NM_003114! N_Shore!
ALS2CL$ 0.009533276! 3! NM_147129! Island!
MT1E$ 0.009755986! 16! NM_175617! Island!
KIAA0146$ 0.009799638! 8! NM_001080394! Open!sea!
HLASJ$ 0.009851689! 6! NR_024240! Island!
ACTA1$ 0.009854989! 1! NM_001100! Island!
VPS37B$ 0.009947739! 12! NM_024667! Island!
COL1A2$ 0.009949633! 7! NM_000089! Open!sea 
NAALAD2$ 0.009979418! 11! NM_005467! Open!sea 
NFKBIZ$ 0.010034748! 3! NM_001005474! Island!
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LZTS2$ 0.010079024! 10! NM_032429! N_Shore!
COL18A1$ 0.010098924! 21! NM_130445! Island!
TEKT3$ 0.010150287! 17! NM_031898! S_Shore!
RNF135$ 0.01015033! 17! NM_197939! N_Shore!
PACS2$ 0.010150688! 14! NM_015197! Island!
MT1E$ 0.010197556! 16! NM_175617! Island!
HHIPL1$ 0.01037231! 14! NM_032425! S_Shore!
ADAMTSL4$ 0.010391012! 1! NM_019032! Island!
RCCD1$ 0.010458274! 15! NM_033544! Island!
EPHA2$ 0.010469907! 1! NM_004431! Island!
MYL12A$ 0.010580165! 18! NM_006471! Island!
LGR5$ 0.010580565! 12! NM_003667! S_Shore!
KIAA0040$ 0.010598752! 1! NM_001162893! Island!
TMEM26$ 0.010656965! 10! NM_178505! S_Shore!
CABYR$ 0.010670367! 18! NM_153768! Island!
TRH$ 0.01069254! 3! NM_007117! Island!
LINGO3$ 0.010703433! 19! NM_001101391! Island!
LBXCOR1$ 0.010708694! 15! NM_001031807! Island!
SYCP2L$ 0.010709324! 6! NM_001040274! N_Shore!
LBXCOR1$ 0.01074912! 15! NM_001031807! Island!
FZD6$ 0.010851146! 8! NM_003506! Island!
TXNRD1$ 0.010874437! 12! NM_182729! N_Shore!
MLLT10$ 0.010893675! 10! NM_004641! Island!
SWAP70$ 0.01090179! 11! NM_015055! Island!
MMP14$ 0.010952897! 14! NM_004995! Island!
TRIM36$ 0.011000632! 5! NM_018700! Island!
RAB38$ 0.011002544! 11! NM_022337! S_Shore!
CD8A$ 0.011039345! 2! NM_001145873! Island!
CAMTA1$ 0.011051768! 1! NM_015215! Open!sea!
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OSBPL1A$ 0.011052691! 18! NM_080597! S_Shore!
LENG9$ 0.011053113! 19! NM_198988! Island!
LHX9$ 0.011099756! 1! NM_001014434! Island!
SCRN1$ 0.011115745! 7! NM_014766! N_Shore!
CD2AP$ 0.011134366! 6! NM_012120! Island!
NSUN7$ 0.011212405! 4! NM_024677! Island!
VILL$ 0.011279357! 3! NM_015873! S_Shore!
ME1$ 0.011311285! 6! NM_002395! Island!
ZNF575$ 0.01132956! 19! NM_174945! S_Shore!
TGFB2$ 0.011350774! 1! NM_003238! Island!
CXCR4$ 0.011373484! 2! NM_003467! Island!
CMTM7$ 0.011386783! 3! NM_181472! Island!
GRIN1$ 0.011447338! 9! NM_000832! Island!
TTBK1$ 0.011461455! 6! NM_032538! N_Shore!
CUL7$ 0.011508819! 6! NM_001168370! Island!
HLASJ$ 0.011516565! 6! NR_024240! Island!
GSX2$ 0.011518104! 4! NM_133267! Island!
MAST1$ 0.011689324! 19! NM_014975! Island!
ACRBP$ 0.011740179! 12! NM_032489! Island!
ZNF389$ 0.011769011! 6! NM_001145129! Open!sea!
VWA1$ 0.011845145! 1! NM_199121! Island!
EPS8L2$ 0.011863541! 11! NM_022772! Island!
TUBA8$ 0.011874498! 22! NM_018943! Island!
TMEM22$ 0.01187812! 3! NM_025246! Island!
BRUNOL5$ 0.011977953! 19! NM_021938! Island!
SYCE2$ 0.012059447! 19! NM_001105578! Island!
LHX9$ 0.012070062! 1! NM_020204! Island!
OSBPL1A$ 0.01213845! 18! NM_080597! Island!
GALNT14$ 0.012162591! 2! NM_024572! Island!
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NSUN7$ 0.012165968! 4! NM_024677! Island!
LBXCOR1$ 0.012288839! 15! NM_001031807! Island!
TLR2$ 0.012416751! 4! NM_003264! Island!
LTBP4$ 0.012481156! 19! NM_001042545! Island!
OGDHL$ 0.012518598! 10! NM_018245! Island!
PICK1$ 0.012553412! 22! NM_001039583! Island!
BCL2$ 0.012557292! 18! NM_000657! Island!
ACADS$ 0.012557547! 12! NM_000017! Island!
ZNF296$ 0.01262203! 19! NM_145288! Island!
MOSC2$ 0.012651971! 1! NM_017898! Island!
RARRES1$ 0.012665941! 3! NM_206963! N_Shore!
ALOX5$ 0.01270606! 10! NM_000698! Island!
WWTR1$ 0.012851172! 3! NM_001168278! Island!
NR3C2$ 0.012896216! 4! NM_000901! N_Shore!
TMEM51$ 0.012899152! 1! NM_001136218! Island!
CCNA1$ 0.012959251! 13! NM_001111047! N_Shore!
KCNIP3$ 0.012964434! 2! NM_013434! Island!
BIRC3$ 0.013017519! 11! NM_182962! Island!
NR3C2$ 0.013035843! 4! NM_000901! N_Shore!
FKBP5$ 0.013108302! 6! NM_001145777! Island!
ACADS$ 0.013125498! 12! NM_000017! N_Shore!
NTSR2$ 0.013147385! 2! NM_012344! Island!
SCRN1$ 0.013153927! 7! NM_014766! N_Shore!
GRB7$ 0.013175577! 17! NM_001030002! Open!sea!
LOXL1$ 0.013190068! 15! NM_005576! Island!
FAM123C$ 0.013257618! 2! NM_001105194! N_Shore!
SST$ 0.01340295! 3! NM_001048! N_Shore!
CYP27A1$ 0.013403319! 2! NM_000784! Island!
MAST1$ 0.013437739! 19! NM_014975! Island!
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HFE$ 0.013461392! 6! NM_139010! Open!sea!
GPR19$ 0.013516055! 12! NM_006143! Island!
SLC35D3$ 0.013606884! 6! NM_001008783! Island!
CD302$ 0.013617459! 2! NM_014880! S_Shore!
BCL6$ 0.013637367! 3! NM_001706! Island!
MMP14$ 0.013642349! 14! NM_004995! Island!
LAMA3$ 0.013694904! 18! NM_198129! Island!
CHST8$ 0.013712362! 19! NM_022467! Island!
GIPC2$ 0.013739528! 1! NM_017655! Island!
HSPA2$ 0.013742167! 14! NM_021979! Island!
AOX1$ 0.013765728! 2! NM_001159! Island!
SLC12A8$ 0.013799611! 3! NM_024628! S_Shore!
ZNF3$ 0.01379979! 7! NM_017715! S_Shore!
MFSD2B$ 0.013839421! 2! NM_001080473! Island!
FGFRL1$ 0.013839911! 4! NM_001004358! Island!
RARRES1$ 0.013843252! 3! NM_206963! Island!
CYB5R2$ 0.013926358! 11! NM_016229! Island!
ZNF296$ 0.013937042! 19! NM_145288! Island!
KLHL1$ 0.013957804! 13! NM_020866! Island!
CHRNB1$ 0.013965699! 17! NM_000747! Island!
SERHL2$ 0.013970837! 22! NM_014509! Island!
SERHL2$ 0.013992254! 22! NM_014509! N_Shore!
STAT4$ 0.014015768! 2! NM_003151! Open!sea!
CAMTA1$ 0.014292638! 1! NM_015215! N_Shore!
RGNEF$ 0.01434726! 5! NM_001080479! Island!
DKK1$ 0.014347293! 10! NM_012242! N_Shore!
EMILIN2$ 0.014361769! 18! NM_032048! Island!
VSX1$ 0.014368502! 20! NM_199425! Island!
ACTA1$ 0.01442471! 1! NM_001100! Island!
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LOXL1$ 0.014425972! 15! NM_005576! Island!
RNLS$ 0.014443498! 10! NM_001031709! Island!
THBS1$ 0.014462304! 15! NM_003246! Island!
FLJ40330$ 0.014697374! 2! NR_015424! S_Shore!
RUSC1$ 0.014715358! 1! NM_001105203! Island!
IGSF21$ 0.014767259! 1! NM_032880! N_Shore!
SCRN1$ 0.014821969! 7! NM_014766! Island!
HNRNPF$ 0.014842882! 10! NM_001098207! N_Shore!
PICK1$ 0.014908869! 22! NM_001039583! Island!
KIAA0146$ 0.014912968! 8! NM_001080394! Open!sea!
FZD6$ 0.01491404! 8! NM_001164616! Island!
LGALS8$ 0.014926042! 1! NM_201544! Island!
ONECUT1$ 0.014980162! 15! NM_004498! Island!
NR1I2$ 0.015048105! 3! NM_033013! Island!
DOK7$ 0.015048968! 4! NM_173660! Island!
KLC2$ 0.015095906! 11! NM_001134776! N_Shore!
EVI5$ 0.015112758! 1! NM_005665! S_Shore!
MYADM$ 0.015134761! 19! NM_001020818! Island!
CTSZ$ 0.015135047! 20! NM_001336! Island!
FBP1$ 0.015136043! 9! NM_000507! Island!
QRFPR$ 0.015137423! 4! NM_198179! S_Shore!
FAM123C$ 0.015164152! 2! NM_001105194! N_Shore!
CRYAB$ 0.015166706! 11! NM_001885! Open!sea!
RARRES1$ 0.015167255! 3! NM_206963! Island!
SYT7$ 0.0151975! 11! NM_004200! Island!
TUBA8$ 0.015231272! 22! NM_018943! Island!
KIF5C$ 0.015252215! 2! NM_004522! Island!
CNTD2$ 0.015266675! 19! NM_024877! Island!
EVI5$ 0.015311134! 1! NM_005665! S_Shore!
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MAST1$ 0.015313197! 19! NM_014975! Island!
SYCP2L$ 0.015342482! 6! NM_001040274! N_Shore!
LTBP3$ 0.015355493! 11! NM_001164266! Island!
RAB3D$ 0.015437932! 19! NM_004283! Island!
USP4$ 0.015598936! 3! NM_199443! S_Shore!
THBS4$ 0.015691629! 5! NM_003248! Island!
GABRA1$ 0.015718802! 5! NM_001127645! Open!sea!
DOK7$ 0.01572927! 4! NM_173660! Island!
TUBA8$ 0.015833887! 22! NM_018943! Island!
TLX1$ 0.0158665! 10! NM_005521! Island!
LGALS8$ 0.015959512! 1! NM_201544! Island!
NAAA$ 0.015978811! 4! NM_001042402! Island!
P2RY2$ 0.015999723! 11! NM_002564! Island!
SLCO2A1$ 0.016023037! 3! NM_005630! Island!
MOGAT3$ 0.016055692! 7! NM_178176! Island!
VPS37B$ 0.016107147! 12! NM_024667! Island!
PHLDB1$ 0.016110534! 11! NM_001144758! Island!
LGR5$ 0.016139245! 12! NM_003667! S_Shore!
SFRP2$ 0.01621487! 4! NM_003013! Island!
GRIN2B$ 0.016215383! 12! NM_000834! N_Shore!
TRIP4$ 0.016215957! 15! NM_016213! S_Shore!
MYADM$ 0.016277339! 19! NM_001020821! Island!
CYB5R2$ 0.016322573! 11! NM_016229! Island!
DLC1$ 0.016468008! 8! NM_182643! N_Shore!
IGSF21$ 0.016476201! 1! NM_032880! Island!
SLC35D3$ 0.016486286! 6! NM_001008783! Island!
CUL7$ 0.016590317! 6! NM_001168370! Island!
NAAA$ 0.01666965! 4! NM_001042402! Island!
COL1A2$ 0.016685448! 7! NM_000089! Open!sea!
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ZNF3$ 0.016695968! 7! NM_017715! S_Shore!
ZMYND10$ 0.016781311! 3! NM_015896! Island!
RUSC1$ 0.016794402! 1! NM_001105205! Island!
TLR2$ 0.016803755! 4! NM_003264! S_Shore!
GIPR$ 0.016803862! 19! NM_000164! Island!
SWAP70$ 0.017030935! 11! NM_015055! N_Shore!
MCF2L2$ 0.017036003! 3! NM_015078! N_Shore!
PLEC1$ 0.01705783! 8! NM_000445! Island!
LMO7$ 0.017118508! 13! NM_005358! S_Shore!
PTPRN$ 0.017125554! 2! NM_002846! Island!
NPY2R$ 0.017242474! 4! NM_000910! Island!
SRRM3$ 0.017267652! 7! NM_001110199! Island!
AOX1$ 0.017376679! 2! NM_001159! Island!
PITX3$ 0.017393865! 10! NM_005029! Island!
SPTBN4$ 0.017401161! 19! NM_025213! S_Shore!
RAB33B$ 0.017453846! 4! NM_031296! Island!
MAP7$ 0.017463734! 6! NM_003980! Island!
EFEMP2$ 0.017580644! 11! NM_016938! Island!
MYADM$ 0.017604071! 19! NM_001020818! Island!
TNXB$ 0.017678436! 6! NM_019105! Island!
HNRNPF$ 0.017747848! 10! NM_001098205! Island!
ACADS$ 0.017763689! 12! NM_000017! Island!
RAP1GAP$ 0.017835144! 1! NM_002885! Island!
KCNIP3$ 0.017854327! 2! NM_013434! Island!
CRIP1$ 0.017868088! 14! NM_001311! Island!
HOXC4$ 0.017870978! 12! NM_014620! N_Shore!
MT1E$ 0.017888471! 16! NM_175617! Island!
NSUN7$ 0.017913085! 4! NM_024677! Island!
TEKT3$ 0.018013601! 17! NM_031898! Island!
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DKK3$ 0.018028274! 11! NM_001018057! S_Shore!
NAALAD2$ 0.018029092! 11! NM_005467! Open!sea!
KLF11$ 0.018061524! 2! NM_003597! Island!
NID2$ 0.018080985! 14! NM_007361! Island!
SFRP2$ 0.018084242! 4! NM_003013! Island!
DEDD2$ 0.018140911! 19! NM_133328! Island!
MYADM$ 0.018275176! 19! NM_001020821! Island!
CD109$ 0.018313843! 6! NM_133493! N_Shore!
ZMYND10$ 0.01846122! 3! NM_015896! Island!
RNF39$ 0.018505125! 6! NM_025236! Island!
PLLP$ 0.018585366! 16! NM_015993! Island!
SYCE2$ 0.01869128! 19! NM_001105578! Island!
UPK3A$ 0.018692227! 22! NM_006953! Island!
IER3$ 0.018722916! 6! NM_003897! S_Shore!
MT1A$ 0.01876313! 16! NM_005946! Island!
RAB33B$ 0.018809065! 4! NM_031296! Island!
HLASJ$ 0.018875396! 6! NR_024240! Island!
ATP5G2$ 0.018878388! 12! NM_001002031! N_Shore!
RNF39$ 0.018895143! 6! NM_025236! Island!
HLASJ$ 0.01889951! 6! NR_024240! Island!
PTPRN$ 0.019014863! 2! NM_002846! Island!
TMEM63A$ 0.019088085! 1! NM_014698! Island!
ZDHHC8P$ 0.019112683! 22! NR_003950! Open!sea!
ZNF296$ 0.019309225! 19! NM_145288! Island!
GPR153$ 0.01934068! 1! NM_207370! S_Shore!
MCF2L2$ 0.019422509! 3! NM_015078! S_Shore!
LTBP4$ 0.019438339! 19! NM_001042545! Island!
NPY2R$ 0.019482173! 4! NM_000910! Island!
MYADM$ 0.019553752! 19! NM_001020818! N_Shore!
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RNF135$ 0.019565041! 17! NM_197939! N_Shore!
HMSD$ 0.019610167! 18! NM_001123366! Open!sea!
STL$ 0.019610621! 6! NR_026876! Island!
ZC3HAV1L$ 0.019692058! 7! NM_080660! Island!
CCNA1$ 0.019729939! 13! NM_001111047! N_Shore!
BMPR2$ 0.019737665! 2! NM_001204! Island!
DEDD2$ 0.019934959! 19! NM_133328! Island!
MCF2L2$ 0.019997167! 3! NM_015078! Island!
FCHSD1$ 0.020038895! 5! NM_033449! N_Shore!
MYADM$ 0.020111441! 19! NM_001020818! Island!
SYT6$ 0.020113169! 1! NM_205848! N_Shore!
MYADM$ 0.020115117! 19! NM_001020818! Island!
MYADM$ 0.020134158! 19! NM_001020818! Island!
MYL12A$ 0.020178622! 18! NM_006471! Island!
TOM1L1$ 0.020227635! 17! NM_005486! N_Shore!
MYADM$ 0.020274321! 19! NM_001020818! Island!
THBS1$ 0.020337745! 15! NM_003246! Island!
DEDD2$ 0.020488942! 19! NM_133328! S_Shore!
ELL3$ 0.020580789! 15! NM_025165! S_Shore!
MEGF10$ 0.020625545! 5! NM_032446! Island!
FAM160A1$ 0.02088686! 4! NM_001109977! Island!
MYADM$ 0.020972959! 19! NM_001020818! Island!
FAM59B$ 0.021019566! 2! NM_001168241! Island!
CRIP1$ 0.02107233! 14! NM_001311! Island!
IQSEC1$ 0.021151178! 3! NM_001134382! S_Shore!
RARRES1$ 0.021194227! 3! NM_206963! Island!
PHLDB1$ 0.02119447! 11! NM_001144758! Island!
LENG9$ 0.021276947! 19! NM_198988! Island!
ZNF296$ 0.021343579! 19! NM_145288! Island!
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NAALAD2$ 0.021348928! 11! NM_005467! Open!sea!
TMEM26$ 0.021404247! 10! NM_178505! S_Shore!
PRKCZ$ 0.02156063! 1! NM_001033582! Island!
LGALS8$ 0.021651744! 1! NM_201544! Island!
TUBA8$ 0.021703463! 22! NM_018943! Island!
RCCD1$ 0.021810415! 15! NM_033544! Island!
MYADM$ 0.021866911! 19! NM_001020818! S_Shore!
KIF19$ 0.021870862! 17! NM_153209! Island!
MYL12A$ 0.021907684! 18! NM_006471! Island!
DERL3$ 0.021980782! 22! NM_001002862! Island!
ELL3$ 0.022062262! 15! NM_025165! Island!
RAP1GAP$ 0.022087816! 1! NM_001145658! Island!
FAM160A1$ 0.022089445! 4! NM_001109977! Island!
PICK1$ 0.022229728! 22! NM_001039583! N_Shore!
CMTM7$ 0.02224274! 3! NM_138410! Island!
PTPRU$ 0.022272995! 1! NM_133178! Island!
UPK3A$ 0.022293832! 22! NM_006953! Island!
MYL12A$ 0.022303692! 18! NM_006471! Island!
LGALS8$ 0.022315416! 1! NM_201544! Island!
RAB27B$ 0.022439882! 18! NM_004163! Island!
CRIP1$ 0.02244055! 14! NM_001311! Island!
MFSD2B$ 0.022445027! 2! NM_001080473! Island!
UCP2$ 0.022507475! 11! NM_003355! Island!
LGALS1$ 0.02254589! 22! NM_002305! N_Shore!
DPYSL5$ 0.02258023! 2! NM_020134! Island!
CDK5R2$ 0.022588717! 2! NM_003936! N_Shore!
DEDD2$ 0.022617072! 19! NM_133328! Island!
LINGO3$ 0.02268067! 19! NM_001101391! S_Shore!
PTRF$ 0.022707145! 17! NM_012232! Island!
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UNC13A$ 0.022729423! 19! NM_001080421! Island!
HCRT$ 0.022732905! 17! NM_001524! Island!
MEOX2$ 0.022737285! 7! NM_005924! Open!sea!
LTBP3$ 0.02284279! 11! NM_001164266! Island!
NFATC4$ 0.022859738! 14! NM_001136022! Island!
PYCARD$ 0.022886261! 16! NM_013258! N_Shore!
USP2$ 0.02292712! 11! NM_171997! Island!
HCRT$ 0.022929918! 17! NM_001524! Island!
ZNF204P$ 0.02294259! 6! NR_024553! Island!
MLLT10$ 0.022955527! 10! NM_001009569! N_Shore!
SCN9A$ 0.023011394! 2! NM_002977! S_Shore!
ZC3HAV1L$ 0.023195996! 7! NM_080660! Island!
CCNA1$ 0.023230729! 13! NM_001111047! N_Shore!
CHD5$ 0.02323348! 1! NM_015557! Island!
PPP1CC$ 0.023251574! 12! NM_002710! S_Shore!
CENPV$ 0.023272656! 17! NM_181716! Island!
MCFD2$ 0.023402211! 2! NM_001171508! Island!
DEDD2$ 0.023507496! 19! NM_133328! Island!
HNRNPF$ 0.023588699! 10! NM_001098207! Island!
NAV2$ 0.023592599! 11! NM_001111018! N_Shore!
MCF2L2$ 0.023605007! 3! NM_015078! N_Shore!
PTRF$ 0.023616273! 17! NM_012232! Island!
KCNQ4$ 0.023621525! 1! NM_004700! Island!
MYADM$ 0.0237004! 19! NM_001020818! Island!
MYADM$ 0.023703489! 19! NM_001020818! Island!
PAX6$ 0.023709861! 11! NM_001127612! Island!
TRIP4$ 0.023800469! 15! NM_016213! Island!
KDELC2$ 0.023828231! 11! NM_153705! Island!
PICK1$ 0.023831896! 22! NM_001039583! N_Shore!
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LGALS8$ 0.023862106! 1! NM_201544! Island!
ACTC1$ 0.02391709! 15! NM_005159! Open!sea!
TMEM22$ 0.023951004! 3! NM_001097599! Island!
BCL6$ 0.023951921! 3! NM_001706! Island!
PLEC1$ 0.024067792! 8! NM_000445! Island!
ESAM$ 0.024100828! 11! NM_138961! Island!
AOX1$ 0.024135876! 2! NM_001159! Island!
CXCR4$ 0.024139288! 2! NM_003467! Island!
CHAD$ 0.024209057! 17! NM_001267! Island!
SCGB3A1$ 0.024217484! 5! NM_052863! Island!
COL9A2$ 0.024309777! 1! NM_001852! Island!
LMO7$ 0.024324092! 13! NM_005358! Island!
UCP2$ 0.024390746! 11! NM_003355! Island!
FAS$ 0.024393857! 10! NR_028034! N_Shore!
BCL6$ 0.024398273! 3! NM_001706! Island!
PLEC1$ 0.024408883! 8! NM_000445! Island!
TNXB$ 0.024414708! 6! NM_019105! Open!sea!
HSPA2$ 0.02441604! 14! NM_021979! N_Shore!
HLCS$ 0.024464904! 21! NM_000411! Island!
EFEMP1$ 0.024544817! 2! NM_001039349! Island!
HPCA$ 0.024627859! 1! NM_002143! Island!
AOX1$ 0.024663987! 2! NM_001159! Island!
LTBP4$ 0.024696108! 19! NM_001042545! Island!
PAK1$ 0.024812177! 11! NM_002576! Island!
PICK1$ 0.024816763! 22! NM_001039583! Island!
FLJ22536$ 0.024824834! 6! NR_015410! Island!
FAS$ 0.02482765! 10! NM_000043! Island!
NEAT1$ 0.024833894! 11! NR_028272! Island!
STARD9$ 0.024859831! 15! NM_020759! Island!
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LTBP4$ 0.024861683! 19! NM_001042545! Island!
SCN9A$ 0.024880906! 2! NM_002977! Island!
TGFBI$ 0.025041637! 5! NM_000358! Island!
CRIP1$ 0.02504291! 14! NM_001311! Island!
TCIRG1$ 0.025070439! 11! NM_006019! Island!
AOX1$ 0.025071967! 2! NM_001159! N_Shore!
PICK1$ 0.02508851! 22! NM_001039583! Island!
SPATS1$ 0.025111489! 6! NM_145026! Open!sea!
SLC12A8$ 0.025112074! 3! NM_024628! S_Shore!
CCND2$ 0.025153821! 12! NM_001759! Open!sea!
ONECUT1$ 0.025206395! 15! NM_004498! Island!
LENG9$ 0.025261285! 19! NM_198988! Island!
PTRF$ 0.025262356! 17! NM_012232! Island!
EVC2$ 0.025276757! 4! NM_001166136! Island!
TNXB$ 0.025301379! 6! NM_019105! Open!sea!
CMTM7$ 0.025484689! 3! NM_138410! Island!
ZIC2$ 0.025609715! 13! NM_007129! N_Shore!
PHLDB1$ 0.025667054! 11! NM_001144758! Island!
NRXN1$ 0.025672898! 2! NM_004801! S_Shore!
ZNF788$ 0.025715285! 19! NR_027049! Island!
GRB7$ 0.025715921! 17! NM_001030002! Open!sea!
RNLS$ 0.025748381! 10! NM_018363! S_Shore!
ADAM12$ 0.025770661! 10! NM_003474! Island!
IQSEC1$ 0.025800791! 3! NM_001134382! S_Shore!
DEDD2$ 0.025831217! 19! NM_133328! Island!
NSUN7$ 0.025884777! 4! NM_024677! Island!
KDELC2$ 0.025911538! 11! NM_153705! Island!
DKFZp761E1
98$
0.025931192! 11! NM_138368! Island!
HPCAL1$ 0.025933387! 2! NM_134421! Island!
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LRRC3B$ 0.025989116! 3! NM_052953! Island!
HLCS$ 0.02599245! 21! NM_000411! Island!
ZNF389$ 0.025995733! 6! NM_001145129! Open!sea!
ZNF788$ 0.026015013! 19! NR_027049! Island!
ZNF788$ 0.026245465! 19! NR_027049! Island!
RPP25$ 0.026265018! 15! NM_017793! Island!
KIAA0495$ 0.02627697! 1! NM_207306! Island!
UCP2$ 0.026307852! 11! NM_003355! Island!
SYNPO2L$ 0.026366832! 10! NM_024875! S_Shore!
PAX6$ 0.026430185! 11! NM_001127612! Island!
CDK5R2$ 0.026437375! 2! NM_003936! N_Shore!
LY6G5C$ 0.026448068! 6! NM_025262! N_Shore!
CD302$ 0.026450819! 2! NM_014880! N_Shore!
SIAH3$ 0.026488059! 13! NM_198849! Open!sea!
DDIT4L$ 0.026495839! 4! NM_145244! Island!
LGALS1$ 0.026587252! 22! NM_002305! N_Shore!
CYB5R1$ 0.026590601! 1! NM_016243! Island!
TTBK1$ 0.026642071! 6! NM_032538! N_Shore!
UPK3A$ 0.026648401! 22! NM_006953! Island!
RCCD1$ 0.02671361! 15! NM_033544! Island!
ALDH5A1$ 0.0268075! 6! NM_001080! Island!
NR2E1$ 0.026811657! 6! NM_003269! Island!
PAX6$ 0.026856485! 11! NM_001127612! Island!
SPATS1$ 0.02689941! 6! NM_145026! Open!sea!
RPP25$ 0.026955326! 15! NM_017793! Island!
RUSC1$ 0.02697766! 1! NM_001105205! Island!
FAM5B$ 0.026982127! 1! NM_021165! N_Shore!
EVC2$ 0.026983323! 4! NM_001166136! Island!
RUSC1$ 0.02699564! 1! NM_001105204! N_Shore!
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SEC31B$ 0.027001575! 10! NM_015490! Island!
TTBK1$ 0.027126621! 6! NM_032538! N_Shore!
SCGB3A1$ 0.027212999! 5! NM_052863! Island!
GPR150$ 0.027213048! 5! NM_199243! Island!
CHRNB1$ 0.027214267! 17! NM_000747! Island!
DKFZp761E1
98$
0.027216974! 11! NM_138368! Island!
DKFZp761E1
98$
0.027301975! 11! NM_138368! Island!
RILP$ 0.027343324! 17! NM_031430! Island!
LECT1$ 0.027373117! 13! NM_001011705! N_Shore!
GRB7$ 0.027377028! 17! NM_001030002! Open!sea!
CD302$ 0.027404805! 2! NM_014880! Island!
PHLDB1$ 0.027406958! 11! NM_001144758! Island!
NAV2$ 0.027407124! 11! NM_001111018! N_Shore!
NAV1$ 0.027408705! 1! NM_001167738! S_Shore!
GRM8$ 0.027408941! 7! NM_001127323! Island!
CABYR$ 0.027410963! 18! NM_153768! Island!
FGFRL1$ 0.027457394! 4! NM_001004358! Island!
TMEM144$ 0.027459876! 4! NM_018342! S_Shore!
SCGB3A1$ 0.027473174! 5! NM_052863! Island!
CLDN10$ 0.027473532! 13! NM_006984! Island!
TRIM36$ 0.027564408! 5! NM_018700! Island!
LIN28$ 0.027565416! 1! NM_024674! N_Shore!
PICK1$ 0.027566687! 22! NM_001039583! N_Shore!
SLC25A20$ 0.027629015! 3! NM_000387! Island!
IMPACT$ 0.027658014! 18! NM_018439! Island!
KLF16$ 0.027743575! 19! NM_031918! Island!
GLB1L3$ 0.027882287! 11! NM_001080407! Island!
AEBP1$ 0.027904547! 7! NM_001129! Open!sea!
GALNTL1$ 0.027904929! 14! NM_001168368! Island!
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JAG1$ 0.027906836! 20! NM_000214! Island!
PLEC1$ 0.028021143! 8! NM_000445! Island!
MT1A$ 0.02802782! 16! NM_005946! Island!
TRANK1$ 0.028262931! 3! NM_014831! Island!
HFE$ 0.028279278! 6! NM_139008! Open!sea!
RUSC1$ 0.028348334! 1! NM_001105203! Island!
MDK$ 0.028371855! 11! NM_002391! Island!
RCCD1$ 0.028378944! 15! NM_033544! Island!
PTRF$ 0.028444346! 17! NM_012232! Island!
CHAD$ 0.028447074! 17! NM_001267! Island!
SYNPO2L$ 0.028450753! 10! NM_024875! Island!
GPR150$ 0.028480274! 5! NM_199243! Island!
CFTR$ 0.02849952! 7! NM_000492! Open!sea!
HNRNPF$ 0.028524828! 10! NM_001098205! Island!
CUL7$ 0.028551898! 6! NM_001168370! Island!
RILP$ 0.028740943! 17! NM_031430! Island!
JAG1$ 0.028793603! 20! NM_000214! Island!
PICK1$ 0.028803794! 22! NM_001039583! Island!
KDELC2$ 0.028813336! 11! NM_153705! Island!
COL9A2$ 0.02885032! 1! NM_001852! Island!
ADAM12$ 0.028863564! 10! NM_003474! Island!
NEUROG1$ 0.028886246! 5! NM_006161! Island!
HNRNPF$ 0.028911938! 10! NM_001098205! S_Shore!
ANXA2$ 0.028994013! 15! NM_001002857! Island!
TCIRG1$ 0.029067492! 11! NM_006019! Island!
TMEM178$ 0.029073518! 2! NM_152390! N_Shore!
SYNPO2L$ 0.029156949! 10! NM_024875! Island!
SORBS3$ 0.029292157! 8! NM_005775! Island!
TGFBI$ 0.029380056! 5! NM_000358! Island!
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NMRAL1$ 0.029531341! 16! NM_020677! N_Shore!
NEAT1$ 0.029714679! 11! NR_028272! Island!
SPATS1$ 0.029826171! 6! NM_145026! Open!sea!
CD109$ 0.029830197! 6! NM_001159588! N_Shore!
RGNEF$ 0.029900267! 5! NM_001080479! Island!
PLD5$ 0.029928573! 1! NM_152666! Island!
LGALS1$ 0.029990469! 22! NM_002305! Island!
SLC13A5$ 0.030045868! 17! NM_001143838! Island!
MIR548H4$ 0.030193691! 15! NR_031680! Island!
SPIB$ 0.03021723! 19! NM_003121! Open!sea!
CCNA1$ 0.030394976! 13! NM_001111047! N_Shore!
PRSS27$ 0.030536678! 16! NM_031948! N_Shore!
SPATS1$ 0.030737483! 6! NM_145026! Open!sea!
ZNF788$ 0.030917919! 19! NR_027049! Island!
SLC22A3$ 0.031137764! 6! NM_021977! Island!
TGFBI$ 0.031227664! 5! NM_000358! Island!
TRIP6$ 0.031415569! 7! NM_003302! S_Shore!
NBL1$ 0.031431515! 1! NM_182744! Island!
DKFZp761E1
98$
0.03165343! 11! NM_138368! Island!
ONECUT2$ 0.031714847! 18! NM_004852! Island!
RNF39$ 0.031717533! 6! NM_025236! Island!
SORBS3$ 0.03177639! 8! NM_005775! N_Shelf!
TCTEX1D1$ 0.031780281! 1! NM_152665! N_Shore!
ESRP2$ 0.031837637! 16! NM_024939! Island!
CCNA1$ 0.031842484! 13! NM_001111047! N_Shore!
NBL1$ 0.031905781! 1! NM_005380! Island!
MIR548H4$ 0.031924981! 15! NR_031680! Island!
SORBS3$ 0.03195139! 8! NM_005775! Island!
IMPACT$ 0.032018447! 18! NM_018439! Island!
 
 342 
TRIM36$ 0.032155973! 5! NM_018700! Island!
BNC1$ 0.032168949! 15! NM_001717! Island!
SLC12A8$ 0.032169322! 3! NM_024628! Island!
RASSF10$ 0.032218303! 11! NM_001080521! Island!
DKFZp761E1
98$
0.032218539! 11! NM_138368! Island!
EVI5$ 0.032292705! 1! NM_005665! S_Shore!
GABRA1$ 0.032293273! 5! NM_000806! Open!sea!
CAMK2B$ 0.032364052! 7! NM_172081! Island!
KDM2B$ 0.032392007! 12! NM_032590! S_Shore!
USP2$ 0.032409213! 11! NM_171997! Island!
STARD9$ 0.032411859! 15! NM_020759! Island!
B3GALT4$ 0.032418275! 6! NM_003782! Island!
SYNPO2L$ 0.032568048! 10! NM_024875! Island!
MAP1LC3A$ 0.032749416! 20! NM_032514! Island!
AEBP1$ 0.032902132! 7! NM_001129! Open!sea!
MYL12A$ 0.033038018! 18! NM_006471! Island!
CHD5$ 0.03304102! 1! NM_015557! Island!
FLJ22536$ 0.033145882! 6! NR_015410! Island!
NRXN1$ 0.033181334! 2! NM_004801! Island!
NEAT1$ 0.03318839! 11! NR_028272! Island!
FGR$ 0.033427338! 1! NM_005248! Island!
TRIP6$ 0.033508793! 7! NM_003302! S_Shore!
SIAH3$ 0.033543072! 13! NM_198849! Open!sea!
PHF11$ 0.03358628! 13! NM_001040444! N_Shore!
CTHRC1$ 0.033637258! 8! NM_138455! Island!
DKK3$ 0.033637576! 11! NM_001018057! Island!
TGFBI$ 0.033638199! 5! NM_000358! Island!
OSBPL9$ 0.033824281! 1! NM_148904! Island!
CXCR4$ 0.033998966! 2! NM_003467! N_Shore!
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LGALS1$ 0.03402873! 22! NM_002305! N_Shore!
FAM188B$ 0.034097753! 7! NM_032222! Island!
KDM2B$ 0.034154004! 12! NM_032590! S_Shore!
THBS1$ 0.03415467! 15! NM_003246! Island!
TCTEX1D1$ 0.034155791! 1! NM_152665! Island!
FAS$ 0.034243462! 10! NM_000043! Island!
NAV1$ 0.034366691! 1! NM_001167738! Island!
NMRAL1$ 0.034377427! 16! NM_020677! Island!
CYB5R2$ 0.034405481! 11! NM_016229! Island!
LY75$ 0.03441098! 2! NM_002349! Island!
FGFRL1$ 0.034427509! 4! NM_001004358! Island!
LHX9$ 0.034455877! 1! NM_001014434! Island!
PHLDB1$ 0.034486785! 11! NM_001144758! Island!
THBS1$ 0.034775632! 15! NM_003246! Island!
XKR8$ 0.034775821! 1! NM_018053! Island!
DRD4$ 0.034866531! 11! NM_000797! Island!
MYRIP$ 0.034960823! 3! NM_015460! Island!
FAM188B$ 0.03496466! 7! NM_032222! Island!
KDM2B$ 0.035066555! 12! NM_032590! S_Shore!
NPHS2$ 0.035084226! 1! NM_014625! Island!
NMRAL1$ 0.03509607! 16! NM_020677! Island!
THBS1$ 0.035224454! 15! NM_003246! Island!
HLASH$ 0.035239402! 6! NR_001434! Island!
ACTC1$ 0.035294134! 15! NM_005159! Open!sea!
PHLDB1$ 0.035346332! 11! NM_001144758! Island!
CENPV$ 0.035355148! 17! NM_181716! Island!
CCND2$ 0.035385599! 12! NM_001759! Island!
SORBS3$ 0.035418958! 8! NM_005775! Island!
ZNF3$ 0.035484171! 7! NM_017715! S_Shore!
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KLHL1$ 0.035608103! 13! NM_020866! S_Shore!
LHX9$ 0.035652361! 1! NM_001014434! S_Shore!
NID2$ 0.035761759! 14! NM_007361! Island!
CCND2$ 0.035862423! 12! NM_001759! Island!
FAM123C$ 0.035869237! 2! NM_001105194! N_Shore!
CHD5$ 0.035904924! 1! NM_015557! Island!
DDIT4L$ 0.035907052! 4! NM_145244! Island!
SORBS3$ 0.035913079! 8! NM_005775! S_Shore!
OSBPL1A$ 0.036136719! 18! NM_080597! Island!
HPCA$ 0.036178171! 1! NM_002143! N_Shore!
AOX1$ 0.036196094! 2! NM_001159! Island!
NPPB$ 0.036241266! 1! NM_002521! S_Shore!
SPIB$ 0.03636725! 19! NM_003121! Open!sea!
B3GALT4$ 0.036425238! 6! NM_003782! Island!
MT1E$ 0.036667606! 16! NM_175617! Island!
NMRAL1$ 0.036746357! 16! NM_020677! Island!
ACVRL1$ 0.036849822! 12! NM_000020! Island!
FLJ22536$ 0.037047991! 6! NR_015410! Island!
NAAA$ 0.037059317! 4! NM_014435! Island!
MYADM$ 0.037135149! 19! NM_001020818! Island!
KDM2B$ 0.037236938! 12! NM_032590! S_Shore!
RAB11FIP4$ 0.037279554! 17! NM_032932! S_Shelf!
CAMK2B$ 0.037285482! 7! NM_172081! Island!
MAP7$ 0.037293336! 6! NM_003980! Island!
NAV1$ 0.037447763! 1! NM_001167738! Island!
VSIG10L$ 0.037462042! 19! NM_001163922! Island!
TRIP6$ 0.03750223! 7! NM_003302! S_Shore!
ZIC2$ 0.037524247! 13! NM_007129! N_Shore!
LINGO3$ 0.037620714! 19! NM_001101391! Island!
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KDELC2$ 0.037653929! 11! NM_153705! Island!
MCF2L2$ 0.037729669! 3! NM_015078! N_Shore!
ACTC1$ 0.037858394! 15! NM_005159! Open!sea!
RPP25$ 0.03793694! 15! NM_017793! Island!
COL9A2$ 0.038166417! 1! NM_001852! Island!
SYNPO2L$ 0.038224847! 10! NM_024875! S_Shore!
IQSEC1$ 0.038251409! 3! NM_001134382! Island!
MAP1LC3A$ 0.038322076! 20! NM_032514! Island!
DLC1$ 0.038332005! 8! NM_006094! Island!
CAMK2B$ 0.038343873! 7! NM_172081! Island!
MOGAT3$ 0.038607218! 7! NM_178176! Island!
NEAT1$ 0.038681251! 11! NR_028272! S_Shelf!
TRH$ 0.03877206! 3! NM_007117! Island!
SIAH3$ 0.038931732! 13! NM_198849! Open!sea!
OSBPL9$ 0.039138539! 1! NM_148904! Island!
KCNJ3$ 0.039169498! 2! NM_002239! Island!
RAB38$ 0.039251347! 11! NM_022337! S_Shore!
WRB$ 0.039305287! 21! NM_004627! N_Shore!
MAP1LC3A$ 0.03935296! 20! NM_032514! Island!
AOX1$ 0.039491094! 2! NM_001159! Island!
FBRSL1$ 0.039633642! 12! NM_001142641! Island!
PLEC1$ 0.039637477! 8! NM_000445! Island!
ADCY1$ 0.039726848! 7! NM_021116! Island!
TRANK1$ 0.039897182! 3! NM_014831! Island!
NSD1$ 0.040112796! 5! NM_022455! Island!
TRIP4$ 0.040142003! 15! NM_016213! Island!
WRB$ 0.040190242! 21! NM_004627! N_Shore!
LY75$ 0.040191949! 2! NM_002349! Island!
IQSEC1$ 0.04019227! 3! NM_001134382! S_Shore!
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NPPB$ 0.040519383! 1! NM_002521! Island!
NID2$ 0.040611738! 14! NM_007361! Island!
NPY5R$ 0.040626362! 4! NM_006174! Island!
FBRSL1$ 0.040667161! 12! NM_001142641! Island!
MAL$ 0.040684253! 2! NM_022439! Island!
GALNTL1$ 0.040690044! 14! NM_020692! Island!
TCTEX1D1$ 0.040763342! 1! NM_152665! Island!
FLJ40330$ 0.040982653! 2! NR_015424! Island!
RBM24$ 0.041101742! 6! NM_001143942! Island!
SEC31B$ 0.041323044! 10! NM_015490! S_Shore!
KLF11$ 0.041458707! 2! NM_003597! Island!
LHX9$ 0.041521249! 1! NM_001014434! Island!
NAALAD2$ 0.041521309! 11! NM_005467! Open!sea!
VWA1$ 0.041637246! 1! NM_022834! Island!
SLCO2A1$ 0.041683258! 3! NM_005630! Island!
KIF19$ 0.041798198! 17! NM_153209! Island!
CHRNB1$ 0.041828656! 17! NM_000747! Island!
NEUROG1$ 0.04196653! 5! NM_006161! Island!
PLD5$ 0.042021741! 1! NM_152666! Island!
CYB5R1$ 0.042067815! 1! NM_016243! S_Shore!
GIPR$ 0.042093969! 19! NM_000164! Island!
RNF39$ 0.042126057! 6! NM_170769! Island!
ADCY1$ 0.042175649! 7! NM_021116! Island!
HOXC4$ 0.042355927! 12! NM_014620! N_Shore!
ZEB1$ 0.042372362! 10! NM_030751! Island!
NID2$ 0.042400258! 14! NM_007361! Island!
WRB$ 0.04247073! 21! NM_004627! Island!
FLJ22536$ 0.042634262! 6! NR_015410! Island!
TUBA8$ 0.04273971! 22! NM_018943! Island!
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NBL1$ 0.042821548! 1! NM_182744! Island!
SORBS3$ 0.042828359! 8! NM_005775! Island!
SLCO2A1$ 0.042950676! 3! NM_005630! S_Shore!
VPS37B$ 0.043024986! 12! NM_024667! Island!
SULT1A1$ 0.043081365! 16! NM_177536! Island!
TUBA8$ 0.043202197! 22! NM_018943! Island!
NEUROG1$ 0.043236593! 5! NM_006161! Island!
LMO7$ 0.043277508! 13! NM_005358! Island!
ZNF389$ 0.043341043! 6! NM_001145129! Open!sea!
PSD3$ 0.043583917! 8! NM_206909! Open!sea!
FAM188B$ 0.043880862! 7! NM_032222! N_Shore!
NAV1$ 0.04393138! 1! NM_001167738! Island!
LY6G5C$ 0.043938139! 6! NM_025262! Island!
NR5A2$ 0.0440449! 1! NM_205860! Island!
XKR8$ 0.044164379! 1! NM_018053! S_Shore!
NEUROG1$ 0.044183502! 5! NM_006161! Island!
TEKT3$ 0.04420307! 17! NM_031898! Island!
RCCD1$ 0.044204031! 15! NM_033544! Island!
RCCD1$ 0.044328602! 15! NM_033544! N_Shore!
CTHRC1$ 0.044728997! 8! NM_138455! Island!
VWDE$ 0.044788631! 7! NM_001135924! Island!
THBS1$ 0.044805988! 15! NM_003246! Island!
FAM123C$ 0.044820048! 2! NM_001105194! N_Shore!
LMO7$ 0.044986377! 13! NM_005358! Island!
NR5A2$ 0.044992077! 1! NM_205860! Island!
TLR2$ 0.045007297! 4! NM_003264! Island!
SPAG1$ 0.045486872! 8! NM_003114! Island!
RNF39$ 0.045555848! 6! NM_170769! Island!
TOM1L1$ 0.045568219! 17! NM_005486! Island!
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LY6G5C$ 0.045608223! 6! NM_025262! Island!
FRZB$ 0.04571933! 2! NM_001463! Island!
TMED7S
TICAM2$
0.045720937! 5! NM_001164468! Island!
SYT6$ 0.045783744! 1! NM_205848! Island!
CXCR4$ 0.045838783! 2! NM_003467! N_Shore!
CHAD$ 0.045940318! 17! NM_001267! Island!
PTRF$ 0.045940391! 17! NM_012232! Island!
NID2$ 0.046117715! 14! NM_007361! Island!
LMO2$ 0.046205901! 11! NM_001142315! Island!
WRB$ 0.046527858! 21! NM_004627! Island!
NEAT1$ 0.047189624! 11! NR_028272! Island!
ADAMTSL4$ 0.047301952! 1! NM_025008! Island!
LRAT$ 0.047306593! 4! NM_004744! Island!
CCNA1$ 0.047310401! 13! NM_001111047! N_Shore!
JAG1$ 0.047409865! 20! NM_000214! Island!
RPP25$ 0.047442861! 15! NM_017793! Island!
TRH$ 0.04758056! 3! NM_007117! Island!
NUDT16$ 0.048044609! 3! NM_152395! Island!
PLA2R1$ 0.048051855! 2! NM_007366! N_Shore!
COL9A2$ 0.048063926! 1! NM_001852! Island!
COL1A2$ 0.048078848! 7! NM_000089! Open!sea!
CCND2$ 0.048080104! 12! NM_001759! Island!
PITX3$ 0.048102464! 10! NM_005029! Island!
B3GALT4$ 0.048102772! 6! NM_003782! Island!
USP2$ 0.04834295! 11! NM_171997! Island!
ACADS$ 0.049037697! 12! NM_000017! Island!
COL9A2$ 0.049343116! 1! NM_001852! Island!
FZD6$ 0.049364781! 8! NM_001164616! Island!
TGFBI$ 0.049437455! 5! NM_000358! Island!
 
 349 
MYADM$ 0.049737974! 19! NM_001020818! Island!
SLC25A20$ 0.049846704! 3! NM_000387! Island!














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































7.6 CoBRA digestion results of the hypermethylated genes in BCBM  
CoBRA digestion results are shown below for selected methylated and unmethylated 






















7.7 Data and results for LOH and MLPA in Schwannoma samples used in chapter five 
 
Sample ID Gender NF2 mutation LOH 22q Loss/Gain of NF2 by MLPA 
S14 Female Yes No - 
S21 Male Yes No - 
S36 Male No No - 
S37 Male No No - 
S44 Female Yes No - 
Lp152 Male Yes No - 
Lp272 Female No No - 
Lp303 Female No No - 
 357 
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